{"01c2f2faed4c6248693bccd231ee2f64c081df2f": [["IntroductionMiddle East respiratory syndrome coronavirus (MERS-CoV) was first detected in 2012 in respiratory specimens of a patient from Saudi Arabia with severe viral pneumonia leading to acute respiratory distress syndrome and death (Zaki et al., 2012) .", [["respiratory specimens", "ANATOMY", 98, 119], ["respiratory", "ANATOMY", 196, 207], ["Middle East respiratory syndrome coronavirus", "DISEASE", 12, 56], ["viral pneumonia", "DISEASE", 163, 178], ["acute respiratory distress syndrome", "DISEASE", 190, 225], ["death", "DISEASE", 230, 235], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 12, 56], ["MERS-CoV", "ORGANISM", 58, 66], ["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132], ["Middle East respiratory syndrome coronavirus", "SPECIES", 12, 56], ["MERS-CoV", "SPECIES", 58, 66], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 12, 56], ["severe viral pneumonia", "PROBLEM", 156, 178], ["acute respiratory distress syndrome", "PROBLEM", 190, 225], ["death", "PROBLEM", 230, 235], ["Middle", "ANATOMY_MODIFIER", 12, 18], ["respiratory syndrome", "OBSERVATION", 24, 44], ["severe", "OBSERVATION_MODIFIER", 156, 162], ["viral", "OBSERVATION_MODIFIER", 163, 168], ["pneumonia", "OBSERVATION", 169, 178], ["acute", "OBSERVATION_MODIFIER", 190, 195], ["respiratory distress syndrome", "OBSERVATION", 196, 225]]], ["As of 19 June 2015, 1338 laboratory confirmed cases of MERS have been reported to the World Health Organization (WHO) leading to at least 475 deaths (WHO, 2015) .", [["MERS", "DISEASE", 55, 59], ["deaths", "DISEASE", 142, 148]]], ["Saudi Arabia is the most affected country with 1030 laboratory confirmed patients.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81]]], ["Middle East respiratory syndrome patients have also been reported from Jordan, Kuwait, Lebanon, Oman, Qatar, United Arab of Emirates (UAE), Iran and Yemen.", [["Middle East respiratory syndrome", "DISEASE", 0, 32], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["Middle East respiratory syndrome", "PROBLEM", 0, 32], ["respiratory syndrome", "OBSERVATION", 12, 32]]], ["MERS has been reported from travellers arriving from these countries into Europe (Austria, France, Germany, Greece, Italy, Netherlands, Turkey, UK), Africa (Algeria, Egypt, Tunisia), Asia (China, Malaysia, Philippines; Republic of Korea, Thailand) and North America (USA).", [["MERS", "PROTEIN", 0, 4]]], ["Some limited secondary transmission has been associated with some travel-associated patients with MERS but one large outbreak in the Republic of Korea led to over 160 human MERS infections (WHO, 2015) .", [["MERS infections", "DISEASE", 173, 188], ["patients", "ORGANISM", 84, 92], ["human", "ORGANISM", 167, 172], ["patients", "SPECIES", 84, 92], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["MERS", "PROBLEM", 98, 102], ["large", "OBSERVATION_MODIFIER", 111, 116], ["outbreak", "OBSERVATION", 117, 125]]], ["Large clusters of human cases have been identified in Saudi Arabia, Jordan and UAE, most of these being associated with human-to-human transmission within healthcare facilities (Assiri et al., 2013; Oboho et al., 2015; WHO, 2015) .", [["human", "ORGANISM", 18, 23], ["human", "ORGANISM", 120, 125], ["human", "ORGANISM", 129, 134], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 120, 125], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 120, 125], ["human", "SPECIES", 129, 134], ["clusters", "OBSERVATION_MODIFIER", 6, 14]]], ["While some of these case clusters are large, humanto-human transmission remains inefficient and sustained community transmission has not being documented so far (Majumder et al., 2014; WHO, 2015) .", [["human", "ORGANISM", 53, 58], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["large", "OBSERVATION_MODIFIER", 38, 43]]], ["However, it is relevant to note that the emergence of SARS in 2002 was heralded by repeated self-limited outbreaks of human disease, but that virus finally adapted to transmission in humans, spreading to 25 countries across five continents, infecting approximately 8000 individuals and leading to almost 800 deaths (Peiris et al., 2004) .", [["SARS", "DISEASE", 54, 58], ["human disease", "DISEASE", 118, 131], ["deaths", "DISEASE", 308, 314], ["human", "ORGANISM", 118, 123], ["humans", "ORGANISM", 183, 189], ["human", "SPECIES", 118, 123], ["humans", "SPECIES", 183, 189], ["human", "SPECIES", 118, 123], ["humans", "SPECIES", 183, 189], ["SARS", "PROBLEM", 54, 58], ["human disease", "PROBLEM", 118, 131], ["virus", "PROBLEM", 142, 147], ["human disease", "OBSERVATION", 118, 131]]], ["Thus, it is important to understand the ecology and epidemiology of MERS so that zoonotic disease can be prevented and epidemic or pandemic threats mitigated.Source of Zoonotic InfectionZoonotic infections may arise from domestic animals as well as wild life.", [["MERS", "DISEASE", 68, 72], ["zoonotic disease", "DISEASE", 81, 97], ["InfectionZoonotic infections", "DISEASE", 177, 205], ["zoonotic disease", "PROBLEM", 81, 97], ["Zoonotic InfectionZoonotic infections", "PROBLEM", 168, 205], ["Zoonotic", "OBSERVATION_MODIFIER", 168, 176], ["InfectionZoonotic", "OBSERVATION_MODIFIER", 177, 194], ["infections", "OBSERVATION", 195, 205]]], ["Seroepidemiological studies have been carried out in domestic livestock (cattle, sheep, goats, horses and poultry) in the Arabian Peninsula and the Middle East, but dromedary camels were the only species from which antibodies specific to MERS-CoV have been detected (Hemida et al., 2013; Perera et al., 2013; Reusken et al., 2013a,b; Meyer et al., 2014) .", [["cattle", "ORGANISM_SUBDIVISION", 73, 79], ["sheep", "ORGANISM_SUBDIVISION", 81, 86], ["goats", "ORGANISM_SUBDIVISION", 88, 93], ["horses", "ORGANISM_SUBDIVISION", 95, 101], ["dromedary camels", "ORGANISM", 165, 181], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 238, 246], ["antibodies", "PROTEIN", 215, 225], ["MERS", "PROTEIN", 238, 242], ["cattle", "SPECIES", 73, 79], ["sheep", "SPECIES", 81, 86], ["goats", "SPECIES", 88, 93], ["cattle", "SPECIES", 73, 79], ["sheep", "SPECIES", 81, 86], ["goats", "SPECIES", 88, 93], ["horses", "SPECIES", 95, 101], ["MERS-CoV", "SPECIES", 238, 246], ["Seroepidemiological studies", "TEST", 0, 27], ["dromedary camels", "PROBLEM", 165, 181], ["Arabian Peninsula", "ANATOMY", 122, 139], ["Middle", "ANATOMY_MODIFIER", 148, 154]]], ["Serological evidence of MERS-CoV infection of dromedaries has been reported from the Arabian Peninsula including Saudi Arabia, United Arab Emirates (UAE), Oman, Qatar and Jordan with seroprevalence in adult animals generally being >90% (Hemida et al., 2013 Reusken et al., 2013a,b; Alexandersen et al., 2014; Nowotny and Kolodziejek, 2014b) .", [["infection", "DISEASE", 33, 42], ["dromedaries", "DISEASE", 46, 57], ["MERS-CoV", "ORGANISM", 24, 32], ["MERS-CoV", "SPECIES", 24, 32], ["MERS", "PROBLEM", 24, 28], ["CoV infection of dromedaries", "PROBLEM", 29, 57], ["MERS", "OBSERVATION", 24, 28], ["CoV", "OBSERVATION_MODIFIER", 29, 32], ["infection", "OBSERVATION", 33, 42]]], ["Serological evidence of MERS-CoV infection has also been demonstrated in dromedaries from Africa, including Egypt, Ethiopia, Nigeria, Tunisia, Sudan and the Canary Islands, with similarly high seroprevalence except Tunisia and Canary Islands, where adult seroprevalence was 54% and 14%, respectively Reusken et al., 2013a Reusken et al., , 2014 Corman et al., 2014b) .", [["MERS-CoV infection", "DISEASE", 24, 42], ["MERS-CoV", "ORGANISM", 24, 32], ["MERS-CoV", "SPECIES", 24, 32], ["MERS", "PROBLEM", 24, 28], ["CoV infection", "PROBLEM", 29, 42], ["MERS", "OBSERVATION", 24, 28], ["CoV infection", "OBSERVATION", 29, 42]]], ["In general, seroprevalence in adult animals was higher than in juveniles.", [["higher", "OBSERVATION_MODIFIER", 48, 54]]], ["Testing of archived dromedary sera has revealed that MERS-CoV has been circulating in camels in the Arabian Peninsula for at least three decades and is not a newly emerged virus from camels (Alagaili et al., 2014; Hemida et al., 2014; Meyer et al., 2014) .", [["sera", "ANATOMY", 30, 34], ["sera", "ORGANISM_SUBSTANCE", 30, 34], ["MERS-CoV", "ORGANISM", 53, 61], ["MERS-CoV", "SPECIES", 53, 61], ["Testing of archived dromedary sera", "TEST", 0, 34], ["Arabian Peninsula", "ANATOMY", 100, 117]]], ["The only region where dromedaries have been seronegative so far is Australia .", [["dromedaries", "CANCER", 22, 33], ["seronegative", "OBSERVATION", 44, 56]]], ["Data from dromedaries in Central Asia are lacking.", [["Central", "ANATOMY_MODIFIER", 25, 32]]], ["Bactrian camels in Mongolia appear seronegative (Chan et al., 2015) .Source of Zoonotic InfectionMERS-CoV viral RNA has been detected in nasal swabs of dromedaries in Qatar, Oman, Saudi Arabia, Egypt and UAE.", [["nasal swabs", "ANATOMY", 137, 148], ["Bactrian camels", "ORGANISM", 0, 15], ["Zoonotic InfectionMERS-CoV", "ORGANISM", 79, 105], ["Zoonotic InfectionMERS-CoV viral RNA", "RNA", 79, 115], ["Zoonotic InfectionMERS", "PROBLEM", 79, 101], ["CoV viral RNA", "PROBLEM", 102, 115], ["Mongolia", "OBSERVATION_MODIFIER", 19, 27], ["seronegative", "OBSERVATION", 35, 47], ["Zoonotic", "OBSERVATION_MODIFIER", 79, 87], ["viral RNA", "OBSERVATION", 106, 115], ["nasal", "ANATOMY", 137, 142]]], ["In camel abattoirs where animals from multiple sources are mixed together prior to slaughter, positive rates range from 1.9% to 34.6% (Alagaili et al., 2014; Chu et al., 2014; Haagmans and Osterhaus, 2014; Hemida et al., 2014; Nowotny and Kolodziejek, 2014a; Raj et al., 2014; Wernery et al., 2015) .", [["camel", "SPECIES", 3, 8]]], ["In a dromedary camel herd where virus transmission was tracked for over 1 month, the virus remained genetically unchanged, suggesting that MERS-CoV is well adapted to this species .", [["camel", "ORGANISM", 15, 20], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 139, 147], ["MERS", "PROTEIN", 139, 143], ["MERS-CoV", "SPECIES", 139, 147], ["virus transmission", "PROBLEM", 32, 50], ["the virus", "PROBLEM", 81, 90], ["CoV", "PROBLEM", 144, 147], ["unchanged", "OBSERVATION_MODIFIER", 112, 121]]], ["Full-genome sequences of dromedary camel MERS-CoV from Saudi Arabia and Qatar revealed that the camel virus is very simi-lar to viruses detected in humans, including in the virus spike protein, suggesting that the virus in dromedaries can potentially infect humans Raj et al., 2014) .", [["camel MERS-CoV", "ORGANISM", 35, 49], ["camel virus", "ORGANISM", 96, 107], ["humans", "ORGANISM", 148, 154], ["humans", "ORGANISM", 258, 264], ["virus spike protein", "PROTEIN", 173, 192], ["camel", "SPECIES", 35, 40], ["camel", "SPECIES", 96, 101], ["humans", "SPECIES", 148, 154], ["humans", "SPECIES", 258, 264], ["dromedary camel MERS-CoV", "SPECIES", 25, 49], ["camel virus", "SPECIES", 96, 107], ["humans", "SPECIES", 148, 154], ["the camel virus", "PROBLEM", 92, 107], ["viruses", "PROBLEM", 128, 135], ["the virus spike protein", "PROBLEM", 169, 192], ["the virus in dromedaries", "PROBLEM", 210, 234]]], ["Virus isolation of dromedary MERS-CoV has been reported in Vero cells Raj et al., 2014) .", [["cells", "ANATOMY", 64, 69], ["Virus", "ORGANISM", 0, 5], ["MERS-CoV", "ORGANISM", 29, 37], ["Vero cells", "CELL", 59, 69], ["Vero cells", "CELL_LINE", 59, 69], ["dromedary MERS-CoV", "SPECIES", 19, 37], ["Virus isolation", "TREATMENT", 0, 15], ["dromedary MERS", "PROBLEM", 19, 33]]], ["Middle East respiratory syndrome coronavirus from humans and dromedaries have comparable capacity to infect and replicate in ex vivo cultures of the human respiratory tract, providing phenotypic evidence for the competence of dromedary viruses to infect humans .", [["respiratory tract", "ANATOMY", 155, 172], ["Middle East respiratory syndrome coronavirus", "DISEASE", 0, 44], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 0, 44], ["humans", "ORGANISM", 50, 56], ["human", "ORGANISM", 149, 154], ["respiratory tract", "ORGANISM_SUBDIVISION", 155, 172], ["dromedary viruses", "ORGANISM", 226, 243], ["humans", "ORGANISM", 254, 260], ["humans", "SPECIES", 50, 56], ["human", "SPECIES", 149, 154], ["humans", "SPECIES", 254, 260], ["Middle East respiratory syndrome coronavirus", "SPECIES", 0, 44], ["humans", "SPECIES", 50, 56], ["human", "SPECIES", 149, 154], ["humans", "SPECIES", 254, 260], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 0, 44], ["dromedaries", "TREATMENT", 61, 72], ["comparable capacity", "PROBLEM", 78, 97], ["ex vivo cultures", "TEST", 125, 141], ["the human respiratory tract", "PROBLEM", 145, 172], ["dromedary viruses", "PROBLEM", 226, 243], ["respiratory syndrome", "OBSERVATION", 12, 32], ["respiratory tract", "ANATOMY", 155, 172]]], ["Temporal relationship between camel infection and development of human disease has been reported (Memish et al., 2014a) .", [["camel infection", "DISEASE", 30, 45], ["human disease", "DISEASE", 65, 78], ["camel", "ORGANISM", 30, 35], ["human", "ORGANISM", 65, 70], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["camel infection", "PROBLEM", 30, 45], ["human disease", "PROBLEM", 65, 78], ["infection", "OBSERVATION", 36, 45], ["human disease", "OBSERVATION", 65, 78]]], ["Virus genetic sequences from a person with MERS-CoV disease and from a camel with whom this person had recently been in close contact were very similar suggesting camel-to-human transmission does occur .Source of Zoonotic InfectionData from experimental camel infections suggest that MERS-CoV is a mild respiratory infection in camels (Adney et al., 2014) , although this study was carried out with a cell culture adapted human MERS-CoV isolate rather than with the camel isolate.", [["respiratory", "ANATOMY", 303, 314], ["cell", "ANATOMY", 401, 405], ["MERS-CoV disease", "DISEASE", 43, 59], ["camel infections", "DISEASE", 254, 270], ["respiratory infection", "DISEASE", 303, 324], ["Virus", "ORGANISM", 0, 5], ["MERS-CoV", "ORGANISM", 43, 51], ["camel", "ORGANISM", 163, 168], ["human", "ORGANISM", 172, 177], ["camel", "ORGANISM", 254, 259], ["MERS-CoV", "ORGANISM", 284, 292], ["cell", "CELL", 401, 405], ["human", "ORGANISM", 422, 427], ["MERS-CoV", "ORGANISM", 428, 436], ["camel", "ORGANISM", 466, 471], ["person", "SPECIES", 31, 37], ["person", "SPECIES", 92, 98], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 422, 427], ["camel", "SPECIES", 466, 471], ["MERS-CoV", "SPECIES", 43, 51], ["camel", "SPECIES", 71, 76], ["human", "SPECIES", 172, 177], ["camel", "SPECIES", 254, 259], ["MERS-CoV", "SPECIES", 284, 292], ["human MERS-CoV", "SPECIES", 422, 436], ["camel", "SPECIES", 466, 471], ["Virus genetic sequences", "PROBLEM", 0, 23], ["CoV disease", "PROBLEM", 48, 59], ["Zoonotic InfectionData", "PROBLEM", 213, 235], ["experimental camel infections", "PROBLEM", 241, 270], ["CoV", "PROBLEM", 289, 292], ["a mild respiratory infection in camels", "PROBLEM", 296, 334], ["this study", "TEST", 367, 377], ["a cell culture", "TEST", 399, 413], ["CoV isolate", "TREATMENT", 433, 444], ["the camel isolate", "TREATMENT", 462, 479], ["Zoonotic", "OBSERVATION_MODIFIER", 213, 221], ["mild", "OBSERVATION_MODIFIER", 298, 302], ["respiratory", "OBSERVATION_MODIFIER", 303, 314], ["infection", "OBSERVATION", 315, 324]]], ["However, camel calves found shedding MERS-CoV in natural field settings also do not have overt clinical symptoms Wernery, 2014) .", [["camel", "ORGANISM", 9, 14], ["calves", "ORGANISM", 15, 21], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 37, 45], ["calves", "SPECIES", 15, 21], ["camel", "SPECIES", 9, 14], ["MERS-CoV", "SPECIES", 37, 45], ["overt clinical symptoms", "PROBLEM", 89, 112]]], ["Furthermore, camels sampled at abattoirs later shown to be shedding MERS-CoV did not have overt clinical symptoms .Source of Zoonotic InfectionWith the ubiquitous nature of MERS-CoV infection of dromedaries the lack of antibodies in Bacterin camels in Mongolia, as assessed by seroprevalence studies (Chan et al., 2015) , it is likely that dromedaries are a natural host for this virus, but whether they are natural reservoir remains to be established.", [["infection", "DISEASE", 182, 191], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 68, 76], ["MERS-CoV", "ORGANISM", 173, 181], ["Bacterin camels", "ORGANISM", 233, 248], ["antibodies", "PROTEIN", 219, 229], ["MERS-CoV", "SPECIES", 68, 76], ["MERS-CoV", "SPECIES", 173, 181], ["overt clinical symptoms", "PROBLEM", 90, 113], ["Zoonotic", "PROBLEM", 125, 133], ["MERS", "PROBLEM", 173, 177], ["CoV infection of dromedaries", "PROBLEM", 178, 206], ["antibodies in Bacterin camels", "PROBLEM", 219, 248], ["seroprevalence studies", "TEST", 277, 299], ["this virus", "PROBLEM", 375, 385], ["natural reservoir", "TREATMENT", 408, 425], ["Zoonotic", "OBSERVATION_MODIFIER", 125, 133], ["CoV", "OBSERVATION_MODIFIER", 178, 181], ["infection", "OBSERVATION", 182, 191]]], ["As an analogy, swine have high seroprevalence to Japanese encephalitis and are an amplifier host for transmission to humans, but wild birds are the natural reservoir for this virus.", [["Japanese encephalitis", "DISEASE", 49, 70], ["swine", "ORGANISM", 15, 20], ["humans", "ORGANISM", 117, 123], ["wild birds", "ORGANISM", 129, 139], ["swine", "SPECIES", 15, 20], ["humans", "SPECIES", 117, 123], ["swine", "SPECIES", 15, 20], ["Japanese encephalitis", "SPECIES", 49, 70], ["humans", "SPECIES", 117, 123], ["Japanese encephalitis", "PROBLEM", 49, 70], ["an amplifier host", "TREATMENT", 79, 96], ["the natural reservoir", "TREATMENT", 144, 165], ["this virus", "PROBLEM", 170, 180]]], ["Similarly, dromedary camels are a natural host and source of human infection but they may or may not be the natural reservoir for the virus.Source of Zoonotic InfectionWhile travel-associated MERS-CoV infections have been recognized in Egypt and Tunisia, no zoonotic transmission has been reported in East or North Africa in spite of virus being ubiquitous in camels.", [["infection", "DISEASE", 67, 76], ["MERS-CoV infections", "DISEASE", 192, 211], ["zoonotic transmission", "DISEASE", 258, 279], ["dromedary camels", "ORGANISM", 11, 27], ["human", "ORGANISM", 61, 66], ["MERS-CoV", "ORGANISM", 192, 200], ["camels", "ORGANISM", 360, 366], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["MERS-CoV", "SPECIES", 192, 200], ["dromedary camels", "PROBLEM", 11, 27], ["human infection", "PROBLEM", 61, 76], ["the virus", "PROBLEM", 130, 139], ["CoV infections", "PROBLEM", 197, 211], ["zoonotic transmission", "PROBLEM", 258, 279], ["virus", "PROBLEM", 334, 339], ["infection", "OBSERVATION", 67, 76], ["Zoonotic", "OBSERVATION_MODIFIER", 150, 158], ["no", "UNCERTAINTY", 255, 257], ["virus", "OBSERVATION", 334, 339]]], ["One possible explanation may be the lack of awareness that MERS may occur outside the Arabian Peninsula without a history of travel.", [["MERS", "DISEASE", 59, 63], ["possible explanation may be", "UNCERTAINTY", 4, 31]]], ["A second possibility is that the MERS-CoV strains circulating in Africa are different in zoonotic potential.", [["MERS-CoV", "ORGANISM", 33, 41], ["MERS-CoV", "SPECIES", 33, 41], ["the MERS", "PROBLEM", 29, 37], ["CoV strains", "PROBLEM", 38, 49], ["different", "OBSERVATION_MODIFIER", 76, 85], ["zoonotic", "OBSERVATION_MODIFIER", 89, 97]]], ["There is limited information on the genetic diversity or biological phenotype of MERS-CoV from Africa.", [["MERS-CoV", "ORGANISM", 81, 89], ["MERS-CoV", "SPECIES", 81, 89], ["Africa", "PROBLEM", 95, 101]]], ["Middle East respiratory syndrome coronavirus from Egypt has been fully genetically sequenced and biologically characterized.", [["Middle East respiratory syndrome coronavirus", "DISEASE", 0, 44], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 0, 44], ["Middle East respiratory syndrome coronavirus", "SPECIES", 0, 44], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 0, 44], ["respiratory syndrome", "OBSERVATION", 12, 32]]], ["While this virus was genetically diverse from viruses causing zoonotic infections in the Arabian Peninsula, the receptor binding domain of the Egyptian viruses is conserved, indicating that these viruses would be able to infect the human respiratory tract .", [["respiratory tract", "ANATOMY", 238, 255], ["zoonotic infections", "DISEASE", 62, 81], ["Egyptian viruses", "ORGANISM", 143, 159], ["human", "ORGANISM", 232, 237], ["respiratory tract", "ORGANISM_SUBDIVISION", 238, 255], ["receptor binding domain", "PROTEIN", 112, 135], ["human", "SPECIES", 232, 237], ["human", "SPECIES", 232, 237], ["this virus", "PROBLEM", 6, 16], ["viruses", "PROBLEM", 46, 53], ["zoonotic infections in the Arabian Peninsula", "PROBLEM", 62, 106], ["the Egyptian viruses", "PROBLEM", 139, 159], ["these viruses", "PROBLEM", 190, 203], ["diverse", "OBSERVATION_MODIFIER", 33, 40], ["viruses", "OBSERVATION", 46, 53], ["zoonotic", "OBSERVATION_MODIFIER", 62, 70], ["infections", "OBSERVATION", 71, 81], ["Arabian", "ANATOMY_MODIFIER", 89, 96], ["Peninsula", "ANATOMY_MODIFIER", 97, 106], ["Egyptian viruses", "OBSERVATION", 143, 159], ["viruses", "OBSERVATION", 196, 203], ["respiratory tract", "ANATOMY", 238, 255]]], ["This contention is supported by the finding that tropism and virus replication competence of MERS-CoV from Egypt in ex vivo cultures of the human bronchial and lung is comparable to that of camel of human virus isolates in the Arabian Peninsula .Seroepidemiology of humans in contact with camelsIn a large countrywide seroepidemiological study of over 10 000 people older than 15 years carried out during 2012-2013 in KSA, an overall seroprevalence of 0.15% was detected while 5 of 140 (3.6%) of slaughterhouse workers were seropositive .", [["bronchial", "ANATOMY", 146, 155], ["lung", "ANATOMY", 160, 164], ["MERS-CoV", "ORGANISM", 93, 101], ["human", "ORGANISM", 140, 145], ["bronchial", "MULTI-TISSUE_STRUCTURE", 146, 155], ["lung", "ORGAN", 160, 164], ["camel", "ORGANISM", 190, 195], ["human", "ORGANISM", 199, 204], ["humans", "ORGANISM", 266, 272], ["camels", "ORGANISM", 289, 295], ["people", "ORGANISM", 359, 365], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 199, 204], ["humans", "SPECIES", 266, 272], ["people", "SPECIES", 359, 365], ["MERS-CoV", "SPECIES", 93, 101], ["human", "SPECIES", 140, 145], ["camel", "SPECIES", 190, 195], ["human virus", "SPECIES", 199, 210], ["humans", "SPECIES", 266, 272], ["MERS", "PROBLEM", 93, 97], ["CoV", "PROBLEM", 98, 101], ["Egypt in ex vivo cultures", "TEST", 107, 132], ["human virus isolates", "PROBLEM", 199, 219], ["human", "ANATOMY_MODIFIER", 140, 145], ["bronchial", "ANATOMY", 146, 155], ["lung", "ANATOMY", 160, 164], ["Arabian", "ANATOMY_MODIFIER", 227, 234], ["Peninsula", "ANATOMY_MODIFIER", 235, 244], ["large", "OBSERVATION_MODIFIER", 300, 305]]], ["The populationbased seroprevalence suggests that tens of thousands of MERS-CoV infections have gone unrecognized in Saudi Arabia (Figs 1 and 2 ).", [["MERS-CoV infections", "DISEASE", 70, 89], ["MERS-CoV", "ORGANISM", 70, 78], ["MERS-CoV", "SPECIES", 70, 78], ["The populationbased seroprevalence", "TREATMENT", 0, 34], ["CoV infections", "PROBLEM", 75, 89], ["tens", "OBSERVATION_MODIFIER", 49, 53]]], ["This suggests that some patients with clinically overt MERS who have no obvious exposure to animals may well have acquired infection from such asymptomatic or mild infections, making the identification of true zoonotic infections a challenge.", [["infection", "DISEASE", 123, 132], ["infections", "DISEASE", 164, 174], ["zoonotic infections", "DISEASE", 210, 229], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["clinically overt MERS", "PROBLEM", 38, 59], ["acquired infection", "PROBLEM", 114, 132], ["such asymptomatic or mild infections", "PROBLEM", 138, 174], ["true zoonotic infections", "PROBLEM", 205, 229], ["infection", "OBSERVATION", 123, 132], ["mild", "OBSERVATION_MODIFIER", 159, 163], ["infections", "OBSERVATION", 164, 174], ["zoonotic", "OBSERVATION_MODIFIER", 210, 218], ["infections", "OBSERVATION", 219, 229]]], ["In a study in Qatar, 2% of camel farm workers, 14% of camel barn workers at an international racing track and 2 of 5 camel slaughterhouse workers were seropositive while none of 204 people with no camel contact were seropositive.", [["camel", "ORGANISM", 27, 32], ["camel", "ORGANISM", 54, 59], ["camel", "ORGANISM", 117, 122], ["people", "ORGANISM", 182, 188], ["camel", "ORGANISM", 197, 202], ["camel", "SPECIES", 54, 59], ["camel", "SPECIES", 117, 122], ["people", "SPECIES", 182, 188], ["camel", "SPECIES", 27, 32], ["camel barn", "SPECIES", 54, 64], ["camel", "SPECIES", 117, 122], ["camel", "SPECIES", 197, 202]]], ["In this slaughterhouse, virus RNA-positive rate in camels was as high as 60% on some sampling occasions indicating massive levels of human exposure (Reusken et al., 2013b (Reusken et al., , 2015 .", [["camels", "ORGANISM", 51, 57], ["human", "ORGANISM", 133, 138], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["virus RNA", "TEST", 24, 33], ["positive rate in camels", "PROBLEM", 34, 57], ["massive levels of human exposure", "PROBLEM", 115, 147], ["virus RNA", "OBSERVATION", 24, 33], ["massive", "OBSERVATION_MODIFIER", 115, 122]]], ["In other studies of some human with exposure to camels, there has been no evidence of seropositive to MERS-CoV Memish et al., 2014b) .", [["human", "ORGANISM", 25, 30], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["no evidence of", "UNCERTAINTY", 71, 85]]], ["Humans regularly exposed to a dromedary herd known to be infected for at least a month had no clinical or serological evidence of infection (Hemida et al., 2015) .", [["infection", "DISEASE", 130, 139], ["Humans", "ORGANISM", 0, 6], ["infection", "PROBLEM", 130, 139], ["infected", "OBSERVATION", 57, 65], ["infection", "OBSERVATION", 130, 139]]], ["In summary, humans with regular and heavy exposure to infected camels do become seropositive but casual exposure to infected camels does not lead to efficient human infection.", [["infection", "DISEASE", 165, 174], ["humans", "ORGANISM", 12, 18], ["camels", "ORGANISM", 63, 69], ["camels", "ORGANISM", 125, 131], ["human", "ORGANISM", 159, 164], ["humans", "SPECIES", 12, 18], ["human", "SPECIES", 159, 164], ["humans", "SPECIES", 12, 18], ["human", "SPECIES", 159, 164], ["infected camels", "PROBLEM", 54, 69], ["seropositive", "PROBLEM", 80, 92], ["infected camels", "PROBLEM", 116, 131], ["efficient human infection", "PROBLEM", 149, 174], ["infection", "OBSERVATION", 165, 174]]], ["Even camel abattoir workers who are exposed daily to animals who are regularly shedding MERS-CoV are not uniformly infected and rarely get overt disease.", [["MERS-CoV", "ORGANISM", 88, 96], ["MERS-CoV", "SPECIES", 88, 96], ["overt disease", "PROBLEM", 139, 152]]], ["Hardly any of the patients diagnosed with MERS so far are workers in these high-risk occupations.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["In many respects, the epidemiology of human MERS shares similarities with that of avian influenza A H5N1 where the virus can be ubiquitous in poultry but human disease is stochastic and rare.", [["influenza A H5N1", "DISEASE", 88, 104], ["human", "ORGANISM", 38, 43], ["MERS", "CANCER", 44, 48], ["avian influenza A H5N1", "ORGANISM", 82, 104], ["human", "ORGANISM", 154, 159], ["human MERS", "PROTEIN", 38, 48], ["human", "SPECIES", 38, 43], ["avian influenza A H5N1", "SPECIES", 82, 104], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 38, 43], ["A H5N1", "SPECIES", 98, 104], ["human", "SPECIES", 154, 159], ["avian influenza A H5N1", "PROBLEM", 82, 104], ["the virus", "PROBLEM", 111, 120], ["human disease", "PROBLEM", 154, 167]]], ["This highlights the many questions that remain to be understood about the susceptibility and epidemiology of human MERS (Fig. 3) .", [["human", "ORGANISM", 109, 114], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114]]], ["It is possible that unusual routes of exposure or heterogeneity of host susceptibility to MERS-CoV are important determinants of human disease.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 90, 98], ["human", "ORGANISM", 129, 134], ["human", "SPECIES", 129, 134], ["MERS-CoV", "SPECIES", 90, 98], ["human", "SPECIES", 129, 134], ["host susceptibility", "PROBLEM", 67, 86], ["human disease", "PROBLEM", 129, 142], ["host susceptibility", "OBSERVATION", 67, 86]]], ["Nevertheless, given the key role that dromedaries play as a natural host in the ecology of MERS-CoV and the potentially important role that dromedaries may play in zoonotic MERS infection, it is important to review the ecology and animal husbandry of dromedary camels in the Arabian Peninsula.Distribution of Dromedary Camels in the Arabian PeninsulaThe global population of camels is estimated to be approximately 30 million, 95% of these being dromedary camels (reviewed in Gossner et al., 2016) .", [["zoonotic MERS infection", "DISEASE", 164, 187], ["MERS-CoV", "ORGANISM", 91, 99], ["camels", "ORGANISM", 375, 381], ["MERS-CoV", "SPECIES", 91, 99], ["zoonotic MERS infection", "PROBLEM", 164, 187], ["Dromedary Camels", "PROBLEM", 309, 325], ["Arabian Peninsula", "ANATOMY", 275, 292], ["Dromedary Camels", "OBSERVATION", 309, 325], ["Arabian Peninsula", "ANATOMY", 333, 350], ["global", "OBSERVATION_MODIFIER", 354, 360], ["population", "OBSERVATION_MODIFIER", 361, 371]]], ["Dromedary camels inhabit the Middle East region, North and East Africa and north-western parts of Asia (Farah, 2001) .", [["Dromedary camels", "PROBLEM", 0, 16], ["Middle", "ANATOMY_MODIFIER", 29, 35]]], ["Bactrian camels (Camelus bactrianus), on the other hand, are native to the Monthly human patients with MERS-CoV distributed by history of animal exposure (dark grey = not exposed, light grey = exposed) after exclusion of patients with hospital, community or healthcare personnel contact.", [["Bactrian camels", "ORGANISM", 0, 15], ["Camelus bactrianus", "ORGANISM", 17, 35], ["human", "ORGANISM", 83, 88], ["patients", "ORGANISM", 89, 97], ["MERS-CoV", "ORGANISM", 103, 111], ["patients", "ORGANISM", 221, 229], ["Camelus bactrianus", "SPECIES", 17, 35], ["human", "SPECIES", 83, 88], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 221, 229], ["Camelus bactrianus", "SPECIES", 17, 35], ["human", "SPECIES", 83, 88], ["MERS-CoV", "SPECIES", 103, 111], ["Bactrian camels (Camelus bactrianus", "TREATMENT", 0, 35], ["animal exposure", "PROBLEM", 138, 153], ["dark grey", "PROBLEM", 155, 164]]], ["Animal exposure (camels and other species) data were available from (September 2014 to January 2015), Saudi Ministry of Health.Distribution of Dromedary Camels in the Arabian Peninsulasteppes of Central Asia and more adapted to regions with cooler climates.", [["Dromedary Camels", "PROBLEM", 143, 159], ["Dromedary Camels", "OBSERVATION", 143, 159], ["Central", "ANATOMY_MODIFIER", 195, 202], ["cooler climates", "OBSERVATION", 241, 256]]], ["The dromedary and Bactrian camels share a common evolutionary origin with llamas, which originate from South America.", [["Bactrian camels", "ORGANISM", 18, 33], ["llamas", "ORGANISM", 74, 80], ["origin", "OBSERVATION_MODIFIER", 62, 68], ["llamas", "OBSERVATION", 74, 80], ["South", "OBSERVATION_MODIFIER", 103, 108]]], ["Of the total of 28.5 million dromedary camels worldwide, 77% are in Africa, the largest camel populations being found in Somalia (6.2 million), Sudan (4.8 million), Kenya (3 million) and Ethiopia (2.3 million).", [["camels", "ORGANISM", 39, 45], ["camel", "ORGANISM", 88, 93], ["total", "OBSERVATION_MODIFIER", 7, 12], ["largest", "OBSERVATION_MODIFIER", 80, 87]]], ["Only approximately 4% are in the Arabian Peninsula.", [["approximately", "OBSERVATION_MODIFIER", 5, 18], ["4%", "OBSERVATION_MODIFIER", 19, 21], ["Arabian", "ANATOMY_MODIFIER", 33, 40], ["Peninsula", "ANATOMY_MODIFIER", 41, 50]]], ["The highest density of camels by land area or by human population in the Arabian Peninsula is found in Qatar and UAE (Gossner et al., 2016) .", [["camels", "ORGANISM_SUBDIVISION", 23, 29], ["human", "ORGANISM", 49, 54], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["density", "OBSERVATION", 12, 19], ["Arabian Peninsula", "ANATOMY", 73, 90]]], ["Table 1 shows the numbers of camels in countries in the Arabian Peninsula.", [["Arabian Peninsula", "ANATOMY", 56, 73]]], ["There is a strong positive correlation (r = 0.95, P < 0.001) between the total number of camels and the reported MERS-CoV cases across the Arabian Peninsula.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 113, 121], ["MERS-CoV", "SPECIES", 113, 121], ["P", "TEST", 50, 51], ["Arabian Peninsula", "ANATOMY", 139, 156]]], ["Saudi Arabia and UAE which have the largest populations of camels are also the ones with the highest number of confirmed cases of MERS.", [["MERS", "DISEASE", 130, 134], ["camels", "ORGANISM", 59, 65], ["largest", "OBSERVATION_MODIFIER", 36, 43]]], ["Although there are differences between the camel census data proposed by FAO and the data from the different Ministries of Agriculture, especially in Saudi Arabia (Table 1) , the overall correlation of camel numbers and human MERS remains high.Distribution of Dromedary Camels in the Arabian PeninsulaIn the Middle East, dromedary camels are indispensable to the traditional nomadic lifestyle, providing milk, meat, wool, leather, medicinal purposes as well as for transport, trade and racing.", [["milk", "ANATOMY", 404, 408], ["meat", "ANATOMY", 410, 414], ["camel", "ORGANISM", 202, 207], ["human", "ORGANISM", 220, 225], ["milk", "ORGANISM_SUBSTANCE", 404, 408], ["meat", "ORGANISM_SUBDIVISION", 410, 414], ["human MERS", "PROTEIN", 220, 230], ["human", "SPECIES", 220, 225], ["camel", "SPECIES", 202, 207], ["human", "SPECIES", 220, 225], ["camel numbers", "TEST", 202, 215], ["human MERS", "TEST", 220, 230], ["Dromedary Camels", "PROBLEM", 260, 276], ["Dromedary Camels", "OBSERVATION", 260, 276], ["Middle", "ANATOMY_MODIFIER", 308, 314]]], ["More recently, camel husbandry in the Middle East has undergone significant changes.", [["camel", "ORGANISM", 15, 20], ["camel", "SPECIES", 15, 20], ["significant changes", "PROBLEM", 64, 83], ["Middle", "ANATOMY_MODIFIER", 38, 44], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["changes", "OBSERVATION", 76, 83]]], ["For example, the human population in Saudi Arabia has changed from being predominantly (80%) rural in the 1960s to currently being predominantly urbanized (87%) leading to associated changes in patterns of camel husbandry.", [["human", "ORGANISM", 17, 22], ["Saudi Arabia", "ORGANISM", 37, 49], ["camel", "ORGANISM_SUBDIVISION", 206, 211], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["camel", "SPECIES", 206, 211], ["human", "OBSERVATION_MODIFIER", 17, 22], ["population", "OBSERVATION_MODIFIER", 23, 33], ["predominantly", "OBSERVATION_MODIFIER", 73, 86], ["predominantly", "OBSERVATION_MODIFIER", 131, 144], ["urbanized", "OBSERVATION_MODIFIER", 145, 154]]], ["In Saudi Arabia, six types of camel farms and husbandry have been described; commercial farms, racing farms, use of camels for leisure for urban dwellers (weekend farms), traditional camel farms, camels for renting and camels for prestige (Abdallah and Faye, 2013) .", [["camel", "ORGANISM", 30, 35], ["camel", "SPECIES", 30, 35], ["camel", "SPECIES", 30, 35], ["camel", "SPECIES", 183, 188]]], ["More recently, a more detailed typology study of camel husbandry in Saudi Arabia identified the following categories: (i) those who are purely camel farmers, some grazing in the desert with more or less integration into the market systems and with variable levels of application of modern animal management methods; (ii) retired people keeping camels for recreational and other purposes; (iii) camel farmers with good integration to the market and with good health management systems; and (iv) multi-active owners practicing camel rearing as a hobby.", [["camel", "ORGANISM", 49, 54], ["people", "ORGANISM", 329, 335], ["camel", "ORGANISM", 525, 530], ["people", "SPECIES", 329, 335], ["camel", "SPECIES", 49, 54], ["modern animal management methods", "TREATMENT", 282, 314]]], ["Integration to the market for milk and meat drives owners to an increasingly peri-urban setting with improved supplemental diet and better health management (Faye, 2013) .", [["milk", "ANATOMY", 30, 34], ["meat", "ANATOMY", 39, 43], ["milk", "ORGANISM_SUBSTANCE", 30, 34], ["meat", "ORGANISM_SUBDIVISION", 39, 43]]], ["Some highly intensive farms are also emerging all over the Arabian Peninsula both for milk production (including milk processing with forms of pasteurized milk) and meat production (feed-lot farms of young male camels (hachi) often imported from the Horn of Africa).Camel Movement Across the Arabian Peninsula and its Implications for the Transmission of MERS-CoVCamel herds frequently move across the Arabian Peninsula for many reasons such as grazing, participation in camel Recently, camel shows called Mazayin al-Ibl (meaning 'best of camels') have been annually held in many Gulf countries.", [["milk", "ANATOMY", 86, 90], ["milk", "ANATOMY", 113, 117], ["milk", "ANATOMY", 155, 159], ["meat", "ANATOMY", 165, 169], ["milk", "ORGANISM_SUBSTANCE", 86, 90], ["milk", "ORGANISM_SUBDIVISION", 113, 117], ["milk", "ORGANISM_SUBDIVISION", 155, 159], ["meat", "ORGANISM_SUBDIVISION", 165, 169], ["camels", "ORGANISM_SUBDIVISION", 211, 217], ["milk", "SPECIES", 155, 159], ["CoVCamel herds", "TREATMENT", 360, 374], ["highly", "OBSERVATION_MODIFIER", 5, 11], ["intensive", "OBSERVATION_MODIFIER", 12, 21], ["farms", "OBSERVATION", 22, 27]]], ["One of the largest camel shows is usually held in November in Um al-Rughaiba in the Eastern Saudi Arabia, a region about 329 km from Riyadh and 160 km from Hafr al Batin city.", [["camel", "ORGANISM", 19, 24], ["largest", "OBSERVATION_MODIFIER", 11, 18]]], ["More than 100 camel herds representing over 160 000 camels from all over the Arabian Peninsula travel every year to participate in this international festival and over than 160 000 people attend this event every year (Harrigan, 2008) .", [["people", "ORGANISM", 181, 187], ["people", "SPECIES", 181, 187]]], ["Other festivals are held in other Gulf countries such as in UAE, the Abu Dhabi Authority of Culture and Heritage (ADACH) international festival in April (Harrigan, 2008).", [["Culture", "TEST", 92, 99]]], ["This regular movement of camels crossing borders of many countries may contribute to the transfer, amplification and evolution of MERS-CoV.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 130, 138], ["MERS-CoV", "SPECIES", 130, 138], ["movement", "OBSERVATION_MODIFIER", 13, 21]]], ["For example, previous studies documented high degree of relatedness between MERS-CoV sequences obtained from camel herds in Al-Ahsa and MERS-CoV from humans in UAE and Burydah .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 76, 84], ["MERS-CoV", "ORGANISM", 136, 144], ["humans", "ORGANISM", 150, 156], ["MERS-CoV sequences", "DNA", 76, 94], ["humans", "SPECIES", 150, 156], ["MERS-CoV", "SPECIES", 76, 84], ["camel", "SPECIES", 109, 114], ["MERS-CoV", "SPECIES", 136, 144], ["humans", "SPECIES", 150, 156], ["previous studies", "TEST", 13, 29], ["CoV sequences", "TEST", 81, 94], ["high degree", "OBSERVATION_MODIFIER", 41, 52]]], ["We speculated that the movement of camels between these locations may spread the virus during their journey.", [["the virus", "PROBLEM", 77, 86]]], ["Middle East respiratory syndrome coronavirus has been detected in camels crossing borders from Saudi Arabia into the UAE (Yusof et al., 2015) .", [["Middle East respiratory syndrome coronavirus", "DISEASE", 0, 44], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 0, 44], ["Middle East respiratory syndrome coronavirus", "SPECIES", 0, 44], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 0, 44], ["respiratory syndrome", "OBSERVATION", 12, 32], ["coronavirus", "OBSERVATION", 33, 44]]], ["These journeys are bidirectional as camel herds actively move between places indicated on the map.Camel Movement Across the Arabian Peninsula and its Implications for the Transmission of MERS-CoVOne of the main aspects regarding the camel economy worldwide is the importance of camel regional markets, mainly for providing animals to the meat market.", [["meat", "ANATOMY", 338, 342], ["camel", "ORGANISM", 36, 41], ["camel", "ORGANISM", 233, 238], ["meat", "ORGANISM_SUBDIVISION", 338, 342]]], ["In this context, important flows of live camels are reported from the Horn of Africa (exporting countries are Somalia, Ethiopia, Sudan, Kenya and Djibouti) to the North of the continent (Egypt, Libya) and to the countries of the Arabia Peninsula (Faye, 2013) .", [["camels", "ORGANISM", 41, 47], ["Arabia Peninsula", "ANATOMY", 229, 245]]], ["These movements could be important in understanding the epidemiology and viral evolution of MERS-CoV.", [["MERS-CoV", "ORGANISM", 92, 100], ["MERS-CoV", "SPECIES", 92, 100], ["CoV", "PROBLEM", 97, 100]]], ["For example in Saudi Arabia, 131 932 camels were officially imported in 2013 representing more than 70% of the animals slaughtered in the Kingdom (Mackay, 2014) .", [["camels", "ORGANISM", 37, 43]]], ["This camel trade through importation and exportation may affect the epidemiology of MERS-CoV and the introduction of viruses.", [["camel", "ORGANISM", 5, 10], ["MERS-CoV", "ORGANISM", 84, 92], ["MERS-CoV", "SPECIES", 84, 92], ["CoV", "PROBLEM", 89, 92], ["viruses", "PROBLEM", 117, 124]]], ["The mixing of camels of different origins and immune status to MERS-CoV potentially provides opportunities for amplification and dissemination of MERS-CoV, analogous to what has been described for bovine coronaviruses in cattle where a high percentage of cattle, some of whom are already seropositive, actively shed bovine coronavirus nasally and in faeces shortly after mixing of animals or like in feed-lot cattle infected with BCoV (Saif, 2010) .", [["faeces", "ANATOMY", 350, 356], ["bovine coronaviruses", "DISEASE", 197, 217], ["camels", "ORGANISM", 14, 20], ["MERS-CoV", "ORGANISM", 63, 71], ["MERS-CoV", "ORGANISM", 146, 154], ["bovine coronaviruses", "ORGANISM", 197, 217], ["cattle", "ORGANISM", 221, 227], ["cattle", "ORGANISM", 255, 261], ["bovine", "ORGANISM", 316, 322], ["coronavirus nasally", "ORGANISM", 323, 342], ["faeces", "ORGANISM_SUBDIVISION", 350, 356], ["cattle", "ORGANISM", 409, 415], ["bovine", "SPECIES", 197, 203], ["cattle", "SPECIES", 221, 227], ["cattle", "SPECIES", 255, 261], ["bovine", "SPECIES", 316, 322], ["coronavirus", "SPECIES", 323, 334], ["cattle", "SPECIES", 409, 415], ["MERS-CoV", "SPECIES", 63, 71], ["MERS-CoV", "SPECIES", 146, 154], ["bovine", "SPECIES", 197, 203], ["cattle", "SPECIES", 221, 227], ["cattle", "SPECIES", 255, 261], ["bovine coronavirus", "SPECIES", 316, 334], ["cattle", "SPECIES", 409, 415], ["BCoV", "SPECIES", 430, 434], ["bovine coronaviruses", "PROBLEM", 197, 217], ["seropositive", "PROBLEM", 288, 300]]], ["A similar situation also occurs with avian influenza in live poultry markets (Sims and Peiris, 2013) .", [["influenza", "DISEASE", 43, 52], ["A similar situation", "PROBLEM", 0, 19], ["avian influenza", "PROBLEM", 37, 52]]], ["There is anecdotal evidence in camels that prior MERS-CoV seropositivity does not preclude re-infection .Camel Movement Across the Arabian Peninsula and its Implications for the Transmission of MERS-CoVImportation of livestock, including camels, from the Horn of Africa led to the outbreak of Rift Valley Fever (RVF) that started in Saudi Arabia in 2000-2001 associated with zoonotic infections and death of several dozen humans.", [["Rift Valley Fever", "DISEASE", 293, 310], ["RVF", "DISEASE", 312, 315], ["zoonotic infections", "DISEASE", 375, 394], ["death", "DISEASE", 399, 404], ["camels", "ORGANISM", 31, 37], ["MERS-CoV", "ORGANISM", 49, 57], ["Rift Valley Fever", "ORGANISM", 293, 310], ["humans", "ORGANISM", 422, 428], ["humans", "SPECIES", 422, 428], ["MERS-CoV", "SPECIES", 49, 57], ["Rift Valley Fever (", "SPECIES", 293, 312], ["RVF", "SPECIES", 312, 315], ["humans", "SPECIES", 422, 428], ["anecdotal evidence in camels", "PROBLEM", 9, 37], ["prior MERS", "PROBLEM", 43, 53], ["CoV seropositivity", "PROBLEM", 54, 72], ["re-infection", "PROBLEM", 91, 103], ["Rift Valley Fever (RVF)", "PROBLEM", 293, 316], ["zoonotic infections", "PROBLEM", 375, 394], ["not preclude", "UNCERTAINTY", 78, 90], ["re-infection", "OBSERVATION", 91, 103], ["Movement", "OBSERVATION_MODIFIER", 111, 119], ["Arabian Peninsula", "ANATOMY", 131, 148], ["zoonotic", "OBSERVATION_MODIFIER", 375, 383], ["infections", "OBSERVATION", 384, 394]]], ["Indeed, some of these camels imported for meat production are fattened within the country of importation for several months before slaughter, providing ample opportunity for interaction with local camel herds and exchange of viruses.", [["meat", "ANATOMY", 42, 46], ["camels", "ORGANISM", 22, 28], ["meat", "ORGANISM_SUBDIVISION", 42, 46], ["local camel herds", "TREATMENT", 191, 208]]], ["Animals imported from some of these countries imported camels proved to be seropositive to MERS-CoV .", [["Animals", "ORGANISM", 0, 7], ["camels", "ORGANISM", 55, 61], ["MERS-CoV", "ORGANISM", 91, 99], ["MERS-CoV", "SPECIES", 91, 99]]], ["Middle East respiratory syndrome coronavirus isolated from dromedaries in the abattoirs in Egypt, animals potentially sourced from Sudan or Ethiopia, were phylogenetically diverse , providing a glimpse of the potential overall diversity of MERS-CoV.", [["Middle East respiratory syndrome coronavirus", "DISEASE", 0, 44], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 0, 44], ["MERS-CoV", "ORGANISM", 240, 248], ["MERS-CoV", "PROTEIN", 240, 248], ["Middle East respiratory syndrome coronavirus", "SPECIES", 0, 44], ["MERS-CoV", "SPECIES", 240, 248], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 0, 44], ["dromedaries", "PROBLEM", 59, 70], ["respiratory syndrome", "OBSERVATION", 12, 32]]], ["Camel movements across the Arabian Peninsula and from the Horn of Africa to the Arabian Peninsula could contribute to or predispose to the introduction and amplifica-tion of MERS-CoV and be associated with an increase of human MERS cases.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 174, 182], ["human", "ORGANISM", 221, 226], ["MERS", "GENE_OR_GENE_PRODUCT", 227, 231], ["human", "SPECIES", 221, 226], ["MERS-CoV", "SPECIES", 174, 182], ["human", "SPECIES", 221, 226], ["Arabian Peninsula", "ANATOMY", 27, 44]]], ["Further studies are required to confirm this hypothesis.", [["Further studies", "TEST", 0, 15], ["this hypothesis", "PROBLEM", 40, 55]]], ["A detailed, spatiotemporal understanding of camel movement patterns may explain the spread of disease and highlight high-risk areas.", [["camel", "ORGANISM", 44, 49], ["disease", "PROBLEM", 94, 101], ["spread", "OBSERVATION_MODIFIER", 84, 90], ["disease", "OBSERVATION", 94, 101], ["high", "OBSERVATION_MODIFIER", 116, 120]]], ["Furthermore, studies to genetically and phenotypically characterize the diversity of MERS-CoV in Africa are urgently needed.Camel Calving Seasons and the Epidemiology of MERS-CoV Infections in Humans and CamelsIn the past few years, seasonal increase of human MERS cases in the Middle East, especially in Saudi Arabia and UAE during winter and early spring has been noted.", [["MERS-CoV Infections", "DISEASE", 170, 189], ["MERS-CoV", "ORGANISM", 85, 93], ["MERS-CoV", "ORGANISM", 170, 178], ["human", "ORGANISM", 254, 259], ["human", "SPECIES", 254, 259], ["MERS-CoV", "SPECIES", 85, 93], ["human", "SPECIES", 254, 259], ["studies", "TEST", 13, 20], ["MERS", "PROBLEM", 85, 89], ["CoV", "PROBLEM", 90, 93], ["Infections", "OBSERVATION", 179, 189], ["Middle", "ANATOMY_MODIFIER", 278, 284]]], ["By providing new na\u20ac \u0131ve hosts into the population in a seasonal manner, this reproductive cycle of dromedary camels could be associated with seasonal patterns of human MERS.", [["camels", "ORGANISM", 110, 116], ["human", "ORGANISM", 163, 168], ["human MERS", "PROTEIN", 163, 173], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 163, 168], ["dromedary camels", "PROBLEM", 100, 116]]], ["The duration of passive maternal antibody and its role in suppressing infection by MERS-CoV remains to be fully defined.", [["infection", "DISEASE", 70, 79], ["MERS-CoV", "ORGANISM", 83, 91], ["passive maternal antibody", "PROTEIN", 16, 41], ["MERS-CoV", "SPECIES", 83, 91], ["passive maternal antibody", "TREATMENT", 16, 41], ["suppressing infection", "PROBLEM", 58, 79], ["infection", "OBSERVATION", 70, 79]]], ["In addition, camel movement across the Arabian Peninsula during these times may also contribute to increased human disease.", [["human", "ORGANISM", 109, 114], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["increased human disease", "PROBLEM", 99, 122], ["Arabian Peninsula", "ANATOMY", 39, 56], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["human disease", "OBSERVATION", 109, 122]]], ["Several viral infections are common during the early life of different animal species such as coronaviruses and rotaviruses.", [["viral infections", "DISEASE", 8, 24], ["coronaviruses", "ORGANISM", 94, 107], ["rotaviruses", "ORGANISM", 112, 123], ["Several viral infections", "PROBLEM", 0, 24], ["different animal species", "PROBLEM", 61, 85], ["coronaviruses", "PROBLEM", 94, 107], ["rotaviruses", "PROBLEM", 112, 123], ["viral", "OBSERVATION_MODIFIER", 8, 13], ["infections", "OBSERVATION", 14, 24]]], ["Coronaviruses other than MERS affect newborn animals such as calves, lambs, foals and piglets (Torres-Medina et al., 1985; Dea et al., 1995; Munoz et al., 1996; Davis et al., 2000) .", [["MERS", "GENE_OR_GENE_PRODUCT", 25, 29], ["calves", "ORGANISM", 61, 67], ["lambs", "ORGANISM", 69, 74], ["foals", "ORGANISM_SUBDIVISION", 76, 81], ["piglets", "ORGANISM", 86, 93], ["calves", "SPECIES", 61, 67], ["lambs", "SPECIES", 69, 74], ["foals", "SPECIES", 76, 81], ["piglets", "SPECIES", 86, 93], ["Coronaviruses", "PROBLEM", 0, 13]]], ["The camel calving season usually occurs during the period late October to late February.", [["camel", "ORGANISM", 4, 9]]], ["Our studies and those of others have noted the association of dromedary MERS-CoV infection in camels and the calving season Wernery, 2014) .", [["MERS-CoV infection", "DISEASE", 72, 90], ["MERS-CoV", "ORGANISM", 72, 80], ["dromedary MERS-CoV", "SPECIES", 62, 80], ["Our studies", "TEST", 0, 11], ["dromedary MERS", "PROBLEM", 62, 76], ["CoV infection", "PROBLEM", 77, 90]]], ["In a follow-up of one camel herd, we detected the initial MERS-CoV infection by RT-PCR as early as late November with the peak of infection at late December, predominantly in calves .", [["infection", "DISEASE", 67, 76], ["infection", "DISEASE", 130, 139], ["camel", "ORGANISM", 22, 27], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 58, 66], ["calves", "ORGANISM", 175, 181], ["calves", "SPECIES", 175, 181], ["camel", "SPECIES", 22, 27], ["MERS-CoV", "SPECIES", 58, 66], ["CoV infection", "PROBLEM", 63, 76], ["PCR", "TEST", 83, 86], ["infection", "PROBLEM", 130, 139], ["infection", "OBSERVATION", 67, 76], ["infection", "OBSERVATION", 130, 139], ["predominantly", "OBSERVATION_MODIFIER", 158, 171], ["calves", "ANATOMY", 175, 181]]], ["By the end of February, the infection has been cleared from the herd.", [["infection", "DISEASE", 28, 37], ["herd", "ORGANISM_SUBDIVISION", 64, 68], ["the infection", "PROBLEM", 24, 37], ["infection", "OBSERVATION", 28, 37]]], ["A study of a camel herd in Dubai found that virus shedding was more common in calves and that virus shedding in calves was of relatively short duration (Wernery et al., 2015) .", [["camel", "ORGANISM", 13, 18], ["calves", "ORGANISM", 78, 84], ["calves", "ORGANISM", 112, 118], ["calves", "SPECIES", 78, 84], ["calves", "SPECIES", 112, 118], ["calves", "SPECIES", 78, 84], ["A study", "TEST", 0, 7], ["virus shedding", "PROBLEM", 44, 58], ["virus", "OBSERVATION", 44, 49], ["more common", "OBSERVATION_MODIFIER", 63, 74], ["virus", "OBSERVATION", 94, 99]]], ["As calves appear to have the highest risk of MERS-CoV infection, it has been suggested that delayed weaning of calves may reduce the opportunity for humans being exposed to calves.Camel Calving Seasons and the Epidemiology of MERS-CoV Infections in Humans and CamelsThere was a large increase in human MERS occurring in Saudi Arabia during the period March-May 2014 (Majumder et al., 2014; Oboho et al., 2015) .", [["MERS-CoV infection", "DISEASE", 45, 63], ["MERS-CoV Infections", "DISEASE", 226, 245], ["calves", "ORGANISM", 3, 9], ["MERS-CoV", "ORGANISM", 45, 53], ["calves", "ORGANISM", 111, 117], ["humans", "ORGANISM", 149, 155], ["calves", "ORGANISM", 173, 179], ["MERS-CoV", "ORGANISM", 226, 234], ["human", "ORGANISM", 296, 301], ["calves", "SPECIES", 3, 9], ["calves", "SPECIES", 111, 117], ["humans", "SPECIES", 149, 155], ["calves", "SPECIES", 173, 179], ["human", "SPECIES", 296, 301], ["MERS-CoV", "SPECIES", 45, 53], ["calves", "SPECIES", 111, 117], ["humans", "SPECIES", 149, 155], ["human", "SPECIES", 296, 301], ["MERS", "PROBLEM", 45, 49], ["CoV infection", "PROBLEM", 50, 63], ["delayed weaning of calves", "TREATMENT", 92, 117], ["a large increase in human MERS", "PROBLEM", 276, 306], ["MERS", "OBSERVATION", 45, 49], ["CoV", "OBSERVATION_MODIFIER", 50, 53], ["infection", "OBSERVATION", 54, 63], ["Infections", "OBSERVATION", 235, 245], ["large", "OBSERVATION_MODIFIER", 278, 283], ["increase", "OBSERVATION_MODIFIER", 284, 292], ["human MERS", "OBSERVATION", 296, 306]]], ["However, it is possible that the calving patterns of camels may seed these large human outbreaks.Potential Roles of Raw Milk, Improperly Cooked Meat and Raw Internal Organs of Camels in the Transmission of MERS-CoVConsumption of raw non-pasteurized milk has been proposed as a source of infection in one human MERS case (Memish et al., 2014a,b) .", [["milk", "ANATOMY", 249, 253], ["infection", "DISEASE", 287, 296], ["camels", "ORGANISM", 53, 59], ["human", "ORGANISM", 81, 86], ["milk", "ORGANISM_SUBSTANCE", 249, 253], ["human", "ORGANISM", 304, 309], ["human", "SPECIES", 81, 86], ["milk", "SPECIES", 249, 253], ["human", "SPECIES", 304, 309], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 304, 309], ["these large human outbreaks", "PROBLEM", 69, 96], ["infection", "PROBLEM", 287, 296], ["large", "OBSERVATION_MODIFIER", 75, 80], ["human", "OBSERVATION_MODIFIER", 81, 86], ["outbreaks", "OBSERVATION", 87, 96], ["infection", "OBSERVATION", 287, 296]]], ["The transmission of Hepatitis A virus, rabies virus and foot-and-mouth disease virus to humans through consumption of contaminated cow milk has been reported (Centers for Disease Control and Prevention, USA 1999; Headrick et al., 1998) .", [["milk", "ANATOMY", 135, 139], ["Hepatitis A virus", "DISEASE", 20, 37], ["rabies virus", "DISEASE", 39, 51], ["foot-and-mouth disease", "DISEASE", 56, 78], ["Hepatitis A virus", "ORGANISM", 20, 37], ["rabies virus", "ORGANISM", 39, 51], ["foot-and-mouth disease virus", "ORGANISM", 56, 84], ["humans", "ORGANISM", 88, 94], ["cow", "ORGANISM", 131, 134], ["milk", "ORGANISM_SUBSTANCE", 135, 139], ["Hepatitis A virus", "SPECIES", 20, 37], ["rabies virus", "SPECIES", 39, 51], ["foot-and-mouth disease virus", "SPECIES", 56, 84], ["humans", "SPECIES", 88, 94], ["cow", "SPECIES", 131, 134], ["Hepatitis A virus", "SPECIES", 20, 37], ["rabies virus", "SPECIES", 39, 51], ["foot-and-mouth disease virus", "SPECIES", 56, 84], ["humans", "SPECIES", 88, 94], ["cow", "SPECIES", 131, 134], ["Hepatitis A virus", "PROBLEM", 20, 37], ["rabies virus and foot", "PROBLEM", 39, 60], ["mouth disease virus", "PROBLEM", 65, 84], ["contaminated cow milk", "TREATMENT", 118, 139], ["Disease Control", "TREATMENT", 171, 186], ["Hepatitis", "OBSERVATION", 20, 29], ["foot", "ANATOMY", 56, 60], ["mouth", "ANATOMY", 65, 70]]], ["Some other viruses such as tick-born encephalitis virus can be shed in milk during the active infection (Caini et al., 2012) .", [["milk", "ANATOMY", 71, 75], ["tick-born encephalitis", "DISEASE", 27, 49], ["infection", "DISEASE", 94, 103], ["tick-born encephalitis virus", "ORGANISM", 27, 55], ["milk", "ORGANISM_SUBSTANCE", 71, 75], ["tick-born encephalitis virus", "SPECIES", 27, 55], ["tick-born encephalitis virus", "SPECIES", 27, 55], ["Some other viruses", "PROBLEM", 0, 18], ["tick-born encephalitis virus", "PROBLEM", 27, 55], ["the active infection", "PROBLEM", 83, 103], ["viruses", "OBSERVATION", 11, 18], ["active", "OBSERVATION_MODIFIER", 87, 93], ["infection", "OBSERVATION", 94, 103]]], ["Despite the potential risk of infection associated with drinking raw camel milk (Mousa et al., 1988) , desert nomads in Arabian Peninsula often use raw camel milk as a whole meal for long periods which may last from days to months.", [["infection", "DISEASE", 30, 39], ["camel", "ORGANISM", 69, 74], ["milk", "ORGANISM_SUBSTANCE", 75, 79], ["camel", "ORGANISM", 152, 157], ["milk", "ORGANISM_SUBSTANCE", 158, 162], ["camel", "SPECIES", 69, 74], ["camel", "SPECIES", 152, 157], ["camel", "SPECIES", 69, 74], ["camel", "SPECIES", 152, 157], ["infection", "PROBLEM", 30, 39], ["infection", "OBSERVATION", 30, 39]]], ["They also drink raw milk because of the widespread belief that camel milk has prophylactic and therapeutic properties against many diseases and that boiling the milk destroys its nourishment and medicinal value (Shamsia, 2009 ).", [["milk", "ANATOMY", 69, 73], ["milk", "ANATOMY", 161, 165], ["milk", "ORGANISM_SUBSTANCE", 20, 24], ["camel", "ORGANISM", 63, 68], ["milk", "ORGANISM_SUBSTANCE", 69, 73], ["milk", "ORGANISM_SUBSTANCE", 161, 165], ["camel", "SPECIES", 63, 68], ["prophylactic", "TREATMENT", 78, 90], ["therapeutic properties", "TREATMENT", 95, 117], ["many diseases", "PROBLEM", 126, 139]]], ["Stability of MERS-CoV (strain Jordan-N3/2012) at different temperatures in camel, cow and goat milk was investigated.", [["milk", "ANATOMY", 95, 99], ["MERS-CoV", "ORGANISM", 13, 21], ["camel", "ORGANISM", 75, 80], ["cow", "ORGANISM", 82, 85], ["goat", "ORGANISM", 90, 94], ["milk", "ORGANISM_SUBSTANCE", 95, 99], ["camel", "SPECIES", 75, 80], ["cow", "SPECIES", 82, 85], ["goat", "SPECIES", 90, 94], ["MERS-CoV", "SPECIES", 13, 21], ["camel", "SPECIES", 75, 80], ["cow", "SPECIES", 82, 85], ["goat", "SPECIES", 90, 94], ["MERS", "OBSERVATION", 13, 17]]], ["The infectivity of MERS-CoV in camel milk was greatly reduced at 22\u00b0C compared to that stored at 4\u00b0C .", [["milk", "ANATOMY", 37, 41], ["MERS-CoV", "ORGANISM", 19, 27], ["camel", "ORGANISM", 31, 36], ["milk", "ORGANISM_SUBSTANCE", 37, 41], ["MERS", "PROTEIN", 19, 23], ["camel", "SPECIES", 31, 36], ["MERS-CoV", "SPECIES", 19, 27], ["camel", "SPECIES", 31, 36], ["CoV in camel milk", "TREATMENT", 24, 41], ["greatly reduced", "PROBLEM", 46, 61], ["infectivity", "OBSERVATION_MODIFIER", 4, 15]]], ["It should be noted, however, that this milk was sourced from seronegative camels for MERS-CoV.", [["milk", "ANATOMY", 39, 43], ["milk", "ORGANISM_SUBSTANCE", 39, 43], ["camels", "ORGANISM", 74, 80], ["MERS-CoV", "ORGANISM", 85, 93], ["MERS-CoV", "SPECIES", 85, 93]]], ["It is known that MERS-CoV-neutralizing antibody is secreted to camel milk and this may neutralize infectivity of any virus that may be present .", [["milk", "ANATOMY", 69, 73], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 17, 25], ["camel", "ORGANISM", 63, 68], ["milk", "ORGANISM_SUBSTANCE", 69, 73], ["MERS-CoV-neutralizing antibody", "PROTEIN", 17, 47], ["camel", "SPECIES", 63, 68], ["camel", "SPECIES", 63, 68], ["neutralizing antibody", "PROBLEM", 26, 47], ["any virus", "PROBLEM", 113, 122], ["virus", "OBSERVATION", 117, 122], ["may be", "UNCERTAINTY", 128, 134]]], ["This study also found evidence of MERS-CoV RNA in samples of camel milk collected by traditional milking practices where the flow of milk ('letting') is initiated by allowing a calf to suckle the dam.", [["samples", "ANATOMY", 50, 57], ["milk", "ANATOMY", 67, 71], ["milk", "ANATOMY", 133, 137], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 34, 42], ["camel", "ORGANISM", 61, 66], ["milk", "ORGANISM_SUBSTANCE", 67, 71], ["milk", "ORGANISM_SUBSTANCE", 133, 137], ["calf", "ORGANISM_SUBDIVISION", 177, 181], ["MERS-CoV RNA", "RNA", 34, 46], ["camel", "SPECIES", 61, 66], ["calf", "SPECIES", 177, 181], ["MERS-CoV", "SPECIES", 34, 42], ["camel", "SPECIES", 61, 66], ["This study", "TEST", 0, 10], ["MERS", "PROBLEM", 34, 38], ["CoV RNA", "PROBLEM", 39, 46], ["camel milk", "TREATMENT", 61, 71], ["traditional milking practices", "TREATMENT", 85, 114], ["the flow of milk ('letting')", "TREATMENT", 121, 149], ["MERS", "OBSERVATION", 34, 38], ["CoV RNA", "OBSERVATION", 39, 46], ["calf", "ANATOMY", 177, 181]]], ["Once the flow of milk is initiated, the herdsman will continue manual milking.", [["milk", "ANATOMY", 17, 21], ["milk", "ORGANISM_SUBSTANCE", 17, 21], ["manual milking", "TREATMENT", 63, 77]]], ["As calves are at high risk of acquiring MERS-CoV infection, it is possible that the milk may get contaminated with virus in the nasal secretions or saliva of calves.", [["milk", "ANATOMY", 84, 88], ["nasal secretions", "ANATOMY", 128, 144], ["MERS-CoV infection", "DISEASE", 40, 58], ["calves", "ORGANISM", 3, 9], ["MERS-CoV", "ORGANISM", 40, 48], ["milk", "ORGANISM_SUBSTANCE", 84, 88], ["nasal secretions", "ORGANISM_SUBSTANCE", 128, 144], ["saliva", "ORGANISM_SUBSTANCE", 148, 154], ["calves", "ORGANISM", 158, 164], ["calves", "SPECIES", 3, 9], ["calves", "SPECIES", 158, 164], ["MERS-CoV", "SPECIES", 40, 48], ["CoV infection", "PROBLEM", 45, 58], ["virus", "PROBLEM", 115, 120], ["the nasal secretions or saliva of calves", "PROBLEM", 124, 164], ["CoV", "OBSERVATION_MODIFIER", 45, 48], ["infection", "OBSERVATION", 49, 58], ["nasal", "ANATOMY", 128, 133], ["secretions", "OBSERVATION", 134, 144], ["calves", "ANATOMY", 158, 164]]], ["In the study which reported detection of MERS-CoV RNA in camel milk, it is unknown whether the virus entered milk through contamination from an infected calf or whether the udder was infected via systemic dissemination of the virus through the blood stream.", [["milk", "ANATOMY", 63, 67], ["milk", "ANATOMY", 109, 113], ["udder", "ANATOMY", 173, 178], ["blood stream", "ANATOMY", 244, 256], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 41, 49], ["camel", "ORGANISM", 57, 62], ["milk", "ORGANISM_SUBSTANCE", 63, 67], ["milk", "ORGANISM_SUBSTANCE", 109, 113], ["calf", "ORGANISM_SUBDIVISION", 153, 157], ["udder", "ORGANISM_SUBDIVISION", 173, 178], ["blood", "ORGANISM_SUBSTANCE", 244, 249], ["MERS-CoV RNA", "RNA", 41, 53], ["camel", "SPECIES", 57, 62], ["calf", "SPECIES", 153, 157], ["MERS-CoV", "SPECIES", 41, 49], ["camel", "SPECIES", 57, 62], ["the study", "TEST", 3, 12], ["the virus", "PROBLEM", 91, 100], ["an infected calf", "PROBLEM", 141, 157], ["the virus", "PROBLEM", 222, 231], ["the blood stream", "TEST", 240, 256], ["virus", "OBSERVATION", 95, 100], ["infected", "OBSERVATION", 144, 152], ["calf", "ANATOMY", 153, 157]]], ["Irrespective of the routes by which the virus can enter the camel milk, the facts support the possibility that raw camel milk could be a source of MERS-CoV infection.", [["milk", "ANATOMY", 66, 70], ["milk", "ANATOMY", 121, 125], ["infection", "DISEASE", 156, 165], ["camel", "ORGANISM", 60, 65], ["milk", "ORGANISM_SUBSTANCE", 66, 70], ["camel", "ORGANISM", 115, 120], ["milk", "ORGANISM_SUBSTANCE", 121, 125], ["MERS-CoV", "ORGANISM", 147, 155], ["camel", "SPECIES", 60, 65], ["camel", "SPECIES", 115, 120], ["camel", "SPECIES", 60, 65], ["camel", "SPECIES", 115, 120], ["MERS-CoV", "SPECIES", 147, 155], ["the virus", "PROBLEM", 36, 45], ["MERS", "PROBLEM", 147, 151], ["CoV infection", "PROBLEM", 152, 165], ["CoV", "OBSERVATION_MODIFIER", 152, 155], ["infection", "OBSERVATION", 156, 165]]], ["Heat treatment or pasteurization may reduce the risk of infection from milk to a minimum .", [["milk", "ANATOMY", 71, 75], ["infection", "DISEASE", 56, 65], ["milk", "ORGANISM_SUBSTANCE", 71, 75], ["Heat treatment", "TREATMENT", 0, 14], ["pasteurization", "TREATMENT", 18, 32], ["infection", "PROBLEM", 56, 65], ["infection", "OBSERVATION", 56, 65]]], ["Further epidemiological studies are needed to investigate the possibility of MERS-CoV shedding in camel milk.Potential Roles of Raw Milk, Improperly Cooked Meat and Raw Internal Organs of Camels in the Transmission of MERS-CoVCamel meat is the most popular type of meat in the Arabian Peninsula and is widely consumed.", [["milk", "ANATOMY", 104, 108], ["meat", "ANATOMY", 265, 269], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 77, 85], ["camel", "ORGANISM", 98, 103], ["milk", "ORGANISM_SUBSTANCE", 104, 108], ["meat", "ORGANISM_SUBDIVISION", 265, 269], ["camel", "SPECIES", 98, 103], ["meat", "SPECIES", 232, 236], ["MERS-CoV", "SPECIES", 77, 85], ["camel", "SPECIES", 98, 103], ["Further epidemiological studies", "TEST", 0, 31], ["MERS", "PROBLEM", 77, 81], ["Internal Organs", "ANATOMY", 169, 184], ["Arabian Peninsula", "ANATOMY", 277, 294], ["widely", "OBSERVATION_MODIFIER", 302, 308]]], ["In addition, some consume raw internal organs of camels, particularly liver and spleen and sometimes the lung.", [["internal organs", "ANATOMY", 30, 45], ["liver", "ANATOMY", 70, 75], ["spleen", "ANATOMY", 80, 86], ["lung", "ANATOMY", 105, 109], ["organs", "ORGAN", 39, 45], ["camels", "ORGANISM_SUBDIVISION", 49, 55], ["liver", "ORGAN", 70, 75], ["spleen", "ORGAN", 80, 86], ["lung", "ORGAN", 105, 109], ["internal", "ANATOMY_MODIFIER", 30, 38], ["organs", "ANATOMY", 39, 45], ["liver", "ANATOMY", 70, 75], ["spleen", "ANATOMY", 80, 86], ["lung", "ANATOMY", 105, 109]]], ["Both the Saudi Min-istry of health and the Centers for Disease Control and Prevention in the USA had reported that eating the raw camel liver caused human bubonic plague in Saudi Arabia in (Bin Saeed et al., 2005 .", [["liver", "ANATOMY", 136, 141], ["camel liver", "DISEASE", 130, 141], ["bubonic plague", "DISEASE", 155, 169], ["camel", "ORGANISM", 130, 135], ["liver", "ORGAN", 136, 141], ["human", "ORGANISM", 149, 154], ["human", "SPECIES", 149, 154], ["human", "SPECIES", 149, 154], ["Disease Control", "TREATMENT", 55, 70], ["liver", "ANATOMY", 136, 141]]], ["From the limited data from experimentally infected animals (Adney et al., 2014) , it appears unlikely that camel meat and internal organs will have MERS-CoV through virus dissemination through a virema.", [["meat", "ANATOMY", 113, 117], ["organs", "ANATOMY", 131, 137], ["camel", "ORGANISM", 107, 112], ["meat", "ORGANISM_SUBDIVISION", 113, 117], ["organs", "ORGAN", 131, 137], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 148, 156], ["camel", "SPECIES", 107, 112], ["camel", "SPECIES", 107, 112], ["MERS-CoV", "SPECIES", 148, 156], ["MERS", "PROBLEM", 148, 152], ["CoV through virus dissemination", "PROBLEM", 153, 184], ["appears unlikely", "UNCERTAINTY", 85, 101], ["internal organs", "ANATOMY", 122, 137]]], ["However, contamination of such organs with respiratory tissues may occur during the process of slaughter, potentially leading to infection via this route.", [["organs", "ANATOMY", 31, 37], ["respiratory tissues", "ANATOMY", 43, 62], ["infection", "DISEASE", 129, 138], ["organs", "ORGAN", 31, 37], ["respiratory tissues", "TISSUE", 43, 62], ["contamination of such organs", "PROBLEM", 9, 37], ["respiratory tissues", "PROBLEM", 43, 62], ["infection", "PROBLEM", 129, 138], ["this route", "TREATMENT", 143, 153], ["respiratory tissues", "OBSERVATION", 43, 62], ["infection", "OBSERVATION", 129, 138]]], ["Further studies are needed to investigate the potential roles of these types of meat in MERS-CoV transmission.Potential Roles of Raw Milk, Improperly Cooked Meat and Raw Internal Organs of Camels in the Transmission of MERS-CoVCamel urine is also used for medicinal purposes and is consumed alone or mixed with camel milk.", [["meat", "ANATOMY", 80, 84], ["milk", "ANATOMY", 317, 321], ["meat", "ORGANISM_SUBDIVISION", 80, 84], ["MERS-CoV", "ORGANISM", 88, 96], ["urine", "ORGANISM_SUBSTANCE", 233, 238], ["camel", "ORGANISM", 311, 316], ["milk", "ORGANISM_SUBSTANCE", 317, 321], ["camel", "SPECIES", 311, 316], ["MERS-CoV", "SPECIES", 88, 96], ["camel", "SPECIES", 311, 316], ["Further studies", "TEST", 0, 15], ["CoVCamel urine", "TEST", 224, 238], ["medicinal purposes", "TREATMENT", 256, 274]]], ["However, experimental infections of dromedaries with MERS-CoV did not reveal evidence of viremia or evidence of virus in the urine (Adney et al., 2014) .", [["urine", "ANATOMY", 125, 130], ["infections", "DISEASE", 22, 32], ["dromedaries", "DISEASE", 36, 47], ["viremia", "DISEASE", 89, 96], ["MERS-CoV", "ORGANISM", 53, 61], ["urine", "ORGANISM_SUBSTANCE", 125, 130], ["MERS-CoV", "SPECIES", 53, 61], ["experimental infections of dromedaries", "PROBLEM", 9, 47], ["viremia", "PROBLEM", 89, 96], ["virus in the urine", "PROBLEM", 112, 130], ["infections", "OBSERVATION", 22, 32], ["viremia", "OBSERVATION", 89, 96], ["virus", "OBSERVATION", 112, 117]]], ["Thus, camel urine is an unlikely source of virus transmission to humans.Potential Roles of Raw Milk, Improperly Cooked Meat and Raw Internal Organs of Camels in the Transmission of MERS-CoVMERS-CoV is relatively more stable in the environment than other enveloped viruses such as influenza (van .", [["urine", "ANATOMY", 12, 17], ["influenza", "DISEASE", 280, 289], ["camel", "ORGANISM", 6, 11], ["urine", "ORGANISM_SUBSTANCE", 12, 17], ["humans", "ORGANISM", 65, 71], ["MERS-CoVMERS-CoV", "ORGANISM", 181, 197], ["humans", "SPECIES", 65, 71], ["camel", "SPECIES", 6, 11], ["humans", "SPECIES", 65, 71], ["MERS-CoVMERS-CoV", "SPECIES", 181, 197], ["camel urine", "TEST", 6, 17], ["CoV", "PROBLEM", 194, 197], ["influenza", "PROBLEM", 280, 289], ["unlikely", "UNCERTAINTY", 24, 32], ["virus", "OBSERVATION", 43, 48], ["more stable", "OBSERVATION_MODIFIER", 212, 223], ["viruses", "OBSERVATION", 264, 271]]], ["Thus, fomites and dust may also be a route of transmission to humans.Role of Other Animal Sources of MERS-CoVBats are incriminated in the origins of many known mammalian coronaviruses (Lau et al., 2013) .", [["humans", "ORGANISM", 62, 68], ["MERS-CoVBats", "GENE_OR_GENE_PRODUCT", 101, 113], ["mammalian coronaviruses", "ORGANISM", 160, 183], ["MERS", "PROTEIN", 101, 105], ["humans", "SPECIES", 62, 68], ["humans", "SPECIES", 62, 68], ["mammalian coronaviruses", "OBSERVATION", 160, 183]]], ["SARS and the human coronavirus 229E appear to have arisen from precursor viruses in bats (Pfefferle et al., 2009; Drexler et al., 2014) .", [["SARS", "DISEASE", 0, 4], ["human", "ORGANISM", 13, 18], ["coronavirus 229E", "ORGANISM", 19, 35], ["human", "SPECIES", 13, 18], ["coronavirus", "SPECIES", 19, 30], ["human coronavirus", "SPECIES", 13, 30], ["SARS", "PROBLEM", 0, 4], ["the human coronavirus", "PROBLEM", 9, 30], ["viruses", "OBSERVATION", 73, 80]]], ["There was one report that a short fragment (around 200 nucleotides) of viral RNA identical to that of MERS-CoV was detected in a Taphozous perforates bat in Saudi Arabia .", [["nucleotides", "CHEMICAL", 55, 66], ["MERS-CoV", "ORGANISM", 102, 110], ["viral RNA", "RNA", 71, 80], ["MERS-CoV", "DNA", 102, 110], ["MERS-CoV", "SPECIES", 102, 110], ["a short fragment", "PROBLEM", 26, 42], ["viral RNA", "PROBLEM", 71, 80], ["CoV", "PROBLEM", 107, 110], ["short fragment", "OBSERVATION_MODIFIER", 28, 42], ["viral RNA", "OBSERVATION", 71, 80]]], ["However, this finding remains unconfirmed and this report needs to be regarded with caution.Role of Other Animal Sources of MERS-CoVCoronavirus closely related to but not identical with MERS-CoV has been detected in Neoromicia capensis bats, but the spike protein in particular is very divergent, and this virus is unlikely to be the precursor of MERS-CoV (Corman et al., 2014a,b) .", [["MERS-CoVCoronavirus", "GENE_OR_GENE_PRODUCT", 124, 143], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 186, 194], ["Neoromicia capensis bats", "ORGANISM", 216, 240], ["MERS-CoV", "ORGANISM", 347, 355], ["MERS", "PROTEIN", 124, 128], ["MERS-CoV", "DNA", 186, 194], ["spike protein", "PROTEIN", 250, 263], ["Neoromicia capensis", "SPECIES", 216, 235], ["MERS-CoV", "SPECIES", 186, 194], ["Neoromicia capensis bats", "SPECIES", 216, 240], ["MERS-CoV", "SPECIES", 347, 355], ["MERS", "PROBLEM", 124, 128], ["CoVCoronavirus", "PROBLEM", 129, 143], ["CoV", "PROBLEM", 191, 194], ["the spike protein", "TEST", 246, 263], ["this virus", "PROBLEM", 301, 311], ["capensis bats", "OBSERVATION", 227, 240]]], ["However, these findings highlight the possibility that the MERS-CoV precursor may indeed be found in bats.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 59, 67], ["the MERS-CoV precursor", "PROBLEM", 55, 77]]], ["In a recent study, we documented introduction of MERS-CoV into a camel farm which was in a closed compound without much intermingling with other animals.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 49, 57], ["camel", "ORGANISM", 65, 70], ["camel", "SPECIES", 65, 70], ["MERS-CoV", "SPECIES", 49, 57], ["camel", "SPECIES", 65, 70], ["a recent study", "TEST", 3, 17]]], ["The source of introduction of this virus was unclear .", [["this virus", "PROBLEM", 30, 40]]], ["Whether another animal host (bats, or other) was responsible for the introduction of the virus remains to be ascertained.", [["bats", "ORGANISM", 29, 33], ["the virus", "PROBLEM", 85, 94]]], ["Mechanical transmission by feed and manure removal trucks is another possibility.Concluding RemarksDromedary camels are likely to be a natural host of MERS, and transmission between camels is clearly documented.", [["camels", "ORGANISM", 182, 188], ["Mechanical transmission", "TREATMENT", 0, 23], ["manure removal trucks", "TREATMENT", 36, 57], ["another possibility", "UNCERTAINTY", 61, 80], ["likely to be", "UNCERTAINTY", 120, 132]]], ["However, it is still unclear whether camels are the natural reservoir of the virus and the only source of human infection.", [["infection", "DISEASE", 112, 121], ["camels", "ORGANISM", 37, 43], ["human", "ORGANISM", 106, 111], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 106, 111], ["the virus", "PROBLEM", 73, 82], ["human infection", "PROBLEM", 106, 121], ["infection", "OBSERVATION", 112, 121]]], ["Clearly, transmission from camels to humans does take place, and camel exposure is a risk factor for human infection but such transmission is not efficient and infection is not directly proportional to exposure.", [["infection", "DISEASE", 107, 116], ["infection", "DISEASE", 160, 169], ["camels", "ORGANISM", 27, 33], ["humans", "ORGANISM", 37, 43], ["camel", "ORGANISM", 65, 70], ["human", "ORGANISM", 101, 106], ["humans", "SPECIES", 37, 43], ["human", "SPECIES", 101, 106], ["humans", "SPECIES", 37, 43], ["human", "SPECIES", 101, 106], ["a risk factor", "PROBLEM", 83, 96], ["human infection", "PROBLEM", 101, 116], ["infection", "PROBLEM", 160, 169], ["infection", "OBSERVATION", 107, 116], ["infection", "OBSERVATION", 160, 169]]], ["Heterogeneity of human susceptibility to MERS-CoV infection may be one possible explanation, as also proposed for avian influenza H5N1.", [["infection", "DISEASE", 50, 59], ["avian influenza H5N1", "DISEASE", 114, 134], ["human", "ORGANISM", 17, 22], ["MERS-CoV", "ORGANISM", 41, 49], ["avian influenza H5N1", "ORGANISM", 114, 134], ["human", "SPECIES", 17, 22], ["avian influenza H5N1", "SPECIES", 114, 134], ["human", "SPECIES", 17, 22], ["MERS-CoV", "SPECIES", 41, 49], ["human susceptibility to MERS", "PROBLEM", 17, 45], ["CoV infection", "PROBLEM", 46, 59], ["avian influenza H5N1", "PROBLEM", 114, 134], ["human susceptibility", "OBSERVATION", 17, 37], ["CoV", "OBSERVATION_MODIFIER", 46, 49], ["infection", "OBSERVATION", 50, 59]]], ["Many thousands of people in the Arabian Peninsula appear to have evidence of unrecognized past MERS-CoV infection.", [["MERS-CoV infection", "DISEASE", 95, 113], ["people", "ORGANISM", 18, 24], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 95, 103], ["people", "SPECIES", 18, 24], ["MERS-CoV", "SPECIES", 95, 103], ["CoV infection", "PROBLEM", 100, 113], ["CoV", "OBSERVATION_MODIFIER", 100, 103], ["infection", "OBSERVATION", 104, 113]]], ["On the other hand, many patients with clinically diagnosed MERS do not have an obvious history of direct exposure to camels or their products.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32]]], ["This may be because such individuals are being infected from other humans who are infected with MERS unrecognized (asymptomatically or with mild illness).", [["MERS", "DISEASE", 96, 100], ["individuals", "ORGANISM", 25, 36], ["humans", "ORGANISM", 67, 73], ["humans", "SPECIES", 67, 73], ["humans", "SPECIES", 67, 73], ["mild illness", "PROBLEM", 140, 152], ["infected", "OBSERVATION", 82, 90]]], ["Thus, the true primary zoonotic infections may be difficult to identify.", [["zoonotic infections", "DISEASE", 23, 42], ["the true primary zoonotic infections", "PROBLEM", 6, 42], ["primary", "OBSERVATION_MODIFIER", 15, 22], ["zoonotic", "OBSERVATION_MODIFIER", 23, 31], ["infections", "OBSERVATION", 32, 42]]], ["Alternate possibilities of other intermediate or reservoir hosts in the transmission of infection to humans also remains possible, and Fig. 3 illustrates the many 'known unknowns' that remain to be elucidated.", [["infection", "DISEASE", 88, 97], ["humans", "ORGANISM", 101, 107], ["humans", "SPECIES", 101, 107], ["humans", "SPECIES", 101, 107], ["reservoir hosts", "TREATMENT", 49, 64], ["infection", "PROBLEM", 88, 97], ["infection", "OBSERVATION", 88, 97]]]], "3735055ce30bb1cb8aa6ef4fb1731dcc8219df35": [["INTRODUCTIONPorcine epidemic diarrhea virus (PEDV) emerged into Canada in January 2014, soon after the initial detection in the United States (1) .", [["diarrhea", "DISEASE", 29, 37], ["INTRODUCTIONPorcine epidemic diarrhea virus", "ORGANISM", 0, 43], ["epidemic diarrhea virus", "SPECIES", 20, 43], ["INTRODUCTIONPorcine epidemic diarrhea virus", "SPECIES", 0, 43], ["PEDV", "SPECIES", 45, 49], ["INTRODUCTIONPorcine epidemic diarrhea virus", "PROBLEM", 0, 43]]], ["The virus is highly contagious and is associated with mortality ranging between 80 and 100% in suckling pigs (2) (3) (4) .", [["pigs", "SPECIES", 104, 108], ["The virus", "PROBLEM", 0, 9], ["mortality", "TEST", 54, 63], ["virus", "OBSERVATION", 4, 9], ["highly", "OBSERVATION_MODIFIER", 13, 19], ["contagious", "OBSERVATION", 20, 30]]], ["Incursion of porcine epidemic diarrhea (PED) has a large impact on animal health and profitability of individual farms; which can result in high loses for the entire swine-producing sector when a large outbreak occurs (4, 5) .", [["porcine epidemic diarrhea", "DISEASE", 13, 38], ["PED", "DISEASE", 40, 43], ["porcine", "ORGANISM", 13, 20], ["porcine", "SPECIES", 13, 20], ["swine", "SPECIES", 166, 171], ["porcine epidemic diarrhea", "PROBLEM", 13, 38], ["porcine", "OBSERVATION_MODIFIER", 13, 20], ["epidemic", "OBSERVATION_MODIFIER", 21, 29], ["large", "OBSERVATION_MODIFIER", 51, 56], ["impact", "OBSERVATION_MODIFIER", 57, 63], ["large", "OBSERVATION_MODIFIER", 196, 201], ["outbreak", "OBSERVATION", 202, 210]]], ["Despite this, PED is not considered a reportable disease at the federal level in Canada, similarly to other jurisdictions.", [["a reportable disease", "PROBLEM", 36, 56], ["not considered", "UNCERTAINTY", 21, 35], ["disease", "OBSERVATION", 49, 56]]], ["Both, legislative framework in the province of Ontario and concerns about the impact of this disease in the swine-producing sector supported establishment of several mechanisms of PEDV surveillance with different surveillance coverage (7) .", [["swine", "SPECIES", 108, 113], ["PEDV", "SPECIES", 180, 184], ["this disease", "PROBLEM", 88, 100], ["PEDV surveillance", "TEST", 180, 197], ["different surveillance coverage", "TREATMENT", 203, 234], ["disease", "OBSERVATION", 93, 100]]], ["The DCP is based on swine producer volunteer participation and was implemented to monitor disease trends over time.", [["swine", "ORGANISM", 20, 25], ["swine", "SPECIES", 20, 25], ["swine", "SPECIES", 20, 25]]], ["The uniqueness of the DCP database is that it tracks the dates of the initial PEDV incursion, as well as the dates the herds declare freedom from infection from PEDV on the basis of established criteria.", [["infection", "DISEASE", 146, 155], ["the DCP database", "TEST", 18, 34], ["infection", "PROBLEM", 146, 155], ["PEDV", "PROBLEM", 161, 165], ["PEDV", "OBSERVATION", 78, 82], ["infection", "OBSERVATION", 146, 155]]], ["Briefly, the estimated prevalence and 95% confidence intervals (CI) of the virus at the end of 2014, 2015, and 2016 were 4.36 (3.07, 5.99), 2.25 (1.49, 3.26), and 1.35 (0.79, 2.16), respectively (7) .", [["CI", "TEST", 64, 66], ["the virus", "PROBLEM", 71, 80]]], ["A decrease in prevalence, despite occurrence of new cases, has been achieved through implementation of targeted elimination programs at the individual herd level.", [["A decrease in prevalence", "PROBLEM", 0, 24], ["targeted elimination programs", "TREATMENT", 103, 132], ["decrease", "OBSERVATION_MODIFIER", 2, 10], ["new", "OBSERVATION_MODIFIER", 48, 51]]], ["Soon after PEDV emerged, veterinary practitioners developed approaches that allowed planned elimination of PEDV from swine herds.", [["PEDV", "CHEMICAL", 11, 15], ["PEDV", "CHEMICAL", 107, 111], ["PEDV", "ORGANISM", 107, 111], ["swine", "SPECIES", 117, 122], ["PEDV", "SPECIES", 11, 15], ["PEDV", "SPECIES", 107, 111], ["swine", "SPECIES", 117, 122], ["PEDV", "PROBLEM", 11, 15], ["PEDV", "PROBLEM", 107, 111]]], ["However, the time to elimination of the virus was premises-dependent and depended on the elimination strategy employed.", [["the virus", "PROBLEM", 36, 45], ["virus", "OBSERVATION", 40, 45]]], ["For planning purposes, the time to PEDV elimination for specific herds could be projected on the basis of the herd type, its demographics, and infection control practices that are planned to be implemented.", [["PEDV", "CHEMICAL", 35, 39], ["infection", "DISEASE", 143, 152], ["PEDV elimination", "TREATMENT", 35, 51], ["infection control practices", "TREATMENT", 143, 170]]], ["However, under field conditions, additional factors such as the demographics of the entire production system, the number of animal movements, availability of resources and the herd owners' overall willingness to eliminate a production-limiting disease could affect time to PEDV elimination for specific herds.", [["PEDV", "CHEMICAL", 273, 277], ["PEDV", "SPECIES", 273, 277], ["a production-limiting disease", "PROBLEM", 222, 251]]], ["Since the dates of disease incursion and elimination in individual herds are available, the DCP database could be an appropriate resource for evaluating the time to PEDV elimination under field conditions in the entire population (source population) participating in the DCP program.", [["PEDV", "CHEMICAL", 165, 169], ["PEDV", "SPECIES", 165, 169], ["disease incursion", "PROBLEM", 19, 36], ["the DCP database", "TEST", 88, 104], ["disease", "OBSERVATION", 19, 26]]], ["Therefore, the objective of this study was to determine time to PEDV elimination in Ontario swine herds infected between 2014 and 2017, on the basis of records from the DCP database; and to identify factors associated with the likelihood of elimination.Data SourceThe source population for this study was the OSHAB PED Ontario Area Regional Control and Elimination program (ARC&E) database.", [["PEDV", "CHEMICAL", 64, 68], ["swine", "SPECIES", 92, 97], ["PEDV", "SPECIES", 64, 68], ["swine", "SPECIES", 92, 97], ["this study", "TEST", 28, 38], ["the DCP database", "TEST", 165, 181], ["this study", "TEST", 290, 300]]], ["This DCP and database was initially created for controlling porcine reproductive and respiratory syndrome virus (PRRSV) (8) and then was adapted to include PEDV when it emerged into Canada in 2014.", [["porcine reproductive and respiratory syndrome", "DISEASE", 60, 105], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 60, 111], ["PRRSV", "ORGANISM", 113, 118], ["PRRSV", "SPECIES", 113, 118], ["PEDV", "SPECIES", 156, 160], ["controlling porcine reproductive", "TREATMENT", 48, 80], ["respiratory syndrome virus", "PROBLEM", 85, 111], ["PEDV", "PROBLEM", 156, 160], ["respiratory syndrome", "OBSERVATION", 85, 105]]], ["The DCP is a voluntary program that collects diagnostic data including PEDV herd status of Ontario swine herds as outbreaks are reported, or as herds are classified as having eliminated PEDV from premises.", [["swine", "SPECIES", 99, 104], ["swine", "SPECIES", 99, 104], ["PEDV", "SPECIES", 186, 190], ["diagnostic data", "TEST", 45, 60], ["PEDV", "PROBLEM", 186, 190]]], ["The data collected from the participating herds include the premises identification number, herd type, herd size, date of enrollment into the database, PEDV status of premises on date of enrollment and the date(s) in which the premises changed their PEDV status to \"free-from-PEDV.\"", [["PEDV", "PROBLEM", 276, 280], ["size", "OBSERVATION_MODIFIER", 108, 112]]], ["For a premises to be included in the current study the following inclusion criteria were fulfilled: (1) the premises participated in the DCP from January 2014 to October 2017, (2) the premises was located in Ontario, and (3) the PEDV infection status of the premises was available.Premises PEDV Infection StatusThe DCP monitors infection status of the volunteer premises over time.", [["infection", "DISEASE", 234, 243], ["infection", "DISEASE", 328, 337], ["the current study", "TEST", 33, 50], ["the PEDV infection", "PROBLEM", 225, 243], ["PEDV Infection", "PROBLEM", 290, 304], ["The DCP monitors infection", "PROBLEM", 311, 337], ["infection", "OBSERVATION", 234, 243], ["Infection", "OBSERVATION", 295, 304]]], ["Thus, the database contains herd (premises) infection status information i.e., whether a herd has eliminated the virus, whether any subsequent infection has occurred or any other changes in infection status, and the dates when the changes in infection status occurred.", [["infection", "DISEASE", 44, 53], ["infection", "DISEASE", 143, 152], ["infection", "DISEASE", 190, 199], ["infection", "DISEASE", 242, 251], ["infection", "PROBLEM", 44, 53], ["the virus", "PROBLEM", 109, 118], ["any subsequent infection", "PROBLEM", 128, 152], ["any other changes in infection status", "PROBLEM", 169, 206], ["the changes in infection status", "PROBLEM", 227, 258], ["infection", "OBSERVATION", 143, 152], ["infection", "OBSERVATION", 190, 199], ["infection", "OBSERVATION", 242, 251]]], ["In the database, there are 4 types of premises infection status classifications: (1) confirmed positive, (2) presumed positive, (3) presumed negative and (4) confirmed negative.", [["infection", "DISEASE", 47, 56], ["premises infection", "PROBLEM", 38, 56], ["4 types", "OBSERVATION_MODIFIER", 27, 34], ["infection", "OBSERVATION", 47, 56], ["negative", "OBSERVATION", 168, 176]]], ["Premises that were classified as PED confirmed positive were premises that had confirmed positive real-time reverse, transcriptase polymerase chain reaction (RT-PCR) test for PEDV at the Animal Health Laboratory (AHL) at the University of Guelph.", [["PEDV", "SPECIES", 175, 179], ["transcriptase polymerase chain reaction", "PROBLEM", 117, 156], ["RT-PCR) test", "TEST", 158, 170], ["PEDV", "PROBLEM", 175, 179]]], ["A presumed positive status was declared based on pig flow and movement as identified by the premises' veterinarian and did not require any diagnostic testing.", [["pig", "ORGANISM", 49, 52], ["pig", "SPECIES", 49, 52], ["any diagnostic testing", "TEST", 135, 157], ["presumed", "UNCERTAINTY", 2, 10], ["positive", "OBSERVATION_MODIFIER", 11, 19]]], ["Thus, premises that housed animals that were sourced from a PED-positive premises were classified as presumed positive due to movement of presumed infected pigs.", [["animals", "ORGANISM", 27, 34], ["pigs", "ORGANISM", 156, 160], ["pigs", "SPECIES", 156, 160], ["positive", "PROBLEM", 110, 118], ["infected pigs", "PROBLEM", 147, 160], ["infected pigs", "OBSERVATION", 147, 160]]], ["Presumed negative premises were previously positive premises (i.e., either previously confirmed or presumed positive), where the producer implemented measures to eliminate PEDV from the herd and confirmed the virus to be eliminated through animal or environmental testing.", [["PEDV", "CHEMICAL", 172, 176], ["PEDV", "ORGANISM", 172, 176], ["PEDV", "SPECIES", 172, 176], ["PEDV", "PROBLEM", 172, 176], ["the virus", "PROBLEM", 205, 214], ["environmental testing", "TEST", 250, 271], ["negative", "OBSERVATION", 9, 17]]], ["Sampling methods for classifying premises as presumed negative were based on herd type and pig flow, and considered different types of samples (i.e., individual swabs, Swiffer samples, oral fluids, etc).", [["samples", "ANATOMY", 135, 142], ["swabs", "ANATOMY", 161, 166], ["samples", "ANATOMY", 176, 183], ["oral fluids", "ANATOMY", 185, 196], ["pig", "ORGANISM", 91, 94], ["oral", "ORGANISM_SUBDIVISION", 185, 189], ["pig", "SPECIES", 91, 94], ["Sampling methods", "TEST", 0, 16], ["pig flow", "TEST", 91, 99], ["samples", "TEST", 135, 142], ["individual swabs", "TEST", 150, 166], ["oral fluids", "TREATMENT", 185, 196]]], ["The basic considerations for all sampling types were: 98% individual test sensitivity, 100% individual test specificity, maximum design prevalence of 10%, and 95% confidence in detection of disease at the design prevalence level (9) .", [["all sampling types", "TEST", 29, 47], ["individual test sensitivity", "TEST", 58, 85], ["maximum design prevalence", "TEST", 121, 146], ["disease", "PROBLEM", 190, 197], ["disease", "OBSERVATION", 190, 197]]], ["Lastly, premises that were classified as confirmed PED negative were premises in which there were no clinical or diagnostic evidence of PED for at least 6 months after the presumed negative status update.Descriptive AnalysisData was entered into Microsoft Excel Version 16.14.1 (Microsoft, Redmond, Washington, USA) and then imported into Stata Version 13.1 (StataCorp, College Station, Texas, USA).", [["PED", "DISEASE", 136, 139], ["PED", "PROBLEM", 136, 139]]], ["The proportion of premises that were confirmed PEDpositive, presumed PED-positive and presumed PED-negative by herd type were documented.", [["PED", "PROBLEM", 95, 98]]], ["Also, the proportion of herds to eliminate PEDV by herd type, season and the year of PEDV diagnosis were recorded.", [["PEDV", "CHEMICAL", 43, 47], ["PEDV", "SPECIES", 43, 47], ["PEDV", "SPECIES", 85, 89], ["PEDV", "PROBLEM", 43, 47], ["PEDV diagnosis", "TEST", 85, 99]]], ["The median time to elimination and the 25th percentile, along with 95% confidence intervals (CI) were estimated by herd type, season and the year of PEDV diagnosis.Statistical AnalysisThe DCP database consisted of 144 confirmed or presumed PEDpositive case herds.", [["PEDV", "SPECIES", 149, 153], ["Statistical Analysis", "TEST", 164, 184], ["The DCP database", "TEST", 184, 200]]], ["Four herds reported subsequent infections, which were excluded from further analysis.", [["infections", "DISEASE", 31, 41], ["subsequent infections", "PROBLEM", 20, 41], ["further analysis", "TEST", 68, 84], ["infections", "OBSERVATION", 31, 41]]], ["In addition, one herd was excluded because the herd type was unknown and another herd was excluded because it was categorized as an isolation/acclimatization unit.", [["herd", "ORGANISM", 47, 51], ["an isolation/acclimatization unit", "TREATMENT", 129, 162]]], ["Therefore, 138 confirmed or presumed PED-positive case herds were included in the study.", [["the study", "TEST", 78, 87]]], ["A binary variable was created to indicate whether the case herds eliminated PEDV (censored = 1) off-site during the study duration and if the herds did not eliminate PEDV (censored = 0) during the study duration or due to loss-to-follow-up (censored = 0).", [["PEDV", "DISEASE", 76, 80], ["PEDV", "PROBLEM", 76, 80], ["the study duration", "TEST", 112, 130], ["PEDV", "PROBLEM", 166, 170], ["the study duration", "TEST", 193, 211], ["loss", "PROBLEM", 222, 226]]], ["For the case herds that did not report a change in the virus status over the study period of interest (n = 8), the herds were considered to be censored at times when their observation period ended.", [["a change in the virus status", "PROBLEM", 39, 67], ["the study", "TEST", 73, 82]]], ["Similarly, there were cases (n = 14) that reported a change in infection status change that was >100 weeks (\u223c2 years) after the initial date of infection.", [["infection", "DISEASE", 63, 72], ["infection", "DISEASE", 144, 153], ["a change in infection status change", "PROBLEM", 51, 86], ["infection", "PROBLEM", 144, 153], ["change", "OBSERVATION_MODIFIER", 53, 59], ["infection", "OBSERVATION", 63, 72], ["infection", "OBSERVATION", 144, 153]]], ["Consequently, a total of 22 herds had their time censored and 116 herds had the event of interest (i.e., reported to have eliminated the virus at least 10% level with 95% confidence).Statistical AnalysisThe time taken to eliminate PEDV from participating premises were estimated using Kaplan-Meier survival curves by herd type, season of diagnosis and year of diagnosis.", [["PEDV", "SPECIES", 231, 235], ["the virus", "PROBLEM", 133, 142], ["Statistical Analysis", "TEST", 183, 203], ["PEDV", "PROBLEM", 231, 235]]], ["Any confirmed or presumed PEDV diagnosis between March 1st and May 31st, June 1st and August 31st and, September 1st and November 30th were classified into the variable season as Spring, Summer, and Fall, respectively (10).", [["September 1st and November 30th", "DNA", 103, 134], ["presumed", "UNCERTAINTY", 17, 25], ["PEDV", "OBSERVATION", 26, 30]]], ["Log-ranked tests were computed for the 3 categories of Kaplan-Meier survival curves (herd type, year of diagnosis and season of diagnosis).Statistical AnalysisA Cox's proportional hazard model was constructed to investigate the effect of explanatory variables including herd type, season of diagnosis and year of diagnosis on the time to eliminate PEDV from the premises.", [["PEDV", "SPECIES", 348, 352], ["PEDV", "PROBLEM", 348, 352]]], ["The time to event (i.e., elimination) was identified as the time in weeks for a premises to change from confirmed or presumed PED-positive to presumed PEDnegative.", [["PEDnegative", "PROBLEM", 151, 162]]], ["A failure occurred if the premises eliminated PEDV.", [["PEDV", "CHEMICAL", 46, 50], ["PEDV", "SPECIES", 46, 50], ["A failure", "PROBLEM", 0, 9], ["PEDV", "PROBLEM", 46, 50], ["failure", "OBSERVATION", 2, 9]]], ["Univariable analysis was done using the 3 predictor variables mentioned above, separately.", [["Univariable analysis", "TEST", 0, 20]]], ["The multivariable model was built using a manual forward selection procedure, with a p < 0.10, based on a partial likelihood ratio test as an inclusion criterion.Statistical AnalysisThe assumption of the Cox's proportional hazard model was evaluated graphically showing the logarithm of the estimated cumulative hazard function.", [["a manual forward selection procedure", "TREATMENT", 40, 76], ["a partial likelihood ratio test", "TEST", 104, 135], ["Statistical Analysis", "TEST", 162, 182], ["the Cox's proportional hazard model", "TEST", 200, 235], ["cumulative", "OBSERVATION_MODIFIER", 301, 311], ["hazard function", "OBSERVATION", 312, 327]]], ["Deviance and score residuals were evaluated.Descriptive AnalysisFrom January 2014 to October 2017, a total of 138 PED cases were reported in the DCP database.", [["score residuals", "TEST", 13, 28], ["the DCP database", "TEST", 141, 157]]], ["From the participating premises in the DCP database, 60.1% were finisher sites (n = 83), 11.6% were nursery sites (n = 16), 10.2% were farrow-to-finish (n = 14), 10.2% were farrow-to-wean (n = 14), 4.3% were wean-to-finish (n = 6) and 3.6% were farrow-to-feeder (n = 5), respectively.Descriptive AnalysisNinety-four cases (65.2%, 90/138) reported that they were confirmed PED-positive.", [["the DCP database", "TEST", 35, 51], ["Descriptive AnalysisNinety", "TEST", 284, 310]]], ["Of these 90 cases, 92.2% (n = 83) reported that they eliminated PEDV and therefore gained a presumed-negative status.", [["PEDV", "PROBLEM", 64, 68], ["PEDV", "OBSERVATION", 64, 68]]], ["Forty-eight cases (34.8%, 48/138) reported that they were initially presumed PED-positive, at their initial date of infection.", [["infection", "DISEASE", 116, 125], ["infection", "PROBLEM", 116, 125], ["infection", "OBSERVATION", 116, 125]]], ["Of these 48 cases, 97.8% (n = 47) reported that they eliminated PEDV during the study period and achieved a presumed-negative status.Descriptive AnalysisKaplan-Meir estimates of the median and 25th percentile time in weeks to eliminate PEDV are displayed in Table 1 .", [["PEDV", "CHEMICAL", 64, 68], ["PEDV", "SPECIES", 236, 240], ["PEDV", "PROBLEM", 64, 68], ["the study", "TEST", 76, 85], ["PEDV", "PROBLEM", 236, 240]]], ["Nursery herds had the shortest median (23 weeks, 95% CI: 14, 31) and 25th percentile (16 weeks, 95% CI: 1, 23) for the duration of time it took in weeks to eliminate PEDV.", [["PEDV", "SPECIES", 166, 170], ["CI", "TEST", 100, 102], ["PEDV", "PROBLEM", 166, 170], ["PEDV", "OBSERVATION", 166, 170]]], ["Farrow-to-feeder herds had the longest median time (43 weeks 95% CI: 18, NA) and second longest 25th percentile (27 weeks, 95% CI: 18, 79) for the amount of time it took in weeks to eliminate PEDV.", [["PEDV", "SPECIES", 192, 196], ["CI", "TEST", 65, 67], ["NA", "TEST", 73, 75], ["CI", "TEST", 127, 129], ["PEDV", "PROBLEM", 192, 196], ["PEDV", "OBSERVATION", 192, 196]]], ["Cases that were diagnosed in the spring and winter seasons had higher medians and 25th percentiles for the amount of time it took in weeks to eliminate PEDV compared to cases that were diagnosed in fall and summer seasons (Statistical AnalysisKaplan-Meier survival functions based on herd type, season and year of diagnosis are presented in Figures 1-3 .", [["PEDV", "SPECIES", 152, 156], ["PEDV", "PROBLEM", 152, 156]]], ["The log-rank test statistic evaluating the equality of survival functions between herd types was statistically significant (p = 0.0029).", [["significant", "OBSERVATION_MODIFIER", 111, 122]]], ["Similarly, the season a premises was declared as PEDV-positive (p < 0.001) and the year of initial PEDV confirmation (p = 0.0105) were both statistically significant.Statistical AnalysisThe results of the univariable analyses conducted through Cox's proportional hazard model are reported in Table 2 .", [["PEDV", "TEST", 49, 53], ["initial PEDV confirmation", "TEST", 91, 116], ["Statistical Analysis", "TEST", 166, 186], ["the univariable analyses", "TEST", 201, 225], ["Cox's proportional hazard model", "TEST", 244, 275], ["significant", "OBSERVATION_MODIFIER", 154, 165]]], ["Briefly, herd type (p = 0.011), season (p < 0.001), and year of initial diagnosis (p = 0.019) were all associated with the likelihood of elimination in univariable analyses.", [["univariable analyses", "TEST", 152, 172]]], ["The final multivariable model also included herd type, season of diagnosis and year of diagnosis and is presented in Table 3 .Statistical AnalysisFarrow-to-wean premises were 3.36 times more likely than farrow-to-feeder herds (referent category) to eliminate the virus throughout the study period ( Table 3) .", [["the virus", "PROBLEM", 259, 268]]], ["The hazard ratio for premises diagnosed in the summer and fall months was 1.40 (p < 0.001, 95% CI: 2.74, 9.27) and 7.32 (p <0.001, 95% CI: 3.12, 17.18), respectively.", [["The hazard ratio", "TEST", 0, 16], ["CI", "TEST", 95, 97], ["p", "TEST", 121, 122], ["CI", "TEST", 135, 137]]], ["Thus, premises that were diagnosed in the summer and fall months were more likely than herds diagnosed in winter months (referent category) to eliminate PEDV.", [["PEDV", "CHEMICAL", 153, 157], ["PEDV", "SPECIES", 153, 157], ["PEDV", "PROBLEM", 153, 157], ["more likely", "UNCERTAINTY", 70, 81]]], ["Premises that were diagnosed with PEDV in 2015, had a hazard of eliminating PEDV that was 0.54 times the hazard of eliminating PEDV in herds diagnosed with PEDV in 2014 (p = 0.015, 95% CI: 0.33, 0.89).", [["PEDV", "CHEMICAL", 127, 131], ["PEDV", "SPECIES", 76, 80], ["PEDV", "SPECIES", 127, 131], ["PEDV", "SPECIES", 156, 160], ["PEDV", "PROBLEM", 34, 38], ["PEDV", "PROBLEM", 76, 80], ["PEDV", "PROBLEM", 127, 131], ["PEDV", "PROBLEM", 156, 160], ["CI", "TEST", 185, 187]]], ["This suggests that herds that were diagnosed with PEDV in 2015 were less likely to eliminate the virus compared to premises that were diagnosed in 2014 (referent category).", [["PEDV", "CHEMICAL", 50, 54], ["PEDV", "PROBLEM", 50, 54], ["the virus", "PROBLEM", 93, 102]]], ["In contrast, premises that were diagnosed in 2016 were 1.62 times more likely to eliminate the virus compared to herds diagnosed in 2014 (p = 0.10, 95% CI: 0.91, 2.89).Statistical AnalysisThe assumption of the Cox's proportional hazard model was examined graphically showing the logarithm of the estimated cumulative hazard function.", [["the virus", "PROBLEM", 91, 100], ["CI", "TEST", 152, 154], ["Statistical Analysis", "TEST", 168, 188], ["the Cox's proportional hazard model", "TEST", 206, 241], ["cumulative", "OBSERVATION_MODIFIER", 306, 316], ["hazard function", "OBSERVATION", 317, 332]]], ["There was no indication that the season of diagnosis and herd type variables had a time varying effect and therefore, the assumption of proportional hazards was met.", [["herd type variables", "PROBLEM", 57, 76], ["proportional hazards", "PROBLEM", 136, 156], ["no indication", "UNCERTAINTY", 10, 23]]], ["The Hosmer-Lemeshow test indicated that the model fits the data (p = 0.46).", [["The Hosmer-Lemeshow test", "TEST", 0, 24]]], ["Also, Harrell's C concordance statistic computed (0.72) found that the model had good overall predictive ability.", [["Harrell's C concordance", "TEST", 6, 29]]], ["There were no outliers or influential observations found.DISCUSSIONFollowing the emergence of PEDV into the United States in 2013, many actions were taken in Ontario in anticipation of the emergence of the virus into Ontario.", [["PEDV", "SPECIES", 94, 98], ["outliers", "PROBLEM", 14, 22], ["no", "UNCERTAINTY", 11, 13]]], ["Following the initial emergence, the outbreak in the province of Ontario was well controlled, which was achieved through quick identification of the suspected source of outbreak and implementation of biosecurity practices aimed to prevent further spread of infection.", [["infection", "DISEASE", 257, 266], ["outbreak", "PROBLEM", 169, 177], ["biosecurity practices", "TREATMENT", 200, 221], ["infection", "PROBLEM", 257, 266], ["infection", "OBSERVATION", 257, 266]]], ["This resulted in a relatively low prevalence of infected herds (7), which could have contributed to willingness to eliminate PEDV infection.", [["PEDV", "CHEMICAL", 125, 129], ["infection", "DISEASE", 130, 139], ["PEDV", "ORGANISM", 125, 129], ["PEDV", "SPECIES", 125, 129], ["PEDV infection", "PROBLEM", 125, 139], ["relatively", "OBSERVATION_MODIFIER", 19, 29], ["low prevalence", "OBSERVATION_MODIFIER", 30, 44], ["infected", "OBSERVATION_MODIFIER", 48, 56], ["herds", "OBSERVATION", 57, 62], ["infection", "OBSERVATION", 130, 139]]], ["Veterinarians have implemented site-specific elimination strategies in Ontario, however the duration of time for a premises to eliminate the virus is variable based on a multitude of factors (i.e., the initial start time for the elimination process may depend on the PEDV status of the sow herd, or the season).", [["the virus", "PROBLEM", 137, 146], ["the elimination process", "TREATMENT", 225, 248], ["virus", "OBSERVATION", 141, 146]]], ["The starting time for the time to elimination in this study was not the start date of control measures aimed at elimination, but the date of original infection.", [["infection", "DISEASE", 150, 159], ["this study", "TEST", 49, 59], ["control measures", "TREATMENT", 86, 102], ["original infection", "PROBLEM", 141, 159], ["infection", "OBSERVATION", 150, 159]]], ["However, we believe that this time to elimination gives veterinary authorities reasonable overview of time to elimination for a newly emerging disease in the area, for which previous experience in elimination did not exist.DISCUSSIONAn important finding in this study is that with the exception of 2015, the estimated hazard of eliminating PEDV increased over the years examined.", [["PEDV", "SPECIES", 340, 344], ["a newly emerging disease in the area", "PROBLEM", 126, 162], ["this study", "TEST", 257, 267], ["PEDV", "PROBLEM", 340, 344], ["disease", "OBSERVATION", 143, 150], ["PEDV", "OBSERVATION", 340, 344], ["increased", "OBSERVATION_MODIFIER", 345, 354]]], ["Veterinary practitioners were initially dealing with a new emerging disease into Canada, and it is possible that they developed more expertise in procedures to eliminate PED from herds as time went on.", [["PED", "DISEASE", 170, 173], ["a new emerging disease", "PROBLEM", 53, 75]]], ["Additionally, most cases occurred during the first 2 years (n = 92 in 2014 and n = 27 in 2015) of the outbreak and it is possible that resources needed to be prioritized between actions needed to prevent further spread and actions to eliminate infection from already infected sites, particularly if such sites required substantial planning.", [["infection", "DISEASE", 244, 253], ["further spread and actions", "PROBLEM", 204, 230], ["infection", "PROBLEM", 244, 253], ["already infected sites", "PROBLEM", 259, 281], ["substantial planning", "TREATMENT", 319, 339], ["infected", "OBSERVATION", 267, 275]]], ["In contrast, the number of new cases in 2016 (n = 16) and 2017 (n = 3) was substantially lower.DISCUSSIONAnother important finding in this study was that herds diagnosed in winter and spring months required more time to eliminate the virus.", [["this study", "TEST", 134, 144], ["the virus", "PROBLEM", 230, 239], ["new", "OBSERVATION_MODIFIER", 27, 30], ["lower", "OBSERVATION_MODIFIER", 89, 94]]], ["This was likely due to PEDV's survivability and ability to remain infectious.", [["PEDV", "SPECIES", 23, 27], ["PEDV", "PROBLEM", 23, 27], ["infectious", "PROBLEM", 66, 76], ["likely due to", "UNCERTAINTY", 9, 22], ["infectious", "OBSERVATION", 66, 76]]], ["Typically, coronaviruses can survive temperatures from 56 \u2022 C for 10-15 mins, 37 \u2022 C for several days, 4 \u2022 C for several months, and while frozen at \u221260 \u2022 C many years without losing infectivity (12) .", [["coronaviruses", "ORGANISM", 11, 24]]], ["Thus, it was likely difficult to eliminate the virus due to its survivability in Ontario's temperatures in the spring and winter months.", [["the virus", "PROBLEM", 43, 52]]], ["It is also possible that due to the lack of external pressures, producers who had positive herds waited until warmer months to start with the PEDV elimination protocol.DISCUSSIONFarrow-to-wean herds were found to eliminate the virus in a shorter amount of time compared to farrow-to-feeder herds.", [["the PEDV elimination protocol", "TREATMENT", 138, 167], ["herds", "TREATMENT", 193, 198], ["the virus", "PROBLEM", 223, 232]]], ["This was an expected finding, since in a farrow-to-wean operation; the system is generally less complex than a farrow-to-feeder or farrow-to-finish operation.", [["operation", "TREATMENT", 56, 65], ["operation", "TREATMENT", 148, 157]]], ["The presence of nursery pigs on the same site as suckling pigs complicates infection control practices since a separate set of control measures and operating procedures need to be designed and implemented for the nursery stage of production.", [["infection", "DISEASE", 75, 84], ["pigs", "ORGANISM", 24, 28], ["pigs", "ORGANISM", 58, 62], ["pigs", "SPECIES", 24, 28], ["pigs", "SPECIES", 58, 62], ["pigs", "SPECIES", 58, 62], ["nursery pigs", "TREATMENT", 16, 28], ["infection control practices", "TREATMENT", 75, 102], ["control measures", "TREATMENT", 127, 143], ["operating procedures", "TREATMENT", 148, 168], ["nursery pigs", "OBSERVATION", 16, 28]]], ["This requires resources, strict adherence to internal biosecurity protocols and often demographic measures, such as creation of an interruption, or gap, in pig flow.", [["pig", "ORGANISM", 156, 159], ["pig", "SPECIES", 156, 159], ["internal biosecurity protocols", "TREATMENT", 45, 75], ["demographic measures", "TEST", 86, 106], ["an interruption", "TREATMENT", 128, 143], ["gap", "TEST", 148, 151], ["pig flow", "OBSERVATION", 156, 164]]], ["Pig flow through a production system, and more specifically, the creation of a gap in pig flow, is now recognized as an essential aspect of achieving earlier farrowing site elimination by allowing more effective cleaning and disinfection protocols required for successful elimination (13) .", [["Pig", "ORGANISM", 0, 3], ["pig", "ORGANISM", 86, 89], ["pig", "SPECIES", 86, 89], ["a production system", "TEST", 17, 36], ["a gap in pig flow", "PROBLEM", 77, 94], ["disinfection protocols", "TREATMENT", 225, 247], ["flow", "OBSERVATION", 4, 8], ["gap", "OBSERVATION_MODIFIER", 79, 82], ["pig flow", "OBSERVATION", 86, 94], ["essential", "OBSERVATION_MODIFIER", 120, 129]]], ["Pig flow through a production system is the frequency of introducing new pigs into a population and the amount of opportunity these pigs have to come in contact with other pigs.DISCUSSIONA gap in pig flow however is often a one-time event to prevent the entrance of new animals to control the spread of the virus.", [["Pig", "ORGANISM", 0, 3], ["pigs", "ORGANISM", 73, 77], ["pigs", "ORGANISM", 132, 136], ["pigs", "ORGANISM", 172, 176], ["pig", "ORGANISM", 196, 199], ["pigs", "SPECIES", 73, 77], ["pigs", "SPECIES", 172, 176], ["pigs", "SPECIES", 132, 136], ["pig", "SPECIES", 196, 199], ["Pig flow", "TREATMENT", 0, 8], ["a production system", "TREATMENT", 17, 36], ["pig flow", "TREATMENT", 196, 204], ["new animals", "TREATMENT", 266, 277], ["the virus", "PROBLEM", 303, 312], ["amount", "OBSERVATION_MODIFIER", 104, 110], ["pig flow", "OBSERVATION", 196, 204]]], ["A partial depopulation could present a gap in pig flow, where infected animals are removed from the herd, followed by cleaning and decontaminating the site.", [["pig", "ORGANISM", 46, 49], ["animals", "ORGANISM", 71, 78], ["pig", "SPECIES", 46, 49], ["A partial depopulation", "TREATMENT", 0, 22], ["a gap in pig flow", "PROBLEM", 37, 54], ["partial", "OBSERVATION_MODIFIER", 2, 9], ["depopulation", "OBSERVATION", 10, 22], ["gap", "OBSERVATION_MODIFIER", 39, 42], ["pig flow", "OBSERVATION", 46, 54], ["infected", "OBSERVATION_MODIFIER", 62, 70], ["animals", "OBSERVATION_MODIFIER", 71, 78]]], ["The database did not include details about specific infection control practices, such as the details of pig flow or attempts to generate a gap in pig flow.", [["infection", "DISEASE", 52, 61], ["pig", "ORGANISM", 104, 107], ["pig", "ORGANISM", 146, 149], ["pig", "SPECIES", 104, 107], ["pig", "SPECIES", 146, 149], ["specific infection control practices", "PROBLEM", 43, 79], ["pig flow", "TREATMENT", 104, 112], ["a gap in pig flow", "TREATMENT", 137, 154], ["pig flow", "OBSERVATION", 146, 154]]], ["Nonetheless, it is also worth pointing out that the variability in the time to elimination was markedly higher in farrow-to-feeder than in other herd types.", [["variability", "OBSERVATION_MODIFIER", 52, 63], ["markedly", "OBSERVATION_MODIFIER", 95, 103], ["higher", "OBSERVATION_MODIFIER", 104, 110]]], ["It is possible that this time to elimination is not only driven by herd demographics and pig flow, but also with other factors such as willingness to eliminate, which was not directly measured in this study.DISCUSSIONAn important concept for this study is that the data collected was from a large-scale industry-based surveillance program.", [["herd", "ORGANISM_SUBDIVISION", 67, 71], ["pig", "ORGANISM", 89, 92], ["pig", "SPECIES", 89, 92], ["pig flow", "TEST", 89, 97], ["this study", "TEST", 196, 206], ["this study", "TEST", 242, 252], ["a large-scale industry", "TREATMENT", 289, 311]]], ["This study does present limitations.", [["This study", "TEST", 0, 10]]], ["The OMAFRA surveillance program only accounts for primary case herds, which are case herds with a positive diagnostic test (RT-PCR) for PEDV (14) .", [["PEDV", "SPECIES", 136, 140], ["diagnostic test", "TEST", 107, 122], ["RT-PCR", "TEST", 124, 130], ["PEDV", "PROBLEM", 136, 140]]], ["Unlike the surveillance program managed by OMAFRA, where 100% coverage of primary PEDV-infected cases were included, the DCP used in the study only includes primary case herds that volunteered to participate in the program, and secondary cases resulting from animal movement from such cases (7) .", [["primary PEDV-infected", "DISEASE", 74, 95], ["DCP", "CHEMICAL", 121, 124], ["PEDV", "ORGANISM", 82, 86], ["PEDV", "SPECIES", 82, 86], ["primary PEDV", "TREATMENT", 74, 86], ["infected cases", "PROBLEM", 87, 101], ["the study", "TEST", 133, 142]]], ["It is also possible that some producers or veterinarians did not follow up to report that the case indeed eliminated PEDV from the premises, in which case the estimated time to elimination would be longer than in reality.", [["PEDV", "PROBLEM", 117, 121], ["also possible", "UNCERTAINTY", 6, 19]]], ["There were 14 premises for which the records indicated that the time between initial infection and a change in status to presumed negative was longer than 100 weeks.", [["infection", "DISEASE", 85, 94], ["initial infection", "PROBLEM", 77, 94], ["a change in status", "PROBLEM", 99, 117], ["infection", "OBSERVATION", 85, 94]]], ["Since participation in this large-scale disease monitoring program is not mandatory, it is possible that some of these premises were not working toward eliminating the virus, since there was no external pressure to do so.", [["the virus", "PROBLEM", 164, 173], ["external pressure", "TREATMENT", 194, 211]]], ["Alternatively, it is likely that owners that had a low prevalence of PEDV on-site, may have not tested pigs to confirm PEDV status (i.e., the absence from infection).", [["infection", "DISEASE", 155, 164], ["pigs", "ORGANISM", 103, 107], ["pigs", "SPECIES", 103, 107], ["pigs", "SPECIES", 103, 107], ["PEDV", "SPECIES", 119, 123], ["PEDV", "PROBLEM", 69, 73], ["PEDV status", "PROBLEM", 119, 130], ["infection", "PROBLEM", 155, 164], ["is likely", "UNCERTAINTY", 18, 27], ["infection", "OBSERVATION", 155, 164]]], ["However, both of these scenarios could occur with a production-limited disease.", [["a production-limited disease", "PROBLEM", 50, 78], ["limited", "OBSERVATION_MODIFIER", 63, 70], ["disease", "OBSERVATION", 71, 78]]], ["If large-scale disease control programs are initiated at the level that is different than a premises, or production-system level; veterinary authorities should be aware of the situations where time to negativity could take a long time.", [["large-scale disease control programs", "TREATMENT", 3, 39], ["large", "OBSERVATION_MODIFIER", 3, 8], ["-scale", "OBSERVATION_MODIFIER", 8, 14], ["disease", "OBSERVATION", 15, 22], ["different", "OBSERVATION_MODIFIER", 75, 84]]], ["In addition, populations with high replacement and/or birth rates such as swine herds could have considerable number of susceptible animals introduced into a population that is partially immune due to recent exposure.", [["swine", "SPECIES", 74, 79], ["swine", "SPECIES", 74, 79], ["high replacement", "TREATMENT", 30, 46], ["birth rates", "PROBLEM", 54, 65], ["susceptible animals", "PROBLEM", 120, 139], ["high replacement", "OBSERVATION", 30, 46]]], ["This situation could provide opportunity for infectious agents to continue circulating at low levels.", [["infectious agents", "TREATMENT", 45, 62]]], ["Consequently, declaring freedom from infection at 10% may not be sufficient.", [["infection", "DISEASE", 37, 46], ["infection", "PROBLEM", 37, 46], ["infection", "OBSERVATION", 37, 46]]], ["However, making a decision about the design prevalence should be weighed against the disease epidemiology and cost to producers.", [["the disease epidemiology", "PROBLEM", 81, 105]]], ["Another limitation is the database was missing variables for herd size.", [["herd", "ORGANISM_SUBDIVISION", 61, 65], ["size", "OBSERVATION_MODIFIER", 66, 70]]], ["Due to this, the authors decided not to consider this variable in the analysis.", [["the analysis", "TEST", 66, 78]]], ["However, despite these limitations, this study provided novel insight in regards to PEDV elimination times in Ontario.DISCUSSIONIn conclusion, this study allowed estimation of time to PEDV elimination based on a large-scale disease control program database, which considered time between initial infection and confirmation of PEDV freedom at a minimum level of 10%.", [["infection", "DISEASE", 296, 305], ["PEDV", "SPECIES", 84, 88], ["PEDV", "SPECIES", 184, 188], ["PEDV", "SPECIES", 326, 330], ["this study", "TEST", 36, 46], ["this study", "TEST", 143, 153], ["PEDV elimination", "TEST", 184, 200], ["a large-scale disease control", "TREATMENT", 210, 239], ["initial infection", "PROBLEM", 288, 305], ["PEDV freedom", "PROBLEM", 326, 338], ["infection", "OBSERVATION", 296, 305]]], ["Under such assumptions, the median time to elimination of PEDV from Ontario swine herds varied between 23 weeks in nursery herds (standard error =1 week), and 43 weeks (standard error =17.5 weeks) in farrow-to-feeder herds.", [["PEDV", "CHEMICAL", 58, 62], ["swine", "SPECIES", 76, 81], ["PEDV", "SPECIES", 58, 62], ["swine", "SPECIES", 76, 81], ["PEDV", "PROBLEM", 58, 62]]], ["Among the sow herds, farrow-to-wean herds had the highest hazard of PEDV elimination.", [["PEDV", "CHEMICAL", 68, 72], ["PEDV", "SIMPLE_CHEMICAL", 68, 72], ["PEDV", "SPECIES", 68, 72], ["herds", "TREATMENT", 36, 41], ["PEDV elimination", "TREATMENT", 68, 84]]], ["These results are reflective of the complexity of the infection control practices applied in herds with different demographics and population structures.", [["infection", "DISEASE", 54, 63], ["the infection control practices", "TREATMENT", 50, 81], ["complexity", "OBSERVATION_MODIFIER", 36, 46], ["infection", "OBSERVATION", 54, 63]]], ["The hazard of elimination was also higher in herds that had the initial infection during summer and fall than in herds that had the initial infection during winter.", [["infection", "DISEASE", 72, 81], ["infection", "DISEASE", 140, 149], ["the initial infection", "PROBLEM", 60, 81], ["the initial infection", "PROBLEM", 128, 149], ["higher", "OBSERVATION_MODIFIER", 35, 41], ["infection", "OBSERVATION", 72, 81], ["infection", "OBSERVATION", 140, 149]]], ["This could be a reflection of seasonal variability in the pathogen transmissibility or decisions made at the level of individual herds to proceed with infection control measures when the likelihood of success is the highest.", [["infection", "DISEASE", 151, 160], ["seasonal variability", "PROBLEM", 30, 50], ["the pathogen transmissibility", "PROBLEM", 54, 83], ["infection control measures", "TREATMENT", 151, 177], ["seasonal", "OBSERVATION_MODIFIER", 30, 38], ["variability", "OBSERVATION_MODIFIER", 39, 50], ["pathogen transmissibility", "OBSERVATION", 58, 83]]], ["With the exception of the second year after initial emergence, the hazard of elimination increased over years, which could reflect the availability of resources to manage an emerging productionlimiting disease.", [["an emerging productionlimiting disease", "PROBLEM", 171, 209], ["elimination", "OBSERVATION_MODIFIER", 77, 88], ["increased", "OBSERVATION_MODIFIER", 89, 98]]], ["However, this could be a consequence of the way it was measured, the decisions about implementation of infection control measures which could be made at the level of individual herds, multi-site production systems or possibly delays related to reporting PEDV elimination.", [["infection", "DISEASE", 103, 112], ["PEDV", "CHEMICAL", 254, 258], ["PEDV", "SIMPLE_CHEMICAL", 254, 258], ["infection control measures", "TREATMENT", 103, 129], ["multi-site production systems", "TREATMENT", 184, 213], ["infection", "OBSERVATION", 103, 112]]], ["Nonetheless, the design of control measures for production-limiting diseases at the regional level should consider these factors.ETHICS STATEMENTResearch Ethics Board of the University of Guelph approved the study.", [["control measures", "TREATMENT", 27, 43], ["production-limiting diseases at the regional level", "PROBLEM", 48, 98], ["the study", "TEST", 204, 213]]], ["Data for this study were obtained from Swine Health Ontario under an appropriate data sharing agreement based on secondary data usage.", [["this study", "TEST", 9, 19]]]], "PMC7308593": [["IntroductionThe current COVID-19 pandemic, caused by the coronavirus SARS-CoV-2 and initiated with the first cases observed in Wuhan (China) in December 2019, has expanded dramatically throughout the world (1, 2).", [["COVID-19", "ORGANISM", 24, 32], ["coronavirus SARS-CoV-2", "ORGANISM", 57, 79], ["coronavirus", "SPECIES", 57, 68], ["coronavirus SARS-CoV", "SPECIES", 57, 77], ["The current COVID", "TEST", 12, 29], ["pandemic", "PROBLEM", 33, 41], ["the coronavirus SARS", "PROBLEM", 53, 73], ["expanded", "OBSERVATION_MODIFIER", 163, 171], ["dramatically", "OBSERVATION_MODIFIER", 172, 184]]], ["This expansion has had devastating effects in many countries due to its contagiousness and the high number of patients presenting with severe infections and elevated death risk, requiring specialized medical care in intensive care units (ICU).", [["infections", "DISEASE", 142, 152], ["death", "DISEASE", 166, 171], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["its contagiousness", "PROBLEM", 68, 86], ["severe infections", "PROBLEM", 135, 152], ["elevated death risk", "PROBLEM", 157, 176], ["devastating", "OBSERVATION_MODIFIER", 23, 34], ["high", "OBSERVATION_MODIFIER", 95, 99], ["severe", "OBSERVATION_MODIFIER", 135, 141], ["infections", "OBSERVATION", 142, 152], ["elevated", "OBSERVATION_MODIFIER", 157, 165]]], ["An important aspect to highlight during the present crisis is the speed at which research studies have been developed, leading toward a better understanding of the epidemiology, clinical manifestations, risk factors, and transmission dynamics (1, 4\u20138), as well as to the identification of the etiological agent (9, 10), including its genome, morphological structure, and molecules (11\u201313), its relationship with other coronaviruses (14), its entrance into the host cells by binding the Angiotensin II Converting Enzyme (ACE2) (9), its intracellular replication (15), and the immune response of the infected individuals (16\u201319).", [["cells", "ANATOMY", 465, 470], ["intracellular", "ANATOMY", 535, 548], ["Angiotensin II", "CHEMICAL", 486, 500], ["host cells", "CELL", 460, 470], ["Angiotensin II Converting Enzyme (ACE2) (9)", "GENE_OR_GENE_PRODUCT", 486, 529], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 535, 548], ["host cells", "CELL_TYPE", 460, 470], ["Angiotensin II Converting Enzyme (ACE2) (9", "PROTEIN", 486, 528], ["transmission dynamics", "TEST", 221, 242], ["other coronaviruses", "PROBLEM", 412, 431], ["the Angiotensin II Converting Enzyme (ACE2)", "TREATMENT", 482, 525], ["its intracellular replication", "TEST", 531, 560], ["the infected individuals", "PROBLEM", 594, 618], ["morphological structure", "OBSERVATION", 342, 365], ["host cells", "OBSERVATION", 460, 470], ["infected", "OBSERVATION_MODIFIER", 598, 606]]], ["All these studies aim at developing diagnostic tests, strategies for clinical management, effective antiviral agents, and eventually, production of a protective vaccine.IntroductionThe goal of this review is to analyze the main aspects of the immune response against SARS-CoV-2 and the relationship between the protective and inflammatory responses and COVID-19 clinical spectrum, ranging from asymptomatic to severe clinical presentations.", [["SARS", "DISEASE", 267, 271], ["SARS-CoV-2", "ORGANISM", 267, 277], ["SARS-CoV", "SPECIES", 267, 275], ["All these studies", "TEST", 0, 17], ["diagnostic tests", "TEST", 36, 52], ["clinical management", "TREATMENT", 69, 88], ["effective antiviral agents", "TREATMENT", 90, 116], ["a protective vaccine", "TREATMENT", 148, 168], ["SARS", "PROBLEM", 267, 271], ["CoV", "TEST", 272, 275], ["COVID", "TEST", 353, 358], ["severe clinical presentations", "PROBLEM", 410, 439], ["inflammatory", "OBSERVATION", 326, 338], ["severe", "OBSERVATION_MODIFIER", 410, 416]]], ["The review also highlights the principal immunological research challenges posed by COVID-19 pandemics.", [["COVID-19", "ORGANISM", 84, 92]]], ["The immune response in humans and experimental animals against infection by SARS-CoV and MERS-CoV has been studied extensively and there are many excellent reviews (20\u201323).", [["infection", "DISEASE", 63, 72], ["SARS", "DISEASE", 76, 80], ["humans", "ORGANISM", 23, 29], ["SARS-CoV", "ORGANISM", 76, 84], ["MERS-CoV", "ORGANISM", 89, 97], ["humans", "SPECIES", 23, 29], ["humans", "SPECIES", 23, 29], ["SARS-CoV", "SPECIES", 76, 84], ["MERS-CoV", "SPECIES", 89, 97], ["infection", "PROBLEM", 63, 72], ["SARS", "PROBLEM", 76, 80], ["immune response", "OBSERVATION", 4, 19], ["infection", "OBSERVATION", 63, 72]]], ["However, due to the similarities of COVID-19 with SARS and MERS, it will be necessary, at certain specific points, to cite the research done on those infections.The VirusThe virus responsible for the epidemic that began in Wuhan was simultaneously identified by Wu et al. (9), and by Zhou et al. (10), who named it WH-Human 1 and 2019-nCoV, respectively.", [["SARS", "DISEASE", 50, 54], ["infections", "DISEASE", 150, 160], ["Virus", "ORGANISM", 165, 170], ["Human", "ORGANISM", 318, 323], ["Human", "SPECIES", 318, 323], ["Virus", "SPECIES", 165, 170], ["COVID", "TEST", 36, 41], ["SARS", "PROBLEM", 50, 54], ["those infections", "PROBLEM", 144, 160], ["The virus", "PROBLEM", 170, 179], ["infections", "OBSERVATION", 150, 160], ["Virus", "OBSERVATION", 165, 170], ["virus", "OBSERVATION", 174, 179]]], ["These researchers also deciphered the virus genome, its origin from bat coronaviruses, and ACE2 as its receptor on the membrane of host cells.", [["membrane", "ANATOMY", 119, 127], ["cells", "ANATOMY", 136, 141], ["bat coronaviruses", "ORGANISM", 68, 85], ["ACE2", "GENE_OR_GENE_PRODUCT", 91, 95], ["membrane", "CELLULAR_COMPONENT", 119, 127], ["host cells", "CELL", 131, 141], ["virus genome", "DNA", 38, 50], ["ACE2", "PROTEIN", 91, 95], ["host cells", "CELL_TYPE", 131, 141], ["bat coronaviruses", "SPECIES", 68, 85], ["the virus genome", "PROBLEM", 34, 50], ["bat coronaviruses", "PROBLEM", 68, 85], ["ACE2", "TREATMENT", 91, 95], ["virus genome", "OBSERVATION", 38, 50], ["origin", "OBSERVATION_MODIFIER", 56, 62], ["bat coronaviruses", "OBSERVATION", 68, 85], ["host cells", "OBSERVATION", 131, 141]]], ["On February 11, 2020, the WHO officially named the infection COVID-19 and the virus as SARS-CoV-2 (24).The VirusSARS-CoV-2 belongs to the family Coronaviridae, which includes a large number of species capable of infecting various wild animals, some of which also affect humans (25\u201327).", [["infection", "DISEASE", 51, 60], ["VirusSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 107, 122], ["humans", "ORGANISM", 270, 276], ["VirusSARS-CoV-2", "DNA", 107, 122], ["humans", "SPECIES", 270, 276], ["COVID-19", "SPECIES", 61, 69], ["SARS-CoV", "SPECIES", 87, 95], ["humans", "SPECIES", 270, 276], ["the infection COVID", "TEST", 47, 66], ["the virus", "TEST", 74, 83], ["SARS", "TEST", 87, 91], ["CoV", "TEST", 92, 95], ["The VirusSARS", "TEST", 103, 116], ["infection", "OBSERVATION", 51, 60], ["large", "OBSERVATION_MODIFIER", 177, 182]]], ["In humans, most coronavirus infections result in mild respiratory Infections and may be responsible for 20\u201330% of common colds (28).", [["respiratory", "ANATOMY", 54, 65], ["coronavirus infections", "DISEASE", 16, 38], ["respiratory Infections", "DISEASE", 54, 76], ["colds", "DISEASE", 121, 126], ["humans", "ORGANISM", 3, 9], ["coronavirus", "ORGANISM", 16, 27], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["most coronavirus infections", "PROBLEM", 11, 38], ["mild respiratory Infections", "PROBLEM", 49, 76], ["common colds", "PROBLEM", 114, 126], ["most coronavirus", "OBSERVATION_MODIFIER", 11, 27], ["infections", "OBSERVATION", 28, 38], ["mild", "OBSERVATION_MODIFIER", 49, 53], ["respiratory Infections", "OBSERVATION", 54, 76]]], ["However, both SARS-CoV and MERS-CoV, which emerged in the last two decades, were responsible for epidemics of severe respiratory syndromes.", [["respiratory", "ANATOMY", 117, 128], ["respiratory syndromes", "DISEASE", 117, 138], ["SARS-CoV", "ORGANISM", 14, 22], ["MERS-CoV", "ORGANISM", 27, 35], ["SARS-CoV", "SPECIES", 14, 22], ["MERS-CoV", "SPECIES", 27, 35], ["severe respiratory syndromes", "PROBLEM", 110, 138], ["CoV", "OBSERVATION_MODIFIER", 19, 22], ["severe", "OBSERVATION_MODIFIER", 110, 116], ["respiratory syndromes", "OBSERVATION", 117, 138]]], ["The three coronaviruses causing more serious pathologies belong to beta-CoV (23) and, despite their genomic and structural similarities, they differ significantly epidemiologically.", [["coronaviruses", "ORGANISM", 10, 23], ["beta-CoV", "GENE_OR_GENE_PRODUCT", 67, 75], ["beta-CoV", "SPECIES", 67, 75], ["The three coronaviruses", "PROBLEM", 0, 23], ["more serious pathologies", "PROBLEM", 32, 56], ["beta-CoV", "TEST", 67, 75]]], ["SARS-CoV and MERS-CoV have a low transmissibility but a high lethality, while SARS-CoV-2 has an extremely high transmissibility and a degree of lethality not yet established globally.The VirusCoronaviruses have a single-stranded positive RNA of nearly 30 Kbp, a spheroidal shape, and a diameter of 80\u2013120 nm.", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 78, 82], ["SARS-CoV", "ORGANISM", 0, 8], ["MERS-CoV", "ORGANISM", 13, 21], ["SARS-CoV-2", "ORGANISM", 78, 88], ["VirusCoronaviruses", "GENE_OR_GENE_PRODUCT", 187, 205], ["VirusCoronaviruses", "DNA", 187, 205], ["single-stranded positive RNA", "RNA", 213, 241], ["SARS-CoV", "SPECIES", 0, 8], ["MERS-CoV", "SPECIES", 13, 21], ["SARS-CoV-2", "SPECIES", 78, 88], ["SARS", "PROBLEM", 0, 4], ["CoV", "PROBLEM", 18, 21], ["a low transmissibility", "PROBLEM", 27, 49], ["a high lethality", "PROBLEM", 54, 70], ["an extremely high transmissibility", "PROBLEM", 93, 127], ["lethality", "PROBLEM", 144, 153], ["a spheroidal shape", "TEST", 260, 278], ["low transmissibility", "OBSERVATION_MODIFIER", 29, 49], ["high lethality", "OBSERVATION_MODIFIER", 56, 70], ["lethality", "OBSERVATION", 144, 153], ["positive RNA", "OBSERVATION_MODIFIER", 229, 241], ["30 Kbp", "OBSERVATION_MODIFIER", 252, 258], ["spheroidal", "OBSERVATION_MODIFIER", 262, 272], ["shape", "OBSERVATION_MODIFIER", 273, 278], ["diameter", "OBSERVATION_MODIFIER", 286, 294]]], ["Their envelope contains the spike \u2013S-, membrane -M-, and envelope -E-, proteins, and the nucleocapsid -N- inside the virion that covers the RNA (23).", [["membrane", "ANATOMY", 39, 47], ["membrane", "CELLULAR_COMPONENT", 39, 47], ["E-", "GENE_OR_GENE_PRODUCT", 67, 69], ["virion", "CELLULAR_COMPONENT", 117, 123], ["spike \u2013S-, membrane -M-, and envelope -E-, proteins", "PROTEIN", 28, 79], ["nucleocapsid -N", "PROTEIN", 89, 104], ["the spike \u2013S", "TEST", 24, 36], ["the nucleocapsid", "TEST", 85, 101], ["the virion", "TREATMENT", 113, 123], ["spike", "OBSERVATION_MODIFIER", 28, 33], ["virion", "ANATOMY", 117, 123]]], ["On the genome, from 5\u2032 to 3\u2032, are located the genes for the replicases ORF 1a,b which occupy two thirds of the genome and code for the polyproteins pp1a and pp1b (9, 23, 29).", [["3", "GENE_OR_GENE_PRODUCT", 26, 27], ["\u2032", "GENE_OR_GENE_PRODUCT", 27, 28], ["replicases ORF 1a", "GENE_OR_GENE_PRODUCT", 60, 77], ["b", "GENE_OR_GENE_PRODUCT", 78, 79], ["pp1a", "GENE_OR_GENE_PRODUCT", 148, 152], ["pp1b", "GENE_OR_GENE_PRODUCT", 157, 161], ["5\u2032 to 3\u2032", "DNA", 20, 28], ["replicases ORF 1a", "DNA", 60, 77], ["polyproteins pp1a", "DNA", 135, 152], ["pp1b", "DNA", 157, 161], ["the polyproteins pp1a", "TEST", 131, 152], ["pp1b", "TEST", 157, 161]]], ["Located toward the 3\u2032 end are the genes for structural proteins S, E, M, and N (9, 23, 30).The VirusProtein S is the best studied of the coronaviruses proteins, since it contains the Receptor-Binding-Domain (RBD) for the ligand on the host cell membrane, and also has epitopes recognized by T and B cells, which induce the production of neutralizing antibodies (31).", [["cell membrane", "ANATOMY", 240, 253], ["T", "ANATOMY", 291, 292], ["B cells", "ANATOMY", 297, 304], ["VirusProtein", "CHEMICAL", 95, 107], ["VirusProtein", "GENE_OR_GENE_PRODUCT", 95, 107], ["coronaviruses", "ORGANISM", 137, 150], ["Receptor-Binding-Domain", "GENE_OR_GENE_PRODUCT", 183, 206], ["cell membrane", "CELLULAR_COMPONENT", 240, 253], ["T", "CELL", 291, 292], ["B cells", "CELL", 297, 304], ["3\u2032 end", "DNA", 19, 25], ["E", "PROTEIN", 67, 68], ["VirusProtein", "PROTEIN", 95, 107], ["coronaviruses proteins", "PROTEIN", 137, 159], ["Receptor-Binding-Domain", "PROTEIN", 183, 206], ["RBD", "PROTEIN", 208, 211], ["epitopes", "PROTEIN", 268, 276], ["T and B cells", "CELL_TYPE", 291, 304], ["neutralizing antibodies", "PROTEIN", 337, 360], ["structural proteins S", "TEST", 44, 65], ["The VirusProtein", "TEST", 91, 107], ["the coronaviruses proteins", "PROBLEM", 133, 159], ["neutralizing antibodies", "TEST", 337, 360], ["VirusProtein", "OBSERVATION", 95, 107], ["host cell membrane", "OBSERVATION", 235, 253]]], ["S is a type I trimeric glycoprotein that protrudes from the virion membrane, giving it the appearance of a crown.", [["virion membrane", "ANATOMY", 60, 75], ["type I trimeric glycoprotein", "GENE_OR_GENE_PRODUCT", 7, 35], ["virion membrane", "CELLULAR_COMPONENT", 60, 75], ["type I trimeric glycoprotein", "PROTEIN", 7, 35], ["a type I trimeric glycoprotein", "PROBLEM", 5, 35], ["glycoprotein", "OBSERVATION", 23, 35], ["virion membrane", "OBSERVATION", 60, 75], ["crown", "OBSERVATION_MODIFIER", 107, 112]]], ["S is formed by two subunits: S1, or bulb, that contains the RBD (32\u201339); and S2, or stalk, responsible for the fusion of the virion with the host cell membrane (23, 35, 36, 38, 40\u201342).The VirusAs described above, the main receptor for SARS-CoV and SARS-CoV-2 on the membrane of the target cells is the Angiotensin 2 Converting Enzyme (ACE2), a metallopeptidase present on the membrane of many cells, including type-I and -II pneumocytes, small intestine enterocytes, kidney proximal tubules cells, the endothelial cells of arteries and veins, and the arterial smooth muscle, among other tissues (43, 44).", [["bulb", "ANATOMY", 36, 40], ["cell membrane", "ANATOMY", 146, 159], ["membrane", "ANATOMY", 266, 274], ["cells", "ANATOMY", 289, 294], ["membrane", "ANATOMY", 376, 384], ["cells", "ANATOMY", 393, 398], ["pneumocytes", "ANATOMY", 425, 436], ["small intestine enterocytes", "ANATOMY", 438, 465], ["kidney proximal tubules cells", "ANATOMY", 467, 496], ["endothelial cells", "ANATOMY", 502, 519], ["arteries", "ANATOMY", 523, 531], ["veins", "ANATOMY", 536, 541], ["arterial smooth muscle", "ANATOMY", 551, 573], ["tissues", "ANATOMY", 587, 594], ["SARS", "DISEASE", 235, 239], ["Angiotensin", "CHEMICAL", 302, 313], ["S1", "GENE_OR_GENE_PRODUCT", 29, 31], ["bulb", "ORGAN", 36, 40], ["S2", "GENE_OR_GENE_PRODUCT", 77, 79], ["cell membrane", "CELLULAR_COMPONENT", 146, 159], ["VirusAs", "GENE_OR_GENE_PRODUCT", 188, 195], ["SARS-CoV", "ORGANISM", 235, 243], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 248, 258], ["membrane", "CELLULAR_COMPONENT", 266, 274], ["cells", "CELL", 289, 294], ["Angiotensin 2 Converting Enzyme", "GENE_OR_GENE_PRODUCT", 302, 333], ["ACE2", "GENE_OR_GENE_PRODUCT", 335, 339], ["membrane", "CELLULAR_COMPONENT", 376, 384], ["cells", "CELL", 393, 398], ["type-I and -II pneumocytes", "GENE_OR_GENE_PRODUCT", 410, 436], ["small intestine enterocytes", "CELL", 438, 465], ["kidney proximal tubules cells", "CELL", 467, 496], ["endothelial cells", "CELL", 502, 519], ["arteries", "MULTI-TISSUE_STRUCTURE", 523, 531], ["veins", "MULTI-TISSUE_STRUCTURE", 536, 541], ["arterial smooth muscle", "TISSUE", 551, 573], ["tissues", "TISSUE", 587, 594], ["S1", "PROTEIN", 29, 31], ["RBD", "PROTEIN", 60, 63], ["32\u201339", "PROTEIN", 65, 70], ["S2", "PROTEIN", 77, 79], ["VirusAs", "PROTEIN", 188, 195], ["target cells", "CELL_TYPE", 282, 294], ["Angiotensin 2 Converting Enzyme", "PROTEIN", 302, 333], ["ACE2", "PROTEIN", 335, 339], ["metallopeptidase", "PROTEIN", 344, 360], ["type-I and -II pneumocytes", "CELL_TYPE", 410, 436], ["small intestine enterocytes", "CELL_TYPE", 438, 465], ["kidney proximal tubules cells", "CELL_TYPE", 467, 496], ["endothelial cells", "CELL_TYPE", 502, 519], ["SARS-CoV", "SPECIES", 235, 243], ["stalk", "PROBLEM", 84, 89], ["SARS", "PROBLEM", 235, 239], ["CoV", "TEST", 240, 243], ["SARS", "TEST", 248, 252], ["CoV", "TEST", 253, 256], ["the Angiotensin", "TREATMENT", 298, 313], ["a metallopeptidase", "TREATMENT", 342, 360], ["small intestine enterocytes, kidney proximal tubules cells", "PROBLEM", 438, 496], ["S1", "ANATOMY", 29, 31], ["bulb", "ANATOMY", 36, 40], ["RBD", "OBSERVATION", 60, 63], ["S2", "ANATOMY", 77, 79], ["fusion", "OBSERVATION", 111, 117], ["host cell membrane", "OBSERVATION", 141, 159], ["target cells", "OBSERVATION", 282, 294], ["many cells", "OBSERVATION", 388, 398], ["pneumocytes", "OBSERVATION", 425, 436], ["small", "OBSERVATION_MODIFIER", 438, 443], ["intestine enterocytes", "ANATOMY", 444, 465], ["kidney", "ANATOMY", 467, 473], ["proximal", "ANATOMY_MODIFIER", 474, 482], ["tubules cells", "OBSERVATION", 483, 496], ["endothelial cells", "OBSERVATION", 502, 519], ["arteries", "ANATOMY", 523, 531], ["veins", "ANATOMY", 536, 541], ["arterial", "ANATOMY_MODIFIER", 551, 559], ["smooth muscle", "ANATOMY", 560, 573]]], ["RBD-ACE2 binding induces conformational changes on S that lead to cleavage of S1 and S2, a process mediated by the serine protease TMPRSS2, allowing S2 to facilitate the fusion of the virus envelope with the cell membrane, thus permitting viral RNA entrance into the cytoplasm of the target cells (23, 31, 35, 42, 45).", [["cell membrane", "ANATOMY", 208, 221], ["cytoplasm", "ANATOMY", 267, 276], ["cells", "ANATOMY", 291, 296], ["serine", "CHEMICAL", 115, 121], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 0, 8], ["S1", "GENE_OR_GENE_PRODUCT", 78, 80], ["S2", "GENE_OR_GENE_PRODUCT", 85, 87], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 131, 138], ["S2", "GENE_OR_GENE_PRODUCT", 149, 151], ["cell membrane", "CELLULAR_COMPONENT", 208, 221], ["cytoplasm", "ORGANISM_SUBSTANCE", 267, 276], ["cells", "CELL", 291, 296], ["RBD", "PROTEIN", 0, 3], ["ACE2", "PROTEIN", 4, 8], ["S1", "PROTEIN", 78, 80], ["S2", "PROTEIN", 85, 87], ["serine protease", "PROTEIN", 115, 130], ["TMPRSS2", "PROTEIN", 131, 138], ["S2", "PROTEIN", 149, 151], ["target cells", "CELL_TYPE", 284, 296], ["ACE2 binding", "PROBLEM", 4, 16], ["conformational changes on S", "PROBLEM", 25, 52], ["cleavage of S1 and S2", "PROBLEM", 66, 87], ["the serine protease TMPRSS2", "TREATMENT", 111, 138], ["S2", "TREATMENT", 149, 151], ["the fusion", "TREATMENT", 166, 176], ["the virus envelope", "PROBLEM", 180, 198], ["the cell membrane", "TREATMENT", 204, 221], ["ACE2 binding", "OBSERVATION", 4, 16], ["S1", "ANATOMY", 78, 80], ["S2", "ANATOMY", 85, 87], ["virus", "OBSERVATION", 184, 189], ["cell membrane", "OBSERVATION", 208, 221], ["viral RNA", "OBSERVATION", 239, 248], ["cytoplasm", "OBSERVATION_MODIFIER", 267, 276], ["target cells", "OBSERVATION", 284, 296]]], ["Thereafter, viral RNA serves as a template for the translation of the polyproteins pp1a and pp1b that are cleaved into 5\u201316 non-structural proteins (nsp2-nsp9), which in turn induce rearrangement of the membranes to form the vesicles where viral replication and transcription complexes are anchored.", [["membranes", "ANATOMY", 203, 212], ["vesicles", "ANATOMY", 225, 233], ["pp1a", "GENE_OR_GENE_PRODUCT", 83, 87], ["pp1b", "GENE_OR_GENE_PRODUCT", 92, 96], ["5\u201316 non-structural proteins", "GENE_OR_GENE_PRODUCT", 119, 147], ["nsp2-nsp9", "GENE_OR_GENE_PRODUCT", 149, 158], ["membranes", "CELLULAR_COMPONENT", 203, 212], ["vesicles", "CELLULAR_COMPONENT", 225, 233], ["viral RNA", "RNA", 12, 21], ["polyproteins", "PROTEIN", 70, 82], ["pp1a", "PROTEIN", 83, 87], ["pp1b", "PROTEIN", 92, 96], ["5\u201316 non-structural proteins", "PROTEIN", 119, 147], ["nsp2", "PROTEIN", 149, 153], ["nsp9", "PROTEIN", 154, 158], ["transcription complexes", "PROTEIN", 262, 285], ["viral RNA serves", "PROBLEM", 12, 28], ["a template", "TREATMENT", 32, 42], ["the polyproteins pp1a", "TREATMENT", 66, 87], ["pp1b", "TREATMENT", 92, 96], ["non-structural proteins", "TEST", 124, 147], ["nsp2", "TEST", 149, 153], ["rearrangement of the membranes", "PROBLEM", 182, 212], ["the vesicles", "PROBLEM", 221, 233], ["viral replication and transcription complexes", "TREATMENT", 240, 285], ["viral RNA", "OBSERVATION", 12, 21], ["vesicles", "ANATOMY", 225, 233], ["viral replication", "OBSERVATION", 240, 257]]], ["The virions are assembled in the ER-Golgi and mature virions are subsequently released by the secretory pathway (23).The InfectionThe COVID-19 pathological process exhibits a wide spectrum of clinical manifestations, ranging from asymptomatic infections, to mild (common cold-type), moderate, and finally severe (~15%) infections; the latter frequently requires hospitalization in ICU to ensure assisted respiratory support and other medical treatments until recovery, or possibly death, of the patient.", [["virions", "ANATOMY", 4, 11], ["ER-Golgi", "ANATOMY", 33, 41], ["virions", "ANATOMY", 53, 60], ["respiratory", "ANATOMY", 404, 415], ["infections", "DISEASE", 243, 253], ["infections", "DISEASE", 319, 329], ["death", "DISEASE", 481, 486], ["ER", "GENE_OR_GENE_PRODUCT", 33, 35], ["Golgi", "CELLULAR_COMPONENT", 36, 41], ["patient", "ORGANISM", 495, 502], ["ER", "PROTEIN", 33, 35], ["patient", "SPECIES", 495, 502], ["The Infection", "PROBLEM", 117, 130], ["The COVID", "TEST", 130, 139], ["pathological process", "PROBLEM", 143, 163], ["clinical manifestations", "PROBLEM", 192, 215], ["asymptomatic infections", "PROBLEM", 230, 253], ["mild (common cold-type)", "PROBLEM", 258, 281], ["finally severe (~15%) infections", "PROBLEM", 297, 329], ["assisted respiratory support", "TREATMENT", 395, 423], ["other medical treatments", "TREATMENT", 428, 452], ["virions", "OBSERVATION", 4, 11], ["mature", "OBSERVATION_MODIFIER", 46, 52], ["virions", "OBSERVATION", 53, 60], ["Infection", "OBSERVATION", 121, 130], ["wide spectrum", "OBSERVATION_MODIFIER", 175, 188], ["asymptomatic", "OBSERVATION_MODIFIER", 230, 242], ["infections", "OBSERVATION", 243, 253], ["mild", "OBSERVATION_MODIFIER", 258, 262], ["moderate", "OBSERVATION_MODIFIER", 283, 291], ["severe", "OBSERVATION_MODIFIER", 305, 311], ["infections", "OBSERVATION", 319, 329]]], ["The wide spectrum of clinical manifestations found in COVID-19 patients has been associated with risk factors such as gender and age.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["clinical manifestations", "PROBLEM", 21, 44], ["risk factors", "PROBLEM", 97, 109], ["wide", "OBSERVATION_MODIFIER", 4, 8]]], ["Diabetes, cardiovascular disease, or diseases, or treatments affecting the immune system result in the highest risk of severe disease and death (6, 8, 8, 46\u201348).", [["cardiovascular", "ANATOMY", 10, 24], ["immune system", "ANATOMY", 75, 88], ["Diabetes", "DISEASE", 0, 8], ["cardiovascular disease", "DISEASE", 10, 32], ["death", "DISEASE", 138, 143], ["cardiovascular", "ANATOMICAL_SYSTEM", 10, 24], ["Diabetes", "PROBLEM", 0, 8], ["cardiovascular disease", "PROBLEM", 10, 32], ["diseases", "PROBLEM", 37, 45], ["treatments", "TREATMENT", 50, 60], ["the immune system", "TEST", 71, 88], ["severe disease", "PROBLEM", 119, 133], ["death", "PROBLEM", 138, 143], ["cardiovascular", "ANATOMY", 10, 24], ["disease", "OBSERVATION", 25, 32], ["diseases", "OBSERVATION", 37, 45], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["disease", "OBSERVATION", 126, 133]]], ["It is, however, estimated that nearly 80% of all infections remain undocumented, either because patients are asymptomatic or present with very mild symptoms (49).", [["infections", "DISEASE", 49, 59], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["all infections", "PROBLEM", 45, 59], ["asymptomatic", "PROBLEM", 109, 121], ["very mild symptoms", "PROBLEM", 138, 156], ["infections", "OBSERVATION", 49, 59], ["mild", "OBSERVATION_MODIFIER", 143, 147]]], ["From the epidemiological point of view, these inapparently infected persons may have low viral loads, while still disseminating the virus and can therefore be responsible either for silent epidemics, leading to infection in more susceptible people who will eventually develop a clinical disease, or for contributing to the establishment of herd immunity (28, 50).The InfectionSARS-CoV-2 is acquired by exposure to microdroplets present in the exhalates of infected individuals or by contact with viral particles present in contaminated fomites.", [["fomites", "ANATOMY", 536, 543], ["infection", "DISEASE", 211, 220], ["persons", "ORGANISM", 68, 75], ["people", "ORGANISM", 241, 247], ["herd", "ORGANISM_SUBDIVISION", 340, 344], ["InfectionSARS-CoV-2", "ORGANISM", 367, 386], ["persons", "SPECIES", 68, 75], ["people", "SPECIES", 241, 247], ["low viral loads", "PROBLEM", 85, 100], ["the virus", "PROBLEM", 128, 137], ["silent epidemics", "PROBLEM", 182, 198], ["infection", "PROBLEM", 211, 220], ["a clinical disease", "PROBLEM", 276, 294], ["microdroplets", "TREATMENT", 414, 427], ["infected individuals", "PROBLEM", 456, 476], ["viral particles", "PROBLEM", 496, 511], ["infected", "OBSERVATION", 59, 67], ["virus", "OBSERVATION", 132, 137], ["infection", "OBSERVATION", 211, 220], ["infected", "OBSERVATION", 456, 464], ["viral particles", "OBSERVATION", 496, 511], ["contaminated fomites", "OBSERVATION", 523, 543]]], ["Once the virus reaches the bronchioles and alveolar spaces, the main targets are the cells of the bronchial epithelium and the type-II ACE2+ pneumocytes of the alveolar epithelium.", [["bronchioles", "ANATOMY", 27, 38], ["alveolar spaces", "ANATOMY", 43, 58], ["cells", "ANATOMY", 85, 90], ["bronchial epithelium", "ANATOMY", 98, 118], ["type-II ACE2+ pneumocytes", "ANATOMY", 127, 152], ["alveolar epithelium", "ANATOMY", 160, 179], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 27, 38], ["alveolar spaces", "MULTI-TISSUE_STRUCTURE", 43, 58], ["cells", "CELL", 85, 90], ["bronchial epithelium", "TISSUE", 98, 118], ["ACE2", "GENE_OR_GENE_PRODUCT", 135, 139], ["alveolar epithelium", "TISSUE", 160, 179], ["ACE2", "PROTEIN", 135, 139], ["the type-II ACE2", "TEST", 123, 139], ["pneumocytes of the alveolar epithelium", "PROBLEM", 141, 179], ["virus", "OBSERVATION", 9, 14], ["bronchioles", "ANATOMY", 27, 38], ["alveolar", "ANATOMY_MODIFIER", 43, 51], ["main", "OBSERVATION_MODIFIER", 64, 68], ["bronchial", "ANATOMY", 98, 107], ["epithelium", "ANATOMY_MODIFIER", 108, 118], ["+ pneumocytes", "OBSERVATION", 139, 152], ["alveolar", "ANATOMY_MODIFIER", 160, 168], ["epithelium", "ANATOMY_MODIFIER", 169, 179]]], ["SARS-CoV infection induces autophagy (51, 52), detachment of the basal membrane, and inhibition of ACE2 expression (20, 53), hence allowing angiotensin II to bind the AT1aR receptor, resulting in acute lung damage (54).", [["basal membrane", "ANATOMY", 65, 79], ["lung", "ANATOMY", 202, 206], ["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 9, 18], ["angiotensin II", "CHEMICAL", 140, 154], ["acute lung damage", "DISEASE", 196, 213], ["SARS-CoV", "ORGANISM", 0, 8], ["basal membrane", "CELLULAR_COMPONENT", 65, 79], ["ACE2", "GENE_OR_GENE_PRODUCT", 99, 103], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 140, 154], ["AT1aR receptor", "GENE_OR_GENE_PRODUCT", 167, 181], ["lung", "ORGAN", 202, 206], ["ACE2", "PROTEIN", 99, 103], ["angiotensin II", "PROTEIN", 140, 154], ["AT1aR receptor", "PROTEIN", 167, 181], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV infection", "PROBLEM", 5, 18], ["autophagy", "PROBLEM", 27, 36], ["detachment of the basal membrane", "PROBLEM", 47, 79], ["ACE2 expression", "TEST", 99, 114], ["angiotensin II", "TREATMENT", 140, 154], ["acute lung damage", "PROBLEM", 196, 213], ["CoV", "OBSERVATION_MODIFIER", 5, 8], ["infection", "OBSERVATION", 9, 18], ["detachment", "OBSERVATION", 47, 57], ["basal membrane", "ANATOMY", 65, 79], ["acute", "OBSERVATION_MODIFIER", 196, 201], ["lung", "ANATOMY", 202, 206], ["damage", "OBSERVATION", 207, 213]]], ["Importantly, the main early defense mechanism of the infected cell is the production of type-I and type -III IFN and, although coronaviruses are sensitive to their anti-viral effects, they are able to inhibit its induction (16, 20, 52, 55).", [["cell", "ANATOMY", 62, 66], ["cell", "CELL", 62, 66], ["type-I", "GENE_OR_GENE_PRODUCT", 88, 94], ["type -III IFN", "GENE_OR_GENE_PRODUCT", 99, 112], ["IFN", "PROTEIN", 109, 112], ["the infected cell", "PROBLEM", 49, 66], ["type-I and type -III IFN", "PROBLEM", 88, 112], ["coronaviruses", "PROBLEM", 127, 140], ["main", "OBSERVATION_MODIFIER", 17, 21], ["early", "OBSERVATION_MODIFIER", 22, 27], ["defense mechanism", "OBSERVATION", 28, 45], ["infected cell", "OBSERVATION", 53, 66]]], ["The release of large number of virions leads to both infection of neighboring target cells and viremia, the latter resulting in systemic infection since ACE2+ cells are widely distributed in many tissues (43, 44).The Innate Immune ResponseDuring viral infections, after viruses enter the host cells they are recognized by Pattern Recognition Receptors (PRR) such as TLR7 and TLR8 in the case of single-stranded RNA viruses, RIG-I-like (RLRs), and NLR, all expressed by epithelial cells as well as by local cells of the innate immune response, such as alveolar macrophages (23).", [["virions", "ANATOMY", 31, 38], ["cells", "ANATOMY", 85, 90], ["ACE2+ cells", "ANATOMY", 153, 164], ["tissues", "ANATOMY", 196, 203], ["cells", "ANATOMY", 293, 298], ["epithelial cells", "ANATOMY", 469, 485], ["cells", "ANATOMY", 506, 511], ["alveolar macrophages", "ANATOMY", 551, 571], ["infection", "DISEASE", 53, 62], ["viremia", "DISEASE", 95, 102], ["infection", "DISEASE", 137, 146], ["viral infections", "DISEASE", 246, 262], ["cells", "CELL", 85, 90], ["ACE2", "GENE_OR_GENE_PRODUCT", 153, 157], ["tissues", "TISSUE", 196, 203], ["Innate Immune ResponseDuring viral", "ORGANISM", 217, 251], ["host cells", "CELL", 288, 298], ["Pattern Recognition Receptors", "GENE_OR_GENE_PRODUCT", 322, 351], ["PRR", "GENE_OR_GENE_PRODUCT", 353, 356], ["TLR7", "GENE_OR_GENE_PRODUCT", 366, 370], ["TLR8", "GENE_OR_GENE_PRODUCT", 375, 379], ["RIG-I-like", "GENE_OR_GENE_PRODUCT", 424, 434], ["RLRs", "GENE_OR_GENE_PRODUCT", 436, 440], ["NLR", "GENE_OR_GENE_PRODUCT", 447, 450], ["epithelial cells", "CELL", 469, 485], ["cells", "CELL", 506, 511], ["alveolar macrophages", "CELL", 551, 571], ["neighboring target cells", "CELL_TYPE", 66, 90], ["ACE2", "PROTEIN", 153, 157], ["host cells", "CELL_TYPE", 288, 298], ["Pattern Recognition Receptors", "PROTEIN", 322, 351], ["PRR", "PROTEIN", 353, 356], ["TLR7", "PROTEIN", 366, 370], ["TLR8", "PROTEIN", 375, 379], ["RLRs", "PROTEIN", 436, 440], ["NLR", "PROTEIN", 447, 450], ["epithelial cells", "CELL_TYPE", 469, 485], ["alveolar macrophages", "CELL_TYPE", 551, 571], ["virions", "TREATMENT", 31, 38], ["neighboring target cells", "PROBLEM", 66, 90], ["viremia", "PROBLEM", 95, 102], ["systemic infection", "PROBLEM", 128, 146], ["ACE2+ cells", "PROBLEM", 153, 164], ["viral infections", "PROBLEM", 246, 262], ["viruses", "PROBLEM", 270, 277], ["TLR7 and TLR8", "TREATMENT", 366, 379], ["single-stranded RNA viruses", "PROBLEM", 395, 422], ["NLR", "TEST", 447, 450], ["epithelial cells", "PROBLEM", 469, 485], ["large", "OBSERVATION_MODIFIER", 15, 20], ["number", "OBSERVATION_MODIFIER", 21, 27], ["virions", "OBSERVATION", 31, 38], ["both", "OBSERVATION_MODIFIER", 48, 52], ["infection", "OBSERVATION", 53, 62], ["neighboring target cells", "OBSERVATION", 66, 90], ["viremia", "OBSERVATION", 95, 102], ["systemic", "OBSERVATION_MODIFIER", 128, 136], ["infection", "OBSERVATION", 137, 146], ["+ cells", "OBSERVATION", 157, 164], ["widely", "OBSERVATION_MODIFIER", 169, 175], ["distributed", "OBSERVATION_MODIFIER", 176, 187], ["many tissues", "OBSERVATION_MODIFIER", 191, 203], ["viral infections", "OBSERVATION", 246, 262], ["RNA viruses", "OBSERVATION", 411, 422], ["epithelial cells", "OBSERVATION", 469, 485], ["immune response", "OBSERVATION", 526, 541], ["alveolar macrophages", "OBSERVATION", 551, 571]]], ["Upon ligand binding, PRRs recruit adaptor proteins which activate crucial down-stream transcription factors, including interferon regulatory factor (IRF), NF-\u03baB, and AP-1, resulting in production of the Type-I and -III antiviral Interferons and different chemokines (56).", [["PRRs", "GENE_OR_GENE_PRODUCT", 21, 25], ["interferon regulatory factor", "GENE_OR_GENE_PRODUCT", 119, 147], ["IRF", "GENE_OR_GENE_PRODUCT", 149, 152], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 155, 160], ["AP-1", "GENE_OR_GENE_PRODUCT", 166, 170], ["Type-I", "GENE_OR_GENE_PRODUCT", 203, 209], ["-III", "GENE_OR_GENE_PRODUCT", 214, 218], ["PRRs", "PROTEIN", 21, 25], ["adaptor proteins", "PROTEIN", 34, 50], ["transcription factors", "PROTEIN", 86, 107], ["interferon regulatory factor", "PROTEIN", 119, 147], ["IRF", "PROTEIN", 149, 152], ["NF-\u03baB", "PROTEIN", 155, 160], ["AP-1", "PROTEIN", 166, 170], ["Type-I and -III antiviral Interferons", "PROTEIN", 203, 240], ["chemokines", "PROTEIN", 255, 265], ["ligand binding", "PROBLEM", 5, 19], ["PRRs recruit adaptor proteins", "PROBLEM", 21, 50], ["crucial down", "PROBLEM", 66, 78], ["stream transcription factors", "PROBLEM", 79, 107], ["interferon regulatory factor", "TEST", 119, 147], ["NF", "TEST", 155, 157], ["AP", "TEST", 166, 168], ["the Type-I and -III antiviral Interferons", "TREATMENT", 199, 240], ["different chemokines", "TREATMENT", 245, 265]]], ["These chemokines attract more innate response cells [polymorphonuclear leukocytes, monocytes, NK cells, dendritic cells (DC)], which also produce chemokines, such as MIG, IP-10, and MCP-1, capable of recruiting lymphocytes, which in turn, will recognize the viral antigens presented by DCs (20, 22).", [["cells", "ANATOMY", 46, 51], ["polymorphonuclear leukocytes", "ANATOMY", 53, 81], ["monocytes", "ANATOMY", 83, 92], ["NK cells", "ANATOMY", 94, 102], ["dendritic cells", "ANATOMY", 104, 119], ["DC", "ANATOMY", 121, 123], ["lymphocytes", "ANATOMY", 211, 222], ["DCs", "ANATOMY", 286, 289], ["cells", "CELL", 46, 51], ["polymorphonuclear leukocytes", "CELL", 53, 81], ["monocytes", "CELL", 83, 92], ["NK cells", "CELL", 94, 102], ["dendritic cells", "CELL", 104, 119], ["DC", "CELL", 121, 123], ["MIG", "GENE_OR_GENE_PRODUCT", 166, 169], ["IP-10", "GENE_OR_GENE_PRODUCT", 171, 176], ["MCP-1", "GENE_OR_GENE_PRODUCT", 182, 187], ["lymphocytes", "CELL", 211, 222], ["DCs", "CELL", 286, 289], ["chemokines", "PROTEIN", 6, 16], ["innate response cells", "CELL_TYPE", 30, 51], ["polymorphonuclear leukocytes", "CELL_TYPE", 53, 81], ["monocytes", "CELL_TYPE", 83, 92], ["NK cells", "CELL_TYPE", 94, 102], ["dendritic cells", "CELL_TYPE", 104, 119], ["DC", "CELL_TYPE", 121, 123], ["chemokines", "PROTEIN", 146, 156], ["MIG", "PROTEIN", 166, 169], ["IP-10", "PROTEIN", 171, 176], ["MCP", "PROTEIN", 182, 185], ["lymphocytes", "CELL_TYPE", 211, 222], ["viral antigens", "PROTEIN", 258, 272], ["DCs", "CELL_TYPE", 286, 289], ["These chemokines", "TEST", 0, 16], ["innate response cells", "TEST", 30, 51], ["polymorphonuclear leukocytes", "TEST", 53, 81], ["monocytes", "TEST", 83, 92], ["NK cells", "TEST", 94, 102], ["dendritic cells", "PROBLEM", 104, 119], ["chemokines", "TEST", 146, 156], ["MIG", "TEST", 166, 169], ["IP", "TEST", 171, 173], ["MCP", "TEST", 182, 185], ["recruiting lymphocytes", "PROBLEM", 200, 222], ["the viral antigens", "PROBLEM", 254, 272], ["polymorphonuclear leukocytes", "OBSERVATION", 53, 81], ["NK cells", "OBSERVATION", 94, 102], ["dendritic cells", "OBSERVATION", 104, 119], ["chemokines", "OBSERVATION", 146, 156], ["recruiting lymphocytes", "OBSERVATION", 200, 222]]], ["Recent publications highlight the initial phases of the SARS-CoV-2 infection, compared to other coronavirus, and their effects on subsequent immune and inflammatory responses.", [["SARS", "DISEASE", 56, 60], ["infection", "DISEASE", 67, 76], ["SARS-CoV-2", "ORGANISM", 56, 66], ["coronavirus", "ORGANISM", 96, 107], ["SARS-CoV-2", "SPECIES", 56, 66], ["Recent publications", "PROBLEM", 0, 19], ["the SARS", "PROBLEM", 52, 60], ["CoV-2 infection", "PROBLEM", 61, 76], ["other coronavirus", "PROBLEM", 90, 107], ["publications", "OBSERVATION", 7, 19], ["infection", "OBSERVATION", 67, 76], ["inflammatory", "OBSERVATION_MODIFIER", 152, 164]]], ["Chu et al. (57) compared the in vitro infection of human lung explants with SARS-CoV and SARS-CoV-2 and demonstrated that both viruses can equally infect type-I and -II pneumocytes, plus alveolar macrophages, although SARS-CoV2 had a better capacity to replicate in pulmonary tissues.", [["lung explants", "ANATOMY", 57, 70], ["pneumocytes", "ANATOMY", 169, 180], ["alveolar macrophages", "ANATOMY", 187, 207], ["pulmonary tissues", "ANATOMY", 266, 283], ["infection", "DISEASE", 38, 47], ["human", "ORGANISM", 51, 56], ["lung explants", "TISSUE", 57, 70], ["SARS-CoV", "ORGANISM", 76, 84], ["SARS-CoV-2", "ORGANISM", 89, 99], ["-II pneumocytes", "CELL", 165, 180], ["alveolar macrophages", "CELL", 187, 207], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 218, 227], ["pulmonary tissues", "TISSUE", 266, 283], ["type-I and -II pneumocytes", "CELL_TYPE", 154, 180], ["alveolar macrophages", "CELL_TYPE", 187, 207], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["SARS-CoV", "SPECIES", 76, 84], ["SARS-CoV", "SPECIES", 89, 97], ["human lung explants", "PROBLEM", 51, 70], ["SARS", "PROBLEM", 76, 80], ["CoV", "PROBLEM", 81, 84], ["SARS", "PROBLEM", 89, 93], ["CoV", "TEST", 94, 97], ["both viruses", "PROBLEM", 122, 134], ["II pneumocytes", "PROBLEM", 166, 180], ["alveolar macrophages", "PROBLEM", 187, 207], ["SARS", "PROBLEM", 218, 222], ["infection", "OBSERVATION", 38, 47], ["lung", "ANATOMY", 57, 61], ["viruses", "OBSERVATION", 127, 134], ["alveolar macrophages", "OBSERVATION", 187, 207], ["pulmonary tissues", "ANATOMY", 266, 283]]], ["Interestingly, while SARS-CoV induced the expression of IFN-I, IFN-II, and IFN-III, SARS-CoV-2 failed to induce any such immune mediators and was also less efficient in inducting other cytokines.", [["SARS-CoV", "ORGANISM", 21, 29], ["IFN-I", "GENE_OR_GENE_PRODUCT", 56, 61], ["IFN-II", "GENE_OR_GENE_PRODUCT", 63, 69], ["IFN-III", "GENE_OR_GENE_PRODUCT", 75, 82], ["SARS-CoV-2", "ORGANISM", 84, 94], ["IFN", "PROTEIN", 56, 59], ["IFN", "PROTEIN", 63, 66], ["IFN-III", "PROTEIN", 75, 82], ["cytokines", "PROTEIN", 185, 194], ["SARS-CoV", "SPECIES", 21, 29], ["SARS", "PROBLEM", 21, 25], ["IFN", "TEST", 56, 59], ["IFN", "TEST", 63, 66], ["IFN", "TEST", 75, 78], ["SARS", "PROBLEM", 84, 88]]], ["SARS-CoV induced the production of the 11 cytokines studied, while SARS-CoV-2 induced only five (IL-6, MCP1, CXCL1, CXCL5, and CXCL10/IP10).", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 67, 77], ["IL-6", "GENE_OR_GENE_PRODUCT", 97, 101], ["MCP1", "GENE_OR_GENE_PRODUCT", 103, 107], ["CXCL1", "GENE_OR_GENE_PRODUCT", 109, 114], ["CXCL5", "GENE_OR_GENE_PRODUCT", 116, 121], ["CXCL10", "GENE_OR_GENE_PRODUCT", 127, 133], ["IP10", "GENE_OR_GENE_PRODUCT", 134, 138], ["cytokines", "PROTEIN", 42, 51], ["MCP1", "PROTEIN", 103, 107], ["CXCL1", "PROTEIN", 109, 114], ["CXCL5", "PROTEIN", 116, 121], ["CXCL10", "PROTEIN", 127, 133], ["IP10", "PROTEIN", 134, 138], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 67, 75], ["SARS", "PROBLEM", 0, 4], ["SARS", "TEST", 67, 71], ["CoV", "TEST", 72, 75], ["IL", "TEST", 97, 99], ["MCP1", "TEST", 103, 107], ["CXCL1", "TEST", 109, 114], ["CXCL5", "TEST", 116, 121], ["CXCL10/IP10", "TREATMENT", 127, 138]]], ["Blanco-Melo et al. (55) studied the transcriptional response to SARS-CoV-2, compared to SAR-CoV, MERS-CoV, respiratory syncytial virus (RSV), parainfluenza virus 3 (HPIV3), and influenza A virus (IAV), in in vitro infection of respiratory cell lines, experimental in vivo infection of ferrets, and post-mortem lung samples of COVID-19 patients.", [["respiratory cell lines", "ANATOMY", 227, 249], ["lung samples", "ANATOMY", 310, 322], ["respiratory syncytial virus", "DISEASE", 107, 134], ["influenza A virus", "DISEASE", 177, 194], ["infection", "DISEASE", 214, 223], ["infection", "DISEASE", 272, 281], ["SARS-CoV-2", "ORGANISM", 64, 74], ["SAR-CoV", "ORGANISM", 88, 95], ["MERS-CoV,", "ORGANISM", 97, 106], ["respiratory syncytial virus", "ORGANISM", 107, 134], ["RSV", "ORGANISM", 136, 139], ["parainfluenza virus 3", "ORGANISM", 142, 163], ["HPIV3", "ORGANISM", 165, 170], ["influenza A virus", "ORGANISM", 177, 194], ["IAV", "ORGANISM", 196, 199], ["respiratory cell lines", "CELL", 227, 249], ["ferrets", "ORGANISM", 285, 292], ["post-mortem lung samples", "CANCER", 298, 322], ["patients", "ORGANISM", 335, 343], ["respiratory cell lines", "CELL_LINE", 227, 249], ["respiratory syncytial virus", "SPECIES", 107, 134], ["parainfluenza virus", "SPECIES", 142, 161], ["influenza A virus", "SPECIES", 177, 194], ["ferrets", "SPECIES", 285, 292], ["patients", "SPECIES", 335, 343], ["SARS-CoV", "SPECIES", 64, 72], ["SAR-CoV", "SPECIES", 88, 95], ["MERS-CoV", "SPECIES", 97, 105], ["respiratory syncytial virus", "SPECIES", 107, 134], ["RSV", "SPECIES", 136, 139], ["parainfluenza virus", "SPECIES", 142, 161], ["HPIV3", "SPECIES", 165, 170], ["influenza A virus", "SPECIES", 177, 194], ["IAV", "SPECIES", 196, 199], ["ferrets", "SPECIES", 285, 292], ["SARS", "TEST", 64, 68], ["CoV", "TEST", 69, 72], ["SAR", "TEST", 88, 91], ["CoV", "TEST", 92, 95], ["MERS", "TEST", 97, 101], ["CoV", "TEST", 102, 105], ["respiratory syncytial virus", "PROBLEM", 107, 134], ["parainfluenza virus", "PROBLEM", 142, 161], ["influenza A virus", "PROBLEM", 177, 194], ["respiratory cell lines", "TREATMENT", 227, 249], ["experimental in vivo infection of ferrets", "PROBLEM", 251, 292], ["post-mortem lung samples", "TEST", 298, 322], ["COVID", "TEST", 326, 331], ["respiratory syncytial", "ANATOMY", 107, 128], ["parainfluenza virus", "OBSERVATION", 142, 161], ["infection", "OBSERVATION", 214, 223], ["respiratory cell lines", "OBSERVATION", 227, 249], ["infection", "OBSERVATION", 272, 281], ["lung", "ANATOMY", 310, 314]]], ["Their results show that SARS-CoV-2 induces a particular signature characterized by reduced IFN-I and IFN-III responses and significant induction of multiple proinflammatory chemokines, IL-1B, IL-6, TNF, and IL1RA.", [["SARS", "DISEASE", 24, 28], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 24, 34], ["IFN-I", "GENE_OR_GENE_PRODUCT", 91, 96], ["IFN-III", "GENE_OR_GENE_PRODUCT", 101, 108], ["IL-1B", "GENE_OR_GENE_PRODUCT", 185, 190], ["IL-6", "GENE_OR_GENE_PRODUCT", 192, 196], ["TNF", "GENE_OR_GENE_PRODUCT", 198, 201], ["IL1RA", "GENE_OR_GENE_PRODUCT", 207, 212], ["IFN", "PROTEIN", 91, 94], ["IFN", "PROTEIN", 101, 104], ["proinflammatory chemokines", "PROTEIN", 157, 183], ["IL-1B", "PROTEIN", 185, 190], ["IL-6", "PROTEIN", 192, 196], ["TNF", "PROTEIN", 198, 201], ["IL1RA", "PROTEIN", 207, 212], ["SARS-CoV", "SPECIES", 24, 32], ["SARS", "TEST", 24, 28], ["CoV", "TEST", 29, 32], ["multiple proinflammatory chemokines", "TEST", 148, 183], ["IL", "TEST", 185, 187], ["IL", "TEST", 192, 194], ["TNF", "TREATMENT", 198, 201], ["IL1RA", "TREATMENT", 207, 212]]], ["These findings were further supported by the increased serum levels of these molecules in COVID-19 patients.", [["serum", "ANATOMY", 55, 60], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["the increased serum levels", "PROBLEM", 41, 67], ["COVID", "TEST", 90, 95], ["increased", "OBSERVATION_MODIFIER", 45, 54]]], ["Altogether, these reports strongly suggest that SARS-CoV-2 differs from other coronaviruses in its capacity to replicate within the pulmonary tissue, elude from the antiviral effects of IFN-I and IFN-III, activate innate responses, and induce the production of the cytokines required for the recruitment of adaptive immunity cells.Adaptive Immune ResponseThe transition between innate and adaptive immune responses is critical for the clinical progress of SARS-CoV-2 infection.", [["pulmonary tissue", "ANATOMY", 132, 148], ["cells", "ANATOMY", 325, 330], ["SARS", "DISEASE", 48, 52], ["SARS-CoV-2 infection", "DISEASE", 456, 476], ["SARS-CoV-2", "ORGANISM", 48, 58], ["coronaviruses", "ORGANISM", 78, 91], ["pulmonary tissue", "TISSUE", 132, 148], ["IFN-I", "GENE_OR_GENE_PRODUCT", 186, 191], ["IFN-III", "GENE_OR_GENE_PRODUCT", 196, 203], ["cells", "CELL", 325, 330], ["SARS-CoV-2", "ORGANISM", 456, 466], ["IFN", "PROTEIN", 186, 189], ["IFN-III", "PROTEIN", 196, 203], ["cytokines", "PROTEIN", 265, 274], ["adaptive immunity cells", "CELL_TYPE", 307, 330], ["SARS-CoV-2", "SPECIES", 456, 466], ["SARS-CoV-2", "PROBLEM", 48, 58], ["other coronaviruses in its capacity", "PROBLEM", 72, 107], ["IFN", "TEST", 186, 189], ["the cytokines", "PROBLEM", 261, 274], ["the recruitment of adaptive immunity cells", "TREATMENT", 288, 330], ["SARS", "PROBLEM", 456, 460], ["CoV-2 infection", "PROBLEM", 461, 476], ["coronaviruses", "OBSERVATION", 78, 91], ["pulmonary tissue", "ANATOMY", 132, 148], ["infection", "OBSERVATION", 467, 476]]], ["It is at this crucial moment when immune regulatory events, still poorly understood, will lead to the development of either a protective immune response or an exacerbated inflammatory response (18, 19, 58, 59).", [["immune regulatory events", "PROBLEM", 34, 58], ["a protective immune response", "PROBLEM", 124, 152], ["an exacerbated inflammatory response", "PROBLEM", 156, 192], ["exacerbated", "OBSERVATION_MODIFIER", 159, 170], ["inflammatory", "OBSERVATION_MODIFIER", 171, 183]]], ["The protective response is T cell dependent, with CD4 helping B cells, geared toward the production of specific neutralizing antibodies, and cytotoxic CD8 cells capable of eliminating infected cells.", [["T cell", "ANATOMY", 27, 33], ["B cells", "ANATOMY", 62, 69], ["CD8 cells", "ANATOMY", 151, 160], ["cells", "ANATOMY", 193, 198], ["T cell", "CELL", 27, 33], ["CD4", "GENE_OR_GENE_PRODUCT", 50, 53], ["B cells", "CELL", 62, 69], ["CD8 cells", "CELL", 151, 160], ["cells", "CELL", 193, 198], ["CD4", "PROTEIN", 50, 53], ["B cells", "CELL_TYPE", 62, 69], ["neutralizing antibodies", "PROTEIN", 112, 135], ["cytotoxic CD8 cells", "CELL_TYPE", 141, 160], ["infected cells", "CELL_TYPE", 184, 198], ["T cell dependent", "PROBLEM", 27, 43], ["CD4 helping B cells", "PROBLEM", 50, 69], ["specific neutralizing antibodies", "TEST", 103, 135], ["cytotoxic CD8 cells", "TEST", 141, 160], ["infected cells", "PROBLEM", 184, 198], ["cell dependent", "OBSERVATION", 29, 43], ["neutralizing antibodies", "OBSERVATION", 112, 135], ["cytotoxic CD8 cells", "OBSERVATION", 141, 160], ["infected cells", "OBSERVATION", 184, 198]]], ["It is worth noting that 80% of the infiltrating cells in COVID-19 are CD8 (16).", [["infiltrating cells", "ANATOMY", 35, 53], ["cells", "CELL", 48, 53], ["COVID-19", "CANCER", 57, 65], ["CD8", "GENE_OR_GENE_PRODUCT", 70, 73], ["infiltrating cells", "CELL_TYPE", 35, 53], ["the infiltrating cells", "TEST", 31, 53], ["COVID", "TEST", 57, 62], ["CD8", "TEST", 70, 73], ["infiltrating cells", "OBSERVATION", 35, 53]]], ["Contrariwise, a dysfunctional response, unable to inhibit viral replication and elimination of the infected cells, may result in an exacerbated inflammatory response leading possibly to a cytokine storm, manifested clinically by severe acute respiratory distress syndrome (ARDS) and systemic consequences, such as disseminated intravascular coagulation.", [["cells", "ANATOMY", 108, 113], ["respiratory", "ANATOMY", 242, 253], ["intravascular", "ANATOMY", 327, 340], ["acute respiratory distress syndrome", "DISEASE", 236, 271], ["ARDS", "DISEASE", 273, 277], ["disseminated intravascular coagulation", "DISEASE", 314, 352], ["cells", "CELL", 108, 113], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 327, 340], ["infected cells", "CELL_TYPE", 99, 113], ["cytokine", "PROTEIN", 188, 196], ["a dysfunctional response", "PROBLEM", 14, 38], ["viral replication", "PROBLEM", 58, 75], ["the infected cells", "PROBLEM", 95, 113], ["an exacerbated inflammatory response", "PROBLEM", 129, 165], ["a cytokine storm", "PROBLEM", 186, 202], ["severe acute respiratory distress syndrome", "PROBLEM", 229, 271], ["ARDS", "PROBLEM", 273, 277], ["systemic consequences", "PROBLEM", 283, 304], ["disseminated intravascular coagulation", "PROBLEM", 314, 352], ["infected cells", "OBSERVATION", 99, 113], ["exacerbated", "OBSERVATION_MODIFIER", 132, 143], ["inflammatory", "OBSERVATION", 144, 156], ["cytokine storm", "OBSERVATION", 188, 202], ["severe", "OBSERVATION_MODIFIER", 229, 235], ["acute", "OBSERVATION_MODIFIER", 236, 241], ["respiratory distress syndrome", "OBSERVATION", 242, 271], ["disseminated", "OBSERVATION_MODIFIER", 314, 326], ["intravascular coagulation", "OBSERVATION", 327, 352]]], ["In a SARS-CoV primate model of infection, Clay et al. (60) showed that the virus replicated in the lungs until Day 10 post-infection; but, surprisingly, lung inflammation was more intense after virus clearance, reaching its peak at Day 14 and remaining so until Day 28.", [["lungs", "ANATOMY", 99, 104], ["lung", "ANATOMY", 153, 157], ["infection", "DISEASE", 31, 40], ["infection", "DISEASE", 123, 132], ["lung inflammation", "DISEASE", 153, 170], ["lungs", "ORGAN", 99, 104], ["lung", "ORGAN", 153, 157], ["SARS-CoV", "SPECIES", 5, 13], ["a SARS", "PROBLEM", 3, 9], ["infection", "PROBLEM", 31, 40], ["the virus", "PROBLEM", 71, 80], ["infection", "PROBLEM", 123, 132], ["lung inflammation", "PROBLEM", 153, 170], ["virus clearance", "TEST", 194, 209], ["SARS", "OBSERVATION", 5, 9], ["CoV primate", "OBSERVATION_MODIFIER", 10, 21], ["infection", "OBSERVATION", 31, 40], ["virus", "OBSERVATION", 75, 80], ["lungs", "ANATOMY", 99, 104], ["infection", "OBSERVATION", 123, 132], ["lung", "ANATOMY", 153, 157], ["inflammation", "OBSERVATION", 158, 170], ["intense", "OBSERVATION_MODIFIER", 180, 187]]], ["These results suggest that an early phase dependent on virus replication does occur, while a later viral-independent, immune-dependent phase seems to be accompanied by an exacerbated inflammatory component.", [["an early phase dependent on virus replication", "PROBLEM", 27, 72], ["an exacerbated inflammatory component", "PROBLEM", 168, 205], ["early", "OBSERVATION_MODIFIER", 30, 35], ["phase", "OBSERVATION_MODIFIER", 36, 41], ["dependent", "OBSERVATION_MODIFIER", 42, 51], ["exacerbated", "OBSERVATION_MODIFIER", 171, 182], ["inflammatory", "OBSERVATION", 183, 195]]], ["The viral-independent phase has been explained by the inflammatory reaction secondary to ACE2 inhibition or by an autoimmune phenomenon due to the epitope spreading caused by prolonged tissue destruction (20, 61).", [["tissue", "ANATOMY", 185, 191], ["autoimmune phenomenon", "DISEASE", 114, 135], ["ACE2", "GENE_OR_GENE_PRODUCT", 89, 93], ["tissue", "TISSUE", 185, 191], ["ACE2", "PROTEIN", 89, 93], ["the inflammatory reaction", "PROBLEM", 50, 75], ["ACE2 inhibition", "PROBLEM", 89, 104], ["an autoimmune phenomenon", "PROBLEM", 111, 135], ["the epitope spreading", "PROBLEM", 143, 164], ["prolonged tissue destruction", "PROBLEM", 175, 203], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["independent phase", "OBSERVATION_MODIFIER", 10, 27], ["inflammatory", "OBSERVATION", 54, 66], ["autoimmune", "OBSERVATION", 114, 124], ["prolonged tissue", "OBSERVATION_MODIFIER", 175, 191], ["destruction", "OBSERVATION", 192, 203]]], ["It remains to be demonstrated whether a similar two-phase course also occurs in COVID-19.Adaptive Immune ResponseAlthough T and B cells, macrophages, and DCs do not express ACE2, some reports suggest that DC-SIGN may serve as a trans receptor for SARS-CoV on DCs, which even when not infected may transfer the virus to other susceptible cells (22, 23, 62).", [["B cells", "ANATOMY", 128, 135], ["macrophages", "ANATOMY", 137, 148], ["DCs", "ANATOMY", 154, 157], ["DC", "ANATOMY", 205, 207], ["DCs", "ANATOMY", 259, 262], ["cells", "ANATOMY", 337, 342], ["Immune ResponseAlthough T", "CELL", 98, 123], ["B cells", "CELL", 128, 135], ["macrophages", "CELL", 137, 148], ["DCs", "CELL", 154, 157], ["ACE2", "GENE_OR_GENE_PRODUCT", 173, 177], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 205, 212], ["SARS-CoV", "ORGANISM", 247, 255], ["DCs", "CELL", 259, 262], ["cells", "CELL", 337, 342], ["Immune ResponseAlthough T and B cells", "CELL_TYPE", 98, 135], ["macrophages", "CELL_TYPE", 137, 148], ["DCs", "CELL_TYPE", 154, 157], ["ACE2", "PROTEIN", 173, 177], ["DC", "CELL_TYPE", 205, 207], ["SIGN", "PROTEIN", 208, 212], ["trans receptor", "PROTEIN", 228, 242], ["DCs", "CELL_TYPE", 259, 262], ["susceptible cells", "CELL_TYPE", 325, 342], ["SARS-CoV", "SPECIES", 247, 255], ["COVID", "TEST", 80, 85], ["macrophages", "PROBLEM", 137, 148], ["SARS", "PROBLEM", 247, 251], ["CoV", "PROBLEM", 252, 255], ["DCs", "TREATMENT", 259, 262]]], ["Recently, Vandakari and Wilce (63) reported that CD26, an aminopeptidase involved in T cell activation, may bind to the S protein of SARS-CoV-2, resulting in a non-productive T cell infection; Wang et al. (64) reported that CD147, a protein of the immunoglobulins superfamily that induces the metalloproteinases of the extracellular matrix, binds to the S1 domain and facilitates viral entrance into host cells.", [["T cell", "ANATOMY", 85, 91], ["T cell", "ANATOMY", 175, 181], ["extracellular matrix", "ANATOMY", 319, 339], ["cells", "ANATOMY", 405, 410], ["infection", "DISEASE", 182, 191], ["CD26", "GENE_OR_GENE_PRODUCT", 49, 53], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 58, 72], ["T cell", "CELL", 85, 91], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 133, 143], ["T cell", "CELL", 175, 181], ["CD147", "GENE_OR_GENE_PRODUCT", 224, 229], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 248, 263], ["metalloproteinases", "GENE_OR_GENE_PRODUCT", 293, 311], ["extracellular matrix", "CELLULAR_COMPONENT", 319, 339], ["host cells", "CELL", 400, 410], ["CD26", "PROTEIN", 49, 53], ["aminopeptidase", "PROTEIN", 58, 72], ["S protein", "PROTEIN", 120, 129], ["CD147", "PROTEIN", 224, 229], ["immunoglobulins superfamily", "PROTEIN", 248, 275], ["metalloproteinases", "PROTEIN", 293, 311], ["S1 domain", "PROTEIN", 354, 363], ["host cells", "CELL_TYPE", 400, 410], ["SARS-CoV", "SPECIES", 133, 141], ["CD26", "TEST", 49, 53], ["an aminopeptidase", "TEST", 55, 72], ["T cell activation", "PROBLEM", 85, 102], ["the S protein", "TEST", 116, 129], ["SARS", "PROBLEM", 133, 137], ["CoV", "TEST", 138, 141], ["a non-productive T cell infection", "PROBLEM", 158, 191], ["CD147", "TEST", 224, 229], ["a protein", "TEST", 231, 240], ["the immunoglobulins superfamily", "PROBLEM", 244, 275], ["non-productive", "OBSERVATION_MODIFIER", 160, 174], ["cell infection", "OBSERVATION", 177, 191], ["extracellular matrix", "ANATOMY", 319, 339], ["S1", "ANATOMY", 354, 356], ["viral entrance", "OBSERVATION", 380, 394], ["host cells", "OBSERVATION", 400, 410]]], ["The significance of non-productive T cells infection is not clear; however, it is tempting to speculate that it may be related to the lymphopenia found in patients with SARS, MERS, and COVID-19 (65).", [["T cells", "ANATOMY", 35, 42], ["infection", "DISEASE", 43, 52], ["lymphopenia", "DISEASE", 134, 145], ["SARS", "DISEASE", 169, 173], ["T cells", "CELL", 35, 42], ["patients", "ORGANISM", 155, 163], ["non-productive T cells", "CELL_TYPE", 20, 42], ["patients", "SPECIES", 155, 163], ["non-productive T cells infection", "PROBLEM", 20, 52], ["the lymphopenia", "PROBLEM", 130, 145], ["SARS", "PROBLEM", 169, 173], ["COVID", "TEST", 185, 190], ["non-productive", "OBSERVATION_MODIFIER", 20, 34], ["T cells infection", "OBSERVATION", 35, 52], ["lymphopenia", "OBSERVATION", 134, 145]]], ["The binding of SARS-CoV-2 S protein to molecules like CD26 and CD147, which participate in T cell activation, would suggest that a non-productive T cell infection may result in activation-induced cell death (AICD).", [["T cell", "ANATOMY", 91, 97], ["T cell", "ANATOMY", 146, 152], ["cell", "ANATOMY", 196, 200], ["infection", "DISEASE", 153, 162], ["death", "DISEASE", 201, 206], ["AICD", "DISEASE", 208, 212], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 15, 25], ["CD26", "GENE_OR_GENE_PRODUCT", 54, 58], ["CD147", "GENE_OR_GENE_PRODUCT", 63, 68], ["T cell", "CELL", 91, 97], ["T cell", "CELL", 146, 152], ["cell", "CELL", 196, 200], ["SARS-CoV-2 S protein", "PROTEIN", 15, 35], ["CD26", "PROTEIN", 54, 58], ["CD147", "PROTEIN", 63, 68], ["SARS", "TEST", 15, 19], ["CoV", "TEST", 20, 23], ["CD26", "TEST", 54, 58], ["CD147", "TEST", 63, 68], ["T cell activation", "PROBLEM", 91, 108], ["a non-productive T cell infection", "PROBLEM", 129, 162], ["activation-induced cell death", "PROBLEM", 177, 206], ["AICD)", "TREATMENT", 208, 213]]], ["MERS-CoV has been reported to induce T cells apoptosis (23, 66), and there is evidence that T cells are functionally exhausted in patients with severe COVID-19 (67).The Role of Secretory Immunoglobulin a (sIgA) ::: The Antibody ResponseIt is worth noting that the role of secretory immunoglobulin A (sIgA) in COVID-19 has received little attention, despite the fact that SARS-CoV-2 enters the body through the respiratory mucosa and sIgA is fundamental to the mucosal defenses.", [["T cells", "ANATOMY", 37, 44], ["T cells", "ANATOMY", 92, 99], ["body", "ANATOMY", 393, 397], ["respiratory mucosa", "ANATOMY", 410, 428], ["mucosal", "ANATOMY", 460, 467], ["COVID-19", "CHEMICAL", 309, 317], ["SARS", "DISEASE", 371, 375], ["COVID-19", "CHEMICAL", 151, 159], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["T cells", "CELL", 37, 44], ["T cells", "CELL", 92, 99], ["patients", "ORGANISM", 130, 138], ["Immunoglobulin", "GENE_OR_GENE_PRODUCT", 187, 201], ["IgA", "GENE_OR_GENE_PRODUCT", 206, 209], ["secretory immunoglobulin A", "GENE_OR_GENE_PRODUCT", 272, 298], ["IgA", "GENE_OR_GENE_PRODUCT", 301, 304], ["COVID-19", "GENE_OR_GENE_PRODUCT", 309, 317], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 371, 381], ["body", "ORGANISM_SUBDIVISION", 393, 397], ["respiratory mucosa", "MULTI-TISSUE_STRUCTURE", 410, 428], ["sIgA", "GENE_OR_GENE_PRODUCT", 433, 437], ["mucosal", "MULTI-TISSUE_STRUCTURE", 460, 467], ["MERS-CoV", "PROTEIN", 0, 8], ["T cells", "CELL_TYPE", 37, 44], ["T cells", "CELL_TYPE", 92, 99], ["Secretory Immunoglobulin", "PROTEIN", 177, 201], ["IgA", "PROTEIN", 206, 209], ["Antibody ResponseIt", "PROTEIN", 219, 238], ["secretory immunoglobulin A", "PROTEIN", 272, 298], ["IgA", "PROTEIN", 301, 304], ["sIgA", "PROTEIN", 433, 437], ["patients", "SPECIES", 130, 138], ["MERS-CoV", "SPECIES", 0, 8], ["T cells apoptosis", "PROBLEM", 37, 54], ["T cells", "PROBLEM", 92, 99], ["severe COVID", "PROBLEM", 144, 156], ["The Antibody ResponseIt", "TEST", 215, 238], ["secretory immunoglobulin", "TEST", 272, 296], ["COVID", "TEST", 309, 314], ["SARS", "TEST", 371, 375], ["CoV", "TEST", 376, 379], ["SARS", "OBSERVATION", 371, 375], ["body", "ANATOMY_MODIFIER", 393, 397], ["respiratory mucosa", "ANATOMY", 410, 428], ["mucosal defenses", "OBSERVATION", 460, 476]]], ["Furthermore, several studies into COVID-19 have shown the presence of serum IgA against SARS-CoV-2 (70, 77\u201379) and, in preclinical studies with anti-SARS vaccines, administered either sub-lingually or intranasally, the presence of neutralizing IgA was demonstrated in bronchoalveolar lavages (80\u201382).", [["serum", "ANATOMY", 70, 75], ["intranasally", "ANATOMY", 201, 213], ["bronchoalveolar lavages", "ANATOMY", 268, 291], ["COVID-19", "GENE_OR_GENE_PRODUCT", 34, 42], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["IgA", "GENE_OR_GENE_PRODUCT", 76, 79], ["SARS-CoV-2", "ORGANISM", 88, 98], ["IgA", "GENE_OR_GENE_PRODUCT", 244, 247], ["bronchoalveolar lavages", "MULTI-TISSUE_STRUCTURE", 268, 291], ["COVID-19", "DNA", 34, 42], ["serum IgA", "PROTEIN", 70, 79], ["neutralizing IgA", "PROTEIN", 231, 247], ["SARS-CoV", "SPECIES", 88, 96], ["several studies", "TEST", 13, 28], ["COVID", "TEST", 34, 39], ["serum IgA", "TEST", 70, 79], ["SARS", "TEST", 88, 92], ["CoV", "TEST", 93, 96], ["anti-SARS vaccines", "TREATMENT", 144, 162], ["neutralizing IgA", "PROBLEM", 231, 247], ["bronchoalveolar lavages", "TEST", 268, 291], ["neutralizing IgA", "OBSERVATION", 231, 247], ["bronchoalveolar lavages", "OBSERVATION", 268, 291]]], ["These findings support the importance of investigating the presence of sIgA in secretions of patients with COVID-19 and defining its possible anti-viral neutralizing activity in respiratory tract mucosa (83).Antibody-Dependent Enhancement (ADE) ::: The Antibody ResponseAn intriguing phenomenon that worries many clinicians and researchers is the \u201cAntibody-Dependent Enhancement\u201d (ADE), which could be linked to the severity of coronavirus infections and could possibly create difficulties with new vaccines (84\u201386).", [["secretions", "ANATOMY", 79, 89], ["respiratory tract mucosa", "ANATOMY", 178, 202], ["COVID-19", "CHEMICAL", 107, 115], ["respiratory tract mucosa", "DISEASE", 178, 202], ["coronavirus infections", "DISEASE", 428, 450], ["sIgA", "GENE_OR_GENE_PRODUCT", 71, 75], ["patients", "ORGANISM", 93, 101], ["respiratory tract mucosa", "MULTI-TISSUE_STRUCTURE", 178, 202], ["coronavirus", "ORGANISM", 428, 439], ["sIgA", "PROTEIN", 71, 75], ["patients", "SPECIES", 93, 101], ["sIgA in secretions", "PROBLEM", 71, 89], ["COVID", "TEST", 107, 112], ["anti-viral neutralizing activity in respiratory tract mucosa", "PROBLEM", 142, 202], ["Antibody", "TEST", 208, 216], ["the \u201cAntibody", "TEST", 343, 356], ["coronavirus infections", "PROBLEM", 428, 450], ["new vaccines", "TREATMENT", 495, 507], ["possible", "UNCERTAINTY", 133, 141], ["anti-viral", "OBSERVATION", 142, 152], ["neutralizing activity", "OBSERVATION", 153, 174], ["respiratory tract", "ANATOMY", 178, 195], ["Dependent Enhancement", "OBSERVATION_MODIFIER", 217, 238], ["Dependent", "OBSERVATION_MODIFIER", 357, 366], ["Enhancement", "OBSERVATION_MODIFIER", 367, 378], ["coronavirus", "OBSERVATION", 428, 439]]], ["Ho et al. (87) studying the antibody response in SARS, found that patients with more severe clinical courses had earlier and higher antibody responses, and hypothesized that earlier responders may have had, during the acute phase, cross-reacting antibodies with non-SARS coronaviruses.", [["SARS", "DISEASE", 49, 53], ["patients", "ORGANISM", 66, 74], ["non-SARS coronaviruses", "ORGANISM", 262, 284], ["cross-reacting antibodies", "PROTEIN", 231, 256], ["patients", "SPECIES", 66, 74], ["the antibody response", "TEST", 24, 45], ["SARS", "PROBLEM", 49, 53], ["higher antibody responses", "PROBLEM", 125, 150], ["the acute phase", "PROBLEM", 214, 229], ["cross-reacting antibodies", "PROBLEM", 231, 256], ["non-SARS coronaviruses", "PROBLEM", 262, 284]]], ["Jaume et al. (88) and Yip et al. (89) demonstrated that anti-S antibodies, while inhibiting viral entrance in permissive cells, potentiated the infection by binding to IgG Fc receptor-II positive (Fc\u03b3RII+) cells, like B cells and macrophages.", [["cells", "ANATOMY", 121, 126], ["Fc\u03b3RII+) cells", "ANATOMY", 197, 211], ["B cells", "ANATOMY", 218, 225], ["macrophages", "ANATOMY", 230, 241], ["infection", "DISEASE", 144, 153], ["anti-S antibodies", "GENE_OR_GENE_PRODUCT", 56, 73], ["cells", "CELL", 121, 126], ["IgG Fc receptor-II", "GENE_OR_GENE_PRODUCT", 168, 186], ["Fc\u03b3RII", "GENE_OR_GENE_PRODUCT", 197, 203], ["B cells", "CELL", 218, 225], ["macrophages", "CELL", 230, 241], ["anti-S antibodies", "PROTEIN", 56, 73], ["permissive cells", "CELL_TYPE", 110, 126], ["IgG Fc receptor-II positive (Fc\u03b3RII+) cells", "CELL_LINE", 168, 211], ["B cells", "CELL_TYPE", 218, 225], ["macrophages", "CELL_TYPE", 230, 241], ["Yip et al.", "TEST", 22, 32], ["anti-S antibodies", "PROBLEM", 56, 73], ["viral entrance in permissive cells", "PROBLEM", 92, 126], ["the infection", "PROBLEM", 140, 153], ["IgG Fc receptor", "TEST", 168, 183], ["II positive", "PROBLEM", 184, 195], ["Fc\u03b3RII", "TEST", 197, 203], ["cells", "TEST", 206, 211], ["permissive cells", "OBSERVATION", 110, 126], ["infection", "OBSERVATION", 144, 153], ["B cells", "OBSERVATION", 218, 225], ["macrophages", "ANATOMY", 230, 241]]], ["Thus, IgG anti-S antibodies bound to Fc\u03b3RII on mononuclear phagocyte membranes enhance viral entrance through canonical viral-receptor pathways, as recently shown for MERS-CoV (90), thereby activating these cells and inducing the production of proinflammatory cytokines.The Clinical-Immunogical Spectrum of COVID-19In order to understand COVID-19 immunopathogenesis, it is important to elucidate what lies at the root of immune response failure occurring in infected individuals resulting at times in deviation of the protective response into a dysfunctional program, leading to cytokine release syndrome (CRS) with severe inflammation and, eventually, a multi-systemic failure.", [["mononuclear phagocyte membranes", "ANATOMY", 47, 78], ["cells", "ANATOMY", 207, 212], ["root", "ANATOMY", 413, 417], ["CRS", "DISEASE", 606, 609], ["inflammation", "DISEASE", 623, 635], ["multi-systemic failure", "DISEASE", 655, 677], ["IgG anti-S antibodies", "GENE_OR_GENE_PRODUCT", 6, 27], ["Fc\u03b3RII", "GENE_OR_GENE_PRODUCT", 37, 43], ["mononuclear phagocyte", "CELL", 47, 68], ["membranes", "CELLULAR_COMPONENT", 69, 78], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 167, 175], ["cells", "CELL", 207, 212], ["COVID-19", "CELL", 338, 346], ["IgG anti-S antibodies", "PROTEIN", 6, 27], ["Fc\u03b3RII", "PROTEIN", 37, 43], ["proinflammatory cytokines", "PROTEIN", 244, 269], ["cytokine", "PROTEIN", 579, 587], ["MERS-CoV", "SPECIES", 167, 175], ["IgG anti-S antibodies", "TEST", 6, 27], ["mononuclear phagocyte membranes", "TREATMENT", 47, 78], ["CoV", "TEST", 172, 175], ["thereby activating these cells", "PROBLEM", 182, 212], ["proinflammatory cytokines", "PROBLEM", 244, 269], ["COVID", "TEST", 307, 312], ["immune response failure", "PROBLEM", 421, 444], ["infected individuals", "PROBLEM", 458, 478], ["a dysfunctional program", "TREATMENT", 543, 566], ["cytokine release syndrome", "PROBLEM", 579, 604], ["CRS", "PROBLEM", 606, 609], ["severe inflammation", "PROBLEM", 616, 635], ["a multi-systemic failure", "PROBLEM", 653, 677], ["mononuclear phagocyte", "OBSERVATION", 47, 68], ["proinflammatory cytokines", "OBSERVATION", 244, 269], ["immune response failure", "OBSERVATION", 421, 444], ["severe", "OBSERVATION_MODIFIER", 616, 622], ["inflammation", "OBSERVATION", 623, 635], ["multi-systemic", "OBSERVATION_MODIFIER", 655, 669], ["failure", "OBSERVATION", 670, 677]]], ["A better understanding of these events would contribute to the design of differential therapeutic approaches, depending on the stage of the disease, and to the delineation of prognostic, and predictive biomarkers.", [["the disease", "PROBLEM", 136, 147], ["predictive biomarkers", "TEST", 191, 212], ["disease", "OBSERVATION", 140, 147]]], ["Unfortunately, there are no studies on the immune response in infected asymptomatic individuals, which would allow a better characterization of the protective immune response as it occurs under the natural conditions of the infection process.", [["infection", "DISEASE", 224, 233], ["infected asymptomatic individuals", "PROBLEM", 62, 95], ["the infection process", "PROBLEM", 220, 241], ["infection", "OBSERVATION", 224, 233]]], ["Thus, the present view is based on the comparison between patients with moderate and those with severe infections, and also with those in the convalescent stage.", [["infections", "DISEASE", 103, 113], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["the present view", "TEST", 6, 22], ["severe infections", "PROBLEM", 96, 113], ["moderate", "OBSERVATION_MODIFIER", 72, 80], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["infections", "OBSERVATION", 103, 113]]], ["Another aspect to be explored is the effect of previous exposure to other less virulent coronaviruses that may have cross-reactivity with more virulent ones.", [["coronaviruses", "ORGANISM", 88, 101], ["other less virulent coronaviruses", "PROBLEM", 68, 101]]], ["Additionally, most of the studies have been done using blood samples, which do not necessarily correlate with the events going on in the affected tissues.", [["blood samples", "ANATOMY", 55, 68], ["tissues", "ANATOMY", 146, 153], ["blood samples", "ORGANISM_SUBSTANCE", 55, 68], ["tissues", "TISSUE", 146, 153], ["the studies", "TEST", 22, 33], ["blood samples", "TEST", 55, 68], ["the events", "PROBLEM", 110, 120]]], ["Fortunately, several studies on bronchoalveolar lavage cells were published recently, as will be discussed below.The Clinical-Immunogical Spectrum of COVID-19From an immunological point of view, the wide clinical spectrum of COVID-19 allows us to postulate different hypotheses, some of them which have already been proven, the remaining requiring more information and longer follow-up observation of recovered patients.", [["bronchoalveolar lavage cells", "ANATOMY", 32, 60], ["bronchoalveolar lavage cells", "CELL", 32, 60], ["patients", "ORGANISM", 411, 419], ["bronchoalveolar lavage cells", "CELL_TYPE", 32, 60], ["patients", "SPECIES", 411, 419], ["several studies", "TEST", 13, 28], ["bronchoalveolar lavage cells", "TEST", 32, 60], ["COVID", "TEST", 150, 155], ["COVID", "TEST", 225, 230]]], ["Figure 1A shows diverse outcomes during the course of COVID-19 and allows for an analysis of the immune response at each clinical stage.", [["COVID", "TEST", 54, 59], ["an analysis", "TEST", 78, 89], ["diverse", "OBSERVATION_MODIFIER", 16, 23]]], ["However, it must be noted that the immune response is conditioned by epidemiological variables, such as intensity and duration of exposure to the virus and possible variations in viral virulence and, on the host side, genetic susceptibility/resistance and health conditions at the time of exposure.", [["the virus", "PROBLEM", 142, 151], ["variations in viral virulence", "PROBLEM", 165, 194], ["genetic susceptibility/resistance and health conditions", "PROBLEM", 218, 273], ["viral virulence", "OBSERVATION", 179, 194]]], ["The latter includes, among other variables, age and the existence of comorbidities that may directly affect the immune system (8, 48).The Clinical-Immunogical Spectrum of COVID-19Despite its high infectivity, not everyone exposed to SARS-CoV-2 becomes infected (15).", [["immune system", "ANATOMY", 112, 125], ["COVID-19Despite", "CHEMICAL", 171, 186], ["SARS", "DISEASE", 233, 237], ["SARS-CoV-2", "ORGANISM", 233, 243], ["SARS-CoV", "SPECIES", 233, 241], ["comorbidities", "PROBLEM", 69, 82], ["COVID", "TEST", 171, 176], ["its high infectivity", "PROBLEM", 187, 207], ["SARS", "PROBLEM", 233, 237], ["CoV", "TEST", 238, 241], ["infected", "PROBLEM", 252, 260], ["comorbidities", "OBSERVATION", 69, 82], ["high infectivity", "OBSERVATION", 191, 207], ["infected", "OBSERVATION", 252, 260]]], ["The reasons for such resistance are still unknown.", [["such resistance", "PROBLEM", 16, 31]]], ["It is possible that a small, occasional inoculum does not reach the lower respiratory tract, where susceptible target cells are found.", [["lower respiratory tract", "ANATOMY", 68, 91], ["cells", "ANATOMY", 118, 123], ["lower", "ORGANISM_SUBDIVISION", 68, 73], ["respiratory tract", "ORGANISM_SUBDIVISION", 74, 91], ["cells", "CELL", 118, 123], ["susceptible target cells", "CELL_TYPE", 99, 123], ["a small, occasional inoculum", "PROBLEM", 20, 48], ["susceptible target cells", "PROBLEM", 99, 123], ["small", "OBSERVATION_MODIFIER", 22, 27], ["occasional", "OBSERVATION_MODIFIER", 29, 39], ["inoculum", "OBSERVATION", 40, 48], ["lower", "ANATOMY_MODIFIER", 68, 73], ["respiratory tract", "ANATOMY", 74, 91], ["susceptible", "OBSERVATION_MODIFIER", 99, 110], ["target cells", "OBSERVATION", 111, 123]]], ["On this regard, no association of SARS with ACE2 polymorphisms was found (91).The Clinical-Immunogical Spectrum of COVID-19A central tenet of our view on COVID-19 immunopathogenesis is that a protective immune response must be present in patients with asymptomatic and mild infections, and even in some with moderate infections who do not progress to severe disease.", [["SARS", "DISEASE", 34, 38], ["infections", "DISEASE", 274, 284], ["infections", "DISEASE", 317, 327], ["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["patients", "ORGANISM", 238, 246], ["ACE2", "PROTEIN", 44, 48], ["patients", "SPECIES", 238, 246], ["SARS", "PROBLEM", 34, 38], ["ACE2 polymorphisms", "TEST", 44, 62], ["COVID", "TEST", 115, 120], ["COVID", "TEST", 154, 159], ["a protective immune response", "PROBLEM", 190, 218], ["asymptomatic and mild infections", "PROBLEM", 252, 284], ["moderate infections", "PROBLEM", 308, 327], ["severe disease", "PROBLEM", 351, 365], ["mild", "OBSERVATION_MODIFIER", 269, 273], ["infections", "OBSERVATION", 274, 284], ["moderate", "OBSERVATION_MODIFIER", 308, 316], ["infections", "OBSERVATION", 317, 327], ["severe", "OBSERVATION_MODIFIER", 351, 357], ["disease", "OBSERVATION", 358, 365]]], ["This response must be capable of inhibiting viral replication and eliminating the host's infected cells with minimal tissue damage and low inflammatory manifestations (Figure 1B).", [["cells", "ANATOMY", 98, 103], ["tissue", "ANATOMY", 117, 123], ["cells", "CELL", 98, 103], ["tissue", "TISSUE", 117, 123], ["infected cells", "CELL_TYPE", 89, 103], ["inhibiting viral replication", "PROBLEM", 33, 61], ["the host's infected cells", "PROBLEM", 78, 103], ["minimal tissue damage", "PROBLEM", 109, 130], ["low inflammatory manifestations", "PROBLEM", 135, 166], ["minimal tissue", "OBSERVATION_MODIFIER", 109, 123], ["damage", "OBSERVATION", 124, 130], ["low", "OBSERVATION_MODIFIER", 135, 138], ["inflammatory", "OBSERVATION_MODIFIER", 139, 151]]], ["The adaptive response includes the existence of genetic conditions for viral antigen presentation by HLA-I and II molecules to CD8 and CD4 T cells, respectively.", [["CD8", "ANATOMY", 127, 130], ["CD4 T cells", "ANATOMY", 135, 146], ["HLA-I", "GENE_OR_GENE_PRODUCT", 101, 106], ["CD8", "GENE_OR_GENE_PRODUCT", 127, 130], ["CD4", "GENE_OR_GENE_PRODUCT", 135, 138], ["HLA-I and II molecules", "PROTEIN", 101, 123], ["CD8 and CD4 T cells", "CELL_TYPE", 127, 146], ["viral antigen presentation", "TEST", 71, 97], ["HLA", "TEST", 101, 104]]], ["In this context, Grifoni et al. (92), using a bioinformatic approach, identified 241 candidate epitopes for HLA-II alleles in SARS-CoV-2, and 628 for class I alleles, which may be bound by the more common HLA alleles, irrespective of their ethnic group.", [["HLA-II", "GENE_OR_GENE_PRODUCT", 108, 114], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 126, 136], ["HLA", "GENE_OR_GENE_PRODUCT", 205, 208], ["HLA-II alleles", "DNA", 108, 122], ["class I alleles", "DNA", 150, 165], ["HLA alleles", "DNA", 205, 216], ["SARS-CoV", "SPECIES", 126, 134], ["a bioinformatic approach", "TREATMENT", 44, 68], ["HLA", "TEST", 108, 111], ["CoV", "TEST", 131, 134]]], ["The high number of epitopes, also present in SARS-CoV (93), may explain the lack of a consistent association of SARS with HLA antigens (94\u201398).HistopathologyIn patients with COVID-19, the post mortem histopathological findings are similar to those reported in SARS (99) and MERS (100).", [["SARS", "DISEASE", 112, 116], ["SARS", "DISEASE", 260, 264], ["SARS-CoV", "ORGANISM", 45, 53], ["HLA antigens", "GENE_OR_GENE_PRODUCT", 122, 134], ["patients", "ORGANISM", 160, 168], ["epitopes", "PROTEIN", 19, 27], ["HLA antigens", "PROTEIN", 122, 134], ["patients", "SPECIES", 160, 168], ["SARS-CoV", "SPECIES", 45, 53], ["SARS", "PROBLEM", 112, 116], ["HLA antigens", "TEST", 122, 134], ["COVID", "TEST", 174, 179], ["the post mortem histopathological findings", "TEST", 184, 226], ["high", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["epitopes", "OBSERVATION", 19, 27]]], ["Xu et al. (101) described bilateral diffuse alveolar damage (DAD) with cellular fibromyxoid exudates, pneumocytes desquamation and hyaline membrane formation, multinucleated syncytial cells, atypical enlarged pneumocytes with large nuclei, amphophilic granular cytoplasm, and prominent nucleoli, as well as interstitial mononuclear infiltration.", [["alveolar", "ANATOMY", 44, 52], ["cellular fibromyxoid exudates", "ANATOMY", 71, 100], ["pneumocytes", "ANATOMY", 102, 113], ["hyaline membrane", "ANATOMY", 131, 147], ["multinucleated syncytial cells", "ANATOMY", 159, 189], ["pneumocytes", "ANATOMY", 209, 220], ["nuclei", "ANATOMY", 232, 238], ["amphophilic granular cytoplasm", "ANATOMY", 240, 270], ["nucleoli", "ANATOMY", 286, 294], ["interstitial mononuclear", "ANATOMY", 307, 331], ["alveolar damage", "DISEASE", 44, 59], ["DAD", "DISEASE", 61, 64], ["interstitial mononuclear infiltration", "DISEASE", 307, 344], ["alveolar", "TISSUE", 44, 52], ["cellular", "CELL", 71, 79], ["pneumocytes", "TISSUE", 102, 113], ["hyaline membrane", "CELLULAR_COMPONENT", 131, 147], ["multinucleated syncytial cells", "CELL", 159, 189], ["pneumocytes", "CELL", 209, 220], ["nuclei", "CELLULAR_COMPONENT", 232, 238], ["cytoplasm", "ORGANISM_SUBSTANCE", 261, 270], ["nucleoli", "CELLULAR_COMPONENT", 286, 294], ["interstitial mononuclear", "CELL", 307, 331], ["multinucleated syncytial cells", "CELL_TYPE", 159, 189], ["atypical enlarged pneumocytes", "CELL_TYPE", 191, 220], ["bilateral diffuse alveolar damage (DAD)", "PROBLEM", 26, 65], ["cellular fibromyxoid exudates", "PROBLEM", 71, 100], ["pneumocytes desquamation", "PROBLEM", 102, 126], ["hyaline membrane formation", "PROBLEM", 131, 157], ["multinucleated syncytial cells", "PROBLEM", 159, 189], ["atypical enlarged pneumocytes", "PROBLEM", 191, 220], ["large nuclei", "PROBLEM", 226, 238], ["amphophilic granular cytoplasm", "PROBLEM", 240, 270], ["prominent nucleoli", "PROBLEM", 276, 294], ["interstitial mononuclear infiltration", "PROBLEM", 307, 344], ["bilateral", "ANATOMY_MODIFIER", 26, 35], ["diffuse", "OBSERVATION_MODIFIER", 36, 43], ["alveolar", "ANATOMY_MODIFIER", 44, 52], ["damage", "OBSERVATION", 53, 59], ["cellular", "OBSERVATION_MODIFIER", 71, 79], ["fibromyxoid exudates", "OBSERVATION", 80, 100], ["pneumocytes desquamation", "OBSERVATION", 102, 126], ["hyaline membrane formation", "OBSERVATION", 131, 157], ["multinucleated", "OBSERVATION_MODIFIER", 159, 173], ["syncytial cells", "OBSERVATION", 174, 189], ["atypical", "OBSERVATION_MODIFIER", 191, 199], ["enlarged", "OBSERVATION_MODIFIER", 200, 208], ["pneumocytes", "OBSERVATION", 209, 220], ["large", "OBSERVATION_MODIFIER", 226, 231], ["nuclei", "OBSERVATION", 232, 238], ["amphophilic", "OBSERVATION_MODIFIER", 240, 251], ["granular cytoplasm", "OBSERVATION", 252, 270], ["prominent", "OBSERVATION_MODIFIER", 276, 285], ["nucleoli", "OBSERVATION", 286, 294], ["interstitial", "ANATOMY_MODIFIER", 307, 319], ["mononuclear infiltration", "OBSERVATION", 320, 344]]], ["Zhang et al. (47) also reported DAD with denudation of the alveolar epithelia, reactive type-II pneumocyte hyperplasia, intra-alveolar fibrinous exudate, and loose fibrous plugs, along with loose interstitial fibrosis and chronic inflammatory infiltrate.", [["alveolar epithelia", "ANATOMY", 59, 77], ["intra-alveolar fibrinous exudate", "ANATOMY", 120, 152], ["fibrous plugs", "ANATOMY", 164, 177], ["interstitial", "ANATOMY", 196, 208], ["hyperplasia", "DISEASE", 107, 118], ["fibrosis", "DISEASE", 209, 217], ["alveolar epithelia", "TISSUE", 59, 77], ["fibrous plugs", "PATHOLOGICAL_FORMATION", 164, 177], ["the alveolar epithelia", "PROBLEM", 55, 77], ["reactive type-II pneumocyte hyperplasia", "PROBLEM", 79, 118], ["intra-alveolar fibrinous exudate", "PROBLEM", 120, 152], ["loose fibrous plugs", "PROBLEM", 158, 177], ["loose interstitial fibrosis", "PROBLEM", 190, 217], ["chronic inflammatory infiltrate", "PROBLEM", 222, 253], ["denudation", "OBSERVATION", 41, 51], ["alveolar epithelia", "ANATOMY", 59, 77], ["reactive", "OBSERVATION_MODIFIER", 79, 87], ["pneumocyte hyperplasia", "OBSERVATION", 96, 118], ["intra-alveolar", "OBSERVATION_MODIFIER", 120, 134], ["fibrinous", "OBSERVATION_MODIFIER", 135, 144], ["exudate", "OBSERVATION", 145, 152], ["loose", "OBSERVATION_MODIFIER", 158, 163], ["fibrous plugs", "OBSERVATION", 164, 177], ["loose", "OBSERVATION_MODIFIER", 190, 195], ["interstitial", "ANATOMY_MODIFIER", 196, 208], ["fibrosis", "OBSERVATION", 209, 217], ["chronic", "OBSERVATION_MODIFIER", 222, 229], ["inflammatory", "OBSERVATION_MODIFIER", 230, 242], ["infiltrate", "OBSERVATION", 243, 253]]], ["Also, these authors, using an anti-Rp3 NP of SARS-CoV-2, demonstrated the presence of the virus on alveolar epithelial cells, including damaged, desquamated cells within the alveolar space, but its presence was only minimally detected on the blood vessels and the interstitium.", [["alveolar epithelial cells", "ANATOMY", 99, 124], ["cells", "ANATOMY", 157, 162], ["alveolar space", "ANATOMY", 174, 188], ["blood vessels", "ANATOMY", 242, 255], ["interstitium", "ANATOMY", 264, 276], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 45, 55], ["alveolar epithelial cells", "CELL", 99, 124], ["cells", "CELL", 157, 162], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 174, 188], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 242, 255], ["interstitium", "TISSUE", 264, 276], ["Rp3 NP", "PROTEIN", 35, 41], ["alveolar epithelial cells", "CELL_TYPE", 99, 124], ["damaged, desquamated cells", "CELL_TYPE", 136, 162], ["SARS-CoV", "TEST", 45, 53], ["the virus on alveolar epithelial cells", "PROBLEM", 86, 124], ["damaged, desquamated cells within the alveolar space", "PROBLEM", 136, 188], ["virus", "OBSERVATION", 90, 95], ["alveolar epithelial cells", "OBSERVATION", 99, 124], ["desquamated cells", "OBSERVATION", 145, 162], ["alveolar space", "ANATOMY", 174, 188], ["blood vessels", "ANATOMY", 242, 255], ["interstitium", "ANATOMY_MODIFIER", 264, 276]]], ["Taken together, the histopathological findings in COVID-19 fatalities support that, in addition to the direct cytopathic effect of SARS-CoV-2 on the pneumocytes, an immunological response exists that includes a severe inflammatory reaction and extensive lung damage (22).Changes in Circulating Cells ::: The Immunological Profile of COVID-19 PatientsRegarding cellular changes, most studies show that lymphopenia, although present in moderate infections, is more pronounced in severe COVID-19 (17, 108) and affects mainly T cells, including CD4 Th1 and Tregs, but particularly CD8 (17, 48, 108\u2013110).", [["pneumocytes", "ANATOMY", 149, 160], ["lung", "ANATOMY", 254, 258], ["Cells", "ANATOMY", 294, 299], ["cellular", "ANATOMY", 360, 368], ["T cells", "ANATOMY", 522, 529], ["CD4 Th1", "ANATOMY", 541, 548], ["Tregs", "ANATOMY", 553, 558], ["SARS", "DISEASE", 131, 135], ["lung damage", "DISEASE", 254, 265], ["lymphopenia", "DISEASE", 401, 412], ["infections", "DISEASE", 443, 453], ["COVID-19", "CHEMICAL", 484, 492], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 131, 141], ["pneumocytes", "CELL", 149, 160], ["lung", "ORGAN", 254, 258], ["Cells", "CELL", 294, 299], ["Patients", "ORGANISM", 342, 350], ["cellular", "CELL", 360, 368], ["T cells", "CELL", 522, 529], ["CD4", "GENE_OR_GENE_PRODUCT", 541, 544], ["Tregs", "CELL", 553, 558], ["CD8", "GENE_OR_GENE_PRODUCT", 577, 580], ["pneumocytes", "CELL_TYPE", 149, 160], ["T cells", "CELL_TYPE", 522, 529], ["CD4 Th1", "CELL_TYPE", 541, 548], ["Tregs", "CELL_TYPE", 553, 558], ["CD8", "PROTEIN", 577, 580], ["Patients", "SPECIES", 342, 350], ["the direct cytopathic effect", "PROBLEM", 99, 127], ["SARS", "PROBLEM", 131, 135], ["CoV", "TEST", 136, 139], ["the pneumocytes", "PROBLEM", 145, 160], ["a severe inflammatory reaction", "PROBLEM", 209, 239], ["extensive lung damage", "PROBLEM", 244, 265], ["COVID", "TEST", 333, 338], ["cellular changes", "PROBLEM", 360, 376], ["lymphopenia", "PROBLEM", 401, 412], ["moderate infections", "PROBLEM", 434, 453], ["severe COVID", "TEST", 477, 489], ["mainly T cells", "PROBLEM", 515, 529], ["CD4 Th1", "TEST", 541, 548], ["Tregs", "TEST", 553, 558], ["CD8", "TEST", 577, 580], ["cytopathic", "OBSERVATION_MODIFIER", 110, 120], ["pneumocytes", "ANATOMY", 149, 160], ["severe", "OBSERVATION_MODIFIER", 211, 217], ["inflammatory", "OBSERVATION_MODIFIER", 218, 230], ["extensive", "OBSERVATION_MODIFIER", 244, 253], ["lung", "ANATOMY", 254, 258], ["damage", "OBSERVATION", 259, 265], ["Circulating Cells", "OBSERVATION", 282, 299], ["lymphopenia", "OBSERVATION", 401, 412], ["moderate", "OBSERVATION_MODIFIER", 434, 442], ["infections", "OBSERVATION", 443, 453], ["more pronounced", "OBSERVATION_MODIFIER", 458, 473], ["severe", "OBSERVATION_MODIFIER", 477, 483], ["CD4 Th1", "OBSERVATION", 541, 548]]], ["Also, in severe COVID-19 the number of circulating naive T cells increases and the number of memory T cells decreases (106).", [["T cells", "ANATOMY", 57, 64], ["memory T cells", "ANATOMY", 93, 107], ["naive T cells", "CELL", 51, 64], ["memory T cells", "CELL", 93, 107], ["circulating naive T cells", "CELL_TYPE", 39, 64], ["memory T cells", "CELL_TYPE", 93, 107], ["severe COVID", "TEST", 9, 21], ["circulating naive T cells", "PROBLEM", 39, 64], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["circulating naive T cells", "OBSERVATION", 39, 64], ["memory T cells", "OBSERVATION", 93, 107], ["decreases", "OBSERVATION_MODIFIER", 108, 117]]], ["Circulating CD8 in patients with severe COVID 19 exhibited phenotypes associated with abnormal functionality (CD8+IFN-\u03b3+GM-CSF+) and exhaustion (Tim3+Pd-1+) (108) or (NKG2+CD107a+IFN-\u03b3+grzB+) (67).", [["CD8", "GENE_OR_GENE_PRODUCT", 12, 15], ["patients", "ORGANISM", 19, 27], ["CD8", "GENE_OR_GENE_PRODUCT", 110, 113], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 114, 119], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 120, 126], ["Tim3+Pd-1", "GENE_OR_GENE_PRODUCT", 145, 154], ["CD107a", "GENE_OR_GENE_PRODUCT", 172, 178], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 179, 184], ["Circulating CD8", "PROTEIN", 0, 15], ["CD8", "PROTEIN", 110, 113], ["IFN", "PROTEIN", 114, 117], ["\u03b3", "PROTEIN", 118, 119], ["GM", "PROTEIN", 120, 122], ["CSF", "PROTEIN", 123, 126], ["Tim3", "PROTEIN", 145, 149], ["Pd", "PROTEIN", 150, 152], ["NKG2", "PROTEIN", 167, 171], ["CD107a", "PROTEIN", 172, 178], ["IFN", "PROTEIN", 179, 182], ["\u03b3", "PROTEIN", 183, 184], ["grzB", "PROTEIN", 185, 189], ["patients", "SPECIES", 19, 27], ["severe COVID", "PROBLEM", 33, 45], ["phenotypes", "PROBLEM", 59, 69], ["abnormal functionality", "PROBLEM", 86, 108], ["CD8", "TEST", 110, 113], ["IFN", "TEST", 114, 117], ["\u03b3", "TEST", 118, 119], ["GM", "TEST", 120, 122], ["CSF", "TEST", 123, 126], ["exhaustion", "TEST", 133, 143], ["Tim3", "TEST", 145, 149], ["Pd", "TEST", 150, 152], ["NKG2", "TEST", 167, 171], ["CD107a", "TEST", 172, 178], ["IFN", "TEST", 179, 182], ["grzB", "TEST", 185, 189]]], ["The latter phenotype is also found in NK cells.", [["NK cells", "ANATOMY", 38, 46], ["NK cells", "CELL", 38, 46], ["NK cells", "CELL_TYPE", 38, 46], ["NK cells", "OBSERVATION", 38, 46]]], ["Interestingly, a negative correlation has been reported between serum levels of IL-6 and IL-8 and the perforin content of NK and CD8+ cells, which also negatively correlate with the increased number of circulating myeloid-derived suppressor cells (MDSC) (109).", [["serum", "ANATOMY", 64, 69], ["NK", "ANATOMY", 122, 124], ["CD8+ cells", "ANATOMY", 129, 139], ["myeloid-derived suppressor cells", "ANATOMY", 214, 246], ["MDSC", "ANATOMY", 248, 252], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["IL-6", "GENE_OR_GENE_PRODUCT", 80, 84], ["IL-8", "GENE_OR_GENE_PRODUCT", 89, 93], ["perforin", "GENE_OR_GENE_PRODUCT", 102, 110], ["NK", "CELL", 122, 124], ["CD8", "GENE_OR_GENE_PRODUCT", 129, 132], ["myeloid-derived suppressor cells", "CELL", 214, 246], ["MDSC", "CELL", 248, 252], ["IL-6", "PROTEIN", 80, 84], ["IL-8", "PROTEIN", 89, 93], ["perforin", "PROTEIN", 102, 110], ["NK and CD8+ cells", "CELL_TYPE", 122, 139], ["circulating myeloid-derived suppressor cells", "CELL_TYPE", 202, 246], ["MDSC", "CELL_TYPE", 248, 252], ["serum levels", "TEST", 64, 76], ["IL", "TEST", 80, 82], ["IL", "TEST", 89, 91], ["the perforin content", "TEST", 98, 118], ["NK", "ANATOMY", 122, 124], ["CD8+ cells", "OBSERVATION", 129, 139], ["increased", "OBSERVATION_MODIFIER", 182, 191], ["circulating myeloid", "OBSERVATION", 202, 221], ["suppressor cells", "OBSERVATION", 230, 246]]], ["Although the number of CD4 cells decreased, they expressed activation markers such as CD69, CD38, CD44, and HLA-DR, including Th17 CD4+CCR6+ cells, (108).", [["CD4 cells", "ANATOMY", 23, 32], ["Th17 CD4+CCR6+ cells", "ANATOMY", 126, 146], ["CD4 cells", "CELL", 23, 32], ["CD69", "GENE_OR_GENE_PRODUCT", 86, 90], ["CD38", "GENE_OR_GENE_PRODUCT", 92, 96], ["CD44", "GENE_OR_GENE_PRODUCT", 98, 102], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 108, 114], ["CD4", "GENE_OR_GENE_PRODUCT", 131, 134], ["CCR6", "GENE_OR_GENE_PRODUCT", 135, 139], ["CD4 cells", "CELL_TYPE", 23, 32], ["activation markers", "PROTEIN", 59, 77], ["CD69", "PROTEIN", 86, 90], ["CD38", "PROTEIN", 92, 96], ["CD44", "PROTEIN", 98, 102], ["HLA", "PROTEIN", 108, 111], ["DR", "PROTEIN", 112, 114], ["CD4", "PROTEIN", 131, 134], ["CCR6", "PROTEIN", 135, 139], ["CD4 cells", "PROBLEM", 23, 32], ["activation markers", "TEST", 59, 77], ["CD69", "TEST", 86, 90], ["CD38", "TEST", 92, 96], ["CD44", "TEST", 98, 102], ["HLA", "TEST", 108, 111], ["Th17 CD4", "TEST", 126, 134], ["cells", "TEST", 141, 146], ["CD4 cells", "OBSERVATION", 23, 32], ["decreased", "OBSERVATION_MODIFIER", 33, 42], ["CCR6", "ANATOMY", 135, 139]]], ["NK cells also decreased in both moderate and severe cases of the disease (107, 110).", [["NK cells", "ANATOMY", 0, 8], ["NK cells", "CELL", 0, 8], ["NK cells", "CELL_TYPE", 0, 8], ["NK cells", "TEST", 0, 8], ["the disease", "PROBLEM", 61, 72], ["decreased", "OBSERVATION_MODIFIER", 14, 23], ["both", "OBSERVATION_MODIFIER", 27, 31], ["moderate", "OBSERVATION_MODIFIER", 32, 40], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["disease", "OBSERVATION", 65, 72]]], ["Monocytopenia is also found in COVID-19 patients, particularly in severe cases, but the circulating monocytes belong mainly to the CD14+CD16+ inflammatory monocyte subset (108).Changes in Cytokine/Chemokine Plasma Levels ::: The Immunological Profile of COVID-19 PatientsPlasma levels of cytokines and chemokines are also increased in COVID-19, but are higher in severe infections, and includes IL-2, IL-2R, IL-6, IL-7, IL-8 IL-10, IP10, MIP1A, and TNF-\u03b1 (5, 17, 106, 109, 110).", [["monocytes", "ANATOMY", 100, 109], ["CD14+CD16+ inflammatory monocyte", "ANATOMY", 131, 163], ["Monocytopenia", "DISEASE", 0, 13], ["infections", "DISEASE", 370, 380], ["patients", "ORGANISM", 40, 48], ["monocytes", "CELL", 100, 109], ["CD14", "GENE_OR_GENE_PRODUCT", 131, 135], ["CD16", "GENE_OR_GENE_PRODUCT", 136, 140], ["Cytokine", "GENE_OR_GENE_PRODUCT", 188, 196], ["Patients", "ORGANISM", 263, 271], ["Plasma", "ORGANISM_SUBSTANCE", 271, 277], ["COVID-19", "CELL", 335, 343], ["IL-2", "GENE_OR_GENE_PRODUCT", 395, 399], ["IL-2R", "GENE_OR_GENE_PRODUCT", 401, 406], ["IL-6", "GENE_OR_GENE_PRODUCT", 408, 412], ["IL-7", "GENE_OR_GENE_PRODUCT", 414, 418], ["IL-8", "GENE_OR_GENE_PRODUCT", 420, 424], ["IL-10", "GENE_OR_GENE_PRODUCT", 425, 430], ["IP10", "GENE_OR_GENE_PRODUCT", 432, 436], ["MIP1A", "GENE_OR_GENE_PRODUCT", 438, 443], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 449, 454], ["circulating monocytes", "CELL_TYPE", 88, 109], ["CD14", "PROTEIN", 131, 135], ["CD16", "PROTEIN", 136, 140], ["Cytokine", "PROTEIN", 188, 196], ["Chemokine", "PROTEIN", 197, 206], ["cytokines", "PROTEIN", 288, 297], ["chemokines", "PROTEIN", 302, 312], ["IP10", "PROTEIN", 432, 436], ["MIP1A", "PROTEIN", 438, 443], ["TNF", "PROTEIN", 449, 452], ["patients", "SPECIES", 40, 48], ["Patients", "SPECIES", 263, 271], ["Monocytopenia", "PROBLEM", 0, 13], ["COVID", "TEST", 31, 36], ["severe cases", "PROBLEM", 66, 78], ["the circulating monocytes", "TEST", 84, 109], ["the CD14", "TEST", 127, 135], ["CD16", "TEST", 136, 140], ["inflammatory monocyte subset", "PROBLEM", 142, 170], ["Cytokine/Chemokine Plasma Levels", "TEST", 188, 220], ["The Immunological Profile", "TEST", 225, 250], ["COVID", "TEST", 254, 259], ["PatientsPlasma levels", "TEST", 263, 284], ["cytokines", "TEST", 288, 297], ["chemokines", "TEST", 302, 312], ["COVID", "TEST", 335, 340], ["severe infections", "PROBLEM", 363, 380], ["IL", "TEST", 395, 397], ["IL", "TEST", 401, 403], ["IL", "TEST", 408, 410], ["IL", "TEST", 414, 416], ["IL", "TEST", 420, 422], ["MIP1A", "TEST", 438, 443], ["TNF", "TEST", 449, 452], ["inflammatory monocyte", "OBSERVATION", 142, 163], ["increased", "OBSERVATION_MODIFIER", 322, 331], ["higher", "OBSERVATION_MODIFIER", 353, 359], ["severe", "OBSERVATION_MODIFIER", 363, 369], ["infections", "OBSERVATION", 370, 380], ["TNF", "ANATOMY", 449, 452]]], ["High levels of plasmatic IL-6 have been consistently reported in COVID-19 and even appear to be associated with poor prognosis and risk of death (8).", [["death", "DISEASE", 139, 144], ["IL-6", "GENE_OR_GENE_PRODUCT", 25, 29], ["COVID-19", "CELL", 65, 73], ["plasmatic IL-6", "PROTEIN", 15, 29], ["plasmatic IL", "TEST", 15, 27], ["death", "PROBLEM", 139, 144]]], ["Thus, its measurement has been proposed as a good biomarker to monitor these patients.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85]]], ["Liu et al. (111) studied sixty COVID-19 patients, half of whom had a severe case of the disease and high IL-6 levels.", [["patients", "ORGANISM", 40, 48], ["IL-6", "GENE_OR_GENE_PRODUCT", 105, 109], ["IL", "PROTEIN", 105, 107], ["patients", "SPECIES", 40, 48], ["the disease", "PROBLEM", 84, 95], ["disease", "OBSERVATION", 88, 95]]], ["Baseline IL-6 was higher in more severe cases and correlated with bilateral interstitial lung involvement and high body temperature, as well as with other serum markers for acute inflammation.", [["interstitial lung", "ANATOMY", 76, 93], ["body", "ANATOMY", 115, 119], ["serum", "ANATOMY", 155, 160], ["inflammation", "DISEASE", 179, 191], ["IL-6", "GENE_OR_GENE_PRODUCT", 9, 13], ["lung", "ORGAN", 89, 93], ["body", "ORGANISM_SUBDIVISION", 115, 119], ["serum", "ORGANISM_SUBSTANCE", 155, 160], ["IL-6", "PROTEIN", 9, 13], ["serum markers", "PROTEIN", 155, 168], ["Baseline IL", "TEST", 0, 11], ["bilateral interstitial lung involvement", "PROBLEM", 66, 105], ["high body temperature", "PROBLEM", 110, 131], ["other serum markers", "TEST", 149, 168], ["acute inflammation", "PROBLEM", 173, 191], ["more severe", "OBSERVATION_MODIFIER", 28, 39], ["bilateral", "ANATOMY_MODIFIER", 66, 75], ["interstitial", "ANATOMY_MODIFIER", 76, 88], ["lung", "ANATOMY", 89, 93], ["involvement", "OBSERVATION", 94, 105], ["high body temperature", "OBSERVATION_MODIFIER", 110, 131], ["acute", "OBSERVATION_MODIFIER", 173, 178], ["inflammation", "OBSERVATION", 179, 191]]], ["Of the 30 patients with severe disease, 25 improved clinically and showed a significant decrease in IL-6 levels, while these levels increased in three patients with disease progression.", [["patients", "ORGANISM", 10, 18], ["IL-6", "GENE_OR_GENE_PRODUCT", 100, 104], ["patients", "ORGANISM", 151, 159], ["IL-6", "PROTEIN", 100, 104], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 151, 159], ["severe disease", "PROBLEM", 24, 38], ["a significant decrease in IL-6 levels", "PROBLEM", 74, 111], ["these levels", "TEST", 119, 131], ["disease progression", "PROBLEM", 165, 184], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["disease", "OBSERVATION", 31, 38], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["decrease", "OBSERVATION_MODIFIER", 88, 96], ["increased", "OBSERVATION_MODIFIER", 132, 141], ["disease", "OBSERVATION", 165, 172]]], ["Coomes et al. (112) performed a meta-analysis of 16 papers, that included 10,798 Chinese patients, in order to test the evidence that IL-6 levels correlate with COVID-19 severity, and the effectiveness of treatment with Tocilizumab, a humanized monoclonal antibody against IL-6 receptor.", [["Tocilizumab", "CHEMICAL", 220, 231], ["Tocilizumab", "CHEMICAL", 220, 231], ["patients", "ORGANISM", 89, 97], ["IL-6", "GENE_OR_GENE_PRODUCT", 134, 138], ["Tocilizumab", "SIMPLE_CHEMICAL", 220, 231], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 273, 286], ["IL-6", "PROTEIN", 134, 138], ["humanized monoclonal antibody", "PROTEIN", 235, 264], ["IL-6 receptor", "PROTEIN", 273, 286], ["patients", "SPECIES", 89, 97], ["a meta-analysis", "TEST", 30, 45], ["IL", "TEST", 134, 136], ["COVID", "TEST", 161, 166], ["treatment", "TREATMENT", 205, 214], ["Tocilizumab", "TREATMENT", 220, 231], ["a humanized monoclonal antibody", "TREATMENT", 233, 264]]], ["All COVID-19 patients had increased levels of serum IL-6, but it was 2.9-fold higher in patients with severe COVID-19.", [["serum", "ANATOMY", 46, 51], ["patients", "ORGANISM", 13, 21], ["serum", "ORGANISM_SUBSTANCE", 46, 51], ["IL-6", "GENE_OR_GENE_PRODUCT", 52, 56], ["patients", "ORGANISM", 88, 96], ["serum IL-6", "PROTEIN", 46, 56], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 88, 96], ["All COVID", "TEST", 0, 9], ["increased levels", "PROBLEM", 26, 42], ["serum IL", "TEST", 46, 54], ["severe COVID", "PROBLEM", 102, 114], ["severe", "OBSERVATION_MODIFIER", 102, 108]]], ["Twenty-one patients treated with tocilizumab improved clinically with no adverse effects or deaths.", [["tocilizumab", "CHEMICAL", 33, 44], ["deaths", "DISEASE", 92, 98], ["patients", "ORGANISM", 11, 19], ["tocilizumab", "SIMPLE_CHEMICAL", 33, 44], ["patients", "SPECIES", 11, 19], ["tocilizumab", "TREATMENT", 33, 44], ["adverse effects", "PROBLEM", 73, 88], ["deaths", "PROBLEM", 92, 98]]], ["Also, Xu et al. (113) reported very promising results using Tocilizumab treatment in 20 patients with severe COVID-19; all patients improved remarkably within a few days and all were discharged from the ICU within an average of 15 days.Dynamics of the Immune and Inflammatory Responses ::: The Immunological Profile of COVID-19 PatientsDuring the course of COVID-19 infection, viral replication, immune response, and inflammatory reaction are dynamic events that can change rapidly, resulting in different outcomes; several reports have addressed these changes.", [["Tocilizumab", "CHEMICAL", 60, 71], ["infection", "DISEASE", 366, 375], ["Tocilizumab", "CHEMICAL", 60, 71], ["Tocilizumab", "SIMPLE_CHEMICAL", 60, 71], ["patients", "ORGANISM", 88, 96], ["patients", "ORGANISM", 123, 131], ["Patients", "ORGANISM", 328, 336], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 123, 131], ["Patients", "SPECIES", 328, 336], ["COVID-19", "SPECIES", 357, 365], ["Tocilizumab treatment", "TREATMENT", 60, 81], ["severe COVID", "PROBLEM", 102, 114], ["COVID", "TEST", 319, 324], ["COVID", "TEST", 357, 362], ["infection", "PROBLEM", 366, 375], ["viral replication", "PROBLEM", 377, 394], ["immune response", "PROBLEM", 396, 411], ["inflammatory reaction", "PROBLEM", 417, 438], ["dynamic events", "PROBLEM", 443, 457], ["Inflammatory", "OBSERVATION_MODIFIER", 263, 275], ["infection", "OBSERVATION", 366, 375], ["viral replication", "OBSERVATION", 377, 394], ["inflammatory", "OBSERVATION_MODIFIER", 417, 429]]], ["Thevarajan et al. (114) reported the case of a patient with mild to moderate infection that was clinically, virologically, and immunologically followed over the course of the disease, including her recovery 13 days after the initiation of symptoms, and through to Day 20 at which point she had recovered.", [["infection", "DISEASE", 77, 86], ["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["mild to moderate infection", "PROBLEM", 60, 86], ["symptoms", "PROBLEM", 239, 247], ["mild", "OBSERVATION_MODIFIER", 60, 64], ["moderate", "OBSERVATION_MODIFIER", 68, 76], ["infection", "OBSERVATION", 77, 86]]], ["The virus was detected on Days 4 and 5 via nasopharyngeal swabs but was undetectable thereafter.", [["nasopharyngeal swabs", "ANATOMY", 43, 63], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 43, 63], ["The virus", "PROBLEM", 0, 9], ["nasopharyngeal swabs", "TEST", 43, 63], ["virus", "OBSERVATION", 4, 9], ["nasopharyngeal", "ANATOMY", 43, 57], ["swabs", "OBSERVATION", 58, 63]]], ["IgM and IgG anti-SARS-CoV-2 antibodies progressively increase from Day 7 through to Day 20.", [["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgG anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 8, 27], ["IgM", "PROTEIN", 0, 3], ["IgG anti-SARS-CoV-2 antibodies", "PROTEIN", 8, 38], ["IgM", "TEST", 0, 3], ["IgG anti-SARS", "TEST", 8, 21], ["CoV", "TEST", 22, 25]]], ["Circulating antibody-secreting B cells, CD3\u2212CD19+CD27hiCD38hi, appeared in the blood at the time of viral clearance (Day 7), peaked on Day 8, and remained high through to Day 20.", [["B cells", "ANATOMY", 31, 38], ["CD3\u2212CD19+CD27hiCD38hi", "ANATOMY", 40, 61], ["blood", "ANATOMY", 79, 84], ["B cells", "CELL", 31, 38], ["CD3", "GENE_OR_GENE_PRODUCT", 40, 43], ["CD19", "GENE_OR_GENE_PRODUCT", 44, 48], ["CD27hiCD38hi", "GENE_OR_GENE_PRODUCT", 49, 61], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["Circulating antibody", "PROTEIN", 0, 20], ["secreting B cells", "CELL_TYPE", 21, 38], ["CD3", "PROTEIN", 40, 43], ["CD19", "PROTEIN", 44, 48], ["CD27hiCD38hi", "PROTEIN", 49, 61], ["Circulating antibody", "TEST", 0, 20], ["CD3", "TEST", 40, 43], ["CD19", "TEST", 44, 48], ["CD27hiCD38hi", "TEST", 49, 61], ["the blood", "PROBLEM", 75, 84], ["viral clearance", "TEST", 100, 115], ["secreting B cells", "OBSERVATION", 21, 38], ["viral clearance", "OBSERVATION", 100, 115]]], ["Follicular helper T cells (TFH), CD4+CXCR5+ICOS+PD-1+, were also detected on Day 7 and continued increasing through to Day 20.", [["Follicular helper T cells", "ANATOMY", 0, 25], ["TFH", "ANATOMY", 27, 30], ["CD4+CXCR5", "ANATOMY", 33, 42], ["Follicular helper T cells", "CELL", 0, 25], ["TFH", "CELL", 27, 30], ["CD4", "GENE_OR_GENE_PRODUCT", 33, 36], ["CXCR5", "GENE_OR_GENE_PRODUCT", 37, 42], ["ICOS", "GENE_OR_GENE_PRODUCT", 43, 47], ["PD-1", "GENE_OR_GENE_PRODUCT", 48, 52], ["Follicular helper T cells", "CELL_TYPE", 0, 25], ["TFH", "CELL_TYPE", 27, 30], ["CD4", "PROTEIN", 33, 36], ["CXCR5", "PROTEIN", 37, 42], ["ICOS", "PROTEIN", 43, 47], ["Follicular helper T cells", "TEST", 0, 25], ["TFH", "TEST", 27, 30], ["CD4", "TEST", 33, 36], ["CXCR5", "TEST", 37, 42], ["ICOS", "TEST", 43, 47], ["PD", "TEST", 48, 50]]], ["Activated cytotoxic CD8 T cells, CD8+CD38+HLA-DR+, were also present on Day 7, increased through to Day 9, and then decreased through to Day 20, although with values higher than in healthy controls.", [["cytotoxic CD8 T cells", "ANATOMY", 10, 31], ["CD8+CD38", "ANATOMY", 33, 41], ["CD8", "GENE_OR_GENE_PRODUCT", 20, 23], ["CD8", "GENE_OR_GENE_PRODUCT", 33, 36], ["CD38", "GENE_OR_GENE_PRODUCT", 37, 41], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 42, 48], ["cytotoxic CD8 T cells", "CELL_TYPE", 10, 31], ["CD8", "PROTEIN", 33, 36], ["CD38", "PROTEIN", 37, 41], ["HLA", "PROTEIN", 42, 45], ["DR", "PROTEIN", 46, 48], ["Activated cytotoxic CD8 T cells", "TEST", 0, 31], ["CD8", "TEST", 33, 36], ["CD38", "TEST", 37, 41], ["HLA", "TEST", 42, 45], ["cytotoxic CD8 T cells", "OBSERVATION", 10, 31]]], ["There was no increase in inflammatory CD14+CD16+ monocytes, nor in activated NK CD3\u2212CD56+HLA-DR+ cells.", [["inflammatory CD14+CD16+ monocytes", "ANATOMY", 25, 58], ["NK CD3\u2212CD56+HLA-DR+ cells", "ANATOMY", 77, 102], ["CD14", "GENE_OR_GENE_PRODUCT", 38, 42], ["CD16", "GENE_OR_GENE_PRODUCT", 43, 47], ["CD3", "GENE_OR_GENE_PRODUCT", 80, 83], ["CD56", "GENE_OR_GENE_PRODUCT", 84, 88], ["CD14", "PROTEIN", 38, 42], ["CD16", "PROTEIN", 43, 47], ["monocytes", "CELL_TYPE", 49, 58], ["NK CD3\u2212CD56+HLA-DR+ cells", "CELL_LINE", 77, 102], ["inflammatory CD14", "TEST", 25, 42], ["CD16", "TEST", 43, 47], ["monocytes", "TEST", 49, 58], ["CD3", "TEST", 80, 83], ["CD56", "TEST", 84, 88], ["HLA", "TEST", 89, 92], ["no", "UNCERTAINTY", 10, 12], ["increase", "OBSERVATION_MODIFIER", 13, 21], ["inflammatory", "OBSERVATION_MODIFIER", 25, 37], ["CD16+ monocytes", "OBSERVATION", 43, 58]]], ["Regarding serum cytokines, of the 17 pro-inflammatory cytokines studied, only low levels of MCP1/CCL2 were found on Days 7\u20139.", [["serum", "ANATOMY", 10, 15], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["MCP1", "GENE_OR_GENE_PRODUCT", 92, 96], ["CCL2", "GENE_OR_GENE_PRODUCT", 97, 101], ["serum cytokines", "PROTEIN", 10, 25], ["inflammatory cytokines", "PROTEIN", 41, 63], ["MCP1", "PROTEIN", 92, 96], ["CCL2", "PROTEIN", 97, 101], ["serum cytokines", "TEST", 10, 25], ["inflammatory cytokines", "TEST", 41, 63], ["MCP1/CCL2", "TEST", 92, 101]]], ["This case is interesting since there are very few studies on patients with mild infections and because IgM and IgG antibodies, antibody secreting B cells, CD4 TFH cells, and activated cytotoxic CD8 cells were shown to be circulating before resolution of the symptoms.Dynamics of the Immune and Inflammatory Responses ::: The Immunological Profile of COVID-19 PatientsOng et al. (115) compared the blood transcriptional profile of three patients in early phases of Infection -one of whom evolved to a severe disease- with 10 healthy volunteers.", [["B cells", "ANATOMY", 146, 153], ["CD4 TFH cells", "ANATOMY", 155, 168], ["cytotoxic CD8 cells", "ANATOMY", 184, 203], ["blood", "ANATOMY", 397, 402], ["infections", "DISEASE", 80, 90], ["patients", "ORGANISM", 61, 69], ["IgM", "GENE_OR_GENE_PRODUCT", 103, 106], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 111, 125], ["B cells", "CELL", 146, 153], ["CD4 TFH cells", "CELL", 155, 168], ["CD8 cells", "CELL", 194, 203], ["Patients", "ORGANISM", 359, 367], ["blood", "ORGANISM_SUBSTANCE", 397, 402], ["patients", "ORGANISM", 436, 444], ["volunteers", "ORGANISM", 532, 542], ["IgM", "PROTEIN", 103, 106], ["IgG antibodies", "PROTEIN", 111, 125], ["antibody secreting B cells", "CELL_TYPE", 127, 153], ["CD4 TFH cells", "CELL_TYPE", 155, 168], ["activated cytotoxic CD8 cells", "CELL_TYPE", 174, 203], ["patients", "SPECIES", 61, 69], ["Patients", "SPECIES", 359, 367], ["patients", "SPECIES", 436, 444], ["mild infections", "PROBLEM", 75, 90], ["IgM", "TEST", 103, 106], ["IgG antibodies", "TEST", 111, 125], ["antibody secreting B cells", "TEST", 127, 153], ["CD4 TFH cells", "TEST", 155, 168], ["activated cytotoxic CD8 cells", "PROBLEM", 174, 203], ["the symptoms", "PROBLEM", 254, 266], ["COVID", "TEST", 350, 355], ["the blood transcriptional profile", "TEST", 393, 426], ["Infection", "PROBLEM", 464, 473], ["a severe disease", "PROBLEM", 498, 514], ["mild", "OBSERVATION_MODIFIER", 75, 79], ["infections", "OBSERVATION", 80, 90], ["CD4 TFH cells", "OBSERVATION", 155, 168], ["cytotoxic CD8 cells", "OBSERVATION", 184, 203], ["Inflammatory", "OBSERVATION_MODIFIER", 294, 306], ["early phases", "OBSERVATION_MODIFIER", 448, 460], ["Infection", "OBSERVATION", 464, 473], ["severe", "OBSERVATION_MODIFIER", 500, 506], ["disease", "OBSERVATION", 507, 514]]], ["The main findings in the patient who progressed to severe disease was that only IL-1A and IL-1B preceded the nadir of the respiratory function, and that the expression of most inflammatory genes, particularly IL-6, IL-2, TNF-\u03b1, and IFNA1/13, peaked thereafter.", [["respiratory", "ANATOMY", 122, 133], ["patient", "ORGANISM", 25, 32], ["IL-1A", "GENE_OR_GENE_PRODUCT", 80, 85], ["IL-1B", "GENE_OR_GENE_PRODUCT", 90, 95], ["IL-6", "GENE_OR_GENE_PRODUCT", 209, 213], ["IL-2", "GENE_OR_GENE_PRODUCT", 215, 219], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 221, 226], ["IFNA1", "GENE_OR_GENE_PRODUCT", 232, 237], ["13", "GENE_OR_GENE_PRODUCT", 238, 240], ["IL", "PROTEIN", 80, 82], ["IL-1B", "PROTEIN", 90, 95], ["inflammatory genes", "DNA", 176, 194], ["TNF", "PROTEIN", 221, 224], ["IFNA1/13", "DNA", 232, 240], ["patient", "SPECIES", 25, 32], ["severe disease", "PROBLEM", 51, 65], ["IL", "TEST", 80, 82], ["IL", "TEST", 90, 92], ["most inflammatory genes", "PROBLEM", 171, 194], ["IL", "TEST", 209, 211], ["IL", "TEST", 215, 217], ["TNF", "TEST", 221, 224], ["IFNA1", "TEST", 232, 237], ["main", "OBSERVATION_MODIFIER", 4, 8], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["disease", "OBSERVATION", 58, 65], ["respiratory function", "OBSERVATION", 122, 142], ["inflammatory genes", "OBSERVATION", 176, 194]]], ["Also, in this patient, transcripts associated with HLA, CD4, and CD8 T cell activation were diminished, while in the other two patients, who did not progress to severe disease, the transcription profile was comparable to that of healthy controls.", [["T cell", "ANATOMY", 69, 75], ["patient", "ORGANISM", 14, 21], ["HLA", "GENE_OR_GENE_PRODUCT", 51, 54], ["CD4", "GENE_OR_GENE_PRODUCT", 56, 59], ["CD8", "GENE_OR_GENE_PRODUCT", 65, 68], ["T cell", "CELL", 69, 75], ["patients", "ORGANISM", 127, 135], ["CD4", "PROTEIN", 56, 59], ["CD8", "PROTEIN", 65, 68], ["patient", "SPECIES", 14, 21], ["patients", "SPECIES", 127, 135], ["CD4", "TEST", 56, 59], ["T cell activation", "PROBLEM", 69, 86], ["severe disease", "PROBLEM", 161, 175], ["the transcription profile", "TEST", 177, 202], ["CD8", "OBSERVATION", 65, 68], ["cell activation", "OBSERVATION", 71, 86], ["diminished", "OBSERVATION_MODIFIER", 92, 102], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["disease", "OBSERVATION", 168, 175]]], ["The authors suggest that in the first case the decreased T cell activation may have helped the inflammatory response by the IL-1 pathway, while in the other two cases the low inflammatory response allowed a moderate T cell response.Effect of Age ::: The Immunological Profile of COVID-19 PatientsOne of the risk factors most strongly associated with severe COVID-19 and death is advanced age.", [["T cell", "ANATOMY", 57, 63], ["T cell", "ANATOMY", 216, 222], ["COVID", "DISEASE", 357, 362], ["death", "DISEASE", 370, 375], ["T cell", "CELL", 57, 63], ["IL-1", "GENE_OR_GENE_PRODUCT", 124, 128], ["T cell", "CELL", 216, 222], ["Patients", "ORGANISM", 288, 296], ["IL", "PROTEIN", 124, 126], ["Patients", "SPECIES", 288, 296], ["the decreased T cell activation", "PROBLEM", 43, 74], ["the low inflammatory response", "PROBLEM", 167, 196], ["a moderate T cell response", "PROBLEM", 205, 231], ["COVID", "TEST", 279, 284], ["the risk factors", "PROBLEM", 303, 319], ["severe COVID", "PROBLEM", 350, 362], ["inflammatory", "OBSERVATION_MODIFIER", 95, 107], ["cell response", "OBSERVATION", 218, 231]]], ["Immunosenescence present in the elderly affects innate immunity (116), but mainly T cell-dependent adaptive responses (117\u2013120).", [["T cell", "ANATOMY", 82, 88], ["Immunosenescence", "DISEASE", 0, 16], ["T cell", "CELL", 82, 88]]], ["In addition, experimental evidence suggests that elderly mice have increased levels of proinflammatory cytokines and that their alveolar macrophages are refractory to activation by IFN-\u03b3 (121).", [["alveolar macrophages", "ANATOMY", 128, 148], ["mice", "ORGANISM", 57, 61], ["alveolar macrophages", "CELL", 128, 148], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 181, 186], ["proinflammatory cytokines", "PROTEIN", 87, 112], ["alveolar macrophages", "CELL_TYPE", 128, 148], ["IFN", "PROTEIN", 181, 184], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 57, 61], ["increased levels of proinflammatory cytokines", "PROBLEM", 67, 112], ["their alveolar macrophages", "PROBLEM", 122, 148], ["IFN", "TEST", 181, 184], ["evidence suggests", "UNCERTAINTY", 26, 43], ["increased", "OBSERVATION_MODIFIER", 67, 76], ["proinflammatory cytokines", "OBSERVATION", 87, 112], ["alveolar macrophages", "OBSERVATION", 128, 148]]], ["This finding is relevant since the protective response that eliminates the virus depends on cytotoxic CD8 cells and Th1 responses, with IFN-\u03b3 playing an important role in both responses, as demonstrated in SARS and MERS (122, 123).Effect of Age ::: The Immunological Profile of COVID-19 PatientsIncreased susceptibility in the elderly to present with severe COVID-19 forms contrasts with the lower frequency of these forms in children and young adults.", [["CD8 cells", "ANATOMY", 102, 111], ["SARS", "DISEASE", 206, 210], ["CD8 cells", "CELL", 102, 111], ["Th1", "CELL", 116, 119], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 136, 141], ["Patients", "ORGANISM", 287, 295], ["children", "ORGANISM", 426, 434], ["cytotoxic CD8 cells", "CELL_TYPE", 92, 111], ["IFN", "PROTEIN", 136, 139], ["\u03b3", "PROTEIN", 140, 141], ["Patients", "SPECIES", 287, 295], ["children", "SPECIES", 426, 434], ["the virus", "PROBLEM", 71, 80], ["cytotoxic CD8 cells", "TEST", 92, 111], ["SARS", "PROBLEM", 206, 210], ["The Immunological Profile", "TEST", 249, 274], ["COVID", "TEST", 278, 283], ["Increased susceptibility", "PROBLEM", 295, 319], ["severe COVID-19 forms contrasts", "PROBLEM", 351, 382], ["cytotoxic CD8 cells", "OBSERVATION", 92, 111], ["Increased", "OBSERVATION_MODIFIER", 295, 304], ["susceptibility", "OBSERVATION", 305, 319]]], ["Ludvigsson (124) reviewed 45 publications on COVID-19 and found that 1\u20135% of the patients are children who, although they present with fever and respiratory symptoms, experience milder symptoms and among whom death was extremely rare.", [["respiratory", "ANATOMY", 145, 156], ["fever", "DISEASE", 135, 140], ["respiratory symptoms", "DISEASE", 145, 165], ["death", "DISEASE", 209, 214], ["patients", "ORGANISM", 81, 89], ["children", "ORGANISM", 94, 102], ["patients", "SPECIES", 81, 89], ["children", "SPECIES", 94, 102], ["COVID", "TEST", 45, 50], ["fever", "PROBLEM", 135, 140], ["respiratory symptoms", "PROBLEM", 145, 165], ["milder symptoms", "PROBLEM", 178, 193]]], ["The increase in inflammatory markers and lymphocytopenia were also less common in children.", [["lymphocytopenia", "DISEASE", 41, 56], ["children", "ORGANISM", 82, 90], ["inflammatory markers", "PROTEIN", 16, 36], ["children", "SPECIES", 82, 90], ["The increase in inflammatory markers", "PROBLEM", 0, 36], ["lymphocytopenia", "PROBLEM", 41, 56], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["inflammatory", "OBSERVATION_MODIFIER", 16, 28], ["lymphocytopenia", "OBSERVATION", 41, 56], ["less common", "OBSERVATION_MODIFIER", 67, 78]]], ["Brodin (125) postulated the following three explanations for the milder COVID-19 presentation in children:Studies in Bronchoalveolar Lavage Fluid (BALF)Findings in blood do not necessarily explain the events occurring in tissues directly affected by the infection, thus studies in bronchoalveolar lavage fluids (BALF) are very relevant (Table 2).", [["blood", "ANATOMY", 164, 169], ["tissues", "ANATOMY", 221, 228], ["bronchoalveolar lavage fluids", "ANATOMY", 281, 310], ["BALF", "ANATOMY", 312, 316], ["Brodin", "CHEMICAL", 0, 6], ["infection", "DISEASE", 254, 263], ["Brodin", "CHEMICAL", 0, 6], ["children", "ORGANISM", 97, 105], ["blood", "ORGANISM_SUBSTANCE", 164, 169], ["tissues", "TISSUE", 221, 228], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 281, 303], ["BALF", "ORGANISM_SUBSTANCE", 312, 316], ["children", "SPECIES", 97, 105], ["Studies", "TEST", 106, 113], ["Bronchoalveolar Lavage Fluid (BALF)", "TEST", 117, 152], ["the events", "PROBLEM", 197, 207], ["the infection", "PROBLEM", 250, 263], ["studies in bronchoalveolar lavage fluids (BALF", "TEST", 270, 316], ["Bronchoalveolar Lavage", "OBSERVATION", 117, 139], ["infection", "OBSERVATION", 254, 263]]], ["Xiong et al. (127) used RNA-seq to study BALFs and peripheral blood mononuclear cells (PBMC) transcriptome from three COVID-19 patients (unfortunately their clinical conditions were not reported) and from three healthy subjects.", [["BALFs", "ANATOMY", 41, 46], ["peripheral blood mononuclear cells", "ANATOMY", 51, 85], ["PBMC", "ANATOMY", 87, 91], ["BALFs", "CELL", 41, 46], ["peripheral blood mononuclear cells", "CELL", 51, 85], ["PBMC", "CELL", 87, 91], ["patients", "ORGANISM", 127, 135], ["BALFs", "CELL_TYPE", 41, 46], ["peripheral blood mononuclear cells", "CELL_TYPE", 51, 85], ["PBMC", "CELL_TYPE", 87, 91], ["patients", "SPECIES", 127, 135], ["RNA", "TEST", 24, 27], ["study BALFs", "TEST", 35, 46], ["peripheral blood mononuclear cells", "PROBLEM", 51, 85], ["peripheral", "ANATOMY_MODIFIER", 51, 61], ["blood", "ANATOMY", 62, 67], ["mononuclear cells", "OBSERVATION", 68, 85]]], ["The BALF cells in these patients expressed 9,609 genes, 679 of which were up-regulated and 325 down-regulated, as opposed to controls.", [["BALF cells", "ANATOMY", 4, 14], ["BALF cells", "CELL", 4, 14], ["patients", "ORGANISM", 24, 32], ["BALF cells", "CELL_TYPE", 4, 14], ["9,609 genes", "DNA", 43, 54], ["patients", "SPECIES", 24, 32], ["The BALF cells", "TEST", 0, 14], ["BALF cells", "OBSERVATION", 4, 14]]], ["In PBMC, 15,726 genes were expressed, with 707 up-regulated and 316 down-regulated.", [["PBMC", "ANATOMY", 3, 7], ["PBMC", "CELL", 3, 7], ["PBMC", "CELL_TYPE", 3, 7]]], ["BALF cells from patients showed a differential expression of genes related to viral invasion and replication (viral RNA was detected in BALFs of all three patients) such as membrane-associated proteins, endoplasmic reticulum, and viral transcription.", [["BALF cells", "ANATOMY", 0, 10], ["BALFs", "ANATOMY", 136, 141], ["membrane", "ANATOMY", 173, 181], ["endoplasmic reticulum", "ANATOMY", 203, 224], ["BALF cells", "CELL", 0, 10], ["patients", "ORGANISM", 16, 24], ["BALFs", "CANCER", 136, 141], ["patients", "ORGANISM", 155, 163], ["membrane", "CELLULAR_COMPONENT", 173, 181], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 203, 224], ["BALF cells", "CELL_TYPE", 0, 10], ["viral RNA", "RNA", 110, 119], ["BALFs", "CELL_TYPE", 136, 141], ["membrane-associated proteins", "PROTEIN", 173, 201], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 155, 163], ["BALF cells", "TEST", 0, 10], ["a differential expression of genes", "PROBLEM", 32, 66], ["viral invasion", "PROBLEM", 78, 92], ["replication (viral RNA", "PROBLEM", 97, 119], ["membrane-associated proteins", "PROBLEM", 173, 201], ["endoplasmic reticulum", "PROBLEM", 203, 224], ["viral transcription", "PROBLEM", 230, 249], ["viral", "OBSERVATION_MODIFIER", 78, 83], ["invasion", "OBSERVATION", 84, 92], ["endoplasmic reticulum", "OBSERVATION", 203, 224], ["viral transcription", "OBSERVATION", 230, 249]]], ["In contrast, PBMCs showed increased expression of genes related to complement activation, immunoglobulins, and B cell-mediated responses, while some genes corresponded to the acute inflammatory response.", [["PBMCs", "ANATOMY", 13, 18], ["B cell", "ANATOMY", 111, 117], ["PBMCs", "CELL", 13, 18], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 90, 105], ["B cell", "CELL", 111, 117], ["PBMCs", "CELL_TYPE", 13, 18], ["immunoglobulins", "PROTEIN", 90, 105], ["PBMCs", "TEST", 13, 18], ["increased expression of genes", "PROBLEM", 26, 55], ["complement activation", "TEST", 67, 88], ["immunoglobulins", "TEST", 90, 105], ["the acute inflammatory response", "PROBLEM", 171, 202], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["acute", "OBSERVATION_MODIFIER", 175, 180], ["inflammatory", "OBSERVATION", 181, 193]]], ["The down-regulated genes in patients' BALF were mostly related to activation of the immune response.", [["BALF", "ANATOMY", 38, 42], ["patients", "ORGANISM", 28, 36], ["BALF", "CELL", 38, 42], ["down-regulated genes", "DNA", 4, 24], ["patients", "SPECIES", 28, 36], ["genes", "OBSERVATION_MODIFIER", 19, 24], ["immune response", "OBSERVATION", 84, 99]]], ["Comparison of the cytokine genes showed that in BALFs the genes for IL-10, CCL2/MCP-1 (together with its CCR2 receptor), CXCL10/IP-10, CCL3/MIP-1A (together with its CCR5 receptor), and CCL4/MIP1B were differentially up-regulated.", [["BALFs", "ANATOMY", 48, 53], ["BALFs", "CANCER", 48, 53], ["IL-10", "GENE_OR_GENE_PRODUCT", 68, 73], ["CCL2", "GENE_OR_GENE_PRODUCT", 75, 79], ["MCP-1", "GENE_OR_GENE_PRODUCT", 80, 85], ["CCR2", "GENE_OR_GENE_PRODUCT", 105, 109], ["CXCL10", "GENE_OR_GENE_PRODUCT", 121, 127], ["IP-10", "GENE_OR_GENE_PRODUCT", 128, 133], ["CCL3", "GENE_OR_GENE_PRODUCT", 135, 139], ["MIP-1A", "GENE_OR_GENE_PRODUCT", 140, 146], ["CCR5", "GENE_OR_GENE_PRODUCT", 166, 170], ["CCL4", "GENE_OR_GENE_PRODUCT", 186, 190], ["MIP1B", "GENE_OR_GENE_PRODUCT", 191, 196], ["cytokine genes", "DNA", 18, 32], ["BALFs", "CELL_TYPE", 48, 53], ["IL-10", "PROTEIN", 68, 73], ["CCL2", "PROTEIN", 75, 79], ["MCP-1", "PROTEIN", 80, 85], ["CCR2 receptor", "PROTEIN", 105, 118], ["CXCL10", "PROTEIN", 121, 127], ["IP-10", "PROTEIN", 128, 133], ["CCL3", "PROTEIN", 135, 139], ["MIP-1A", "PROTEIN", 140, 146], ["CCR5 receptor", "PROTEIN", 166, 179], ["CCL4", "PROTEIN", 186, 190], ["MIP1B", "PROTEIN", 191, 196], ["the cytokine genes", "TEST", 14, 32], ["IL", "TEST", 68, 70], ["CCL2/MCP", "TEST", 75, 83], ["CXCL10", "TEST", 121, 127], ["IP", "TEST", 128, 130], ["CCL3/MIP", "TEST", 135, 143], ["its CCR5 receptor", "TEST", 162, 179], ["CCL4/MIP1B", "TEST", 186, 196], ["CCL4", "ANATOMY", 186, 190]]], ["Another relevant finding was that in PBMC, genes related to autophagy, apotopsis, and p53 pathways were up-regulated, a finding that could be related to the lymphopenia detected in the three patients.", [["PBMC", "ANATOMY", 37, 41], ["lymphopenia", "DISEASE", 157, 168], ["PBMC", "CELL", 37, 41], ["apotopsis", "GENE_OR_GENE_PRODUCT", 71, 80], ["p53", "GENE_OR_GENE_PRODUCT", 86, 89], ["patients", "ORGANISM", 191, 199], ["PBMC", "CELL_TYPE", 37, 41], ["p53", "PROTEIN", 86, 89], ["patients", "SPECIES", 191, 199], ["autophagy", "PROBLEM", 60, 69], ["apotopsis", "PROBLEM", 71, 80], ["p53 pathways", "PROBLEM", 86, 98], ["the lymphopenia", "PROBLEM", 153, 168], ["could be related to", "UNCERTAINTY", 133, 152], ["lymphopenia", "OBSERVATION", 157, 168]]], ["Interestingly, IL-6 transcripts were not increased in PBMCs, although the patients had high plasma levels of such cytokine, suggesting that circulating IL-6 could have been produced in the lungs, either by alveolar epithelial cells or by recruited inflammatory cells.Studies in Bronchoalveolar Lavage Fluid (BALF)In another study, Liao et al. (128) used scRNA-seq and scTCR-seq to determine BALF cells' transcriptional signature in three patients with severe and another three with moderate COVID-19, and compared them with eight healthy subjects, previously studied.", [["PBMCs", "ANATOMY", 54, 59], ["plasma", "ANATOMY", 92, 98], ["lungs", "ANATOMY", 189, 194], ["alveolar epithelial cells", "ANATOMY", 206, 231], ["inflammatory cells", "ANATOMY", 248, 266], ["BALF cells", "ANATOMY", 391, 401], ["IL-6", "GENE_OR_GENE_PRODUCT", 15, 19], ["PBMCs", "CELL", 54, 59], ["patients", "ORGANISM", 74, 82], ["plasma", "ORGANISM_SUBSTANCE", 92, 98], ["IL-6", "GENE_OR_GENE_PRODUCT", 152, 156], ["lungs", "ORGAN", 189, 194], ["alveolar epithelial cells", "CELL", 206, 231], ["cells", "CELL", 261, 266], ["scRNA-seq", "GENE_OR_GENE_PRODUCT", 354, 363], ["BALF cells", "CELL", 391, 401], ["patients", "ORGANISM", 438, 446], ["IL-6 transcripts", "RNA", 15, 31], ["PBMCs", "CELL_TYPE", 54, 59], ["cytokine", "PROTEIN", 114, 122], ["IL-6", "PROTEIN", 152, 156], ["alveolar epithelial cells", "CELL_TYPE", 206, 231], ["inflammatory cells", "CELL_TYPE", 248, 266], ["scTCR", "PROTEIN", 368, 373], ["BALF cells", "CELL_TYPE", 391, 401], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 438, 446], ["PBMCs", "TEST", 54, 59], ["high plasma levels of such cytokine", "PROBLEM", 87, 122], ["circulating IL", "TEST", 140, 154], ["alveolar epithelial cells", "PROBLEM", 206, 231], ["recruited inflammatory cells", "PROBLEM", 238, 266], ["Studies", "TEST", 267, 274], ["Bronchoalveolar Lavage Fluid (BALF", "TEST", 278, 312], ["another study", "TEST", 316, 329], ["scRNA", "TEST", 354, 359], ["scTCR", "TEST", 368, 373], ["BALF cells", "PROBLEM", 391, 401], ["transcriptional signature", "TEST", 403, 428], ["moderate COVID", "PROBLEM", 482, 496], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["lungs", "ANATOMY", 189, 194], ["alveolar epithelial cells", "OBSERVATION", 206, 231], ["inflammatory cells", "OBSERVATION", 248, 266], ["Bronchoalveolar", "ANATOMY", 278, 293], ["BALF cells", "OBSERVATION", 391, 401]]], ["Their main findings were related to macrophages and CD8 cells.", [["macrophages", "ANATOMY", 36, 47], ["CD8 cells", "ANATOMY", 52, 61], ["macrophages", "CELL", 36, 47], ["CD8 cells", "CELL", 52, 61], ["macrophages", "CELL_TYPE", 36, 47], ["CD8 cells", "CELL_TYPE", 52, 61], ["macrophages", "PROBLEM", 36, 47], ["CD8 cells", "PROBLEM", 52, 61], ["related to", "UNCERTAINTY", 25, 35], ["macrophages", "OBSERVATION", 36, 47], ["CD8 cells", "OBSERVATION", 52, 61]]], ["Macrophages were predominant in BALFs from patients with severe infection, with a minor proportion of T and NK cells, as compared with patients with moderate disease.", [["Macrophages", "ANATOMY", 0, 11], ["BALFs", "ANATOMY", 32, 37], ["T", "ANATOMY", 102, 103], ["NK cells", "ANATOMY", 108, 116], ["infection", "DISEASE", 64, 73], ["Macrophages", "CELL", 0, 11], ["BALFs", "CANCER", 32, 37], ["patients", "ORGANISM", 43, 51], ["T", "CELL", 102, 103], ["NK cells", "CELL", 108, 116], ["patients", "ORGANISM", 135, 143], ["Macrophages", "CELL_TYPE", 0, 11], ["BALFs", "CELL_TYPE", 32, 37], ["T and NK cells", "CELL_TYPE", 102, 116], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 135, 143], ["Macrophages", "PROBLEM", 0, 11], ["severe infection", "PROBLEM", 57, 73], ["T and NK cells", "PROBLEM", 102, 116], ["moderate disease", "PROBLEM", 149, 165], ["predominant", "OBSERVATION_MODIFIER", 17, 28], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["infection", "OBSERVATION", 64, 73], ["NK cells", "OBSERVATION", 108, 116], ["moderate", "OBSERVATION_MODIFIER", 149, 157], ["disease", "OBSERVATION", 158, 165]]], ["Macrophages were classified in 22 clusters, according to their expression of FCN1 (monocyte-derived), SPP1 (pro-fibrotic), and FABP4 (alveolar macrophages).", [["Macrophages", "ANATOMY", 0, 11], ["monocyte", "ANATOMY", 83, 91], ["alveolar macrophages", "ANATOMY", 134, 154], ["Macrophages", "CELL", 0, 11], ["FCN1", "GENE_OR_GENE_PRODUCT", 77, 81], ["monocyte", "CELL", 83, 91], ["SPP1", "GENE_OR_GENE_PRODUCT", 102, 106], ["FABP4", "GENE_OR_GENE_PRODUCT", 127, 132], ["alveolar macrophages", "CELL", 134, 154], ["Macrophages", "CELL_TYPE", 0, 11], ["FCN1", "PROTEIN", 77, 81], ["SPP1", "PROTEIN", 102, 106], ["pro-fibrotic", "PROTEIN", 108, 120], ["FABP4", "PROTEIN", 127, 132], ["alveolar macrophages", "CELL_TYPE", 134, 154], ["Macrophages", "PROBLEM", 0, 11], ["FCN1", "TEST", 77, 81], ["SPP1", "TEST", 102, 106], ["FABP4", "ANATOMY", 127, 132], ["alveolar macrophages", "ANATOMY", 134, 154]]], ["These genes were differentially expressed both among the two groups of patients and the healthy controls.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79]]], ["FABP4 was preferentially expressed in healthy controls and in patients with moderate COVID-19, while FCN1 and SPP1 were expressed in patients with severe COVID-19.", [["FABP4", "GENE_OR_GENE_PRODUCT", 0, 5], ["patients", "ORGANISM", 62, 70], ["FCN1", "GENE_OR_GENE_PRODUCT", 101, 105], ["SPP1", "GENE_OR_GENE_PRODUCT", 110, 114], ["patients", "ORGANISM", 133, 141], ["FABP4", "PROTEIN", 0, 5], ["FCN1", "PROTEIN", 101, 105], ["SPP1", "PROTEIN", 110, 114], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 133, 141], ["FABP4", "TEST", 0, 5], ["moderate COVID", "PROBLEM", 76, 90], ["FCN1", "TEST", 101, 105], ["SPP1", "TEST", 110, 114], ["severe COVID", "PROBLEM", 147, 159]]], ["Further macrophages classification resulted in four groups: Group 1, FCN1hi only; Group 2, FCN1loSPP1+; Group 3, FCN1\u2212SPP1+; and Group 4, FABP4+.", [["macrophages", "ANATOMY", 8, 19], ["macrophages", "CELL", 8, 19], ["FABP4", "GENE_OR_GENE_PRODUCT", 138, 143], ["macrophages", "CELL_TYPE", 8, 19], ["SPP1", "PROTEIN", 118, 122], ["FABP4", "PROTEIN", 138, 143], ["Further macrophages classification", "TEST", 0, 34], ["FCN1loSPP1", "TEST", 91, 101], ["FCN1", "TEST", 113, 117], ["SPP1", "TEST", 118, 122], ["FABP4", "TEST", 138, 143], ["macrophages", "OBSERVATION", 8, 19]]], ["Group 1 macrophages expressed genes associated with inflammatory monocytes; Group 2 expressed chemokines and interferon stimulated genes (ISG); Group 3, genes related with immune regulation and profibrotic events; and Group 4 were alveolar macrophage typical genes.", [["macrophages", "ANATOMY", 8, 19], ["monocytes", "ANATOMY", 65, 74], ["alveolar macrophage", "ANATOMY", 231, 250], ["Group 1 macrophages", "CELL", 0, 19], ["monocytes", "CELL", 65, 74], ["interferon stimulated genes", "GENE_OR_GENE_PRODUCT", 109, 136], ["ISG", "GENE_OR_GENE_PRODUCT", 138, 141], ["Group 3", "GENE_OR_GENE_PRODUCT", 144, 151], ["alveolar macrophage", "CELL", 231, 250], ["macrophages", "CELL_TYPE", 8, 19], ["inflammatory monocytes", "CELL_TYPE", 52, 74], ["chemokines", "PROTEIN", 94, 104], ["interferon stimulated genes", "DNA", 109, 136], ["ISG", "DNA", 138, 141], ["Group 3", "DNA", 144, 151], ["alveolar macrophage typical genes", "DNA", 231, 264], ["inflammatory monocytes", "PROBLEM", 52, 74], ["Group 2 expressed chemokines", "TREATMENT", 76, 104], ["interferon stimulated genes", "TREATMENT", 109, 136], ["immune regulation", "PROBLEM", 172, 189], ["profibrotic events", "PROBLEM", 194, 212], ["inflammatory monocytes", "OBSERVATION", 52, 74], ["profibrotic", "OBSERVATION_MODIFIER", 194, 205], ["alveolar macrophage", "OBSERVATION", 231, 250], ["typical genes", "OBSERVATION", 251, 264]]], ["According to the investigators, these results suggest that during SARS-CoV-2 infection, inflammatory monocytes (FCN1+) are recruited from the circulation into the lungs, where they differentiate into SPP1+ macrophages, constituents of the severe inflammatory reaction.", [["inflammatory monocytes", "ANATOMY", 88, 110], ["lungs", "ANATOMY", 163, 168], ["macrophages", "ANATOMY", 206, 217], ["infection", "DISEASE", 77, 86], ["SARS-CoV-2", "ORGANISM", 66, 76], ["inflammatory monocytes", "CELL", 88, 110], ["FCN1+", "CELL", 112, 117], ["lungs", "ORGAN", 163, 168], ["SPP1", "GENE_OR_GENE_PRODUCT", 200, 204], ["macrophages", "CELL", 206, 217], ["inflammatory monocytes", "CELL_TYPE", 88, 110], ["FCN1", "CELL_TYPE", 112, 116], ["SPP1", "PROTEIN", 200, 204], ["macrophages", "CELL_TYPE", 206, 217], ["SARS-CoV-2", "SPECIES", 66, 76], ["SARS", "TEST", 66, 70], ["CoV", "TEST", 71, 74], ["2 infection", "PROBLEM", 75, 86], ["inflammatory monocytes", "PROBLEM", 88, 110], ["FCN1", "TEST", 112, 116], ["macrophages", "PROBLEM", 206, 217], ["the severe inflammatory reaction", "PROBLEM", 235, 267], ["inflammatory monocytes", "OBSERVATION", 88, 110], ["lungs", "ANATOMY", 163, 168], ["macrophages", "OBSERVATION", 206, 217], ["severe", "OBSERVATION_MODIFIER", 239, 245], ["inflammatory", "OBSERVATION_MODIFIER", 246, 258], ["reaction", "OBSERVATION", 259, 267]]], ["Analysis of the BALF transcriptome showed that T and NK cells are increased in COVID-19 patients, compared to healthy controls, which according to their gene expression can be classified in NK, CD8, CD4, Tregs, and proliferating cells.", [["BALF", "ANATOMY", 16, 20], ["T", "ANATOMY", 47, 48], ["NK cells", "ANATOMY", 53, 61], ["NK", "ANATOMY", 190, 192], ["CD8", "ANATOMY", 194, 197], ["CD4", "ANATOMY", 199, 202], ["Tregs", "ANATOMY", 204, 209], ["cells", "ANATOMY", 229, 234], ["BALF", "CELL", 16, 20], ["T", "CELL", 47, 48], ["NK cells", "CELL", 53, 61], ["patients", "ORGANISM", 88, 96], ["NK", "CELL", 190, 192], ["CD8", "GENE_OR_GENE_PRODUCT", 194, 197], ["CD4", "GENE_OR_GENE_PRODUCT", 199, 202], ["Tregs", "GENE_OR_GENE_PRODUCT", 204, 209], ["cells", "CELL", 229, 234], ["T and NK cells", "CELL_TYPE", 47, 61], ["NK, CD8, CD4, Tregs, and proliferating cells", "CELL_TYPE", 190, 234], ["patients", "SPECIES", 88, 96], ["the BALF transcriptome", "TEST", 12, 34], ["T and NK cells", "PROBLEM", 47, 61], ["COVID", "TEST", 79, 84], ["NK", "TEST", 190, 192], ["CD8", "TEST", 194, 197], ["CD4", "TEST", 199, 202], ["Tregs", "TEST", 204, 209], ["proliferating cells", "PROBLEM", 215, 234], ["NK cells", "OBSERVATION", 53, 61], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["Tregs", "ANATOMY", 204, 209], ["proliferating cells", "OBSERVATION", 215, 234]]], ["An important finding was that genes related to activating molecules, migration, calcium signaling, and effector molecules were highly expressed by CD8 cells in patients with moderate infection, compared with patients with severe COVID-19; this further supports the role of CD8 cells in the elimination of the virus and their subsequent, protective immunity.", [["CD8 cells", "ANATOMY", 147, 156], ["CD8 cells", "ANATOMY", 273, 282], ["calcium", "CHEMICAL", 80, 87], ["infection", "DISEASE", 183, 192], ["calcium", "CHEMICAL", 80, 87], ["calcium", "SIMPLE_CHEMICAL", 80, 87], ["CD8 cells", "CELL", 147, 156], ["patients", "ORGANISM", 160, 168], ["patients", "ORGANISM", 208, 216], ["CD8 cells", "CELL", 273, 282], ["effector molecules", "PROTEIN", 103, 121], ["CD8 cells", "CELL_TYPE", 147, 156], ["CD8 cells", "CELL_TYPE", 273, 282], ["patients", "SPECIES", 160, 168], ["patients", "SPECIES", 208, 216], ["activating molecules", "PROBLEM", 47, 67], ["calcium signaling", "PROBLEM", 80, 97], ["effector molecules", "PROBLEM", 103, 121], ["moderate infection", "PROBLEM", 174, 192], ["severe COVID", "PROBLEM", 222, 234], ["CD8 cells", "PROBLEM", 273, 282], ["the virus", "PROBLEM", 305, 314], ["CD8 cells", "OBSERVATION", 147, 156], ["moderate", "OBSERVATION_MODIFIER", 174, 182], ["infection", "OBSERVATION", 183, 192], ["CD8 cells", "OBSERVATION", 273, 282]]], ["In contrast, patients with severe disease had a higher expression of genes related to proliferation, energy generation, and initiation of translation.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["severe disease", "PROBLEM", 27, 41], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["disease", "OBSERVATION", 34, 41]]], ["These results suggest that in patients with moderate infection CD8 cells are more differentiated and efficient, while in severe Infection T cells are in a proliferative stage.", [["CD8 cells", "ANATOMY", 63, 72], ["T cells", "ANATOMY", 138, 145], ["infection", "DISEASE", 53, 62], ["patients", "ORGANISM", 30, 38], ["CD8 cells", "CELL", 63, 72], ["T cells", "CELL", 138, 145], ["CD8 cells", "CELL_TYPE", 63, 72], ["Infection T cells", "CELL_TYPE", 128, 145], ["patients", "SPECIES", 30, 38], ["moderate infection CD8 cells", "PROBLEM", 44, 72], ["severe Infection T cells", "PROBLEM", 121, 145], ["a proliferative stage", "PROBLEM", 153, 174], ["moderate", "OBSERVATION_MODIFIER", 44, 52], ["infection", "OBSERVATION", 53, 62], ["CD8 cells", "OBSERVATION", 63, 72], ["more differentiated", "OBSERVATION_MODIFIER", 77, 96], ["severe", "OBSERVATION_MODIFIER", 121, 127], ["Infection", "OBSERVATION", 128, 137], ["proliferative", "OBSERVATION_MODIFIER", 155, 168]]], ["Additionally, the finding that the TCR repertoire is higher in CD8 than in CD4 cells, suggests a larger clonal expansion of the CD8 cells taking part in the resolution of the infection.Studies in Bronchoalveolar Lavage Fluid (BALF)Zhou et al. (129) used metatranscriptomic sequencing to profile immune signatures in the BALF of eight COVID-19 patients, compared to 146 community-acquired pneumonia patients and 20 healthy controls.", [["CD8", "ANATOMY", 63, 66], ["CD4 cells", "ANATOMY", 75, 84], ["CD8 cells", "ANATOMY", 128, 137], ["BALF", "ANATOMY", 320, 324], ["infection", "DISEASE", 175, 184], ["pneumonia", "DISEASE", 388, 397], ["TCR", "GENE_OR_GENE_PRODUCT", 35, 38], ["CD8", "GENE_OR_GENE_PRODUCT", 63, 66], ["CD4 cells", "CELL", 75, 84], ["CD8 cells", "CELL", 128, 137], ["patients", "ORGANISM", 343, 351], ["patients", "ORGANISM", 398, 406], ["TCR repertoire", "PROTEIN", 35, 49], ["CD8", "PROTEIN", 63, 66], ["CD4 cells", "CELL_TYPE", 75, 84], ["CD8 cells", "CELL_TYPE", 128, 137], ["patients", "SPECIES", 343, 351], ["patients", "SPECIES", 398, 406], ["the TCR repertoire", "TEST", 31, 49], ["a larger clonal expansion of the CD8 cells", "PROBLEM", 95, 137], ["the infection", "PROBLEM", 171, 184], ["Studies", "TEST", 185, 192], ["Bronchoalveolar Lavage Fluid (BALF)", "TEST", 196, 231], ["Zhou et al.", "TEST", 231, 242], ["metatranscriptomic sequencing", "TREATMENT", 254, 283], ["immune signatures", "TEST", 295, 312], ["the BALF", "TEST", 316, 324], ["eight COVID", "TEST", 328, 339], ["acquired pneumonia", "PROBLEM", 379, 397], ["higher", "OBSERVATION_MODIFIER", 53, 59], ["CD4 cells", "OBSERVATION", 75, 84], ["larger", "OBSERVATION_MODIFIER", 97, 103], ["clonal", "OBSERVATION_MODIFIER", 104, 110], ["expansion", "OBSERVATION_MODIFIER", 111, 120], ["CD8 cells", "OBSERVATION", 128, 137], ["resolution", "OBSERVATION_MODIFIER", 157, 167], ["infection", "OBSERVATION", 175, 184], ["Bronchoalveolar Lavage", "OBSERVATION", 196, 218], ["pneumonia", "OBSERVATION", 388, 397]]], ["Their results show that in BALF from COVID-19, the differentially expressed genes (DEGs) included up-regulated proinflammatory chemokines genes, such as CXCL17, CXCL8, and CXCL2, as well as the CXCR2 receptor, critical to neutrophil recruitment, and CCL2 and CCL7, needed for monocyte recruitment.", [["BALF", "ANATOMY", 27, 31], ["neutrophil", "ANATOMY", 222, 232], ["monocyte", "ANATOMY", 276, 284], ["BALF", "CELL", 27, 31], ["COVID-19", "CELL", 37, 45], ["CXCL17", "GENE_OR_GENE_PRODUCT", 153, 159], ["CXCL8", "GENE_OR_GENE_PRODUCT", 161, 166], ["CXCL2", "GENE_OR_GENE_PRODUCT", 172, 177], ["CXCR2 receptor", "GENE_OR_GENE_PRODUCT", 194, 208], ["neutrophil", "CELL", 222, 232], ["CCL2", "GENE_OR_GENE_PRODUCT", 250, 254], ["CCL7", "GENE_OR_GENE_PRODUCT", 259, 263], ["monocyte", "CELL", 276, 284], ["BALF", "CELL_TYPE", 27, 31], ["differentially expressed genes", "DNA", 51, 81], ["DEGs", "DNA", 83, 87], ["proinflammatory chemokines genes", "DNA", 111, 143], ["CXCL17", "PROTEIN", 153, 159], ["CXCL8", "PROTEIN", 161, 166], ["CXCL2", "PROTEIN", 172, 177], ["CXCR2 receptor", "PROTEIN", 194, 208], ["CCL2", "PROTEIN", 250, 254], ["CCL7", "PROTEIN", 259, 263], ["BALF", "TEST", 27, 31], ["COVID", "TEST", 37, 42], ["CXCL17", "TEST", 153, 159], ["CXCL8", "TEST", 161, 166], ["CXCL2", "TEST", 172, 177], ["the CXCR2 receptor", "TEST", 190, 208], ["neutrophil recruitment", "TEST", 222, 244], ["CCL2", "TEST", 250, 254], ["CCL7", "TEST", 259, 263], ["monocyte recruitment", "TREATMENT", 276, 296], ["proinflammatory chemokines", "OBSERVATION", 111, 137], ["neutrophil recruitment", "OBSERVATION", 222, 244]]], ["These authors also found that COVID-19 patients up-regulated IL-1\u03b2, antiviral Interferon stimulated genes (ISGs), and genes related to the IL-17, TNF, and NF-\u03baB signaling pathways.", [["patients", "ORGANISM", 39, 47], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 61, 66], ["Interferon stimulated genes", "GENE_OR_GENE_PRODUCT", 78, 105], ["ISGs", "GENE_OR_GENE_PRODUCT", 107, 111], ["IL-17", "GENE_OR_GENE_PRODUCT", 139, 144], ["TNF", "GENE_OR_GENE_PRODUCT", 146, 149], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 155, 160], ["IL-1\u03b2", "PROTEIN", 61, 66], ["antiviral Interferon stimulated genes", "DNA", 68, 105], ["ISGs", "DNA", 107, 111], ["patients", "SPECIES", 39, 47], ["COVID", "TEST", 30, 35], ["IL", "TREATMENT", 61, 63], ["antiviral Interferon stimulated genes", "TREATMENT", 68, 105], ["the IL", "TEST", 135, 141], ["TNF", "TREATMENT", 146, 149]]], ["In addition, the cellular analysis showed an increased neutrophil to lymphocyte ratio (NLR) in patients with COVID-19 compared to patients with other pneumonias.Studies in Bronchoalveolar Lavage Fluid (BALF)Taken together, findings in BALF demonstrate both a highly dysregulated innate and adaptive immune response in the affected lungs of patients with COVID-19.ConclusionsJust 5 months after the initiation of the COVID-19 pandemic in China, which extended quickly worldwide to greatly impact public health and economies, the amount of information gathered on all aspects of the infection and the celerity with which the international scientific community has shared such information is truly amazing.", [["cellular", "ANATOMY", 17, 25], ["neutrophil", "ANATOMY", 55, 65], ["lymphocyte", "ANATOMY", 69, 79], ["BALF", "ANATOMY", 235, 239], ["lungs", "ANATOMY", 331, 336], ["COVID-19", "CHEMICAL", 109, 117], ["pneumonias", "DISEASE", 150, 160], ["infection", "DISEASE", 581, 590], ["cellular", "CELL", 17, 25], ["neutrophil", "CELL", 55, 65], ["lymphocyte", "CELL", 69, 79], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 130, 138], ["BALF", "ORGANISM_SUBSTANCE", 235, 239], ["lungs", "ORGAN", 331, 336], ["patients", "ORGANISM", 340, 348], ["BALF", "CELL_TYPE", 235, 239], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 340, 348], ["the cellular analysis", "TEST", 13, 34], ["an increased neutrophil to lymphocyte ratio", "PROBLEM", 42, 85], ["NLR", "TEST", 87, 90], ["COVID", "TEST", 109, 114], ["other pneumonias", "PROBLEM", 144, 160], ["Studies", "TEST", 161, 168], ["Bronchoalveolar Lavage Fluid (BALF)", "TEST", 172, 207], ["findings in BALF", "TEST", 223, 239], ["a highly dysregulated innate", "PROBLEM", 257, 285], ["COVID", "TEST", 354, 359], ["the COVID", "TEST", 412, 421], ["the infection", "PROBLEM", 577, 590], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["neutrophil to lymphocyte", "OBSERVATION", 55, 79], ["pneumonias", "OBSERVATION", 150, 160], ["Bronchoalveolar Lavage", "OBSERVATION", 172, 194], ["BALF", "ANATOMY", 235, 239], ["highly", "OBSERVATION_MODIFIER", 259, 265], ["dysregulated", "OBSERVATION", 266, 278], ["immune response", "OBSERVATION", 299, 314], ["lungs", "ANATOMY", 331, 336], ["infection", "OBSERVATION", 581, 590]]], ["A note of caution is therefore in order, if such information is to be used in defining new diagnostic, therapeutic, or prophylactic protocols.", [["prophylactic protocols", "TREATMENT", 119, 141]]], ["It is also important to consider the brief amount of time elapsed since the beginning of the pandemic, during which time it has not been possible to gather sufficient results from in vitro and experimental animal models to ensure further understanding of COVID-19's biology.", [["COVID-19's", "CELL", 255, 265]]], ["Even when considering these limitations, the information provided by the papers reviewed herein strongly supports quantitative and qualitative differences in the immune responses of those infected with SARS-CoV-2 which seem to correlate with the clinical manifestations of COVID-19.", [["SARS", "DISEASE", 202, 206], ["COVID-19", "CHEMICAL", 273, 281], ["SARS-CoV-2", "ORGANISM", 202, 212], ["SARS-CoV", "SPECIES", 202, 210], ["SARS-CoV", "TEST", 202, 210], ["COVID", "TEST", 273, 278]]], ["Although studies of asymptomatic infected individuals are lacking, the immunological profiles of patients with moderate infections indicate a protective T cell-dependent response, in contrast to patients with severe disease who exhibit an exacerbated systemic inflammation, with signs of T cells exhaustion.ConclusionsThe following fundamental aspects need to be defined through close collaboration between clinicians and basic researchers, with strong support from the public and private financial agencies:ConclusionsFinally, it is important to remember what many investigators of SARS and MERS have written in their publications, long before the emergency of COVID-19 pandemics: what will be learned from this pandemic must be used to prevent future coronavirus epidemics.Author ContributionsLG: wrote and edited the manuscript.Conflict of InterestThe author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["T cell", "ANATOMY", 153, 159], ["T cells", "ANATOMY", 288, 295], ["infections", "DISEASE", 120, 130], ["inflammation", "DISEASE", 260, 272], ["SARS", "DISEASE", 583, 587], ["coronavirus", "DISEASE", 753, 764], ["patients", "ORGANISM", 97, 105], ["T cell", "CELL", 153, 159], ["patients", "ORGANISM", 195, 203], ["T cells", "CELL", 288, 295], ["coronavirus", "ORGANISM", 753, 764], ["T cells", "CELL_TYPE", 288, 295], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 195, 203], ["asymptomatic infected individuals", "PROBLEM", 20, 53], ["moderate infections", "PROBLEM", 111, 130], ["severe disease", "PROBLEM", 209, 223], ["an exacerbated systemic inflammation", "PROBLEM", 236, 272], ["T cells exhaustion", "PROBLEM", 288, 306], ["SARS", "PROBLEM", 583, 587], ["future coronavirus epidemics", "PROBLEM", 746, 774], ["asymptomatic", "OBSERVATION_MODIFIER", 20, 32], ["infected", "OBSERVATION", 33, 41], ["moderate", "OBSERVATION_MODIFIER", 111, 119], ["infections", "OBSERVATION", 120, 130], ["severe", "OBSERVATION_MODIFIER", 209, 215], ["disease", "OBSERVATION", 216, 223], ["exacerbated", "OBSERVATION_MODIFIER", 239, 250], ["systemic", "OBSERVATION_MODIFIER", 251, 259], ["inflammation", "OBSERVATION", 260, 272], ["cells exhaustion", "OBSERVATION", 290, 306]]]], "PMC5884222": [["IntroductionThere is enormous variability in the complexity of living organisms.", [["enormous variability", "PROBLEM", 21, 41], ["enormous", "OBSERVATION_MODIFIER", 21, 29], ["variability", "OBSERVATION_MODIFIER", 30, 41], ["complexity", "OBSERVATION_MODIFIER", 49, 59]]], ["Small simple viruses may contain fewer than a dozen genes on a genome consisting of a few kilo-bases that encode up to a dozen proteins.", [["kilo-bases", "DNA", 90, 100], ["dozen proteins", "PROTEIN", 121, 135], ["Small simple viruses", "PROBLEM", 0, 20], ["simple", "OBSERVATION_MODIFIER", 6, 12], ["viruses", "OBSERVATION", 13, 20], ["fewer", "OBSERVATION_MODIFIER", 33, 38], ["bases", "ANATOMY_MODIFIER", 95, 100]]], ["Significantly more complex eukaryotic organisms possess genomes in the mega-base range that, with alternative splicing and various possible post-translational modifications, may encode upwards of millions of protein permutations.", [["Significantly more complex eukaryotic organisms", "PROBLEM", 0, 47], ["alternative splicing", "TREATMENT", 98, 118], ["post-translational modifications", "PROBLEM", 140, 172], ["protein permutations", "PROBLEM", 208, 228], ["complex", "OBSERVATION_MODIFIER", 19, 26], ["eukaryotic organisms", "OBSERVATION", 27, 47], ["possess genomes", "OBSERVATION", 48, 63], ["base", "ANATOMY_MODIFIER", 76, 80], ["translational modifications", "OBSERVATION", 145, 172], ["upwards", "OBSERVATION_MODIFIER", 185, 192], ["protein permutations", "OBSERVATION", 208, 228]]], ["With advances in whole genome sequencing, bioinformatics and instrumentation, it has been possible for more than a decade to assess, both quantitatively and simultaneously, changes in the levels of total mRNA expression and in levels of thousands of proteins.", [["whole genome sequencing", "TREATMENT", 17, 40], ["instrumentation", "TREATMENT", 61, 76], ["total mRNA expression", "TREATMENT", 198, 219]]], ["Despite these advances, cellular regulation is more often determined by protein post translation modifications than by absolute quantity.", [["cellular", "ANATOMY", 24, 32], ["cellular", "CELL", 24, 32], ["cellular regulation", "TEST", 24, 43], ["protein post translation modifications", "TREATMENT", 72, 110]]], ["This review will focus on one of the largest and best-studied subsets of proteins, which are proteins involved in kinase signaling.", [["kinase signaling", "TEST", 114, 130], ["largest", "OBSERVATION_MODIFIER", 37, 44]]], ["This field of \u201ckinomics\u201d encompasses kinases, kinase targets and antagonistic phosphatases [1].IntroductionThe development of genomics and proteomics tools has made it possible to create large amounts of information about many processes that occur throughout a cell or tissue in response to a stimulus.", [["cell", "ANATOMY", 261, 265], ["tissue", "ANATOMY", 269, 275], ["cell", "CELL", 261, 265], ["tissue", "TISSUE", 269, 275], ["kinases", "PROTEIN", 37, 44], ["kinase targets", "PROTEIN", 46, 60], ["antagonistic phosphatases", "PROTEIN", 65, 90], ["kinases", "TEST", 37, 44], ["kinase targets", "TEST", 46, 60], ["antagonistic phosphatases", "TEST", 65, 90], ["genomics and proteomics tools", "PROBLEM", 126, 155], ["many processes", "PROBLEM", 222, 236]]], ["The first such technologies - microarrays and quantitative proteomics - were revolutionary in their ability to simultaneously measure thousands of genes and proteins within a single experiment.", [["quantitative proteomics", "TEST", 46, 69]]], ["This ability to globally assess the state of a cell or tissue has since expanded and evolved into numerous other techniques that have been adapted to allow more high-throughput analyses.", [["cell", "ANATOMY", 47, 51], ["tissue", "ANATOMY", 55, 61], ["cell", "CELL", 47, 51], ["tissue", "TISSUE", 55, 61], ["a cell or tissue", "PROBLEM", 45, 61]]], ["In an effort to probe even deeper into the cellular proteome, tools have been developed to detect and isolate specific subsets of proteins that might not otherwise be detected.", [["cellular proteome", "ANATOMY", 43, 60], ["cellular", "CELL", 43, 51], ["isolate specific subsets of proteins", "PROBLEM", 102, 138]]], ["Examples of these protein subsets include those with post-translational modifications (e.g. phosphorylation, ubiquitination, lipidation) and localizations in response to different stimuli.", [["these protein subsets", "PROBLEM", 12, 33], ["post-translational modifications", "TREATMENT", 53, 85], ["phosphorylation", "TREATMENT", 92, 107], ["different stimuli", "TEST", 170, 187], ["protein subsets", "OBSERVATION", 18, 33]]], ["Similarly, different classes of enzymes (e.g. kinases, proteases, hydrolases) can be probed for their activity levels in response to various conditions.IntroductionKinase signaling is a powerful and central cellular mechanism that mediates signal transduction events and is involved in a wide range of nearly all cellular processes including, but not limited to, the control of cell cycle progression, transcriptional regulation, cell transformation, proliferation, differentiation, and apoptosis.", [["cellular", "ANATOMY", 207, 215], ["cellular", "ANATOMY", 313, 321], ["cell", "ANATOMY", 378, 382], ["cell", "ANATOMY", 430, 434], ["Kinase", "GENE_OR_GENE_PRODUCT", 164, 170], ["cellular", "CELL", 207, 215], ["cellular", "CELL", 313, 321], ["cell", "CELL", 378, 382], ["cell", "CELL", 430, 434], ["enzymes", "PROTEIN", 32, 39], ["kinases", "PROTEIN", 46, 53], ["proteases", "PROTEIN", 55, 64], ["hydrolases", "PROTEIN", 66, 76], ["enzymes", "TEST", 32, 39], ["kinases", "TEST", 46, 53], ["proteases", "TEST", 55, 64], ["hydrolases", "TEST", 66, 76], ["IntroductionKinase signaling", "PROBLEM", 152, 180], ["signal transduction events", "PROBLEM", 240, 266], ["cell cycle progression", "PROBLEM", 378, 400], ["transcriptional regulation", "PROBLEM", 402, 428], ["cell transformation", "PROBLEM", 430, 449], ["proliferation", "PROBLEM", 451, 464], ["apoptosis", "PROBLEM", 487, 496], ["cellular processes", "OBSERVATION", 313, 331], ["cell transformation", "OBSERVATION", 430, 449], ["proliferation", "OBSERVATION_MODIFIER", 451, 464], ["apoptosis", "OBSERVATION_MODIFIER", 487, 496]]], ["Given its central role in cellular function, aberrant regulation of kinase signaling can profoundly affect homeostasis and has been found to be involved in many disease states including insulin resistance [3,4], autoimmunity [5,6], viral infection [7,8], and oncogenesis [9,10].", [["cellular", "ANATOMY", 26, 34], ["autoimmunity", "DISEASE", 212, 224], ["viral infection", "DISEASE", 232, 247], ["cellular", "CELL", 26, 34], ["insulin", "GENE_OR_GENE_PRODUCT", 186, 193], ["aberrant regulation of kinase signaling", "PROBLEM", 45, 84], ["many disease states", "PROBLEM", 156, 175], ["insulin resistance", "TEST", 186, 204], ["autoimmunity", "PROBLEM", 212, 224], ["viral infection", "PROBLEM", 232, 247], ["central", "OBSERVATION_MODIFIER", 10, 17], ["cellular function", "OBSERVATION", 26, 43], ["disease", "OBSERVATION", 161, 168], ["infection", "OBSERVATION", 238, 247]]], ["Hence, assessing the kinome can provide insight into complex pathological processes across a wide array of diseases and has also been a well-studied target for therapeutics.", [["complex pathological processes", "PROBLEM", 53, 83], ["diseases", "PROBLEM", 107, 115], ["diseases", "OBSERVATION", 107, 115]]], ["It is therefore not surprisingly that many approved pharmaceuticals target kinases in an effort to restore homeostatic cell signaling events, and that efforts have been made to explore repurposing these drugs for other diseases [[11], [12], [13], [14]].", [["cell", "ANATOMY", 119, 123], ["cell", "CELL", 119, 123], ["[11], [12], [13], [14]]", "SIMPLE_CHEMICAL", 229, 252], ["kinases", "PROTEIN", 75, 82], ["homeostatic cell signaling events", "PROBLEM", 107, 140], ["these drugs", "TREATMENT", 197, 208], ["other diseases", "PROBLEM", 213, 227], ["homeostatic cell", "OBSERVATION", 107, 123]]], ["Notably, kinase signaling may also be exploited clinically as a diagnostic tool and will be discussed below.IntroductionIn this current review, we provide an overview of some of the popular high-throughput methodologies, analysis tools and databases that are commonly used in kinase signaling studies and how they may be used to understand particular disease processes in virology, cancer and clinical diagnostics.", [["cancer", "ANATOMY", 382, 388], ["cancer", "DISEASE", 382, 388], ["cancer", "CANCER", 382, 388], ["kinase signaling", "PROBLEM", 9, 25], ["analysis tools", "TEST", 221, 235], ["kinase signaling studies", "TEST", 276, 300], ["particular disease processes", "PROBLEM", 340, 368], ["clinical diagnostics", "TEST", 393, 413], ["may also be", "UNCERTAINTY", 26, 37]]], ["Some important areas of current research include the purification and characterization of protein kinases (both natural and recombinant), the elucidation of biological functions and ligands of kinases and the development of specific kinase inhibitors.siRNA ::: Nucleic acid-based approaches ::: High throughput systems methodologies for studying the kinomesiRNAs, or small interfering RNAs, are regulators of expression and function of genes [15].", [["protein kinases", "GENE_OR_GENE_PRODUCT", 90, 105], ["Nucleic acid", "SIMPLE_CHEMICAL", 261, 273], ["kinomesiRNAs", "GENE_OR_GENE_PRODUCT", 350, 362], ["protein kinases", "PROTEIN", 90, 105], ["kinases", "PROTEIN", 193, 200], ["kinomesiRNAs", "DNA", 350, 362], ["small interfering RNAs", "RNA", 367, 389], ["the purification", "TEST", 49, 65], ["protein kinases", "PROBLEM", 90, 105], ["kinases", "TEST", 193, 200], ["the kinomesiRNAs", "TEST", 346, 362], ["small interfering RNAs", "PROBLEM", 367, 389], ["areas", "OBSERVATION_MODIFIER", 15, 20], ["small", "OBSERVATION_MODIFIER", 367, 372], ["interfering RNAs", "OBSERVATION", 373, 389]]], ["Double stranded precursors are cleaved by dicer proteins into short fragments.", [["fragments", "ANATOMY", 68, 77], ["dicer", "GENE_OR_GENE_PRODUCT", 42, 47], ["dicer proteins", "PROTEIN", 42, 56], ["Double stranded precursors", "TREATMENT", 0, 26], ["short fragments", "PROBLEM", 62, 77], ["stranded precursors", "OBSERVATION", 7, 26], ["short fragments", "OBSERVATION_MODIFIER", 62, 77]]], ["The siRNA consists of a guide strand that is assembled into a RISC-loading complex which binds to dsRNA, cutting it into a single stranded functional siRNA.", [["RISC-loading complex", "PROTEIN", 62, 82], ["dsRNA", "DNA", 98, 103], ["a guide strand", "TREATMENT", 22, 36], ["a RISC-loading complex", "TREATMENT", 60, 82], ["dsRNA", "PROBLEM", 98, 103], ["a single stranded functional siRNA", "PROBLEM", 121, 155], ["siRNA", "OBSERVATION", 4, 9], ["RISC", "OBSERVATION", 62, 66], ["dsRNA", "ANATOMY", 98, 103], ["functional siRNA", "OBSERVATION", 139, 155]]], ["This RISC complex will recognize a complementary mRNA strand and cleaves this strand at a single site, releasing the fragments, which are ready to cleave more mRNA.", [["fragments", "ANATOMY", 117, 126], ["RISC", "GENE_OR_GENE_PRODUCT", 5, 9], ["RISC complex", "PROTEIN", 5, 17], ["complementary mRNA strand", "RNA", 35, 60], ["mRNA", "RNA", 159, 163], ["a complementary mRNA strand", "PROBLEM", 33, 60], ["this strand", "PROBLEM", 73, 84], ["fragments", "OBSERVATION", 117, 126]]], ["The resulting decrease in mRNA in the cell leads to a decrease in expression of the gene.", [["cell", "ANATOMY", 38, 42], ["cell", "CELL", 38, 42], ["mRNA", "RNA", 26, 30], ["The resulting decrease in mRNA in the cell leads", "PROBLEM", 0, 48], ["resulting", "OBSERVATION_MODIFIER", 4, 13], ["decrease", "OBSERVATION_MODIFIER", 14, 22], ["mRNA", "OBSERVATION_MODIFIER", 26, 30], ["cell leads", "OBSERVATION", 38, 48], ["decrease", "OBSERVATION_MODIFIER", 54, 62]]], ["By using this endogenous host mechanism, siRNA fragments can be transfected into the cell for targeted gene knockdown.siRNA ::: Nucleic acid-based approaches ::: High throughput systems methodologies for studying the kinomeRNAi panel screening is a high throughput method using siRNAs to determine the effects of multiple genes in a specific experimental system. siRNA panels can be purchased against target genes of choice in each well of multiwall plates from different companies.", [["fragments", "ANATOMY", 47, 56], ["cell", "ANATOMY", 85, 89], ["Nucleic acid", "CHEMICAL", 128, 140], ["cell", "CELL", 85, 89], ["Nucleic acid", "SIMPLE_CHEMICAL", 128, 140], ["siRNA fragments", "DNA", 41, 56], ["target genes", "DNA", 401, 413], ["this endogenous host mechanism", "TREATMENT", 9, 39], ["siRNA fragments", "PROBLEM", 41, 56], ["the kinomeRNAi panel screening", "TEST", 213, 243], ["siRNAs", "TREATMENT", 278, 284], ["siRNA panels", "TREATMENT", 363, 375], ["siRNA fragments", "OBSERVATION", 41, 56]]], ["Some panels are specific for particular cellular functional pathways, such as Qiagen's SureSilencing\u00ae siRNA arrays (http://www.sabiosciences.com/pathwaymagazine/pathways9/suresilencing-sirna-arrays.php), which are predesigned to target main cellular genes in a biological or functional pathway.siRNA ::: Nucleic acid-based approaches ::: High throughput systems methodologies for studying the kinomeBy using siRNA panels specific to targeting kinases or phosphorylases, expression patterns or cell pathways affected by these enzymes can be determined.", [["cellular", "ANATOMY", 40, 48], ["cellular", "ANATOMY", 241, 249], ["cell", "ANATOMY", 493, 497], ["Nucleic acid", "CHEMICAL", 304, 316], ["cellular", "CELL", 40, 48], ["cellular", "CELL", 241, 249], ["Nucleic acid", "SIMPLE_CHEMICAL", 304, 316], ["cell", "CELL", 493, 497], ["cellular genes", "DNA", 241, 255], ["kinomeBy", "DNA", 393, 401], ["kinases", "PROTEIN", 443, 450], ["enzymes", "PROTEIN", 525, 532], ["Some panels", "TEST", 0, 11], ["Qiagen's SureSilencing\u00ae siRNA arrays", "TREATMENT", 78, 114], ["siRNA panels", "TEST", 408, 420], ["phosphorylases", "PROBLEM", 454, 468], ["expression patterns", "TEST", 470, 489], ["cell pathways", "PROBLEM", 493, 506], ["these enzymes", "TEST", 519, 532]]], ["For example, Azorsa et al. used this method to determine kinases involved in tau protein hyperphosphorylation, which is known to occur during Alzheimer's disease [16].", [["Alzheimer's disease", "DISEASE", 142, 161], ["tau protein", "GENE_OR_GENE_PRODUCT", 77, 88], ["kinases", "PROTEIN", 57, 64], ["tau protein", "PROTEIN", 77, 88], ["this method", "TREATMENT", 32, 43], ["tau protein hyperphosphorylation", "PROBLEM", 77, 109], ["Alzheimer's disease", "PROBLEM", 142, 161]]], ["In this study, siRNA transfection was used for 572 kinases, then increases or decreases in tau phosphorylation levels in a neuroglioma cell line were observed.", [["neuroglioma cell line", "ANATOMY", 123, 144], ["tau", "GENE_OR_GENE_PRODUCT", 91, 94], ["neuroglioma cell line", "CELL", 123, 144], ["572 kinases", "PROTEIN", 47, 58], ["tau", "PROTEIN", 91, 94], ["neuroglioma cell line", "CELL_LINE", 123, 144], ["this study", "TEST", 3, 13], ["siRNA transfection", "TREATMENT", 15, 33], ["tau phosphorylation levels", "TEST", 91, 117], ["a neuroglioma cell line", "TREATMENT", 121, 144], ["decreases", "OBSERVATION_MODIFIER", 78, 87], ["neuroglioma cell line", "OBSERVATION", 123, 144]]], ["Alternatively, using kinase or phosphorylase siRNA screens in cell lines to determine cell viability can also be performed.", [["cell lines", "ANATOMY", 62, 72], ["cell", "ANATOMY", 86, 90], ["cell lines", "CELL", 62, 72], ["cell", "CELL", 86, 90], ["cell lines", "CELL_LINE", 62, 72], ["kinase or phosphorylase siRNA screens", "TEST", 21, 58], ["cell lines", "TREATMENT", 62, 72], ["cell viability", "TEST", 86, 100]]], ["Hu and colleagues used a genome-wide siRNA library screen of 206 phosphatases and 691 kinases to observe those detrimental to the viability of a Rhabdomyosarcoma cell line, which is the most common type of sarcoma in children [17].", [["Rhabdomyosarcoma cell line", "ANATOMY", 145, 171], ["sarcoma", "ANATOMY", 206, 213], ["Rhabdomyosarcoma", "DISEASE", 145, 161], ["sarcoma", "DISEASE", 206, 213], ["Rhabdomyosarcoma cell line", "CELL", 145, 171], ["sarcoma", "CANCER", 206, 213], ["children", "ORGANISM", 217, 225], ["206 phosphatases", "PROTEIN", 61, 77], ["691 kinases", "PROTEIN", 82, 93], ["Rhabdomyosarcoma cell line", "CELL_LINE", 145, 171], ["children", "SPECIES", 217, 225], ["phosphatases", "TEST", 65, 77], ["kinases", "TEST", 86, 93], ["a Rhabdomyosarcoma cell line", "PROBLEM", 143, 171], ["Rhabdomyosarcoma cell line", "OBSERVATION", 145, 171], ["most common", "OBSERVATION_MODIFIER", 186, 197], ["sarcoma", "OBSERVATION", 206, 213]]], ["Using siRNA screening of a panel of inhibitors that target kinases, Kim et al. were able to identify a host factor kinase that is involved in hepatitis C virus entry [18].", [["hepatitis C", "DISEASE", 142, 153], ["hepatitis C virus", "ORGANISM", 142, 159], ["kinases", "PROTEIN", 59, 66], ["host factor kinase", "PROTEIN", 103, 121], ["hepatitis C virus", "SPECIES", 142, 159], ["hepatitis C virus", "SPECIES", 142, 159], ["siRNA screening", "TEST", 6, 21], ["a panel", "TEST", 25, 32], ["inhibitors", "TREATMENT", 36, 46], ["hepatitis C virus entry", "PROBLEM", 142, 165]]], ["Jansen and colleagues used a kinome-wide siRNA screen to identify kinases that have a role in acquired resistance to CDK4/6 small-molecule inhibitors which are associated with breast cancer [19].", [["breast cancer", "ANATOMY", 176, 189], ["breast cancer", "DISEASE", 176, 189], ["CDK4", "GENE_OR_GENE_PRODUCT", 117, 121], ["breast cancer", "CANCER", 176, 189], ["kinases", "PROTEIN", 66, 73], ["CDK4", "PROTEIN", 117, 121], ["wide siRNA screen", "TEST", 36, 53], ["CDK4", "TEST", 117, 121], ["small-molecule inhibitors", "TREATMENT", 124, 149], ["breast cancer", "PROBLEM", 176, 189], ["breast", "ANATOMY", 176, 182], ["cancer", "OBSERVATION", 183, 189]]], ["This study was able to determine which kinase was a key modifier of sensitivity to the inhibitor, and was also able to restore sensitivity by targeting this factor.", [["This study", "TEST", 0, 10]]], ["This example clearly shows how powerful this tool can be to narrow the focus from a large number of possible targets to one or two key kinases.", [["kinases", "PROTEIN", 135, 142], ["large", "OBSERVATION_MODIFIER", 84, 89]]], ["In a contrasting direction of focus, another study by Giroux et al. was able to probe the kinome with an siRNA panel to try and induce apoptosis in a pancreatic adenocarcinoma cell line, directly identifying therapeutic targets [20].Polymerase chain reaction ::: Nucleic acid-based approaches ::: High throughput systems methodologies for studying the kinomePolymerase chain reaction (PCR) is a highly sensitive technique that rapidly amplifies specific segments of DNA in a sample [21].", [["pancreatic adenocarcinoma cell line", "ANATOMY", 150, 185], ["pancreatic adenocarcinoma", "DISEASE", 150, 175], ["Nucleic acid", "CHEMICAL", 263, 275], ["pancreatic adenocarcinoma cell line", "CELL", 150, 185], ["Nucleic acid", "SIMPLE_CHEMICAL", 263, 275], ["kinomePolymerase chain", "GENE_OR_GENE_PRODUCT", 352, 374], ["DNA", "CELLULAR_COMPONENT", 466, 469], ["pancreatic adenocarcinoma cell line", "CELL_LINE", 150, 185], ["another study", "TEST", 37, 50], ["an siRNA panel", "TREATMENT", 102, 116], ["apoptosis", "PROBLEM", 135, 144], ["a pancreatic adenocarcinoma cell line", "PROBLEM", 148, 185], ["High throughput systems methodologies", "PROBLEM", 297, 334], ["the kinomePolymerase chain reaction", "PROBLEM", 348, 383], ["PCR", "TEST", 385, 388], ["pancreatic", "ANATOMY", 150, 160], ["adenocarcinoma cell line", "OBSERVATION", 161, 185]]], ["Amplification of DNA fragments into billions of copies allows detection and identification of gene sequences in a sample using specific primers that are short DNA fragments with defined sequences complementary to the target DNA sequence.", [["sample", "ANATOMY", 114, 120], ["DNA", "CELLULAR_COMPONENT", 17, 20], ["DNA", "CELLULAR_COMPONENT", 159, 162], ["DNA", "CELLULAR_COMPONENT", 224, 227], ["DNA fragments", "DNA", 17, 30], ["short DNA fragments", "DNA", 153, 172], ["target DNA sequence", "DNA", 217, 236], ["DNA fragments", "PROBLEM", 17, 30], ["gene sequences", "PROBLEM", 94, 108], ["specific primers", "TREATMENT", 127, 143], ["short DNA fragments", "PROBLEM", 153, 172], ["the target DNA sequence", "TEST", 213, 236], ["DNA fragments", "OBSERVATION", 17, 30]]], ["Quantitative measurements of gene expression can be obtained using a modified technique called real-time PCR, and is used to determine how much DNA is present in a sample while it is being synthesized.", [["DNA", "CELLULAR_COMPONENT", 144, 147], ["a modified technique", "TEST", 67, 87]]], ["Two methods are commonly used; either fluorescent dyes that non-specifically integrate into double stranded DNA, or sequence specific fluorescent DNA probes.", [["DNA", "CELLULAR_COMPONENT", 108, 111], ["DNA", "CELLULAR_COMPONENT", 146, 149], ["double stranded DNA", "DNA", 92, 111], ["fluorescent DNA probes", "DNA", 134, 156], ["Two methods", "TREATMENT", 0, 11], ["fluorescent dyes", "TREATMENT", 38, 54], ["double stranded DNA", "PROBLEM", 92, 111]]], ["In these experiments, specialized thermal cyclers equipped with fluorescence detection modules are used.", [["specialized thermal cyclers", "TREATMENT", 22, 49], ["fluorescence detection modules", "TREATMENT", 64, 94]]], ["The fluorescence signals are measured as amplification occurs and the signals are proportional to the total amount of target DNA, allowing the determination of the initial number of copies of template DNA with accuracy and high sensitivity.", [["DNA", "CELLULAR_COMPONENT", 125, 128], ["DNA", "CELLULAR_COMPONENT", 201, 204], ["The fluorescence signals", "TEST", 0, 24], ["target DNA", "PROBLEM", 118, 128], ["template DNA", "PROBLEM", 192, 204], ["accuracy", "TEST", 210, 218], ["high sensitivity", "PROBLEM", 223, 239], ["target DNA", "OBSERVATION", 118, 128]]], ["Gene expression measurements can be determined by coupling qPCR with reverse transcription (RT-qPCR), where RNA is reverse transcribed into cDNA, then the cDNA is used as the template for qPCR.", [["cDNA", "DNA", 140, 144], ["cDNA", "DNA", 155, 159], ["Gene expression measurements", "TEST", 0, 28], ["reverse transcription", "TREATMENT", 69, 90], ["the cDNA", "TREATMENT", 151, 159], ["qPCR", "TEST", 188, 192]]], ["This can be used to target specific phosphatases or kinases of interest.", [["phosphatases", "PROTEIN", 36, 48], ["kinases", "PROTEIN", 52, 59]]], ["For example, Fu and colleagues targeted inositol polyphosphatase-like 1 by qPCR and showed a significantly higher level of this phosphatase in hepatocellular carcinoma tissue in comparison to non-cancerous tissues [22].Polymerase chain reaction ::: Nucleic acid-based approaches ::: High throughput systems methodologies for studying the kinomeThe expression of gene copy number for numerous kinases and phosphatases in a sample can be determined using qPCR assays that are tailored to detect these enzymes.", [["hepatocellular carcinoma tissue", "ANATOMY", 143, 174], ["non-cancerous tissues", "ANATOMY", 192, 213], ["sample", "ANATOMY", 422, 428], ["inositol", "CHEMICAL", 40, 48], ["hepatocellular carcinoma", "DISEASE", 143, 167], ["Nucleic acid", "CHEMICAL", 249, 261], ["inositol", "CHEMICAL", 40, 48], ["inositol polyphosphatase-like 1", "GENE_OR_GENE_PRODUCT", 40, 71], ["hepatocellular carcinoma tissue", "TISSUE", 143, 174], ["non-cancerous tissues", "TISSUE", 192, 213], ["Nucleic acid", "SIMPLE_CHEMICAL", 249, 261], ["inositol polyphosphatase", "PROTEIN", 40, 64], ["phosphatase", "PROTEIN", 128, 139], ["kinases", "PROTEIN", 392, 399], ["phosphatases", "PROTEIN", 404, 416], ["enzymes", "PROTEIN", 499, 506], ["inositol polyphosphatase", "TEST", 40, 64], ["qPCR", "TEST", 75, 79], ["this phosphatase", "PROBLEM", 123, 139], ["hepatocellular carcinoma tissue", "PROBLEM", 143, 174], ["numerous kinases", "TEST", 383, 399], ["phosphatases", "TEST", 404, 416], ["qPCR assays", "TEST", 453, 464], ["these enzymes", "TEST", 493, 506], ["hepatocellular", "ANATOMY", 143, 157], ["carcinoma", "OBSERVATION", 158, 167]]], ["Arrays predesigned to profile gene expression in a sample for a specific pathway can be purchased from a variety of companies, such as the MAP kinase signaling pathway, or a specific family of enzymes such as tyrosine kinases.", [["tyrosine", "CHEMICAL", 209, 217], ["tyrosine", "CHEMICAL", 209, 217], ["MAP kinase", "GENE_OR_GENE_PRODUCT", 139, 149], ["MAP kinase", "PROTEIN", 139, 149], ["enzymes", "PROTEIN", 193, 200], ["tyrosine kinases", "PROTEIN", 209, 225], ["the MAP kinase signaling pathway", "TEST", 135, 167], ["enzymes", "TEST", 193, 200], ["tyrosine kinases", "TREATMENT", 209, 225]]], ["In one example, Wu et al. used RT-qPCR to identify a phosphatase (among other genes) to characterize the mechanism of stretch-induced cell rearrangement [23].DNA microarrays ::: Nucleic acid-based approaches ::: High throughput systems methodologies for studying the kinomeDNA chips (microarrays) are assays that examine the expression levels of a large number of genes simultaneously.", [["cell", "ANATOMY", 134, 138], ["Nucleic acid", "CHEMICAL", 178, 190], ["cell", "CELL", 134, 138], ["DNA", "CELLULAR_COMPONENT", 158, 161], ["Nucleic acid", "SIMPLE_CHEMICAL", 178, 190], ["phosphatase", "PROTEIN", 53, 64], ["kinomeDNA chips", "DNA", 267, 282], ["RT-qPCR", "TEST", 31, 38], ["a phosphatase", "TEST", 51, 64], ["the kinomeDNA chips", "TREATMENT", 263, 282], ["cell rearrangement", "OBSERVATION", 134, 152], ["large", "OBSERVATION_MODIFIER", 348, 353]]], ["Microscopic slots are fitted onto a microchip slide with DNA molecules (nucleic acid sequences) attached to the surface in each slot [24].", [["surface", "ANATOMY", 112, 119], ["nucleic acid", "CHEMICAL", 72, 84], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["surface", "CELLULAR_COMPONENT", 112, 119], ["DNA molecules", "PROTEIN", 57, 70], ["nucleic acid sequences", "PROTEIN", 72, 94], ["Microscopic slots", "PROBLEM", 0, 17], ["a microchip slide with DNA molecules", "TREATMENT", 34, 70], ["nucleic acid sequences", "TREATMENT", 72, 94]]], ["The DNA attached to the slides are probes and the relative concentration of DNA in a mixture is detected by hybridization events that are measured in multiple ways.", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["DNA", "CELLULAR_COMPONENT", 76, 79], ["hybridization events", "PROBLEM", 108, 128], ["concentration", "OBSERVATION_MODIFIER", 59, 72], ["DNA", "OBSERVATION", 76, 79]]], ["The two most common detection methods are by the incorporation of fluorescently-labeled nucleotides during synthesis, or the incorporation of biotin-labeled nucleotides which are subsequently stained with fluorescently-labeled streptavidin. mRNA molecules are taken from a sample and a reference, the samples are converted into complementary DNA, then are labeled with separate fluorescent probes.", [["samples", "ANATOMY", 301, 308], ["biotin", "CHEMICAL", 142, 148], ["nucleotides", "CHEMICAL", 88, 99], ["biotin", "CHEMICAL", 142, 148], ["nucleotides", "CHEMICAL", 157, 168], ["biotin", "SIMPLE_CHEMICAL", 142, 148], ["streptavidin", "GENE_OR_GENE_PRODUCT", 227, 239], ["DNA", "CELLULAR_COMPONENT", 342, 345], ["mRNA molecules", "RNA", 241, 255], ["complementary DNA", "DNA", 328, 345], ["synthesis", "TREATMENT", 107, 116], ["biotin-labeled nucleotides", "TREATMENT", 142, 168], ["fluorescently-labeled streptavidin", "TREATMENT", 205, 239], ["mRNA molecules", "PROBLEM", 241, 255], ["the samples", "TEST", 297, 308]]], ["After mixing, they are added to the chip for hybridization and scanned to measure the relative expression of the two colored samples.", [["samples", "ANATOMY", 125, 132], ["hybridization", "TREATMENT", 45, 58]]], ["Expression of the kinome can be observed with this method by using probe sequences of kinases and phosphatases.", [["kinases", "PROTEIN", 86, 93], ["phosphatases", "PROTEIN", 98, 110], ["probe sequences of kinases", "TEST", 67, 93], ["phosphatases", "TEST", 98, 110]]], ["Using a cDNA microarray, Lee and colleagues were able to identify a cysteine-rich receptor-like kinase that is responsive to a fungal pathogen Alternaria brassiciola, and went on to determine the function of this kinase in plant immunity [25].Protein microarrays ::: Protein & peptide arrays ::: High throughput systems methodologies for studying the kinomeProtein microarrays, set up similarly to DNA microarrays, can be used to identify kinase activity by spotting proteins onto microarray slides, then adding kinases with radiolabeled ATP.", [["ATP", "CHEMICAL", 538, 541], ["cysteine", "CHEMICAL", 68, 76], ["ATP", "CHEMICAL", 538, 541], ["Alternaria brassiciola", "ORGANISM", 143, 165], ["DNA", "CELLULAR_COMPONENT", 398, 401], ["ATP", "SIMPLE_CHEMICAL", 538, 541], ["cysteine-rich receptor-like kinase", "PROTEIN", 68, 102], ["kinase", "PROTEIN", 213, 219], ["kinases", "PROTEIN", 512, 519], ["Alternaria brassiciola", "SPECIES", 143, 165], ["Alternaria brassiciola", "SPECIES", 143, 165], ["a cysteine", "TEST", 66, 76], ["a fungal pathogen Alternaria brassiciola", "PROBLEM", 125, 165], ["Protein microarrays", "TEST", 243, 262], ["Protein microarrays", "TEST", 357, 376], ["DNA microarrays", "TEST", 398, 413], ["microarray slides", "TEST", 481, 498], ["radiolabeled ATP", "TREATMENT", 525, 541]]], ["The amount of kinase activity is detected and quantified by autoradiography [26].Peptide arrays ::: Protein & peptide arrays ::: High throughput systems methodologies for studying the kinomePeptide arrays have become a productive, high-throughput method for studying cellular or tissue kinomes [27].", [["cellular", "ANATOMY", 267, 275], ["tissue", "ANATOMY", 279, 285], ["cellular", "CELL", 267, 275], ["tissue", "TISSUE", 279, 285], ["kinomePeptide arrays", "DNA", 184, 204], ["kinase activity", "TEST", 14, 29], ["autoradiography", "TEST", 60, 75], ["High throughput systems methodologies", "PROBLEM", 129, 166], ["the kinomePeptide arrays", "TEST", 180, 204], ["a productive", "PROBLEM", 217, 229], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["kinase activity", "OBSERVATION", 14, 29], ["productive", "OBSERVATION_MODIFIER", 219, 229]]], ["This technique involves spotting glass arrays or 96 well plates with peptide sequences that are kinase-targets.", [["This technique", "TREATMENT", 0, 14], ["spotting glass arrays", "TREATMENT", 24, 45], ["peptide sequences", "TEST", 69, 86], ["kinase", "TEST", 96, 102]]], ["The array is then exposed to a lysate containing active kinases, which results in peptide phosphorylation and which generates a visual signal of substrate-enzyme phosphorylation such as HRP or autoradiography [26].", [["lysate", "ANATOMY", 31, 37], ["HRP", "GENE_OR_GENE_PRODUCT", 186, 189], ["active kinases", "PROTEIN", 49, 63], ["HRP", "PROTEIN", 186, 189], ["a lysate containing active kinases", "TREATMENT", 29, 63], ["peptide phosphorylation", "PROBLEM", 82, 105], ["autoradiography", "TEST", 193, 208]]], ["By comparing the relative signals of experimental cell or tissue samples, one can identify changes in signal transduction pathways and phosphorylation-regulated events.", [["cell", "ANATOMY", 50, 54], ["tissue samples", "ANATOMY", 58, 72], ["cell", "CELL", 50, 54], ["tissue samples", "TISSUE", 58, 72], ["experimental cell or tissue samples", "PROBLEM", 37, 72], ["changes in signal transduction pathways", "PROBLEM", 91, 130], ["phosphorylation-regulated events", "PROBLEM", 135, 167], ["experimental cell", "OBSERVATION", 37, 54]]], ["A detailed description of this technique can be found in Daigle et al. [28].Peptide arrays ::: Protein & peptide arrays ::: High throughput systems methodologies for studying the kinomeA particular advantage of peptide arrays is their versatility.", [["this technique", "TREATMENT", 26, 40], ["peptide arrays", "TREATMENT", 211, 225]]], ["For example, the peptides spotted onto the array can be designed for a variety of different consensus sequences, such as those specific to different classes of kinase activity such as tyrosine kinases, serine kinases or threonine kinases.", [["tyrosine", "CHEMICAL", 184, 192], ["tyrosine", "CHEMICAL", 184, 192], ["serine", "CHEMICAL", 202, 208], ["threonine", "CHEMICAL", 220, 229], ["tyrosine", "AMINO_ACID", 184, 192], ["serine", "AMINO_ACID", 202, 208], ["threonine", "AMINO_ACID", 220, 229], ["consensus sequences", "DNA", 92, 111], ["tyrosine kinases", "PROTEIN", 184, 200], ["serine kinases", "PROTEIN", 202, 216], ["threonine kinases", "PROTEIN", 220, 237], ["kinase activity", "TREATMENT", 160, 175], ["tyrosine kinases", "TREATMENT", 184, 200], ["serine kinases", "TREATMENT", 202, 216], ["threonine kinases", "TREATMENT", 220, 237]]], ["A second very useful aspect of peptide arrays is that they can be adapted for any particular species for which the genome sequence is known [[29], [30], [31]].", [["peptide arrays", "TREATMENT", 31, 45], ["any particular species", "PROBLEM", 78, 100]]], ["This is particularly useful for species which do not have many, or any, other tools available, such as microarrays, specific phospho-antibodies or commercial kits that measure kinase activity.", [["phospho-antibodies", "PROTEIN", 125, 143], ["species", "PROBLEM", 32, 39], ["microarrays", "TEST", 103, 114], ["commercial kits", "TREATMENT", 147, 162]]], ["For example, the use of this technology in agricultural species has been immensely valuable (reviewed by Daigle 2014 [28]) and has been applied to studies with cows [32] and poultry [33].", [["cows", "TEST", 160, 164]]], ["Protein arrays have been equally successful in smaller models for which reagents are difficult to find, such as hamsters [34], guinea pigs [35] and yeast [36].", [["hamsters", "ORGANISM", 112, 120], ["guinea pigs", "ORGANISM", 127, 138], ["guinea pigs", "SPECIES", 127, 138], ["yeast", "SPECIES", 148, 153], ["hamsters", "SPECIES", 112, 120], ["yeast", "SPECIES", 148, 153], ["Protein arrays", "TEST", 0, 14]]], ["The main disadvantage of this method is the upfront cost of the detection scanner and a substantial amount of needed expertise in setting up custom arrays; thus, these are typically provided by a core facility.Phospho-ELISAs ::: Protein & peptide arrays ::: High throughput systems methodologies for studying the kinomePhospho-ELISAs are another technique that can be used to detect phopho-peptides and are readily available from a variety of biochemical companies.", [["the detection scanner", "TEST", 60, 81], ["Phospho-ELISAs", "TEST", 210, 224], ["Phospho-ELISAs", "TEST", 319, 333], ["main", "OBSERVATION_MODIFIER", 4, 8], ["disadvantage", "OBSERVATION_MODIFIER", 9, 21], ["substantial", "OBSERVATION_MODIFIER", 88, 99], ["amount", "OBSERVATION_MODIFIER", 100, 106]]], ["Just like regular ELISAs, phospho-ELISAs are quick, sensitive, and relatively high throughput.", [["phospho", "CHEMICAL", 26, 33], ["phospho-ELISAs", "GENE_OR_GENE_PRODUCT", 26, 40], ["phospho", "PROTEIN", 26, 33], ["regular ELISAs", "TEST", 10, 24], ["phospho-ELISAs", "TEST", 26, 40], ["high", "OBSERVATION_MODIFIER", 78, 82]]], ["In addition, ELISAs can analyze small volumes of either cell or tissue lysates as well as purified enzymes.", [["cell", "ANATOMY", 56, 60], ["tissue lysates", "ANATOMY", 64, 78], ["cell", "CELL", 56, 60], ["tissue lysates", "ORGANISM_SUBSTANCE", 64, 78], ["purified enzymes", "PROTEIN", 90, 106], ["ELISAs", "TEST", 13, 19], ["tissue lysates", "PROBLEM", 64, 78], ["purified enzymes", "TEST", 90, 106], ["cell", "OBSERVATION", 56, 60]]], ["Phospho-ELISAs can be found both for specific kinases, such as ERK1/2 or EGFR, as well as for broader kinase classes such as phospho-tyrosine [37] or phospho-serine/threonine activity.", [["phospho-tyrosine", "CHEMICAL", 125, 141], ["threonine", "CHEMICAL", 165, 174], ["phospho-tyrosine", "CHEMICAL", 125, 141], ["phospho", "CHEMICAL", 150, 157], ["serine", "CHEMICAL", 158, 164], ["threonine", "CHEMICAL", 165, 174], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 63, 69], ["EGFR", "GENE_OR_GENE_PRODUCT", 73, 77], ["phospho-tyrosine [37]", "GENE_OR_GENE_PRODUCT", 125, 146], ["phospho-", "SIMPLE_CHEMICAL", 150, 158], ["serine", "AMINO_ACID", 158, 164], ["threonine", "AMINO_ACID", 165, 174], ["Phospho-ELISAs", "PROTEIN", 0, 14], ["kinases", "PROTEIN", 46, 53], ["ERK1/2", "PROTEIN", 63, 69], ["EGFR", "PROTEIN", 73, 77], ["kinase classes", "PROTEIN", 102, 116], ["Phospho-ELISAs", "TEST", 0, 14], ["specific kinases", "TEST", 37, 53], ["ERK1", "TEST", 63, 67], ["EGFR", "TEST", 73, 77], ["broader kinase classes", "TREATMENT", 94, 116], ["phospho-tyrosine", "TREATMENT", 125, 141], ["phospho-serine/threonine activity", "TREATMENT", 150, 183]]], ["A common use of this technique is to determine or confirm whether specific kinase signaling pathways are activated under different conditions.", [["this technique", "TREATMENT", 16, 30], ["specific kinase signaling pathways", "PROBLEM", 66, 100]]], ["For example, Janssens and colleagues showed that the nitration of chemokine CXCL12 decreased ERK1/2 phosphorylation in monocytes, which may result in the downregulation of inflammatory responses [38].Flow cytometry ::: Cellular assays ::: High throughput systems methodologies for studying the kinomeFlow cytometry can be easily used to evaluate phosphorylation events where fresh or fixed cells are incubated with phospho-specific antibodies and then conjugated to a fluorescent tag for detection.", [["monocytes", "ANATOMY", 119, 128], ["cells", "ANATOMY", 390, 395], ["CXCL12", "GENE_OR_GENE_PRODUCT", 76, 82], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 93, 99], ["monocytes", "CELL", 119, 128], ["cells", "CELL", 390, 395], ["chemokine", "PROTEIN", 66, 75], ["CXCL12", "PROTEIN", 76, 82], ["ERK1/2", "PROTEIN", 93, 99], ["monocytes", "CELL_TYPE", 119, 128], ["phospho-specific antibodies", "PROTEIN", 415, 442], ["chemokine CXCL12", "TEST", 66, 82], ["ERK1", "TEST", 93, 97], ["monocytes", "TEST", 119, 128], ["inflammatory responses", "PROBLEM", 172, 194], ["Cellular assays", "TEST", 219, 234], ["Flow cytometry", "TEST", 300, 314], ["phosphorylation events", "PROBLEM", 346, 368], ["fresh or fixed cells", "PROBLEM", 375, 395], ["phospho-specific antibodies", "TEST", 415, 442], ["a fluorescent tag", "TEST", 466, 483], ["inflammatory", "OBSERVATION_MODIFIER", 172, 184]]], ["This method has the distinct advantage of providing detailed and quantitative information about single cells in addition to the entire population of cells.", [["cells", "ANATOMY", 103, 108], ["cells", "ANATOMY", 149, 154], ["cells", "CELL", 103, 108], ["cells", "CELL", 149, 154], ["single cells", "PROBLEM", 96, 108]]], ["For example, one can calculate the number of cells that become phosphorylated, as well as measure the relative amount of phosphorylation per cell.", [["cells", "ANATOMY", 45, 50], ["cell", "ANATOMY", 141, 145], ["cells", "CELL", 45, 50], ["cell", "CELL", 141, 145], ["phosphorylated", "PROBLEM", 63, 77], ["amount", "OBSERVATION_MODIFIER", 111, 117], ["phosphorylation per cell", "OBSERVATION", 121, 145]]], ["Newer flow cytometers can also analyze samples in a 96-well plate format and run in an automated fashion [39] (For example: BDSciences http://www.vp-scientific.com/bd_biosciences_protocol.htm).", [["samples", "ANATOMY", 39, 46], ["Newer flow cytometers", "TEST", 0, 21]]], ["A second advantage of flow cytometry is the ability to multiplex multiple antibodies.", [["multiplex multiple antibodies", "PROTEIN", 55, 84], ["flow cytometry", "TEST", 22, 36], ["flow cytometry", "OBSERVATION", 22, 36]]], ["For example, an increasing number of kits and protocols have optimized conditions that allow for 8- to 27-plex assays (see Krutzik et al. [40] for one such protocol).", [["increasing", "OBSERVATION_MODIFIER", 16, 26], ["number", "OBSERVATION_MODIFIER", 27, 33]]], ["Multiple samples may also be barcoded and combined into a single tube for high-throughput analysis [41].", [["samples", "ANATOMY", 9, 16], ["tube", "TISSUE", 65, 69], ["Multiple samples", "TEST", 0, 16], ["a single tube", "TREATMENT", 56, 69], ["may also be", "UNCERTAINTY", 17, 28]]], ["One popular application of flow cytometry is to monitor changes in immune cell populations and activation states in response to cancer treatments [42].", [["immune cell", "ANATOMY", 67, 78], ["cancer", "ANATOMY", 128, 134], ["cancer", "DISEASE", 128, 134], ["immune cell populations", "CELL", 67, 90], ["cancer", "CANCER", 128, 134], ["flow cytometry", "TEST", 27, 41], ["immune cell populations", "TREATMENT", 67, 90], ["cancer treatments", "TREATMENT", 128, 145], ["flow cytometry", "OBSERVATION", 27, 41], ["immune cell populations", "OBSERVATION", 67, 90]]], ["Increasingly, single cell flow cytometry is also a useful tool for analyzing a multitude of cell signaling pathways in one experiment, for example by examining patterns of B-cell activation [43].Microscopy ::: Cellular assays ::: High throughput systems methodologies for studying the kinomeAdherent cells can also be rapidly screened for phosphorylation by using automated microscopy in 96-well plates [44].", [["cell", "ANATOMY", 21, 25], ["cell", "ANATOMY", 92, 96], ["B-cell", "ANATOMY", 172, 178], ["kinomeAdherent cells", "ANATOMY", 285, 305], ["cell", "CELL", 21, 25], ["cell", "CELL", 92, 96], ["B-cell", "CELL", 172, 178], ["kinomeAdherent cells", "CELL", 285, 305], ["kinomeAdherent cells", "CELL_LINE", 285, 305], ["single cell flow cytometry", "TEST", 14, 40], ["Cellular assays", "TEST", 210, 225], ["High throughput systems methodologies", "PROBLEM", 230, 267], ["the kinomeAdherent cells", "PROBLEM", 281, 305], ["automated microscopy", "TEST", 364, 384], ["single cell", "OBSERVATION", 14, 25], ["flow cytometry", "OBSERVATION", 26, 40], ["one experiment", "OBSERVATION_MODIFIER", 119, 133]]], ["Similar to flow cytometry, cells may be fixed and stained with a phospho-specific antibody that is then conjugated to a fluorescent tag for detection.", [["cells", "ANATOMY", 27, 32], ["cells", "CELL", 27, 32], ["phospho-specific antibody", "PROTEIN", 65, 90], ["flow cytometry", "TEST", 11, 25], ["a phospho-specific antibody", "TEST", 63, 90], ["flow cytometry", "OBSERVATION", 11, 25]]], ["Alternatively, other assays have been designed to monitor wound healing in the presence of different chemical compounds [45] or for proteins that carry a fluorescent reporter that is modified under given experimental conditions after which the cells are fixed and analyzed [46].", [["wound", "ANATOMY", 58, 63], ["cells", "ANATOMY", 244, 249], ["wound", "PATHOLOGICAL_FORMATION", 58, 63], ["cells", "CELL", 244, 249], ["other assays", "TEST", 15, 27], ["wound healing", "PROBLEM", 58, 71]]], ["McDonough et al. were able to quantify lipase phosphorylation and colocalization using automated digital microscopy coupled with high content analysis [47], while Bhadriraju and colleagues used automated fluorescence microscopy to measure relative myosin light chain phosphorylation in individual adherent cells with simultaneous correlations to cellular morphology [48].", [["cells", "ANATOMY", 306, 311], ["cellular", "ANATOMY", 346, 354], ["lipase", "GENE_OR_GENE_PRODUCT", 39, 45], ["myosin light chain", "GENE_OR_GENE_PRODUCT", 248, 266], ["cells", "CELL", 306, 311], ["cellular", "CELL", 346, 354], ["lipase", "PROTEIN", 39, 45], ["myosin light chain", "PROTEIN", 248, 266], ["adherent cells", "CELL_TYPE", 297, 311], ["lipase phosphorylation", "TEST", 39, 61], ["automated digital microscopy", "TEST", 87, 115], ["high content analysis", "PROBLEM", 129, 150], ["automated fluorescence microscopy", "TEST", 194, 227], ["relative myosin light chain phosphorylation", "PROBLEM", 239, 282], ["cellular morphology", "TEST", 346, 365], ["adherent cells", "OBSERVATION", 297, 311]]], ["Trask et al. used high content screening and fluorescent microscopy in a kinase-focused library to identify novel kinase inhibitors of p38-mediated MK2-EGFP translocation [49].Metal oxide affinity chromatography (MOAC) ::: Phospho-proteomics ::: High throughput systems methodologies for studying the kinomeMetal oxide affinity chromatography (MOAC) uses beads composed of metal oxides such as TiO2 or ZrO2 to bind phosphorylated peptides and separate them from their non-modified counterparts.", [["Metal oxide", "CHEMICAL", 176, 187], ["kinomeMetal oxide", "CHEMICAL", 301, 318], ["TiO2", "CHEMICAL", 394, 398], ["ZrO2", "CHEMICAL", 402, 406], ["Metal oxide", "CHEMICAL", 176, 187], ["kinomeMetal oxide", "CHEMICAL", 301, 318], ["metal oxides", "CHEMICAL", 373, 385], ["TiO2", "CHEMICAL", 394, 398], ["ZrO2", "CHEMICAL", 402, 406], ["p38", "GENE_OR_GENE_PRODUCT", 135, 138], ["MK2", "GENE_OR_GENE_PRODUCT", 148, 151], ["EGFP", "GENE_OR_GENE_PRODUCT", 152, 156], ["Metal oxide", "SIMPLE_CHEMICAL", 176, 187], ["kinomeMetal oxide", "SIMPLE_CHEMICAL", 301, 318], ["metal oxides", "SIMPLE_CHEMICAL", 373, 385], ["TiO2", "SIMPLE_CHEMICAL", 394, 398], ["ZrO2", "SIMPLE_CHEMICAL", 402, 406], ["kinase", "PROTEIN", 73, 79], ["p38", "PROTEIN", 135, 138], ["MK2", "PROTEIN", 148, 151], ["EGFP", "PROTEIN", 152, 156], ["high content screening", "TEST", 18, 40], ["fluorescent microscopy", "TEST", 45, 67], ["a kinase", "TEST", 71, 79], ["novel kinase inhibitors", "TREATMENT", 108, 131], ["p38", "TEST", 135, 138], ["Metal oxide affinity chromatography", "TREATMENT", 176, 211], ["High throughput systems methodologies", "PROBLEM", 246, 283], ["the kinomeMetal oxide affinity chromatography (MOAC)", "TREATMENT", 297, 349], ["metal oxides", "TREATMENT", 373, 385], ["TiO2 or ZrO2 to bind phosphorylated peptides", "TREATMENT", 394, 438]]], ["Under acidic conditions, phosphorylated peptides will adsorb to the surface of metal oxide beads.", [["surface", "ANATOMY", 68, 75], ["metal oxide", "CHEMICAL", 79, 90], ["metal oxide", "CHEMICAL", 79, 90], ["surface", "CELLULAR_COMPONENT", 68, 75], ["metal oxide beads", "SIMPLE_CHEMICAL", 79, 96], ["phosphorylated peptides", "TREATMENT", 25, 48], ["metal oxide beads", "TREATMENT", 79, 96], ["acidic conditions", "OBSERVATION", 6, 23], ["metal oxide beads", "OBSERVATION", 79, 96]]], ["After washing, phosphorylated peptides are eluted at high pH where they can be purified and subsequently sequenced by mass spectrometry.", [["phosphorylated peptides", "TREATMENT", 15, 38]]], ["This method can be performed either in batch format by adding beads directly to the peptide solution, by using a TiO2 column in an HPLC format [53], or in a microcolumn format where metal oxide beads are packed into a pipette tip containing C8 material [54,55].", [["TiO2", "CHEMICAL", 113, 117], ["metal oxide", "CHEMICAL", 182, 193], ["TiO2", "CHEMICAL", 113, 117], ["metal oxide", "CHEMICAL", 182, 193], ["metal oxide beads", "SIMPLE_CHEMICAL", 182, 199], ["This method", "TREATMENT", 0, 11], ["the peptide solution", "TREATMENT", 80, 100], ["a TiO2 column", "TREATMENT", 111, 124], ["a microcolumn format", "TREATMENT", 155, 175], ["metal oxide beads", "TREATMENT", 182, 199], ["a pipette tip containing C8 material", "TREATMENT", 216, 252], ["C8", "OBSERVATION_MODIFIER", 241, 243]]], ["The C8 acts as a frit that holds metal oxide beads in place and does not bind non-modified or phosphorylated peptides to a significant extent.Metal oxide affinity chromatography (MOAC) ::: Phospho-proteomics ::: High throughput systems methodologies for studying the kinomeAs is the case for all metal affinity based methods, nonspecific binding of negatively charged acidic peptides with high aspartate or glutamate content was identified in early studies as a significant problem in metal affinity chromatography.", [["metal oxide", "CHEMICAL", 33, 44], ["Metal oxide", "CHEMICAL", 142, 153], ["aspartate", "CHEMICAL", 394, 403], ["glutamate", "CHEMICAL", 407, 416], ["metal oxide", "CHEMICAL", 33, 44], ["Metal oxide", "CHEMICAL", 142, 153], ["aspartate", "CHEMICAL", 394, 403], ["glutamate", "CHEMICAL", 407, 416], ["metal oxide beads", "SIMPLE_CHEMICAL", 33, 50], ["Metal oxide", "SIMPLE_CHEMICAL", 142, 153], ["aspartate", "SIMPLE_CHEMICAL", 394, 403], ["glutamate", "SIMPLE_CHEMICAL", 407, 416], ["metal oxide beads", "TREATMENT", 33, 50], ["Metal oxide affinity chromatography", "TREATMENT", 142, 177], ["negatively charged acidic peptides", "PROBLEM", 349, 383], ["high aspartate or glutamate content", "PROBLEM", 389, 424], ["a significant problem in metal affinity chromatography", "PROBLEM", 460, 514], ["oxide beads", "OBSERVATION", 39, 50], ["significant", "OBSERVATION_MODIFIER", 123, 134], ["extent", "OBSERVATION_MODIFIER", 135, 141], ["significant", "OBSERVATION_MODIFIER", 462, 473]]], ["This problem was somewhat alleviated through the addition of hydroxy acids such as glycolic or lactic acid to the dissolution and wash buffers.", [["hydroxy acids", "CHEMICAL", 61, 74], ["glycolic", "CHEMICAL", 83, 91], ["lactic acid", "CHEMICAL", 95, 106], ["hydroxy acids", "CHEMICAL", 61, 74], ["glycolic or lactic acid", "CHEMICAL", 83, 106], ["hydroxy acids", "SIMPLE_CHEMICAL", 61, 74], ["glycolic", "SIMPLE_CHEMICAL", 83, 91], ["lactic acid", "SIMPLE_CHEMICAL", 95, 106], ["hydroxy acids", "TREATMENT", 61, 74], ["glycolic", "TREATMENT", 83, 91], ["lactic acid", "TREATMENT", 95, 106], ["wash buffers", "TREATMENT", 130, 142]]], ["The addition of hydroxy acids prevents interaction between the acidic peptides and the positively charged surface but leaves the interaction between phosphorylated peptide and metal oxide surface intact.", [["surface", "ANATOMY", 106, 113], ["hydroxy acids", "CHEMICAL", 16, 29], ["metal oxide", "CHEMICAL", 176, 187], ["hydroxy acids", "CHEMICAL", 16, 29], ["metal oxide", "CHEMICAL", 176, 187], ["hydroxy acids", "SIMPLE_CHEMICAL", 16, 29], ["surface", "CELLULAR_COMPONENT", 106, 113], ["hydroxy acids", "TREATMENT", 16, 29], ["the acidic peptides", "TREATMENT", 59, 78], ["phosphorylated peptide", "TREATMENT", 149, 171], ["metal oxide surface", "TREATMENT", 176, 195], ["hydroxy acids", "OBSERVATION", 16, 29], ["metal oxide", "OBSERVATION", 176, 187]]], ["This technique increases the efficiency of phosphorylated peptide binding and allows for the isolation of phosphorylated peptides from as low as 100 \u03bcg of cell lysate [56].Metal oxide affinity chromatography (MOAC) ::: Phospho-proteomics ::: High throughput systems methodologies for studying the kinomeThe type of metal used may affect the binding affinity of specific phosphorylated sequences.", [["cell lysate", "ANATOMY", 155, 166], ["Metal oxide", "CHEMICAL", 172, 183], ["metal", "CHEMICAL", 315, 320], ["Metal oxide", "CHEMICAL", 172, 183], ["cell", "CELL", 155, 159], ["Metal oxide", "SIMPLE_CHEMICAL", 172, 183], ["This technique", "TREATMENT", 0, 14], ["phosphorylated peptide binding", "PROBLEM", 43, 73], ["the isolation of phosphorylated peptides", "TREATMENT", 89, 129], ["cell lysate", "TREATMENT", 155, 166], ["Metal oxide affinity chromatography", "TREATMENT", 172, 207], ["specific phosphorylated sequences", "TEST", 361, 394]]], ["Sugiyama et al. evaluated the ability of TiO2 and ZrO2 beads for phosphopeptide enrichment in the presence of different aliphatic hydroxy acids [57].", [["TiO2", "CHEMICAL", 41, 45], ["ZrO2", "CHEMICAL", 50, 54], ["aliphatic hydroxy acids", "CHEMICAL", 120, 143], ["TiO2", "CHEMICAL", 41, 45], ["ZrO2", "CHEMICAL", 50, 54], ["aliphatic hydroxy acids", "CHEMICAL", 120, 143], ["TiO2", "SIMPLE_CHEMICAL", 41, 45], ["ZrO2 beads", "SIMPLE_CHEMICAL", 50, 60], ["aliphatic hydroxy acids", "SIMPLE_CHEMICAL", 120, 143], ["TiO2 and ZrO2 beads", "TREATMENT", 41, 60], ["phosphopeptide enrichment", "TREATMENT", 65, 90], ["different aliphatic hydroxy acids", "TEST", 110, 143]]], ["They found that lactic acid and B-hydroxypropanoic acid (HPA) provided the best results in terms of preventing non-specific binding of acidic peptides.", [["lactic acid", "CHEMICAL", 16, 27], ["B-hydroxypropanoic acid", "CHEMICAL", 32, 55], ["lactic acid", "CHEMICAL", 16, 27], ["B-hydroxypropanoic acid", "CHEMICAL", 32, 55], ["lactic acid", "SIMPLE_CHEMICAL", 16, 27], ["B-hydroxypropanoic acid", "SIMPLE_CHEMICAL", 32, 55], ["HPA", "SIMPLE_CHEMICAL", 57, 60], ["lactic acid", "TEST", 16, 27], ["B-hydroxypropanoic acid", "TREATMENT", 32, 55], ["non-specific binding of acidic peptides", "PROBLEM", 111, 150], ["lactic acid", "OBSERVATION", 16, 27], ["acidic peptides", "OBSERVATION", 135, 150]]], ["This suggests that a combination of both methods may be the best approach for more comprehensive phosphopeptide analysis.", [["more comprehensive phosphopeptide analysis", "TEST", 78, 120]]], ["In a later study, the same research group used a combination of six different methods to analyze the phosphoproteome of Arabidopsis.", [["Arabidopsis", "ORGANISM", 120, 131], ["Arabidopsis", "SPECIES", 120, 131], ["a later study", "TEST", 3, 16], ["six different methods", "TREATMENT", 64, 85]]], ["They used a combination of TiO2, ZrO2 and iron-immobilized metal affinity chromatography (Fe-IMAC) coupled to ammonia or phosphate buffers for phosphopeptide elution.", [["TiO2", "CHEMICAL", 27, 31], ["ZrO2", "CHEMICAL", 33, 37], ["ammonia", "CHEMICAL", 110, 117], ["phosphate", "CHEMICAL", 121, 130], ["TiO2", "CHEMICAL", 27, 31], ["ZrO2", "CHEMICAL", 33, 37], ["ammonia", "CHEMICAL", 110, 117], ["phosphate", "CHEMICAL", 121, 130], ["TiO2", "SIMPLE_CHEMICAL", 27, 31], ["ZrO2", "SIMPLE_CHEMICAL", 33, 37], ["ammonia", "SIMPLE_CHEMICAL", 110, 117], ["phosphate buffers", "SIMPLE_CHEMICAL", 121, 138], ["a combination of TiO2, ZrO2", "TREATMENT", 10, 37], ["iron-immobilized metal affinity chromatography", "TREATMENT", 42, 88], ["Fe-IMAC", "TREATMENT", 90, 97], ["phosphate buffers", "TREATMENT", 121, 138], ["phosphopeptide elution", "TREATMENT", 143, 165]]], ["In total, they identified 2171 phosphorylation sites on 1346 proteins, including 94 phosphorylated tyrosine residues.Immobilized metal affinity chromatography (IMAC) ::: Phospho-proteomics ::: High throughput systems methodologies for studying the kinomeImmobilized metal affinity chromatography (IMAC) enriches phosphopeptides through interaction between a metal ion immobilized by a chelating agent coupled to the surface of sepharose or agarose beads.", [["surface", "ANATOMY", 416, 423], ["tyrosine", "CHEMICAL", 99, 107], ["tyrosine", "CHEMICAL", 99, 107], ["tyrosine", "AMINO_ACID", 99, 107], ["surface", "CELLULAR_COMPONENT", 416, 423], ["sepharose", "SIMPLE_CHEMICAL", 427, 436], ["agarose beads", "SIMPLE_CHEMICAL", 440, 453], ["2171 phosphorylation sites", "PROTEIN", 26, 52], ["proteins", "TEST", 61, 69], ["phosphorylated tyrosine residues", "TREATMENT", 84, 116], ["High throughput systems methodologies", "PROBLEM", 193, 230], ["the kinomeImmobilized metal affinity chromatography (IMAC) enriches phosphopeptides", "TREATMENT", 244, 327], ["a metal ion immobilized", "TREATMENT", 356, 379], ["a chelating agent", "TREATMENT", 383, 400], ["sepharose or agarose beads", "TREATMENT", 427, 453], ["tyrosine residues", "OBSERVATION", 99, 116], ["agarose beads", "OBSERVATION", 440, 453]]], ["In one of the first examples, Anderssen and Porath used Fe3+ ions held in place by bidentate iminodiacetic acid to separate phosphoproteins from ovalbumin [58].", [["Fe3", "CHEMICAL", 56, 59], ["iminodiacetic acid", "CHEMICAL", 93, 111], ["Fe3+", "CHEMICAL", 56, 60], ["iminodiacetic acid", "CHEMICAL", 93, 111], ["Anderssen", "SIMPLE_CHEMICAL", 30, 39], ["Fe3+ ions", "SIMPLE_CHEMICAL", 56, 65], ["bidentate iminodiacetic acid", "SIMPLE_CHEMICAL", 83, 111], ["phosphoproteins", "PROTEIN", 124, 139], ["Anderssen and Porath used Fe3+ ions", "TREATMENT", 30, 65], ["bidentate iminodiacetic acid", "TREATMENT", 83, 111], ["ovalbumin", "TEST", 145, 154]]], ["The phosphate groups organize the free coordination sites on the metal ion under acidic conditions allowing them to be separated from non-phosphorylated proteins.", [["phosphate", "CHEMICAL", 4, 13], ["phosphate", "CHEMICAL", 4, 13], ["phosphate", "SIMPLE_CHEMICAL", 4, 13], ["non-phosphorylated proteins", "PROTEIN", 134, 161], ["The phosphate groups", "TREATMENT", 0, 20], ["acidic conditions", "TREATMENT", 81, 98], ["free coordination", "OBSERVATION", 34, 51]]], ["Currently, it is common to use nitrilotriacetic acid (NTA) supports coordinated to a variety of metal ions including Fe, Ga [59], and Zn [60].Immobilized metal affinity chromatography (IMAC) ::: Phospho-proteomics ::: High throughput systems methodologies for studying the kinomeLike MOAC, non-specific binding of acidic peptides is a significant issue with IMAC.", [["nitrilotriacetic acid", "CHEMICAL", 31, 52], ["NTA", "CHEMICAL", 54, 57], ["Fe", "CHEMICAL", 117, 119], ["Ga [59]", "CHEMICAL", 121, 128], ["Zn", "CHEMICAL", 134, 136], ["nitrilotriacetic acid", "CHEMICAL", 31, 52], ["NTA", "CHEMICAL", 54, 57], ["Fe", "CHEMICAL", 117, 119], ["Ga", "CHEMICAL", 121, 123], ["Zn [60]", "CHEMICAL", 134, 141], ["nitrilotriacetic acid", "SIMPLE_CHEMICAL", 31, 52], ["NTA", "SIMPLE_CHEMICAL", 54, 57], ["metal ions", "SIMPLE_CHEMICAL", 96, 106], ["Fe", "SIMPLE_CHEMICAL", 117, 119], ["Ga [59]", "SIMPLE_CHEMICAL", 121, 128], ["Zn [60]", "SIMPLE_CHEMICAL", 134, 141], ["kinomeLike MOAC", "PROTEIN", 273, 288], ["IMAC", "PROTEIN", 358, 362], ["nitrilotriacetic acid (NTA)", "TREATMENT", 31, 58], ["non-specific binding of acidic peptides", "PROBLEM", 290, 329], ["acidic peptides", "OBSERVATION", 314, 329]]], ["One method to prevent non-specific binding with IMAC is to chemically modify acidic residues via methyl esterification.", [["methyl esterification", "CHEMICAL", 97, 118], ["methyl", "CHEMICAL", 97, 103], ["methyl", "SIMPLE_CHEMICAL", 97, 103], ["IMAC", "PROTEIN", 48, 52], ["One method", "TREATMENT", 0, 10], ["non-specific binding", "PROBLEM", 22, 42], ["IMAC", "TREATMENT", 48, 52], ["methyl esterification", "TREATMENT", 97, 118]]], ["Ficarro et al. used this method to analyze the phosphoproteome of Saccharomyces cervisiae and found increased efficiency of phosphopeptide binding [61].", [["Saccharomyces cervisiae", "ORGANISM", 66, 89], ["Saccharomyces cervisiae", "SPECIES", 66, 89], ["Saccharomyces cervisiae", "SPECIES", 66, 89], ["this method", "TREATMENT", 20, 31], ["Saccharomyces cervisiae", "TREATMENT", 66, 89], ["increased efficiency of phosphopeptide binding", "PROBLEM", 100, 146]]], ["They reported detection of 5 fmol of phosphoprotein within a standard mixture of proteins.", [["phosphoprotein", "PROTEIN", 37, 51], ["5 fmol of phosphoprotein", "PROBLEM", 27, 51]]], ["They mention that another advantage of using methylesterification is that heavy and light labels can be used in the labelling reagent to perform phosphosite quantification.", [["methylesterification", "TREATMENT", 45, 65], ["phosphosite quantification", "TEST", 145, 171]]], ["The disadvantage to using methylesterification is increased variation during the sample labelling steps.", [["sample", "ANATOMY", 81, 87], ["methylesterification", "CHEMICAL", 26, 46], ["methylesterification", "TREATMENT", 26, 46], ["increased variation", "PROBLEM", 50, 69], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["variation", "OBSERVATION_MODIFIER", 60, 69]]], ["It is also possible to prevent non-specific binding by changing buffer conditions.", [["non-specific binding", "PROBLEM", 31, 51], ["changing buffer conditions", "TREATMENT", 55, 81]]], ["Tsai et al. [62] tested a number of different acids and varied pH using a Fe-NTA resin to find optimal binding conditions for phosphopeptides.", [["Fe", "CHEMICAL", 74, 76], ["NTA", "CHEMICAL", 77, 80], ["Fe-NTA", "CHEMICAL", 74, 80], ["Fe-NTA", "SIMPLE_CHEMICAL", 74, 80], ["different acids", "TREATMENT", 36, 51], ["varied pH", "PROBLEM", 56, 65], ["a Fe-NTA resin", "TREATMENT", 72, 86], ["phosphopeptides", "PROBLEM", 126, 141]]], ["They found that a solution of 6% acetic acid adjusted to pH 3.5 with NaOH provided optimal conditions for phosphopeptide binding.", [["acetic acid", "CHEMICAL", 33, 44], ["NaOH", "CHEMICAL", 69, 73], ["acetic acid", "CHEMICAL", 33, 44], ["NaOH", "CHEMICAL", 69, 73], ["acetic acid", "SIMPLE_CHEMICAL", 33, 44], ["NaOH", "SIMPLE_CHEMICAL", 69, 73], ["a solution of 6% acetic acid", "TREATMENT", 16, 44], ["pH", "TEST", 57, 59], ["NaOH", "TREATMENT", 69, 73], ["phosphopeptide binding", "PROBLEM", 106, 128]]], ["In a single step procedure, they identified 386 phosphoproteins from 550 \u03bcg of non-small-cell lung cancer cell lysate with 96% specificity.Chromatography based methods ::: Phospho-proteomics ::: High throughput systems methodologies for studying the kinomeThe other option to enrich phosphopeptides is to exploit their hydrophilic and ionic nature and separate them from non-modified peptides with liquid chromatography-based methods.", [["non-small-cell lung cancer cell lysate", "ANATOMY", 79, 117], ["non-small-cell lung cancer", "DISEASE", 79, 105], ["non-small-cell lung cancer cell lysate", "CELL", 79, 117], ["phosphoproteins", "PROTEIN", 48, 63], ["a single step procedure", "TREATMENT", 3, 26], ["phosphoproteins", "TEST", 48, 63], ["non-small-cell lung cancer", "PROBLEM", 79, 105], ["cell lysate", "TEST", 106, 117], ["enrich phosphopeptides", "TREATMENT", 276, 298], ["liquid chromatography", "TEST", 398, 419], ["cell", "OBSERVATION", 89, 93], ["lung", "ANATOMY", 94, 98], ["cancer cell lysate", "OBSERVATION", 99, 117]]], ["Ion exchange materials such as strong anion exchange (SAX) and strong cation exchange (SCX) interact with ionic molecules where they can be eluted by modifying the salt content and/or pH of the mobile phase.", [["anion", "SIMPLE_CHEMICAL", 38, 43], ["cation", "SIMPLE_CHEMICAL", 70, 76], ["salt", "SIMPLE_CHEMICAL", 164, 168], ["Ion exchange materials", "TREATMENT", 0, 22], ["strong anion exchange (SAX", "TREATMENT", 31, 57], ["strong cation exchange (SCX)", "TREATMENT", 63, 91], ["ionic molecules", "TREATMENT", 106, 121]]], ["The anionic nature of phosphate allows the use of SAX to separate phosphopeptides from non-modified peptides.", [["phosphate", "CHEMICAL", 22, 31], ["phosphate", "CHEMICAL", 22, 31], ["phosphate", "SIMPLE_CHEMICAL", 22, 31], ["SAX", "SIMPLE_CHEMICAL", 50, 53], ["SAX", "PROTEIN", 50, 53], ["phosphate", "TREATMENT", 22, 31], ["SAX", "TREATMENT", 50, 53], ["non-modified peptides", "TREATMENT", 87, 108]]], ["Han et al. compared the efficiency of Fe3+-IMAC to SAX chromatography to identify phosphorylation sites in human liver tissue [63].", [["liver tissue", "ANATOMY", 113, 125], ["Fe3+-", "CHEMICAL", 38, 43], ["Fe3+-", "CHEMICAL", 38, 43], ["Fe3", "SIMPLE_CHEMICAL", 38, 41], ["SAX", "SIMPLE_CHEMICAL", 51, 54], ["human", "ORGANISM", 107, 112], ["liver tissue", "TISSUE", 113, 125], ["phosphorylation sites", "PROTEIN", 82, 103], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["SAX chromatography", "TEST", 51, 69], ["phosphorylation sites in human liver tissue", "PROBLEM", 82, 125], ["human", "ANATOMY_MODIFIER", 107, 112], ["liver", "ANATOMY", 113, 118]]], ["A direct comparison of the two methods resulted in 47 phosphopeptides identified by SAX and 24 identified by IMAC at 0.96% FDR.", [["SAX", "PROTEIN", 84, 87], ["phosphopeptides", "TEST", 54, 69], ["SAX", "TEST", 84, 87], ["IMAC", "TEST", 109, 113]]], ["Twelve of the phosphopeptides were identified by both methods, again showing how using multiple methods can increase the number of phosphopeptide identifications.Chromatography based methods ::: Phospho-proteomics ::: High throughput systems methodologies for studying the kinomeHydrophilic interaction chromatography (HILIC) uses hydrophilic column material coupled with hydrophobic mobile phases to separate hydrophilic from hydrophobic compounds.", [["the phosphopeptides", "TEST", 10, 29], ["multiple methods", "TREATMENT", 87, 103], ["High throughput systems methodologies", "PROBLEM", 218, 255], ["the kinomeHydrophilic interaction chromatography", "TEST", 269, 317], ["hydrophilic column material", "PROBLEM", 331, 358], ["hydrophobic mobile phases", "TREATMENT", 372, 397], ["hydrophilic", "OBSERVATION_MODIFIER", 410, 421], ["hydrophobic compounds", "OBSERVATION", 427, 448]]], ["Phosphopeptides are typically more hydrophilic than non-phosphorylated peptides, making them an ideal candidate for separation by HILIC.", [["Phosphopeptides", "SIMPLE_CHEMICAL", 0, 15], ["Phosphopeptides", "TREATMENT", 0, 15], ["more hydrophilic", "OBSERVATION_MODIFIER", 30, 46]]], ["McNulty and Annan used HILIC with a combination of IMAC enrichment to analyze the phosphoproteome of HeLa cell digests [64].", [["HeLa cell", "ANATOMY", 101, 110], ["HeLa cell", "CELL", 101, 110], ["IMAC enrichment", "TREATMENT", 51, 66], ["HeLa cell digests", "TREATMENT", 101, 118], ["HeLa cell", "OBSERVATION_MODIFIER", 101, 110]]], ["The phosphopeptides from HeLa cell digests were first enriched by HILIC chromatography followed by enrichment by Fe-IMAC.", [["HeLa cell", "ANATOMY", 25, 34], ["HeLa cell", "CELL", 25, 34], ["Fe-IMAC", "SIMPLE_CHEMICAL", 113, 120], ["The phosphopeptides", "TREATMENT", 0, 19], ["HeLa cell digests", "TREATMENT", 25, 42], ["HILIC chromatography", "TEST", 66, 86], ["HeLa cell digests", "OBSERVATION", 25, 42]]], ["After each fraction was enriched by IMAC they were able to increase the efficiency of phosphopeptide detection to 96%.", [["phosphopeptide detection", "TEST", 86, 110]]], ["From 300 \u03bcg of HeLa cell protein they were able to identify 1000 unique phosphorylation sites, including 700 novel sites not previously discovered.", [["HeLa cell", "ANATOMY", 15, 24], ["HeLa cell", "CELL", 15, 24], ["HeLa cell protein", "PROTEIN", 15, 32], ["HeLa cell protein", "TREATMENT", 15, 32]]], ["The disadvantages to using these chromatography-based methods is the extra de-salting and or purification steps after fraction collection and decreased throughput from having to analyze multiple fractions from a single replicate.ATPase probes ::: Measuring kinase activity ::: High throughput systems methodologies for studying the kinomeWhen establishing kinase networks, it is important to identify both the kinase and the kinase target.", [["ATPase", "GENE_OR_GENE_PRODUCT", 229, 235], ["kinase networks", "PROTEIN", 356, 371], ["kinase", "PROTEIN", 410, 416], ["kinase target", "PROTEIN", 425, 438], ["these chromatography", "TEST", 27, 47], ["the extra de-salting", "TREATMENT", 65, 85], ["fraction collection", "TEST", 118, 137], ["decreased", "OBSERVATION_MODIFIER", 142, 151]]], ["Bottom-up proteomics cannot only identify the site of phosphorylation but can also identify potential kinases responsible for the phosphorylation event.", [["kinases", "PROTEIN", 102, 109], ["potential kinases", "PROBLEM", 92, 109], ["the phosphorylation event", "PROBLEM", 126, 151]]], ["Due to the large dynamic range of the proteome, it is usually necessary to separate kinases from protein mixtures prior to LC-MS/MS analysis in order to identify an acceptable number of kinases.", [["kinases", "PROTEIN", 84, 91], ["kinases", "PROTEIN", 186, 193], ["protein mixtures", "TEST", 97, 113], ["LC", "TEST", 123, 125], ["MS/MS analysis", "TEST", 126, 140], ["large", "OBSERVATION_MODIFIER", 11, 16], ["dynamic", "OBSERVATION", 17, 24]]], ["The ActivX system is a commercially available system that utilizes active site probes that react specifically with the ATP-binding site of kinases and other ATP-binding enzymes [65].", [["ATP", "CHEMICAL", 119, 122], ["ATP", "CHEMICAL", 157, 160], ["ATP", "CHEMICAL", 119, 122], ["ATP", "CHEMICAL", 157, 160], ["ATP", "SIMPLE_CHEMICAL", 119, 122], ["ATP", "SIMPLE_CHEMICAL", 157, 160], ["ATP-binding site", "PROTEIN", 119, 135], ["kinases", "PROTEIN", 139, 146], ["ATP-binding enzymes", "PROTEIN", 157, 176], ["active site probes", "TREATMENT", 67, 85], ["the ATP", "TEST", 115, 122], ["other ATP-binding enzymes", "TEST", 151, 176]]], ["The probe consists of an ATP moiety attached to a desthiobiotin molecule through an acyl linker.", [["ATP", "CHEMICAL", 25, 28], ["ATP", "CHEMICAL", 25, 28], ["desthiobiotin", "CHEMICAL", 50, 63], ["acyl", "CHEMICAL", 84, 88], ["ATP", "SIMPLE_CHEMICAL", 25, 28], ["desthiobiotin", "SIMPLE_CHEMICAL", 50, 63], ["desthiobiotin molecule", "PROTEIN", 50, 72], ["The probe", "TREATMENT", 0, 9], ["an ATP moiety", "TREATMENT", 22, 35], ["a desthiobiotin molecule", "TREATMENT", 48, 72], ["an acyl linker", "TREATMENT", 81, 95], ["ATP moiety", "OBSERVATION", 25, 35], ["acyl linker", "OBSERVATION", 84, 95]]], ["Upon binding to the ATP-binding site, the acyl group reacts with a conserved lysine residue in most ATP-binding sites leaving behind the desthiobiotin tag.", [["ATP", "CHEMICAL", 20, 23], ["acyl", "CHEMICAL", 42, 46], ["lysine", "CHEMICAL", 77, 83], ["ATP", "CHEMICAL", 100, 103], ["ATP", "CHEMICAL", 20, 23], ["acyl", "CHEMICAL", 42, 46], ["lysine", "CHEMICAL", 77, 83], ["ATP", "CHEMICAL", 100, 103], ["desthiobiotin", "CHEMICAL", 137, 150], ["ATP", "SIMPLE_CHEMICAL", 20, 23], ["acyl", "SIMPLE_CHEMICAL", 42, 46], ["lysine", "AMINO_ACID", 77, 83], ["ATP", "SIMPLE_CHEMICAL", 100, 103], ["ATP-binding site", "DNA", 20, 36], ["ATP-binding sites", "PROTEIN", 100, 117], ["desthiobiotin tag", "PROTEIN", 137, 154], ["a conserved lysine residue", "PROBLEM", 65, 91], ["binding sites", "PROBLEM", 104, 117], ["lysine residue", "OBSERVATION", 77, 91], ["most ATP", "OBSERVATION_MODIFIER", 95, 103]]], ["Kinases and other ATPases are enriched through binding to avidin or streptavidin agarose and then eluted for LC-MS/MS analysis.", [["avidin", "GENE_OR_GENE_PRODUCT", 58, 64], ["streptavidin agarose", "SIMPLE_CHEMICAL", 68, 88], ["Kinases", "PROTEIN", 0, 7], ["ATPases", "PROTEIN", 18, 25], ["avidin", "PROTEIN", 58, 64], ["other ATPases", "PROBLEM", 12, 25], ["avidin or streptavidin agarose", "TREATMENT", 58, 88], ["LC", "TEST", 109, 111], ["MS/MS analysis", "TEST", 112, 126]]], ["Kinases can be isolated in their intact state after reaction with the ATPase probe and subsequently trypsin-digested on-bead, or desthiobiotin-modified peptides can be collected after trypsin digestion [66].", [["desthiobiotin", "CHEMICAL", 129, 142], ["Kinases", "GENE_OR_GENE_PRODUCT", 0, 7], ["ATPase", "GENE_OR_GENE_PRODUCT", 70, 76], ["trypsin", "GENE_OR_GENE_PRODUCT", 100, 107], ["desthiobiotin", "SIMPLE_CHEMICAL", 129, 142], ["trypsin", "GENE_OR_GENE_PRODUCT", 184, 191], ["ATPase probe", "DNA", 70, 82], ["trypsin", "PROTEIN", 100, 107], ["trypsin", "PROTEIN", 184, 191], ["the ATPase probe", "TREATMENT", 66, 82], ["desthiobiotin", "TREATMENT", 129, 142], ["modified peptides", "TREATMENT", 143, 160], ["trypsin digestion", "PROBLEM", 184, 201]]], ["The former method will identify multiple peptides per kinase and provides stronger evidence for identification while the latter can be used to quantify the extent of active site labelling, thus quantifying that particular kinase.", [["kinase", "PROTEIN", 222, 228], ["active site labelling", "PROBLEM", 166, 187], ["active", "OBSERVATION_MODIFIER", 166, 172], ["site", "OBSERVATION", 173, 177]]], ["Ideally, both approaches should be used for a more comprehensive identification and quantification of kinases in the system of interest.", [["kinases", "PROTEIN", 102, 109]]], ["The main disadvantage of this technique is that, although there is still significant enrichment of kinases, the probe will also bind non-kinases that have ATP- or nucleotide-binding capabilities.ATPase probes ::: Measuring kinase activity ::: High throughput systems methodologies for studying the kinomeThe ActivX system can be used to comprehensively identify kinases at the global level.", [["ATP", "CHEMICAL", 155, 158], ["nucleotide", "CHEMICAL", 163, 173], ["ATP", "CHEMICAL", 155, 158], ["nucleotide", "CHEMICAL", 163, 173], ["non-kinases", "GENE_OR_GENE_PRODUCT", 133, 144], ["ATP", "SIMPLE_CHEMICAL", 155, 158], ["nucleotide", "SIMPLE_CHEMICAL", 163, 173], ["ATPase", "GENE_OR_GENE_PRODUCT", 195, 201], ["kinases", "PROTEIN", 99, 106], ["non-kinases", "PROTEIN", 133, 144], ["ActivX", "PROTEIN", 308, 314], ["kinases", "PROTEIN", 362, 369], ["significant enrichment of kinases", "PROBLEM", 73, 106], ["ATP", "TEST", 155, 158], ["nucleotide-binding capabilities", "TEST", 163, 194], ["The ActivX system", "TREATMENT", 304, 321], ["main", "OBSERVATION_MODIFIER", 4, 8], ["disadvantage", "OBSERVATION_MODIFIER", 9, 21], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["enrichment", "OBSERVATION", 85, 95]]], ["However, its most interesting application is the potential to identify inhibitors for aberrant kinases in a disease state.", [["aberrant kinases", "PROTEIN", 86, 102], ["inhibitors", "TREATMENT", 71, 81], ["aberrant kinases", "PROBLEM", 86, 102], ["a disease state", "PROBLEM", 106, 121]]], ["Phosphorylation signaling is involved in cell division and growth, among many other processes.", [["cell", "ANATOMY", 41, 45], ["cell", "CELL", 41, 45], ["Phosphorylation signaling", "PROBLEM", 0, 25], ["cell division", "OBSERVATION", 41, 54], ["growth", "OBSERVATION_MODIFIER", 59, 65]]], ["The focus on kinases as potential drug targets led to the development of the kinase inhibitor Gleevec\u00ae as a treatment for chronic myelogenous leukemia, now used in clinical practice.", [["chronic myelogenous leukemia", "ANATOMY", 122, 150], ["Gleevec\u00ae", "CHEMICAL", 94, 102], ["chronic myelogenous leukemia", "DISEASE", 122, 150], ["Gleevec\u00ae", "CHEMICAL", 94, 102], ["Gleevec\u00ae", "SIMPLE_CHEMICAL", 94, 102], ["chronic myelogenous leukemia", "CANCER", 122, 150], ["kinases", "PROTEIN", 13, 20], ["kinases", "TREATMENT", 13, 20], ["the kinase inhibitor Gleevec\u00ae", "TREATMENT", 73, 102], ["a treatment", "TREATMENT", 106, 117], ["chronic myelogenous leukemia", "PROBLEM", 122, 150], ["chronic", "OBSERVATION_MODIFIER", 122, 129], ["myelogenous leukemia", "OBSERVATION", 130, 150]]], ["Most kinase assays to measure activity and find potential inhibitors are performed with the purified kinase.", [["purified kinase", "PROTEIN", 92, 107], ["Most kinase assays", "TEST", 0, 18], ["potential inhibitors", "TREATMENT", 48, 68], ["the purified kinase", "TEST", 88, 107]]], ["The issue with this approach is that kinases exist in a state of constant interaction with other proteins in the cellular network that may modify their activity.", [["cellular network", "ANATOMY", 113, 129], ["cellular network", "MULTI-TISSUE_STRUCTURE", 113, 129], ["kinases", "PROTEIN", 37, 44]]], ["This is at least part of the reason for poor translation of many kinase inhibitors from in vitro assays into being used as treatment for disease.", [["many kinase inhibitors", "TREATMENT", 60, 82], ["vitro assays", "TREATMENT", 91, 103], ["disease", "PROBLEM", 137, 144]]], ["Patricelli et al. [67] used the ActivX system to profile kinases and identify potential kinase inhibitors in HL60 and PC3 cancer cell lines.", [["HL60", "ANATOMY", 109, 113], ["PC3 cancer cell lines", "ANATOMY", 118, 139], ["cancer", "DISEASE", 122, 128], ["HL60", "CELL", 109, 113], ["PC3 cancer cell lines", "CELL", 118, 139], ["HL60", "CELL_LINE", 109, 113], ["PC3 cancer cell lines", "CELL_LINE", 118, 139], ["profile kinases", "TEST", 49, 64], ["potential kinase inhibitors", "TREATMENT", 78, 105], ["HL60", "PROBLEM", 109, 113], ["PC3 cancer cell lines", "TREATMENT", 118, 139], ["PC3 cancer", "OBSERVATION", 118, 128], ["cell lines", "OBSERVATION", 129, 139]]], ["Using a combination of ADP- and ATP-binding site probes, they identified approximately 220 kinases in both cell types.", [["cell", "ANATOMY", 107, 111], ["ADP", "CHEMICAL", 23, 26], ["ATP", "CHEMICAL", 32, 35], ["ADP", "CHEMICAL", 23, 26], ["ATP", "CHEMICAL", 32, 35], ["ADP", "SIMPLE_CHEMICAL", 23, 26], ["ATP", "SIMPLE_CHEMICAL", 32, 35], ["cell", "CELL", 107, 111], ["220 kinases", "PROTEIN", 87, 98], ["ADP- and ATP-binding site probes", "TREATMENT", 23, 55], ["approximately", "OBSERVATION_MODIFIER", 73, 86], ["220 kinases", "OBSERVATION_MODIFIER", 87, 98], ["both cell types", "OBSERVATION", 102, 117]]], ["To quantify these proteins, they specifically targeted the active site peptides of approximately 100 of these kinases.", [["kinases", "PROTEIN", 110, 117]]], ["They measured the effect of several different inhibitors on the signal intensity of these peptides to find IC50 values and binding affinities.", [["several different inhibitors", "TREATMENT", 28, 56], ["these peptides", "TEST", 84, 98], ["IC50 values", "TEST", 107, 118], ["binding affinities", "PROBLEM", 123, 141]]], ["In most cases, the affinity of kinase inhibitors discovered through the ActivX system closely matched the affinities found using the recombinant, purified enzymes.", [["ActivX", "PROTEIN", 72, 78], ["recombinant, purified enzymes", "PROTEIN", 133, 162], ["kinase inhibitors", "TREATMENT", 31, 48], ["the affinities", "PROBLEM", 102, 116], ["purified enzymes", "TEST", 146, 162]]], ["However, they did find several cases where the affinity of inhibitors measured by the ActivX system differed from the in vitro assays.", [["ActivX", "PROTEIN", 86, 92], ["inhibitors", "TREATMENT", 59, 69], ["the in vitro assays", "TEST", 114, 133]]], ["They conclude that, although the reasons for these differences are unknown, it shows the potential of this system to identify kinase inhibitors that may behave differently in cell-based systems compared to their activities in the purified state [67].Luciferase based detection of enzyme activity ::: Measuring kinase activity ::: High throughput systems methodologies for studying the kinomeLuciferase assays are based on an analytical technique that harnesses the bioluminescence phenomenon of light emission by live organisms [68].", [["cell", "ANATOMY", 175, 179], ["cell", "CELL", 175, 179], ["kinase inhibitors", "TREATMENT", 126, 143], ["High throughput systems methodologies", "PROBLEM", 330, 367], ["the kinomeLuciferase assays", "TEST", 381, 408], ["an analytical technique", "TEST", 422, 445]]], ["The reaction is generally caused by the oxidation of luciferin with oxygen, catalyzed by luciferase, resulting in an oxyluciferin molecule that is in an excited state.", [["luciferin", "CHEMICAL", 53, 62], ["oxygen", "CHEMICAL", 68, 74], ["oxyluciferin", "CHEMICAL", 117, 129], ["luciferin", "CHEMICAL", 53, 62], ["oxygen", "CHEMICAL", 68, 74], ["oxyluciferin", "CHEMICAL", 117, 129], ["luciferin", "SIMPLE_CHEMICAL", 53, 62], ["oxygen", "SIMPLE_CHEMICAL", 68, 74], ["luciferase", "GENE_OR_GENE_PRODUCT", 89, 99], ["oxyluciferin", "SIMPLE_CHEMICAL", 117, 129], ["luciferase", "PROTEIN", 89, 99], ["oxyluciferin molecule", "PROTEIN", 117, 138], ["The reaction", "PROBLEM", 0, 12], ["oxygen", "TREATMENT", 68, 74], ["an oxyluciferin molecule", "PROBLEM", 114, 138]]], ["The oxyluciferin molecule emits visible light, then returns to its original state.", [["oxyluciferin", "CHEMICAL", 4, 16], ["oxyluciferin", "CHEMICAL", 4, 16], ["oxyluciferin", "SIMPLE_CHEMICAL", 4, 16], ["oxyluciferin molecule", "PROTEIN", 4, 25], ["The oxyluciferin molecule emits", "TREATMENT", 0, 31]]], ["The most well-defined is the D-luciferin bioluminescence system.", [["D-luciferin", "CHEMICAL", 29, 40], ["D-luciferin", "CHEMICAL", 29, 40], ["D-luciferin", "SIMPLE_CHEMICAL", 29, 40], ["the D-luciferin bioluminescence system", "TREATMENT", 25, 63], ["most well-defined", "OBSERVATION_MODIFIER", 4, 21]]], ["The first step in this chemical reaction is the reversible conversion of D-luciferin to luciferyl adenylate using ATP.", [["D-luciferin", "CHEMICAL", 73, 84], ["luciferyl", "CHEMICAL", 88, 97], ["ATP", "CHEMICAL", 114, 117], ["D-luciferin", "CHEMICAL", 73, 84], ["luciferyl adenylate", "CHEMICAL", 88, 107], ["ATP", "CHEMICAL", 114, 117], ["D-luciferin", "SIMPLE_CHEMICAL", 73, 84], ["luciferyl adenylate", "SIMPLE_CHEMICAL", 88, 107], ["ATP", "SIMPLE_CHEMICAL", 114, 117], ["this chemical reaction", "PROBLEM", 18, 40], ["D-luciferin", "TREATMENT", 73, 84], ["luciferyl adenylate", "TREATMENT", 88, 107], ["ATP", "TREATMENT", 114, 117], ["reversible", "OBSERVATION_MODIFIER", 48, 58]]], ["It is because of this reaction that this luciferase has been used to design a high throughput kinase activity detection method.", [["luciferase", "GENE_OR_GENE_PRODUCT", 41, 51], ["luciferase", "PROTEIN", 41, 51], ["this reaction", "PROBLEM", 17, 30], ["this luciferase", "PROBLEM", 36, 51]]], ["In these assays, the luminescence signal is inversely proportional to the amount of kinase activity; the assays quantify the amount of ATP that remains in a sample after a kinase reaction.", [["ATP", "CHEMICAL", 135, 138], ["ATP", "CHEMICAL", 135, 138], ["ATP", "SIMPLE_CHEMICAL", 135, 138], ["kinase", "PROTEIN", 84, 90], ["these assays", "TEST", 3, 15], ["the luminescence signal", "TEST", 17, 40], ["kinase activity", "PROBLEM", 84, 99], ["the assays", "TEST", 101, 111], ["ATP", "PROBLEM", 135, 138], ["a kinase reaction", "PROBLEM", 170, 187], ["inversely", "OBSERVATION_MODIFIER", 44, 53], ["proportional", "OBSERVATION_MODIFIER", 54, 66], ["amount", "OBSERVATION_MODIFIER", 74, 80], ["kinase activity", "OBSERVATION", 84, 99], ["amount", "OBSERVATION_MODIFIER", 125, 131]]], ["In short, kinase-dependent ATP depletion is measured.", [["ATP", "CHEMICAL", 27, 30], ["ATP", "CHEMICAL", 27, 30], ["ATP", "SIMPLE_CHEMICAL", 27, 30], ["kinase-dependent ATP depletion", "TREATMENT", 10, 40], ["short", "OBSERVATION_MODIFIER", 3, 8], ["dependent", "OBSERVATION_MODIFIER", 17, 26], ["ATP depletion", "OBSERVATION", 27, 40]]], ["High throughput kits can be purchased through several companies, such as Promega's \u2018Kinase-Glo\u00ae Luminescent Kinase Assay\u2019.Kinase activity kits ::: Measuring kinase activity ::: High throughput systems methodologies for studying the kinomeA variety of companies offer a good selection of enzyme activity kits that measure specific kinase activities (ex.", [["Kinase", "GENE_OR_GENE_PRODUCT", 84, 90], ["Kinase", "GENE_OR_GENE_PRODUCT", 122, 128], ["Promega", "TEST", 73, 80], ["Kinase", "TEST", 84, 90], ["enzyme activity kits", "TEST", 287, 307]]], ["Abcam) as well as universal kinase activity (ex.", [["Abcam", "GENE_OR_GENE_PRODUCT", 0, 5], ["Abcam", "PROTEIN", 0, 5], ["universal kinase activity", "TEST", 18, 43]]], ["These kits come with a purified, recombinant enzyme as a positive control and can be compared to experimental cellular or tissue lysates.", [["cellular", "ANATOMY", 110, 118], ["tissue lysates", "ANATOMY", 122, 136], ["cellular", "CELL", 110, 118], ["tissue lysates", "ORGANISM_SUBSTANCE", 122, 136], ["recombinant enzyme", "PROTEIN", 33, 51], ["These kits", "TEST", 0, 10], ["recombinant enzyme", "TEST", 33, 51], ["experimental cellular or tissue lysates", "PROBLEM", 97, 136], ["tissue lysates", "OBSERVATION", 122, 136]]], ["Although the kits are not high-throughput, they have high specificity, relatively easy workflows, fast turnaround times and employ simple detection methods.Virology ::: Application and integration of systems kinomics to diseasesA growing number of kinomic peptide arrays are being performed on virally infected cells, including Cytomegalovirus [[69], [70], [71]], Ebola virus [72], Herpesvirus [73] and Hepatitis C virus [18,74,75].", [["cells", "ANATOMY", 311, 316], ["Ebola virus", "DISEASE", 364, 375], ["Hepatitis C", "DISEASE", 403, 414], ["cells", "CELL", 311, 316], ["Cytomegalovirus", "ORGANISM", 328, 343], ["Ebola virus", "ORGANISM", 364, 375], ["Herpesvirus [73]", "ORGANISM", 382, 398], ["Hepatitis C virus", "ORGANISM", 403, 420], ["virally infected cells", "CELL_TYPE", 294, 316], ["Ebola virus", "SPECIES", 364, 375], ["Hepatitis C virus", "SPECIES", 403, 420], ["Ebola virus", "SPECIES", 364, 375], ["Hepatitis C virus", "SPECIES", 403, 420], ["the kits", "TEST", 9, 17], ["systems kinomics", "TREATMENT", 200, 216], ["diseasesA", "PROBLEM", 220, 229], ["kinomic peptide arrays", "TREATMENT", 248, 270], ["virally infected cells", "PROBLEM", 294, 316], ["Cytomegalovirus", "TEST", 328, 343], ["Ebola virus", "TEST", 364, 375], ["Herpesvirus", "TEST", 382, 393], ["Hepatitis C virus", "PROBLEM", 403, 420], ["not", "UNCERTAINTY", 22, 25], ["high", "OBSERVATION_MODIFIER", 26, 30]]], ["Some studies have published whole kinome screens with the identification of specific kinases that are activated during viral infection, while others have begun to evaluate the antiviral impact of inhibiting identified kinases or related signaling pathways in vitro [[76], [77], [78], [79]].", [["viral infection", "DISEASE", 119, 134], ["[[76], [77], [78]", "SIMPLE_CHEMICAL", 265, 282], ["kinases", "PROTEIN", 85, 92], ["kinases", "PROTEIN", 218, 225], ["Some studies", "TEST", 0, 12], ["whole kinome screens", "TEST", 28, 48], ["specific kinases", "PROBLEM", 76, 92], ["viral infection", "PROBLEM", 119, 134]]], ["Kindrachuk and colleagues examined specific kinases activated by in vivo Ebola virus infection [72].", [["Ebola virus infection", "DISEASE", 73, 94], ["Ebola virus", "ORGANISM", 73, 84], ["Ebola virus", "SPECIES", 73, 84], ["Ebola virus", "SPECIES", 73, 84], ["vivo Ebola virus infection", "PROBLEM", 68, 94]]], ["Although many variables affect the kinases identified including the type of virus, species, and timepoint, several kinases have been identified in multiple screens.", [["kinases", "PROTEIN", 35, 42], ["kinases", "PROTEIN", 115, 122], ["the kinases", "TEST", 31, 42], ["the type of virus", "PROBLEM", 64, 81], ["several kinases", "TEST", 107, 122], ["virus", "OBSERVATION", 76, 81]]], ["For example, Hutterer et al. showed Aurora A activity was upregulated during cytomegalovirus infection [69] and Gabrielli and colleagues showed upregulation of the same activity during papillomavirus infection [80].", [["cytomegalovirus infection", "DISEASE", 77, 102], ["papillomavirus infection", "DISEASE", 185, 209], ["Aurora A", "GENE_OR_GENE_PRODUCT", 36, 44], ["cytomegalovirus", "ORGANISM", 77, 92], ["papillomavirus", "ORGANISM", 185, 199], ["Aurora A", "PROTEIN", 36, 44], ["Aurora A activity", "PROBLEM", 36, 53], ["cytomegalovirus infection", "PROBLEM", 77, 102], ["papillomavirus infection", "PROBLEM", 185, 209], ["activity", "OBSERVATION_MODIFIER", 45, 53]]], ["Similarly, systemic screens of kinase inhibitors have proven useful in discovering novel drug targets as was recently performed against hepatitis D virus [81] in which GSK-3\u03b2 and Cdk inhibitors were identified.", [["hepatitis D virus", "DISEASE", 136, 153], ["hepatitis D virus", "ORGANISM", 136, 153], ["GSK-3\u03b2", "GENE_OR_GENE_PRODUCT", 168, 174], ["Cdk", "GENE_OR_GENE_PRODUCT", 179, 182], ["GSK-3\u03b2", "PROTEIN", 168, 174], ["Cdk", "PROTEIN", 179, 182], ["hepatitis D virus", "SPECIES", 136, 153], ["hepatitis D virus", "SPECIES", 136, 153], ["systemic screens", "TEST", 11, 27], ["kinase inhibitors", "TREATMENT", 31, 48], ["hepatitis D virus", "PROBLEM", 136, 153], ["GSK", "TEST", 168, 171], ["Cdk inhibitors", "TREATMENT", 179, 193]]], ["Kinases involved in the host antiviral response against Sendai virus have also been elegantly characterized by using an interferon-gamma promoter-driven luciferase assay [82] which identified FYN and SRPK1 as novel contributors to the host immune response.", [["Sendai virus", "ORGANISM", 56, 68], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 120, 136], ["luciferase", "GENE_OR_GENE_PRODUCT", 153, 163], ["FYN", "GENE_OR_GENE_PRODUCT", 192, 195], ["SRPK1", "GENE_OR_GENE_PRODUCT", 200, 205], ["interferon-gamma promoter", "DNA", 120, 145], ["luciferase", "PROTEIN", 153, 163], ["FYN", "PROTEIN", 192, 195], ["SRPK1", "PROTEIN", 200, 205], ["Sendai virus", "SPECIES", 56, 68], ["Sendai virus", "SPECIES", 56, 68], ["Sendai virus", "PROBLEM", 56, 68], ["an interferon-gamma promoter", "TREATMENT", 117, 145]]], ["Finally, the ability to probe a wide variety of species has proven particularly useful within virology and includes the development of arrays for hamsters [34], guinea pigs [35], cow [32], monkey [79], pig, and poultry [33].Cancer ::: Application and integration of systems kinomics to diseasesKinomics has also been applied in a variety of cancer studies.", [["Cancer", "ANATOMY", 224, 230], ["cancer", "ANATOMY", 341, 347], ["Cancer", "DISEASE", 224, 230], ["cancer", "DISEASE", 341, 347], ["hamsters", "ORGANISM", 146, 154], ["guinea pigs", "ORGANISM", 161, 172], ["cow", "ORGANISM", 179, 182], ["monkey", "ORGANISM", 189, 195], ["pig", "ORGANISM", 202, 205], ["Cancer", "CANCER", 224, 230], ["cancer", "CANCER", 341, 347], ["guinea pigs", "SPECIES", 161, 172], ["cow", "SPECIES", 179, 182], ["monkey", "SPECIES", 189, 195], ["pig", "SPECIES", 202, 205], ["poultry", "SPECIES", 211, 218], ["hamsters", "SPECIES", 146, 154], ["cow", "SPECIES", 179, 182], ["pig", "SPECIES", 202, 205], ["a wide variety of species", "PROBLEM", 30, 55], ["systems kinomics", "TREATMENT", 266, 282], ["Kinomics", "TREATMENT", 294, 302], ["cancer studies", "TEST", 341, 355], ["cancer", "OBSERVATION", 341, 347]]], ["For example, a major focus has been the identification of kinases that promote survival of cancerous cells, and, by extension, large screens to determine viability of cancerous cells treated with various kinase inhibitors [[83], [84], [85], [86]].", [["cancerous cells", "ANATOMY", 91, 106], ["cancerous cells", "ANATOMY", 167, 182], ["cancerous cells", "CELL", 91, 106], ["cancerous cells", "CELL", 167, 182], ["[83], [84], [85], [86]", "SIMPLE_CHEMICAL", 223, 245], ["kinases", "PROTEIN", 58, 65], ["cancerous cells", "CELL_TYPE", 91, 106], ["cancerous cells", "CELL_TYPE", 167, 182], ["cancerous cells", "PROBLEM", 91, 106], ["large screens", "TEST", 127, 140], ["cancerous cells", "PROBLEM", 167, 182], ["various kinase inhibitors", "TREATMENT", 196, 221], ["cancerous cells", "OBSERVATION", 91, 106], ["cancerous cells", "OBSERVATION", 167, 182]]], ["Similarly, screenings of migration inhibitors have also led to the discovery of potential therapeutic kinase targets [45].", [["migration inhibitors", "TREATMENT", 25, 45], ["potential therapeutic kinase targets", "PROBLEM", 80, 116]]], ["These large screens of uncharacterized compounds are well complemented by other methods such as activity-based protein profiling (ABPP) [[87], [88], [89], [90]], peptide arrays or siRNA arrays that can identify the specific proteins and pathways targeted by the inhibitor.Cancer ::: Application and integration of systems kinomics to diseasesA second area of kinomics research in cancer consists of phenotyping tumors [87] and cancerous tissues that may lead to improved diagnostics and course of therapies as well as the development of novel therapeutics.", [["Cancer", "ANATOMY", 272, 278], ["cancer", "ANATOMY", 380, 386], ["tumors", "ANATOMY", 411, 417], ["cancerous tissues", "ANATOMY", 427, 444], ["Cancer", "DISEASE", 272, 278], ["cancer", "DISEASE", 380, 386], ["tumors", "DISEASE", 411, 417], ["[88]", "SIMPLE_CHEMICAL", 143, 147], ["[89]", "SIMPLE_CHEMICAL", 149, 153], ["[90]", "SIMPLE_CHEMICAL", 155, 159], ["Cancer", "CANCER", 272, 278], ["cancer", "CANCER", 380, 386], ["tumors", "CANCER", 411, 417], ["cancerous tissues", "TISSUE", 427, 444], ["activity-based protein profiling", "TEST", 96, 128], ["peptide arrays or siRNA arrays", "PROBLEM", 162, 192], ["Cancer", "PROBLEM", 272, 278], ["systems kinomics", "TREATMENT", 314, 330], ["diseases", "PROBLEM", 334, 342], ["kinomics research in cancer", "PROBLEM", 359, 386], ["phenotyping tumors", "PROBLEM", 399, 417], ["cancerous tissues", "PROBLEM", 427, 444], ["therapies", "TREATMENT", 497, 506], ["novel therapeutics", "TREATMENT", 537, 555], ["large", "OBSERVATION_MODIFIER", 6, 11], ["compounds", "OBSERVATION_MODIFIER", 39, 48], ["cancer", "OBSERVATION", 380, 386]]], ["Single cell flow cytometry has been extremely valuable for these studies as tissues and tumors can be heterogeneous cell populations and are not always well represented or understood without a representation of their variability.Clinical samples and diagnostics ::: Application and integration of systems kinomics to diseasesIn addition to its value in basic science, kinomics research has also led to improved or novel diagnostic tests.", [["cell", "ANATOMY", 7, 11], ["tissues", "ANATOMY", 76, 83], ["tumors", "ANATOMY", 88, 94], ["cell", "ANATOMY", 116, 120], ["samples", "ANATOMY", 238, 245], ["tumors", "DISEASE", 88, 94], ["cell", "CELL", 7, 11], ["tissues", "TISSUE", 76, 83], ["tumors", "CANCER", 88, 94], ["cell populations", "CELL", 116, 132], ["Single cell flow cytometry", "TEST", 0, 26], ["these studies", "TEST", 59, 72], ["tumors", "PROBLEM", 88, 94], ["heterogeneous cell populations", "PROBLEM", 102, 132], ["systems kinomics", "TREATMENT", 297, 313], ["novel diagnostic tests", "TEST", 414, 436], ["cell", "OBSERVATION", 7, 11], ["flow cytometry", "OBSERVATION", 12, 26], ["tumors", "OBSERVATION", 88, 94], ["heterogeneous", "OBSERVATION_MODIFIER", 102, 115]]], ["For example, many kinases that were initially identified in cancer studies are currently in various stages of clinical trials and have shown great promise in treatment of cancer (reviewed by Ku et al. [91]).", [["cancer", "ANATOMY", 60, 66], ["cancer", "ANATOMY", 171, 177], ["cancer", "DISEASE", 60, 66], ["cancer", "DISEASE", 171, 177], ["cancer", "CANCER", 60, 66], ["cancer", "CANCER", 171, 177], ["kinases", "PROTEIN", 18, 25], ["many kinases", "PROBLEM", 13, 25], ["cancer studies", "TEST", 60, 74], ["cancer", "PROBLEM", 171, 177], ["cancer", "OBSERVATION", 60, 66], ["great", "OBSERVATION_MODIFIER", 141, 146], ["promise", "OBSERVATION_MODIFIER", 147, 154], ["cancer", "OBSERVATION", 171, 177]]], ["In addition, the field of infectious diseases has been impacted by the discovery of kinases that are unique to infectious organisms; this can allow for rapid, sensitive and specific diagnosis testing as was recently described by Wayengera et al. for Mycobacterium [92].", [["infectious diseases", "DISEASE", 26, 45], ["kinases", "PROTEIN", 84, 91], ["infectious diseases", "PROBLEM", 26, 45], ["kinases", "PROBLEM", 84, 91], ["infectious organisms", "PROBLEM", 111, 131], ["specific diagnosis testing", "TEST", 173, 199], ["Mycobacterium", "PROBLEM", 250, 263], ["infectious", "OBSERVATION", 26, 36]]], ["Some kinases are well-known biomarkers of disease and many studies have actively screened serum, tissue and urine samples to identify new markers.", [["serum", "ANATOMY", 90, 95], ["tissue", "ANATOMY", 97, 103], ["urine samples", "ANATOMY", 108, 121], ["serum", "ORGANISM_SUBSTANCE", 90, 95], ["tissue", "TISSUE", 97, 103], ["urine samples", "ORGANISM_SUBSTANCE", 108, 121], ["kinases", "PROTEIN", 5, 12], ["Some kinases", "PROBLEM", 0, 12], ["disease", "PROBLEM", 42, 49], ["many studies", "TEST", 54, 66], ["urine samples", "TEST", 108, 121], ["new markers", "TEST", 134, 145]]], ["Some new potential markers include STK1c in response to lung surgery [93], plasma creatine kinase B for injury in professional boxers [94], creatinine kinase activity in the development of high blood pressure [95] and various kinases in different types of cancer (reviewed by Quan et al. [96]).Detecting phosphorylation sites ::: Phosphorylation databases and integration tools ::: Application and integration of systems kinomics to diseasesIt is estimated that there are potentially 500,000 phosphorylation sites in the human proteome [97], the majority of which have unknown cognate kinases.", [["lung", "ANATOMY", 56, 60], ["plasma", "ANATOMY", 75, 81], ["blood", "ANATOMY", 194, 199], ["cancer", "ANATOMY", 256, 262], ["creatine", "CHEMICAL", 82, 90], ["creatinine", "CHEMICAL", 140, 150], ["cancer", "DISEASE", 256, 262], ["creatine", "CHEMICAL", 82, 90], ["creatinine", "CHEMICAL", 140, 150], ["STK1c", "GENE_OR_GENE_PRODUCT", 35, 40], ["lung", "ORGAN", 56, 60], ["plasma", "ORGANISM_SUBSTANCE", 75, 81], ["creatine kinase B", "GENE_OR_GENE_PRODUCT", 82, 99], ["creatinine kinase", "GENE_OR_GENE_PRODUCT", 140, 157], ["blood", "ORGANISM_SUBSTANCE", 194, 199], ["cancer", "CANCER", 256, 262], ["human", "ORGANISM", 521, 526], ["STK1c", "PROTEIN", 35, 40], ["plasma creatine kinase B", "PROTEIN", 75, 99], ["creatinine kinase", "PROTEIN", 140, 157], ["kinases", "PROTEIN", 226, 233], ["phosphorylation sites", "PROTEIN", 304, 325], ["phosphorylation sites", "PROTEIN", 492, 513], ["cognate kinases", "PROTEIN", 577, 592], ["human", "SPECIES", 521, 526], ["human", "SPECIES", 521, 526], ["Some new potential markers", "PROBLEM", 0, 26], ["STK1c", "PROBLEM", 35, 40], ["lung surgery", "TREATMENT", 56, 68], ["plasma creatine kinase B", "TEST", 75, 99], ["injury", "PROBLEM", 104, 110], ["professional boxers", "TEST", 114, 133], ["creatinine kinase activity", "TEST", 140, 166], ["high blood pressure", "PROBLEM", 189, 208], ["various kinases", "PROBLEM", 218, 233], ["cancer", "PROBLEM", 256, 262], ["Phosphorylation databases", "TEST", 330, 355], ["systems kinomics", "TREATMENT", 413, 429], ["the human proteome", "TEST", 517, 535], ["new", "OBSERVATION_MODIFIER", 5, 8], ["lung", "ANATOMY", 56, 60], ["surgery", "OBSERVATION", 61, 68], ["different types", "OBSERVATION_MODIFIER", 237, 252], ["cancer", "OBSERVATION", 256, 262], ["cognate kinases", "OBSERVATION", 577, 592]]], ["These estimates are based on the multitude of phosphoproteomic experiments conducted identifying thousands of phosphorylation sites.", [["phosphorylation sites", "PROTEIN", 110, 131], ["phosphoproteomic experiments", "TREATMENT", 46, 74], ["phosphorylation sites", "TREATMENT", 110, 131], ["phosphorylation sites", "OBSERVATION", 110, 131]]], ["Organizing all of this information is a challenging task, taking into account all of the kinases and phosphatases involved in regulating phosphorylation reactions.", [["kinases", "PROTEIN", 89, 96], ["phosphatases", "PROTEIN", 101, 113], ["the kinases", "TEST", 85, 96], ["phosphatases", "TEST", 101, 113], ["regulating phosphorylation reactions", "PROBLEM", 126, 162], ["phosphorylation reactions", "OBSERVATION", 137, 162]]], ["There are several databases available for many organisms that organize the information we have on phosphorylation sites including Phospho.ELM [98], PhosphoGRID [99], SysPTM ([100]), UniProt ([101]), PhosphoPep ([102]), PhosphositePlus ([103]).Detecting phosphorylation sites ::: Phosphorylation databases and integration tools ::: Application and integration of systems kinomics to diseasesPhosphorylation site database (PHOSIDA) ([104]) is a database developed in the Matthias Mann lab that contains information on thousands of phosphorylation events in both prokaryotic and eukaryotic species generated through mass spectrometry experiments.", [["PhosphoPep", "CHEMICAL", 199, 209], ["PhosphoPep", "CHEMICAL", 199, 209], ["PhosphositePlus", "CHEMICAL", 219, 234], ["Phospho", "GENE_OR_GENE_PRODUCT", 130, 137], ["PhosphoPep", "SIMPLE_CHEMICAL", 199, 209], ["PhosphositePlus", "SIMPLE_CHEMICAL", 219, 234], ["phosphorylation sites", "PROTEIN", 98, 119], ["Phospho", "PROTEIN", 130, 137], ["phosphorylation sites", "PROTEIN", 253, 274], ["several databases", "TEST", 10, 27], ["many organisms", "PROBLEM", 42, 56], ["phosphorylation sites", "TREATMENT", 98, 119], ["Phospho", "TEST", 130, 137], ["ELM", "TEST", 138, 141], ["PhosphoGRID", "TEST", 148, 159], ["SysPTM", "TEST", 166, 172], ["UniProt", "TEST", 182, 189], ["PhosphoPep", "TEST", 199, 209], ["PhosphositePlus", "TEST", 219, 234], ["Phosphorylation databases", "TEST", 279, 304], ["systems kinomics", "TREATMENT", 362, 378], ["Phosphorylation site database", "TEST", 390, 419], ["a database", "TEST", 441, 451], ["phosphorylation events", "PROBLEM", 529, 551], ["eukaryotic species", "PROBLEM", 576, 594], ["mass spectrometry experiments", "PROBLEM", 613, 642], ["eukaryotic species", "OBSERVATION", 576, 594]]], ["They give an example of using their database to study the protein structure found in phosphorylation sites using solvent accessibility calculations.", [["phosphorylation sites", "PROTEIN", 85, 106], ["phosphorylation sites", "TREATMENT", 85, 106], ["solvent accessibility calculations", "TREATMENT", 113, 147]]], ["They found that phosphosites are generally found in loop or hinge regions and are typically highly accessible to the surrounding environment.", [["hinge regions", "PROTEIN", 60, 73], ["phosphosites", "PROBLEM", 16, 28], ["phosphosites", "OBSERVATION", 16, 28], ["loop", "OBSERVATION", 52, 56], ["hinge", "OBSERVATION_MODIFIER", 60, 65]]], ["These results largely confirm other studies showing that phosphosites require accessibility due to the need to interact with other proteins in the kinase/phosphatase network.Data integration ::: Phosphorylation databases and integration tools ::: Application and integration of systems kinomics to diseasesThe large number of phosphorylation site databases available has led to attempts to integrate this data into databases that contain all of this information in one source. dbPAF ([105]) is one example that combined information from several databases into a single source of information on animal and fungal phosphosites.", [["dbPAF", "CHEMICAL", 477, 482], ["dbPAF", "CHEMICAL", 477, 482], ["dbPAF", "SIMPLE_CHEMICAL", 477, 482], ["kinase/phosphatase network", "PROTEIN", 147, 173], ["other studies", "TEST", 30, 43], ["phosphosites", "PROBLEM", 57, 69], ["the kinase/phosphatase network", "TEST", 143, 173], ["Phosphorylation databases", "TEST", 195, 220], ["systems kinomics", "TREATMENT", 278, 294], ["phosphorylation site databases", "PROBLEM", 326, 356], ["animal and fungal phosphosites", "TEST", 594, 624], ["large", "OBSERVATION_MODIFIER", 310, 315], ["number", "OBSERVATION_MODIFIER", 316, 322], ["fungal phosphosites", "OBSERVATION", 605, 624]]], ["After integrating data from the literature and from public databases they found a total of 54,148 phosphoproteins with 483,001 phosphorylation sites.", [["54,148 phosphoproteins", "PROTEIN", 91, 113], ["483,001 phosphorylation sites", "PROTEIN", 119, 148], ["public databases", "TEST", 52, 68], ["phosphorylation sites", "PROBLEM", 127, 148]]], ["They used this database to detect conserved sequence motifs of phosphorylation sites, predicted kinases, and analyzed conservation of phosphosite sequences across several species.", [["phosphorylation sites", "PROTEIN", 63, 84], ["kinases", "PROTEIN", 96, 103], ["phosphosite sequences", "DNA", 134, 155], ["phosphorylation sites", "PROBLEM", 63, 84], ["phosphosite sequences", "TEST", 134, 155]]], ["KinMap is a second very useful and user-friendly resource that can be found online and allows interactive navigation through biochemical, structural, and disease association data ([106]).ConclusionThere are numerous powerful high-throughput systems biology tools available for the study of kinases, kinase targets, the presence of phosphorylated proteins, and antagonistic phosphatases.", [["kinases", "PROTEIN", 290, 297], ["kinase targets", "PROTEIN", 299, 313], ["phosphorylated proteins", "PROTEIN", 331, 354], ["antagonistic phosphatases", "PROTEIN", 360, 385], ["the study of kinases", "TEST", 277, 297], ["kinase targets", "TEST", 299, 313], ["phosphorylated proteins", "TREATMENT", 331, 354], ["antagonistic phosphatases", "TEST", 360, 385], ["numerous", "OBSERVATION_MODIFIER", 207, 215], ["powerful", "OBSERVATION_MODIFIER", 216, 224], ["high", "OBSERVATION_MODIFIER", 225, 229]]], ["Since kinases are key regulators of cellular processes and are integral to many different signaling pathways, kinomics is an important topic with respect to determining the mechanisms of how a disease can cause damage to cells.", [["cellular", "ANATOMY", 36, 44], ["cells", "ANATOMY", 221, 226], ["cellular", "CELL", 36, 44], ["cells", "CELL", 221, 226], ["kinases", "PROTEIN", 6, 13], ["cellular processes", "PROBLEM", 36, 54], ["a disease", "PROBLEM", 191, 200], ["damage to cells", "PROBLEM", 211, 226], ["cellular processes", "OBSERVATION", 36, 54]]], ["However, there are currently 518 putative kinases in the cell [2] and it is difficult to focus on relevant pathways using single molecule style experiments.", [["cell", "ANATOMY", 57, 61], ["cell", "CELL", 57, 61], ["putative kinases", "PROTEIN", 33, 49], ["single molecule style experiments", "TREATMENT", 122, 155]]], ["Using these high-throughput methods, the most pertinent kinases in the study system can be identified before more focused experiments are performed.", [["kinases", "PROTEIN", 56, 63], ["the study system", "TEST", 67, 83], ["high", "OBSERVATION_MODIFIER", 12, 16]]]], "PMC7229446": [["FundingThis study was supported by the 10.13039/501100012226Fundamental Research Funds for the Central Universities (No. 14380459).Declaration of competing interestNone of the authors has any conflict of interest to declare.", [["This study", "TEST", 7, 17]]]], "2a5290cdbad2b75e11cbe0282425d71ce4ac90f5": [["IntroductionThe COVID-19 pandemic caused severe impact on public health and shocked global economy.", [["The COVID", "TREATMENT", 12, 21], ["severe", "OBSERVATION_MODIFIER", 41, 47]]], ["In addition, the outbreak of COVID-19 had a serious impact on environment, more specifically on carbon emission.", [["COVID-19", "CHEMICAL", 29, 37], ["COVID-19", "CHEMICAL", 29, 37], ["carbon", "CHEMICAL", 96, 102], ["carbon", "SIMPLE_CHEMICAL", 96, 102], ["COVID", "TEST", 29, 34], ["carbon emission", "TEST", 96, 111]]], ["Le Qu\u00e9r\u00e9 et al.(Le Qu\u00e9r\u00e9 et al., 2020) found forced confinement has an important impact on global carbon emission changes.", [["carbon", "CHEMICAL", 98, 104], ["global carbon emission changes", "PROBLEM", 91, 121], ["carbon emission", "OBSERVATION", 98, 113]]], ["They estimated that the confinement is to decline global carbon emission by early April 2020 by 17% compared with 2019 mean level.", [["carbon", "CHEMICAL", 57, 63], ["carbon", "CHEMICAL", 57, 63], ["global carbon emission", "PROBLEM", 50, 72], ["carbon emission", "OBSERVATION", 57, 72]]], ["As for carbon emission in the rest of the year, it depends on the duration and extent of the confinement.", [["carbon", "CHEMICAL", 7, 13], ["carbon", "CHEMICAL", 7, 13], ["carbon emission", "TEST", 7, 22]]], ["JeffIntroductionTollefson analyzed several studies on carbon emission changes during the COVID-19m and he found carbon emission is bound to decline more than one billion tons in the first months compared with the same period in 2019 (Tollefson, 202) .", [["carbon", "CHEMICAL", 54, 60], ["carbon", "CHEMICAL", 112, 118], ["carbon", "CHEMICAL", 54, 60], ["carbon", "CHEMICAL", 112, 118], ["carbon emission changes", "PROBLEM", 54, 77], ["carbon emission", "PROBLEM", 112, 127]]], ["A report from Carbon Brief indicates that COVID-19 is likely to cause the largest annual fall in carbon emission as more countries enforcing lockdowns to stop this pandemic (Carbon Brief, 2020a) .", [["Carbon", "CHEMICAL", 14, 20], ["carbon", "CHEMICAL", 97, 103], ["COVID", "TEST", 42, 47], ["carbon emission", "TREATMENT", 97, 112], ["largest", "OBSERVATION_MODIFIER", 74, 81], ["carbon emission", "OBSERVATION", 97, 112]]], ["Then another report from Carbon Brief predicts that carbon emission probably see a decline up to 2729 million tons carbon emission in 2020 as a whole, which is the first one to quantify carbon emission changes on a daily basis (Carbon Brief, 2020b) .", [["Carbon", "CHEMICAL", 25, 31], ["carbon", "CHEMICAL", 52, 58], ["carbon", "CHEMICAL", 115, 121], ["carbon", "CHEMICAL", 186, 192], ["Carbon", "CHEMICAL", 228, 234], ["carbon", "SIMPLE_CHEMICAL", 52, 58], ["carbon emission", "TEST", 52, 67]]], ["Moreover, IEA(International Energy Agency, 2020) forecasted a decrease of 8% in 2020 carbon emission.", [["carbon", "CHEMICAL", 85, 91], ["decrease", "OBSERVATION_MODIFIER", 62, 70]]], ["Besides, Evans (Evans, 2020) believed that as work resumption and economy stimulation, energy consumption will surge and carbon emission will rebound sharply.", [["carbon", "CHEMICAL", 121, 127], ["economy stimulation", "TREATMENT", 66, 85], ["carbon emission", "TEST", 121, 136]]], ["EIA estimated that carbon emission will decrease by 12.2% in 2020 and increase by 6.0% in 2021 in the United J o u r n a l P r e -p r o o f 6 situation .", [["carbon", "CHEMICAL", 19, 25], ["carbon", "CHEMICAL", 19, 25], ["carbon", "SIMPLE_CHEMICAL", 19, 25], ["EIA", "TEST", 0, 3], ["carbon emission", "TEST", 19, 34]]], ["However, in late 2019, a new pandemic emerged and rapidly spread out, which will definitely threaten human security, but also has a serious impact on economic growth and carbon emission.IntroductionWhat the post-epidemic carbon emission like?", [["carbon", "CHEMICAL", 170, 176], ["carbon", "CHEMICAL", 221, 227], ["human", "ORGANISM", 101, 106], ["carbon", "SIMPLE_CHEMICAL", 170, 176], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["a new pandemic", "PROBLEM", 23, 37], ["economic growth and carbon emission", "PROBLEM", 150, 185], ["the post-epidemic carbon emission", "TREATMENT", 203, 236], ["new", "OBSERVATION_MODIFIER", 25, 28], ["carbon emission", "OBSERVATION", 170, 185]]], ["How to achieve established carbon emission target?IntroductionPeople have gotten through several crisis and accumulated some practical experience.", [["carbon", "CHEMICAL", 27, 33]]], ["When dealing with carbon emission change after COVID-19 pandemic, it may be helpful to take a lesson from 2008 global economic crisis.", [["carbon", "CHEMICAL", 18, 24], ["carbon", "CHEMICAL", 18, 24], ["carbon emission change", "TREATMENT", 18, 40], ["COVID", "TEST", 47, 52]]], ["In addition, in order to promote carbon emission, it is necessary to monitor carbon emission changes and even go a step forward to figure out factors driving carbon emission changes.IntroductionDecomposition analysis is usually available to investigate carbon emission driving factors.", [["carbon", "CHEMICAL", 33, 39], ["carbon", "CHEMICAL", 77, 83], ["carbon", "CHEMICAL", 158, 164], ["carbon", "CHEMICAL", 253, 259], ["carbon", "SIMPLE_CHEMICAL", 33, 39], ["carbon", "SIMPLE_CHEMICAL", 158, 164], ["carbon emission driving factors", "PROTEIN", 253, 284], ["carbon emission changes", "PROBLEM", 77, 100], ["IntroductionDecomposition analysis", "TEST", 182, 216]]], ["Generally speaking, the structural decomposition analysis (SDA); the production-theoretical decomposition analysis (PDA); and the index decomposition analysis (IDA) are three frequently applied methods Zhang and Da, 2015) .", [["the structural decomposition analysis", "TEST", 20, 57], ["theoretical decomposition analysis", "TEST", 80, 114], ["the index decomposition analysis", "TEST", 126, 158]]], ["In accordance with the purpose of this study, IDA is properly applied.", [["IDA", "CHEMICAL", 46, 49], ["IDA", "SIMPLE_CHEMICAL", 46, 49], ["this study", "TEST", 34, 44], ["IDA", "TREATMENT", 46, 49]]], ["Among various IDA methods, LMDI is J o u r n a l P r e -p r o o f 8 will worsen.", [["a l P r e -p r o o f 8", "TEST", 45, 67]]], ["Ahmed et al. (Ahmed et al., 2015) argued that the implementation of measures to cut down carbon emissions worldwide can only be achieved through the form of international trade.", [["carbon", "CHEMICAL", 89, 95], ["carbon emissions", "TREATMENT", 89, 105]]], ["Trade openness helped more underdeveloped economies improved the national economic level and get rid of poverty.", [["poverty", "DISEASE", 104, 111]]], ["In essence, the contradiction between trade and environmental pressure is indirect, based on the fundamental theory that free trade stimulates economic growth and thus accelerates environmental degradation.IntroductionHowever, the impact of trade development on the environment has various performances in different countries, which may depend on the actual national conditions of each country, including economic development level, relevant economic policies, industrial structure and other aspects (Forslid and Okubo, 2015) .", [["pressure", "OBSERVATION_MODIFIER", 62, 70]]], ["Given that, this chapter provides a brief review of existing literature on trade--carbon emissions.IntroductionFrom the perspective of single country, Andersson (Andersson, 2018) combined input-output frameworks and nonlinear models to explore the impact of trade liberalization on the rapid growth of CO2 emissions in China.", [["CO2", "CHEMICAL", 302, 305], ["carbon", "CHEMICAL", 82, 88], ["CO2", "CHEMICAL", 302, 305], ["CO2", "SIMPLE_CHEMICAL", 302, 305], ["input-output frameworks", "TREATMENT", 188, 211], ["nonlinear models", "TREATMENT", 216, 232], ["trade liberalization", "TREATMENT", 258, 278], ["rapid", "OBSERVATION_MODIFIER", 286, 291], ["growth", "OBSERVATION_MODIFIER", 292, 298]]], ["Their results supported the fact that trade liberalization is the key determinant of the increment of carbon emissions embodied in import of China during the period 1995-2008.", [["carbon", "CHEMICAL", 102, 108], ["carbon", "SIMPLE_CHEMICAL", 102, 108], ["carbon emissions", "TREATMENT", 102, 118], ["carbon emissions", "OBSERVATION", 102, 118]]], ["Based on the multi-regional output-output tables, Ren et al.(Ren et al., 2014) showed that the continued expansion of trade openness and the continuous inflow of foreign investment are important reasons for the soaring carbon emissions in China's industrial sector.", [["carbon", "CHEMICAL", 219, 225], ["the multi-regional output", "TEST", 9, 34], ["expansion", "OBSERVATION_MODIFIER", 105, 114], ["trade openness", "OBSERVATION", 118, 132], ["foreign investment", "OBSERVATION", 162, 180]]], ["It is worth mentioning that trade openness is seen as a pivotal indicator of inward direct investment, which is usually used to verify the authenticity of the PHH hypothesis.", [["the PHH hypothesis", "PROBLEM", 155, 173], ["trade openness", "OBSERVATION", 28, 42], ["PHH", "OBSERVATION", 159, 162]]], ["Actually, the PHH hypothesis depicts the long-term linkage J o u r n a l P r e -p r o o f 9 between carbon emissions, trade, and foreign direct investment.", [["carbon", "CHEMICAL", 100, 106], ["carbon", "SIMPLE_CHEMICAL", 100, 106], ["the PHH hypothesis", "PROBLEM", 10, 28], ["a l P r e -p r o o f", "TREATMENT", 69, 89], ["carbon emissions", "TREATMENT", 100, 116], ["foreign direct investment", "TREATMENT", 129, 154], ["PHH", "OBSERVATION", 14, 17]]], ["For instance, Farhani and Ozturk investigated the drivers of total carbon emissions in Tunisia from 1971 to 2012.", [["carbon", "CHEMICAL", 67, 73], ["carbon", "CHEMICAL", 67, 73], ["carbon", "SIMPLE_CHEMICAL", 67, 73]]], ["The results were found to be against the PHH hypothesis, but the increase in trade openness would sacrifice environmental quality (Farhani and Ozturk, 2015) .", [["the PHH hypothesis", "PROBLEM", 37, 55], ["PHH", "OBSERVATION", 41, 44], ["increase", "OBSERVATION_MODIFIER", 65, 73], ["trade openness", "OBSERVATION", 77, 91]]], ["Shahzad et al.(Shahbaz et al., 2017) found that Pakistan's trade openness and financial development led to an increase in carbon emissions during the period 1971-2011, illustrating that trade liberalization adversely affected the environment.IntroductionFrom the perspective of multi-region, some important economic organizations and emerging economies have aroused the interest of scholars, such as OECD, South Africa, BRICS and so on due to the increasing impact of unilateral trade on the free trade system.", [["carbon", "CHEMICAL", 122, 128], ["carbon", "SIMPLE_CHEMICAL", 122, 128], ["an increase in carbon emissions", "PROBLEM", 107, 138], ["increase", "OBSERVATION_MODIFIER", 110, 118], ["carbon emissions", "OBSERVATION", 122, 138], ["unilateral trade", "OBSERVATION", 468, 484]]], ["Managi et al.(Managi et al., 2009 ) investigated the impact of trade openness on carbon emissions in OECD countries and non-OECD countries and concluded that trade benefited the environmental improvement of OECD countries but accelerated GHG emissions in non-OECD countries.", [["carbon", "CHEMICAL", 81, 87], ["carbon", "CHEMICAL", 81, 87], ["carbon", "SIMPLE_CHEMICAL", 81, 87], ["carbon emissions", "TREATMENT", 81, 97]]], ["In order to verify the existence of the PHH hypothesis, Kearsley and Riddel(Kearsley and Riddel, 2010) focused on the impact of international trade on seven common environmental pollutants in 27 OECD countries.", [["the PHH hypothesis", "PROBLEM", 36, 54], ["PHH", "OBSERVATION", 40, 43]]], ["They concluded that a higher degree of trade openness was good for improving the environment and boost economic prosperity.J o u r n a l P r e -p r o o fThis study has made contributions to the relevant research of carbon emission changes in major two aspects.", [["carbon", "CHEMICAL", 215, 221], ["a higher degree of trade openness", "PROBLEM", 20, 53], ["fThis study", "TEST", 152, 163], ["carbon emission changes", "PROBLEM", 215, 238], ["trade openness", "OBSERVATION", 39, 53], ["carbon emission", "OBSERVATION", 215, 230]]], ["Firstly, in short-term research, this paper took 2008 global financial crisis as a lesson, tried to figure out possible carbon emission changes after COVID-19.", [["carbon", "CHEMICAL", 120, 126], ["COVID-19", "CHEMICAL", 150, 158], ["carbon", "SIMPLE_CHEMICAL", 120, 126], ["carbon emission changes", "PROBLEM", 120, 143], ["COVID", "TEST", 150, 155]]], ["Then, learning from previous experience, this paper exerted efforts to investigate factors driving carbon emission by applying LMDI decomposition analysis.", [["carbon", "CHEMICAL", 99, 105], ["carbon", "SIMPLE_CHEMICAL", 99, 105], ["carbon emission", "TREATMENT", 99, 114], ["LMDI decomposition analysis", "TEST", 127, 154]]], ["Secondly, different from previous researches, this paper took trade into consideration and tried to uncover the impact of trade on carbon emission changes in a long-term research.", [["carbon", "CHEMICAL", 131, 137], ["carbon", "SIMPLE_CHEMICAL", 131, 137], ["carbon emission changes", "TREATMENT", 131, 154], ["a long-term research", "TREATMENT", 158, 178], ["different", "OBSERVATION_MODIFIER", 10, 19]]], ["On the whole, this paper examined carbon emission changes and influencing factors in both short-term and long-term, expecting to provide helpful references for carbon emission control after COVID-19.LMDI Decomposition modelAccording to Kaya identity, carbon emission (indicated by C) can be decomposed as follow: In accordance with LMDI decomposition model, the changes of carbon emission from base year to target year can be described as follows:LMDI Decomposition modelIn Eq.", [["carbon", "CHEMICAL", 160, 166], ["COVID-19.LMDI", "CHEMICAL", 190, 203], ["carbon", "CHEMICAL", 373, 379], ["carbon", "CHEMICAL", 34, 40], ["carbon", "CHEMICAL", 160, 166], ["carbon", "CHEMICAL", 251, 257], ["carbon", "CHEMICAL", 373, 379], ["carbon", "SIMPLE_CHEMICAL", 251, 257], ["carbon", "SIMPLE_CHEMICAL", 373, 379], ["carbon emission changes", "PROBLEM", 34, 57], ["carbon emission control", "TREATMENT", 160, 183], ["COVID", "TEST", 190, 195], ["carbon emission", "TEST", 251, 266], ["LMDI decomposition model", "TREATMENT", 332, 356], ["the changes of carbon emission", "PROBLEM", 358, 388], ["carbon emission", "OBSERVATION", 373, 388]]], ["(3), \u2206 , \u2206 , \u2206 , \u2206 demonstrate carbon intensity effect, energy intensity effect, affluence level effect and population scale effect.", [["carbon", "CHEMICAL", 31, 37], ["carbon", "CHEMICAL", 31, 37], ["carbon", "SIMPLE_CHEMICAL", 31, 37], ["\u2206", "TEST", 13, 14], ["carbon intensity effect", "PROBLEM", 31, 54], ["energy intensity effect", "PROBLEM", 56, 79], ["affluence level effect", "PROBLEM", 81, 103], ["population scale effect", "PROBLEM", 108, 131], ["carbon intensity", "OBSERVATION", 31, 47]]], ["(8).Estimating equationIn order to investigate the impact of trade activities on total carbon emissions and per capita carbon emissions, two indicators related to free trade: trade output and foreign direct investment are introduced.", [["carbon", "CHEMICAL", 87, 93], ["carbon", "CHEMICAL", 87, 93], ["carbon", "CHEMICAL", 119, 125], ["total carbon emissions", "TREATMENT", 81, 103], ["capita carbon emissions", "TREATMENT", 112, 135], ["trade output", "TREATMENT", 175, 187], ["foreign direct investment", "TREATMENT", 192, 217]]], ["Additionally, per capita energy consumption, energy intensity and energy structure 1 are considered.", [["energy intensity and energy structure 1", "PROBLEM", 45, 84]]], ["Consequently, On the basis of the specifications of Shahzad et al. (Shahzad et al., 2017) and Zoundi (Zoundi, 2017), the long-term estimation equations of this paper are as follows: ln = 1 + 2 + 3 + 4 + 5 + 1 (9) lnper = 1 + 2 + 3 + 4 + 5 + 2 (10)Estimating equationIn the above formula, = 1,2,3, \u22ef represents the time span; represents the natural logarithmic form of the variables. represents carbon emissions at time t;Estimating equationperC represents the per capita carbon emissions at time t; is the per capita energy consumption, is the energy structure, represented by the proportion of renewable energy in the primary energy consumption structure. denotes foreign direct investment, denotes trade output, calculated by the ratio of total import and export trade to GDP. is the long-time elastic coefficient between the influencing factors and the interpreted variable, and is the error term.Co-integration testing techniqueThe stability of time series is the basic condition for conducting time series related research, and it is also a necessary prerequisite for ensuring the validity and reliability of empirical results.", [["GDP", "CHEMICAL", 774, 777], ["carbon", "CHEMICAL", 394, 400], ["carbon", "CHEMICAL", 471, 477], ["GDP", "CHEMICAL", 774, 777], ["carbon", "SIMPLE_CHEMICAL", 394, 400], ["GDP", "SIMPLE_CHEMICAL", 774, 777], ["ln", "TEST", 182, 184], ["lnper", "TEST", 213, 218], ["Estimating equation", "TEST", 247, 266], ["trade output", "TEST", 700, 712], ["Co-integration testing technique", "TEST", 900, 932], ["natural logarithmic", "OBSERVATION", 340, 359], ["carbon emissions", "OBSERVATION", 394, 410], ["long-time elastic", "OBSERVATION_MODIFIER", 786, 803], ["stability", "OBSERVATION_MODIFIER", 936, 945]]], ["This paper uses the ADF unit root test method, which is widely used for examining the stability of raw time series, the regression model can be rearranged into the following formCo-integration testing techniquewhere = (\u2211 =1 ) \u2212 1\uff1b = \u2212 \u2211 = +1 \uff0c c is a constant term.", [["testing", "TEST", 193, 200], ["techniquewhere", "TEST", 201, 215], ["a constant term", "PROBLEM", 249, 264]]], ["The Null hypothesis of the ADF test is 0 : = 0; that is, the time series contains a unit root and is unstable; the alternative hypothesis is 0 : < 0, indicating that the original sequence is stationary.", [["root", "ANATOMY", 89, 93], ["ADF", "PROTEIN", 27, 30], ["the ADF test", "TEST", 23, 35], ["Null", "OBSERVATION", 4, 8], ["unstable", "OBSERVATION_MODIFIER", 101, 109]]], ["Only when the null hypothesis is rejected can the time series be proved to be stable and suitable for modeling.Co-integration testing techniqueJohansen co-integration procedure is applied to detect the existence of a long-term co-integration relationship between variables.", [["the null hypothesis", "PROBLEM", 10, 29], ["Co-integration testing technique", "TEST", 111, 143], ["Johansen co-integration procedure", "TREATMENT", 143, 176], ["rejected", "OBSERVATION", 33, 41], ["stable", "OBSERVATION_MODIFIER", 78, 84]]], ["Compared with the traditional E-G co-integration approach, the Johansen test method has better J o u r n a l P r e -p r o o f 13 adaptability and accuracy.", [["accuracy", "TEST", 146, 154]]], ["It can not only detect long-term relationships between multiple variables, but also obtain the number of co-integration relationships.", [["long-term relationships", "OBSERVATION_MODIFIER", 23, 46], ["multiple", "OBSERVATION_MODIFIER", 55, 63]]], ["The main principle of the Johansen test program is the loop test, which verifies whether the variables are integrated for a long time from the null hypothesis.", [["the loop test", "TEST", 51, 64], ["the null hypothesis", "PROBLEM", 139, 158], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["The principle of Johansen co-integration program can be expressed in the following form:Co-integration testing techniqueIn the above Eq.", [["Johansen co-integration program", "TREATMENT", 17, 48], ["Co-integration testing technique", "TEST", 88, 120]]], ["The null hypothesis of co-integration test ( 0 : 0 = 1 = 2 = 0 )Co-integration testing techniqueconsiders that there is no cointegration between study variables, and the alternative hypothesis ( 1 : 0 \u2260 1 \u2260 2 \u2260 0) indicates that the study variables are long-term integrated.", [["co-integration test", "TEST", 23, 42], ["Co-integration testing techniqueconsiders", "TEST", 64, 105], ["cointegration between study variables", "PROBLEM", 123, 160], ["the alternative hypothesis", "TEST", 166, 192], ["the study variables", "TEST", 229, 248], ["no", "UNCERTAINTY", 120, 122]]], ["It treats all variables as endogenous variables and overcomes the shortcomings of errors due to subjective settings in the simultaneous equation model (Cheng et al., 2019; Dolatabadi et al., 2018) .", [["endogenous variables", "PROBLEM", 27, 47]]], ["The general form of the VAR model can be expressed as follows:Model specificationWhere Y denotes an \u00d7 1 endogenous vector, A represents the corresponding J o u r n a l P r e -p r o o f 14 \u00d7 coefficient matrix. p is the number of lag periods of economic model, and is a random error term.Impulse response functionIR analysis is one of the most important analytical procedures in the VAR system.Impulse response functionIt can comprehensively capture the impact of the impact variable on the response variable during the study period, reflecting the complex dynamic relationship between variables.", [["Impulse response functionIR analysis", "TEST", 287, 323], ["the study", "TEST", 515, 524], ["economic model", "OBSERVATION_MODIFIER", 244, 258], ["response function", "OBSERVATION", 401, 418], ["complex", "OBSERVATION_MODIFIER", 548, 555], ["dynamic", "OBSERVATION", 556, 563]]], ["The model can be rearranged as follows to perform an impulse response analysis:Variance decompositionVD refers to decomposing the variance of an endogenous variable to other explanatory variables.", [["an impulse response analysis", "TEST", 50, 78], ["Variance decompositionVD", "PROBLEM", 79, 103]]], ["(16), each term represents the total effects of the j-th perturbation term on from the past to the present.", [["the j-th perturbation term", "TREATMENT", 48, 74]]], ["(16), this study J o u r n a l P r e -p r o o f assumes that does not have sequence correlation, then the variance of the variable can be expressed as:Variance decompositionAs shown in the Eq.", [["this study", "TEST", 6, 16], ["a l P r e -p r o o f assumes", "TEST", 27, 55], ["sequence correlation", "TEST", 75, 95]]], ["(17), this model uses the variance to estimate the total effects of the perturbation term j on the variable i from the past to the present.", [["the perturbation term j", "TREATMENT", 68, 91]]], ["In this case, the variance of the variable can be decomposed into K different and unrelated effects.Data sourceAs for short-term research, this study selects global economy and three income level groups (high-income, upper-middle income, lower-middle income) as objects to investigate the changes of carbon emission.", [["carbon", "CHEMICAL", 300, 306], ["carbon", "SIMPLE_CHEMICAL", 300, 306], ["short-term research", "PROBLEM", 118, 137], ["this study", "TEST", 139, 149], ["the changes of carbon emission", "PROBLEM", 285, 315], ["middle", "ANATOMY_MODIFIER", 223, 229], ["carbon emission", "OBSERVATION", 300, 315]]], ["The low-income countries are excluded because the energy consumption data is not available.", [["the energy consumption data", "TEST", 46, 73], ["low", "OBSERVATION_MODIFIER", 4, 7]]], ["Besides, data of carbon emission, energy consumption, GDP and population all come from the World Development Indicators released online by the World Bank(The World Bank, 2020).Data sourceIn order to eliminate the impact of inflation, the GDP is constant in 2010 US$.Data sourceAs for long-term research, this paper focuses on the multi-faceted effects of trade on carbon emissions.", [["GDP", "CHEMICAL", 238, 241], ["carbon", "CHEMICAL", 17, 23], ["GDP", "CHEMICAL", 238, 241], ["carbon", "CHEMICAL", 364, 370], ["carbon", "SIMPLE_CHEMICAL", 17, 23], ["GDP", "SIMPLE_CHEMICAL", 54, 57], ["GDP", "SIMPLE_CHEMICAL", 238, 241], ["carbon", "SIMPLE_CHEMICAL", 364, 370], ["carbon emission", "TEST", 17, 32], ["GDP", "PROBLEM", 54, 57], ["carbon emissions", "TREATMENT", 364, 380], ["inflation", "OBSERVATION", 223, 232], ["constant", "OBSERVATION_MODIFIER", 245, 253]]], ["Five economic variables are used to explore the long-term effects J o u r n a l P r e -p r o o f 16 to GDP.", [["GDP", "CHEMICAL", 103, 106], ["GDP", "SIMPLE_CHEMICAL", 103, 106], ["the long-term effects", "PROBLEM", 44, 65], ["a l P r e", "TREATMENT", 76, 85]]], ["All above data are collected from the World Bank(The World Bank, 2020).carbon emission decomposition analysis of world economyAs shown in Fig 1, Appliances to the Countryside\" program, which aimed to stimulate consumption by providing subsidy.", [["carbon", "CHEMICAL", 71, 77], ["carbon", "SIMPLE_CHEMICAL", 71, 77], ["All above data", "TEST", 0, 14], ["carbon emission decomposition analysis", "TEST", 71, 109]]], ["Hence, energy intensity reversely deteriorated and caused carbon emission increase when recovering economy.carbon emission decomposition analysis of world economyIn addition, in late 2008, oil price was decreasing due to the declining demand.carbon emission decomposition analysis of world economyAs the crisis deepening, the oil price continued to go down.", [["oil", "ANATOMY", 189, 192], ["oil", "ANATOMY", 326, 329], ["carbon", "CHEMICAL", 58, 64], ["carbon", "CHEMICAL", 107, 113], ["carbon", "CHEMICAL", 242, 248], ["carbon", "SIMPLE_CHEMICAL", 58, 64], ["carbon", "SIMPLE_CHEMICAL", 107, 113], ["oil", "ORGANISM_SUBSTANCE", 189, 192], ["carbon", "SIMPLE_CHEMICAL", 242, 248], ["oil", "ORGANISM_SUBSTANCE", 326, 329], ["carbon emission", "PROBLEM", 58, 73], ["carbon emission decomposition analysis", "TEST", 107, 145], ["oil price", "TREATMENT", 189, 198], ["the declining demand", "PROBLEM", 221, 241], ["carbon emission decomposition analysis", "TEST", 242, 280], ["the crisis deepening", "PROBLEM", 300, 320], ["the oil price", "TREATMENT", 322, 335], ["carbon emission", "OBSERVATION", 58, 73], ["crisis", "OBSERVATION_MODIFIER", 304, 310]]], ["Low price oil will be a better choice out of economic reason.", [["oil", "ORGANISM_SUBSTANCE", 10, 13], ["Low price oil", "TREATMENT", 0, 13]]], ["But as oil demand increase and economic recovery, oil price will also recover. in developing countries, using the labor and environmental resources of developing countries to produce, thus meeting the actual needs of the country .Long-term estimationIn this process, along with the transfer of funds, developed countries have transferred part of the environmental pressure to developing countries.", [["oil", "ANATOMY", 7, 10], ["oil", "ANATOMY", 50, 53], ["oil", "ORGANISM_SUBSTANCE", 7, 10], ["oil", "ORGANISM_SUBSTANCE", 50, 53], ["economic recovery", "TREATMENT", 31, 48], ["oil price", "TREATMENT", 50, 59], ["the labor", "PROBLEM", 110, 119], ["increase", "OBSERVATION_MODIFIER", 18, 26]]], ["FDI is not conducive to developing countries to implement carbon emission reduction measures.Long-term estimationTo sum up, EI has a positive impact on CE in MI group, while its impact in other two groups is negative.", [["MI", "DISEASE", 158, 160], ["carbon", "CHEMICAL", 58, 64], ["carbon", "SIMPLE_CHEMICAL", 58, 64], ["carbon emission reduction measures", "TREATMENT", 58, 92], ["not conducive", "UNCERTAINTY", 7, 20], ["positive", "OBSERVATION", 133, 141], ["negative", "OBSERVATION", 208, 216]]], ["This result shows that EI of developing countries is still at a higher level, which may hinder their carbon emissions reduction.", [["carbon", "CHEMICAL", 101, 107], ["carbon", "SIMPLE_CHEMICAL", 101, 107], ["their carbon emissions reduction", "TREATMENT", 95, 127], ["carbon emissions", "OBSERVATION", 101, 117]]], ["Compared with the other two groups, the countries in MI group should pay more attention to improving energy efficiency and accelerating the research and development and innovation of energy-saving technologies, thereby achieving the goal of reducing energy intensity.Long-term estimationES negatively affected CE in all three groups.", [["MI", "DISEASE", 53, 55], ["improving energy efficiency", "PROBLEM", 91, 118], ["saving technologies", "TREATMENT", 190, 209], ["reducing energy intensity", "PROBLEM", 241, 266], ["energy efficiency", "OBSERVATION", 101, 118]]], ["This indicates that the higher the proportion of renewable energy in the energy mix, the better the reduction of carbon emissions (Wang and Ye, 2017) .", [["carbon", "CHEMICAL", 113, 119], ["carbon", "SIMPLE_CHEMICAL", 113, 119], ["higher", "OBSERVATION_MODIFIER", 24, 30], ["renewable energy", "OBSERVATION", 49, 65], ["reduction", "OBSERVATION_MODIFIER", 100, 109], ["carbon emissions", "OBSERVATION", 113, 129]]], ["In view of this, strengthening the development and utilization of renewable energy, such as wind energy and solar energy, can accelerate the realization of carbon emission reduction targets.Long-term estimationJ o u r n a l P r e -p r o o f 31 According to long-term estimates, TRD accelerates carbon emissions growth.", [["TRD", "DISEASE", 278, 281], ["carbon", "CHEMICAL", 156, 162], ["carbon", "CHEMICAL", 294, 300], ["carbon", "SIMPLE_CHEMICAL", 156, 162], ["carbon", "SIMPLE_CHEMICAL", 294, 300], ["carbon emission reduction targets", "TREATMENT", 156, 189], ["TRD accelerates carbon emissions growth", "PROBLEM", 278, 317], ["carbon emission", "OBSERVATION", 156, 171], ["carbon emissions", "OBSERVATION", 294, 310]]], ["With the deepening of economic globalization, the international division of labor and the global production network become more complete, leading to closer trade links between countries.", [["economic globalization", "TREATMENT", 22, 44], ["labor", "PROBLEM", 76, 81], ["economic", "OBSERVATION_MODIFIER", 22, 30], ["globalization", "OBSERVATION_MODIFIER", 31, 44]]], ["In this system, countries share talents, technologies and knowledge, expand trade openness, thus greatly reducing production costs and further promoting international trade.", [["greatly reducing production costs", "PROBLEM", 97, 130]]], ["Under these circumstances, higher trade openness would promote carbon emissions rather than the reduction.Impulse response analysisThe model should be tested for stability before building, since the robustness of the model directly determines the accuracy and effectiveness of the experimental results.", [["carbon", "CHEMICAL", 63, 69], ["carbon", "SIMPLE_CHEMICAL", 63, 69], ["carbon emissions", "TREATMENT", 63, 79], ["the reduction", "TREATMENT", 92, 105], ["Impulse response analysis", "TEST", 106, 131], ["higher", "OBSERVATION_MODIFIER", 27, 33], ["trade openness", "OBSERVATION", 34, 48], ["carbon emissions", "OBSERVATION", 63, 79]]], ["This paper uses the AR eigenvalue to detect the robustness of the model.", [["the AR eigenvalue", "TEST", 16, 33]]], ["It is verified that the AR roots of the variables are all within the unit circle, as shown in Figure 7 , indicating that the six economic models established are stable. trend.", [["roots", "ANATOMY", 27, 32], ["AR", "GENE_OR_GENE_PRODUCT", 24, 26], ["AR", "PROTEIN", 24, 26], ["roots", "OBSERVATION_MODIFIER", 27, 32], ["stable", "OBSERVATION_MODIFIER", 161, 167]]], ["Finally, as the growth rate of EC slows down, its contribution to CE continues to decrease, and the image eventually stabilizes around zero (greater than zero).", [["EC", "ANATOMY", 31, 33], ["EC", "CELL", 31, 33], ["EC", "CELL_TYPE", 31, 33], ["the growth rate", "TEST", 12, 27], ["CE", "TEST", 66, 68], ["the image", "TEST", 96, 105]]], ["In a nutshell, EC is positively correlated with changes in CE because the release of GHG (Behera and Dash, 2017) .", [["EC", "ANATOMY", 15, 17], ["EC", "CELL", 15, 17], ["EC", "CELL_TYPE", 15, 17]]], ["Consequently, reducing EC levels is helpful in controlling carbon emissions.", [["EC", "ANATOMY", 23, 25], ["carbon", "CHEMICAL", 59, 65], ["EC", "CELL", 23, 25], ["carbon", "SIMPLE_CHEMICAL", 59, 65], ["EC", "CELL_TYPE", 23, 25], ["reducing EC levels", "TEST", 14, 32]]], ["From a long-term perspective, EI has a positive impact on CE, and this impact is more pronounced in the short term.", [["CE", "TEST", 58, 60], ["positive impact", "OBSERVATION_MODIFIER", 39, 54], ["more pronounced", "OBSERVATION_MODIFIER", 81, 96], ["short term", "OBSERVATION_MODIFIER", 104, 114]]], ["Improving energy efficiency is considered effective in reducing energy consumption.", [["Improving energy efficiency", "PROBLEM", 0, 27], ["energy efficiency", "OBSERVATION", 10, 27], ["effective", "OBSERVATION_MODIFIER", 42, 51], ["energy consumption", "OBSERVATION", 64, 82]]], ["It minimizes energy waste by improving and innovating energy technologies, thereby mitigating energy consumption in the production process.Impulse response analysisES negatively affected CE, indicating that the improvement in energy mix help cut down carbon emissions.", [["CE", "CHEMICAL", 187, 189], ["carbon", "CHEMICAL", 251, 257], ["carbon", "SIMPLE_CHEMICAL", 251, 257], ["affected CE", "PROBLEM", 178, 189], ["energy waste", "OBSERVATION", 13, 25]]], ["As a result, these measures brought about an increasing share of renewable energy in the energy mix and slowed the accumulation of CE.", [["CE", "CHEMICAL", 131, 133], ["renewable energy", "OBSERVATION", 65, 81], ["accumulation", "OBSERVATION_MODIFIER", 115, 127]]], ["FDI plays a negative role in promoting carbon emissions, although this hindrance is less significant.", [["carbon", "CHEMICAL", 39, 45], ["carbon", "SIMPLE_CHEMICAL", 39, 45], ["FDI", "PROTEIN", 0, 3], ["promoting carbon emissions", "PROBLEM", 29, 55], ["carbon emissions", "OBSERVATION", 39, 55], ["less", "OBSERVATION_MODIFIER", 84, 88], ["significant", "OBSERVATION_MODIFIER", 89, 100]]], ["Governments should encourage enterprises to introduce foreign capital and expand production scale, which can not only promote economic prosperity, but also prevent environmental degradation.", [["foreign capital", "TREATMENT", 54, 69], ["environmental degradation", "PROBLEM", 164, 189]]], ["TRD initially exerted a negative impact on CE, but since the third period, as trade share increased in GDP, it has a gradual weakening effect on CE.", [["TRD", "DISEASE", 0, 3], ["GDP", "CHEMICAL", 103, 106], ["CE", "CHEMICAL", 145, 147], ["GDP", "CHEMICAL", 103, 106], ["GDP", "SIMPLE_CHEMICAL", 103, 106], ["TRD", "PROBLEM", 0, 3], ["CE", "TEST", 43, 45], ["a gradual weakening effect on CE", "PROBLEM", 115, 147], ["negative", "OBSERVATION", 24, 32], ["impact", "OBSERVATION_MODIFIER", 33, 39], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["gradual", "OBSERVATION_MODIFIER", 117, 124], ["weakening", "OBSERVATION_MODIFIER", 125, 134], ["effect", "OBSERVATION_MODIFIER", 135, 141]]], ["Although TRD has a positive impact on CE, this promotion is minimal and does not cause a significant increase in CE.Impulse response analysisJ o u r n a l P r e -p r o o f 34 Figure 9 -a.", [["TRD", "DISEASE", 9, 12], ["TRD", "PROBLEM", 9, 12], ["CE", "TEST", 38, 40], ["a significant increase in CE", "PROBLEM", 87, 115], ["Figure", "TEST", 175, 181], ["positive", "OBSERVATION_MODIFIER", 19, 27], ["impact", "OBSERVATION_MODIFIER", 28, 34], ["minimal", "OBSERVATION_MODIFIER", 60, 67], ["significant", "OBSERVATION_MODIFIER", 89, 100], ["increase", "OBSERVATION_MODIFIER", 101, 109]]], ["Impulse-response functions of perCE to variables in HI Figure 9 illustrates the IR images of HI.", [["HI", "DISEASE", 93, 95], ["perCE", "PROTEIN", 30, 35], ["the IR images", "TEST", 76, 89], ["HI", "PROBLEM", 93, 95]]], ["EC has a positive influence on CE throughout the study interval.", [["EC", "ANATOMY", 0, 2], ["EC", "CELL", 0, 2], ["EC", "CELL_TYPE", 0, 2], ["a positive influence", "PROBLEM", 7, 27], ["positive", "OBSERVATION", 9, 17]]], ["It can be inferred that the EI of HI countries will cause carbon emissions growth in the future.", [["carbon", "CHEMICAL", 58, 64], ["carbon", "SIMPLE_CHEMICAL", 58, 64], ["carbon emissions growth", "PROBLEM", 58, 81], ["carbon emissions", "OBSERVATION", 58, 74]]], ["Therefore, it is necessary for developed countries to take measures to showed an upward trend implying that EC will promote CE in MI countries in the future.Impulse response analysisSimilarly, the impact of EI on CE also shows obvious phase characteristics, with positive and negative effects alternating.", [["EC", "ANATOMY", 108, 110], ["CE", "CHEMICAL", 124, 126], ["MI", "DISEASE", 130, 132], ["EC", "CELL", 108, 110], ["EC", "CELL_TYPE", 108, 110], ["an upward trend", "PROBLEM", 78, 93], ["Impulse response analysisSimilarly", "PROBLEM", 157, 191], ["EI on CE", "TEST", 207, 215], ["obvious phase characteristics", "PROBLEM", 227, 256]]], ["These results indicate that EI in developing countries is still at a high level, which is a barrier to carbon reduction.Impulse response analysisJ o u r n a l P r e -p r o o f 36 The difference is that FDI can reduce carbon emissions in a short period of time, while TRD may promote CE in the short run.", [["TRD", "DISEASE", 267, 270], ["CE", "CHEMICAL", 283, 285], ["carbon", "CHEMICAL", 103, 109], ["carbon", "CHEMICAL", 217, 223], ["carbon", "SIMPLE_CHEMICAL", 103, 109], ["carbon", "SIMPLE_CHEMICAL", 217, 223], ["P", "DNA", 159, 160], ["a barrier to carbon reduction", "TREATMENT", 90, 119], ["carbon emissions", "TREATMENT", 217, 233], ["carbon emissions", "OBSERVATION", 217, 233]]], ["Therefore, although free trade is beneficial for developing countries to achieve CE reduction targets in the long run, and it causes rapid accumulation of CE in a short time.", [["CE", "CHEMICAL", 155, 157], ["CE reduction targets", "TREATMENT", 81, 101], ["rapid accumulation of CE", "PROBLEM", 133, 157], ["rapid", "OBSERVATION_MODIFIER", 133, 138], ["accumulation", "OBSERVATION_MODIFIER", 139, 151]]], ["This finding supports trade liberalization.Impulse response analysisIn summary, in three groups, EC is positively correlated with CE.", [["EC", "ANATOMY", 97, 99], ["EC", "CELL", 97, 99], ["EC", "CELL_TYPE", 97, 99], ["CE", "TEST", 130, 132], ["trade liberalization", "OBSERVATION", 22, 42]]], ["The impact of EI on CE varies among three groups.", [["EI on CE varies", "TREATMENT", 14, 29]]], ["This mainly because HI countries have advanced energy technologies, which can ensure that the energy intensity is basically stable at a relatively low level and will not promote excessive growth of carbon emissions.", [["carbon", "CHEMICAL", 198, 204], ["carbon", "SIMPLE_CHEMICAL", 198, 204], ["advanced energy technologies", "TREATMENT", 38, 66], ["the energy intensity", "PROBLEM", 90, 110], ["excessive growth of carbon emissions", "PROBLEM", 178, 214], ["stable", "OBSERVATION_MODIFIER", 124, 130], ["carbon emissions", "OBSERVATION", 198, 214]]], ["But for MI economies, there is still much room for energy intensity reduction, so the promotion of carbon emissions is relatively significant.", [["MI", "DISEASE", 8, 10], ["carbon", "CHEMICAL", 99, 105], ["carbon", "SIMPLE_CHEMICAL", 99, 105], ["MI economies", "PROBLEM", 8, 20], ["energy intensity reduction", "TREATMENT", 51, 77], ["carbon emissions", "TEST", 99, 115], ["carbon emissions", "OBSERVATION", 99, 115], ["significant", "OBSERVATION_MODIFIER", 130, 141]]], ["ES negatively affects CE, as renewable energy plays an increasingly important role in the energy mix.", [["CE", "CHEMICAL", 22, 24]]], ["FDI has a negative impact on CE in the long run, although it causes CE to increase in the short term.", [["CE", "TEST", 29, 31], ["CE", "PROBLEM", 68, 70], ["negative", "OBSERVATION", 10, 18], ["impact", "OBSERVATION_MODIFIER", 19, 25], ["CE", "OBSERVATION", 68, 70], ["increase", "OBSERVATION_MODIFIER", 74, 82], ["short term", "OBSERVATION_MODIFIER", 90, 100]]], ["This finding suggests that the establishment of the PHH hypothesis is conditional, that is, the large inflow of foreign investment in a short period will indeed damage the country's environment and bring about an increase in pollutant emissions; but in the long run, FDI will not lead to a sharp increase on CE.Impulse response analysisThe impact of TRD on CE is uncertain and depends on the country's income level.", [["TRD", "DISEASE", 350, 353], ["the PHH hypothesis", "PROBLEM", 48, 66], ["a sharp increase on CE", "PROBLEM", 288, 310], ["Impulse response analysis", "TEST", 311, 336], ["TRD", "PROBLEM", 350, 353], ["PHH", "OBSERVATION", 52, 55], ["large", "OBSERVATION_MODIFIER", 96, 101], ["inflow", "OBSERVATION_MODIFIER", 102, 108], ["foreign investment", "OBSERVATION", 112, 130], ["pollutant emissions", "OBSERVATION", 225, 244], ["sharp", "OBSERVATION_MODIFIER", 290, 295], ["increase", "OBSERVATION_MODIFIER", 296, 304]]], ["For developed countries, trade is conducive to carbon emission reduction, while for MI countries, trade negatively affects CE in the long run, but may accelerate it in the short term.", [["MI", "DISEASE", 84, 86], ["CE", "CHEMICAL", 123, 125], ["carbon", "CHEMICAL", 47, 53], ["carbon", "SIMPLE_CHEMICAL", 47, 53], ["carbon emission reduction", "TREATMENT", 47, 72]]], ["There is not sufficient evidence in this paper that free trade is conducive to global carbon reduction.Conclusions and policy implicationsThis paper aims to explore carbon emission changes and factors influencing this change after this COVID-19 pandemic from both short-term research and long-term research.", [["carbon", "CHEMICAL", 86, 92], ["carbon", "CHEMICAL", 165, 171], ["global carbon reduction", "TREATMENT", 79, 102], ["carbon emission changes", "PROBLEM", 165, 188], ["this COVID", "TEST", 231, 241], ["pandemic", "PROBLEM", 245, 253], ["long-term research", "TREATMENT", 288, 306], ["not sufficient evidence", "UNCERTAINTY", 9, 32], ["carbon reduction", "OBSERVATION", 86, 102]]], ["We have come to the following conclusions and proposed scientific and practical policy implications:Conclusions and policy implicationsFor short-term research, high-income level group initially achieved carbon reduction.", [["carbon", "CHEMICAL", 203, 209], ["carbon", "SIMPLE_CHEMICAL", 203, 209], ["short-term research", "PROBLEM", 139, 158], ["carbon reduction", "TREATMENT", 203, 219], ["carbon reduction", "OBSERVATION", 203, 219]]], ["As for middle-income level group, which significantly increased carbon emission, upper-middle income level group was deemed as the largest contributor.Conclusions and policy implicationsMoreover, from the perspective of specific countries, it may come to a conclusion that developed countries were likely to curb carbon increase, while developing countries may still struggle with carbon emission control.", [["carbon", "CHEMICAL", 64, 70], ["carbon", "CHEMICAL", 64, 70], ["carbon", "CHEMICAL", 313, 319], ["carbon", "CHEMICAL", 381, 387], ["carbon", "SIMPLE_CHEMICAL", 64, 70], ["carbon", "SIMPLE_CHEMICAL", 381, 387], ["significantly increased carbon emission", "PROBLEM", 40, 79], ["carbon emission control", "TREATMENT", 381, 404], ["increased", "OBSERVATION_MODIFIER", 54, 63], ["carbon emission", "OBSERVATION", 64, 79], ["upper", "ANATOMY_MODIFIER", 81, 86], ["middle", "ANATOMY_MODIFIER", 87, 93]]], ["In addition, since the impact of global economic crisis, most countries tended to slower or even reduce carbon emission in 2008-2009 and present a retaliatory rebound of carbon emission in 2009-2010, which may teach a lesson for carbon emission changes after COVID-19 pandemic.Conclusions and policy implicationsAffluence level effect was prominent inhibitor to carbon reduction in all studies objects, particularly the upper-middle income level group and lower-middle income level group, which almost located in the process of rising economy.", [["carbon", "CHEMICAL", 104, 110], ["carbon", "CHEMICAL", 170, 176], ["carbon", "CHEMICAL", 229, 235], ["carbon", "CHEMICAL", 362, 368], ["carbon", "CHEMICAL", 104, 110], ["carbon", "CHEMICAL", 170, 176], ["carbon", "CHEMICAL", 229, 235], ["carbon", "CHEMICAL", 362, 368], ["carbon", "SIMPLE_CHEMICAL", 362, 368], ["global economic crisis", "PROBLEM", 33, 55], ["carbon emission", "TEST", 104, 119], ["carbon emission changes", "PROBLEM", 229, 252], ["COVID", "TEST", 259, 264], ["pandemic", "PROBLEM", 268, 276], ["Affluence level effect", "PROBLEM", 312, 334], ["carbon reduction", "TREATMENT", 362, 378], ["all studies objects", "TEST", 382, 401], ["global", "OBSERVATION_MODIFIER", 33, 39], ["economic crisis", "OBSERVATION", 40, 55], ["lower", "ANATOMY_MODIFIER", 456, 461], ["middle", "ANATOMY_MODIFIER", 462, 468], ["rising", "OBSERVATION_MODIFIER", 528, 534], ["economy", "OBSERVATION", 535, 542]]], ["Energy intensity effect prominently drove carbon reduction, especially in high-income level group and G7 group.", [["carbon", "CHEMICAL", 42, 48], ["carbon", "SIMPLE_CHEMICAL", 42, 48], ["G7 group", "CELL_LINE", 102, 110], ["Energy intensity effect", "PROBLEM", 0, 23], ["carbon reduction", "TREATMENT", 42, 58], ["carbon reduction", "OBSERVATION", 42, 58]]], ["In these countries, the positive impact of energy intensity was stronger than passive impact of affluence level on carbon reduction.", [["carbon", "CHEMICAL", 115, 121], ["carbon", "CHEMICAL", 115, 121], ["carbon", "SIMPLE_CHEMICAL", 115, 121], ["energy intensity", "PROBLEM", 43, 59], ["carbon reduction", "TREATMENT", 115, 131], ["positive", "OBSERVATION_MODIFIER", 24, 32], ["carbon reduction", "OBSERVATION", 115, 131]]], ["Consequently, improving energy intensity may also help to reduce carbon emission after COVID-19 pandemic.Conclusions and policy implicationsMore investment shall be put to promote energy-saving technologies and strengthen research and development in related technologies; more clean and renewable energy shall be used in present energy system; encourage more monetary and fiscal polies implicated to improve energy intensity.Conclusions and policy implicationsimpact on CE in middle-income level group, while negative impact on the other groups.", [["CE", "CHEMICAL", 470, 472], ["carbon", "CHEMICAL", 65, 71], ["carbon", "SIMPLE_CHEMICAL", 65, 71], ["carbon emission", "TEST", 65, 80], ["COVID", "TEST", 87, 92], ["pandemic", "PROBLEM", 96, 104], ["saving technologies", "TREATMENT", 187, 206], ["strengthen research", "TREATMENT", 211, 230], ["fiscal polies", "TREATMENT", 372, 385], ["Conclusions", "TEST", 425, 436], ["policy implicationsimpact", "TEST", 441, 466], ["CE", "TEST", 470, 472]]], ["It is essential to strengthen the research and development (R&D) and innovation of energy technology to reduce the energy intensity.", [["energy technology", "TREATMENT", 83, 100], ["the energy intensity", "PROBLEM", 111, 131]]], ["Trade is shown to accelerate carbon emissions, but this promotion effect is minimal in the long-run.", [["carbon", "CHEMICAL", 29, 35], ["carbon", "SIMPLE_CHEMICAL", 29, 35], ["carbon emissions", "TREATMENT", 29, 45], ["carbon emissions", "OBSERVATION", 29, 45], ["minimal", "OBSERVATION_MODIFIER", 76, 83]]], ["In comparison, international trade is more likely to contribute to the carbon emissions of middle-income countries.Conclusions and policy implicationsAccording to the results of IR analysis, ES has a negative impact on CE, as renewable energy plays an increasingly important role in the energy mix, inhibiting the accelerated growth of CE.", [["CE", "CHEMICAL", 219, 221], ["CE", "CHEMICAL", 336, 338], ["carbon", "CHEMICAL", 71, 77], ["IR analysis", "TEST", 178, 189], ["the accelerated growth of CE", "PROBLEM", 310, 338], ["growth", "OBSERVATION_MODIFIER", 326, 332]]], ["In all income groups, FDI is negatively correlated with CE in the long run but cause an increase in CE in the short term.", [["CE", "CHEMICAL", 56, 58], ["an increase in CE", "PROBLEM", 85, 102], ["increase", "OBSERVATION_MODIFIER", 88, 96]]], ["This finding supports the PHH hypothesis under certain conditions.", [["the PHH hypothesis", "PROBLEM", 22, 40], ["PHH", "OBSERVATION", 26, 29]]], ["For developed countries, TRD is conducive to carbon emission reduction; for middle-income countries, TRD exerts a negative impact on CE in the long term but accelerates CE growth in the short term.Conclusions and policy implicationsConsequently, government shall de devoted themselves to promote trade openness in long-term, since adhering to free trade is good for achieving global emissions reduction targets.", [["TRD", "DISEASE", 25, 28], ["TRD", "DISEASE", 101, 104], ["carbon", "CHEMICAL", 45, 51], ["carbon emission reduction", "TREATMENT", 45, 70], ["TRD", "PROBLEM", 101, 104], ["accelerates CE growth", "PROBLEM", 157, 178], ["global emissions reduction targets", "TREATMENT", 376, 410], ["long term", "OBSERVATION_MODIFIER", 143, 152], ["long-term", "OBSERVATION_MODIFIER", 314, 323]]]], "PMC7453862": [["An event is serious (based on the ICH definition) when the patient outcome is:", [["ICH", "DISEASE", 34, 37], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["the ICH definition", "TEST", 30, 48], ["serious", "OBSERVATION_MODIFIER", 12, 19]]]], "345522eebf3ee6310095f992fd83104503362e2a": [["I. INTRODUCTIONThe novel and respiratory infectious coronavirus disease (COVID-19) has proliferated and spread exponentially across the globe in recent days.", [["respiratory infectious coronavirus disease", "DISEASE", 29, 71], ["COVID-19", "CHEMICAL", 73, 81], ["respiratory infectious coronavirus", "ORGANISM", 29, 63], ["respiratory infectious coronavirus disease (COVID-19", "SPECIES", 29, 81], ["The novel and respiratory infectious coronavirus disease", "PROBLEM", 15, 71], ["COVID", "TEST", 73, 78], ["respiratory", "OBSERVATION_MODIFIER", 29, 40], ["infectious", "OBSERVATION_MODIFIER", 41, 51], ["coronavirus disease", "OBSERVATION", 52, 71], ["proliferated", "OBSERVATION_MODIFIER", 87, 99], ["spread", "OBSERVATION_MODIFIER", 104, 110], ["exponentially", "OBSERVATION_MODIFIER", 111, 124], ["globe", "ANATOMY", 136, 141]]], ["1 A few possible fluid mechanical routes of disease transmission happen via human respiratory activities such as breathing, talking loudly, coughing, and sneezing.", [["fluid", "ANATOMY", 17, 22], ["respiratory", "ANATOMY", 82, 93], ["coughing", "DISEASE", 140, 148], ["sneezing", "DISEASE", 154, 162], ["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["fluid mechanical routes", "TREATMENT", 17, 40], ["disease transmission", "PROBLEM", 44, 64], ["human respiratory activities", "PROBLEM", 76, 104], ["coughing", "PROBLEM", 140, 148], ["sneezing", "PROBLEM", 154, 162], ["few", "OBSERVATION_MODIFIER", 4, 7], ["possible", "UNCERTAINTY", 8, 16], ["fluid mechanical", "OBSERVATION", 17, 33], ["disease", "OBSERVATION", 44, 51], ["sneezing", "OBSERVATION", 154, 162]]], ["2, 3 In particular, coughing and sneezing are spasmodic events and multiphase dynamical phenomena.", [["coughing", "DISEASE", 20, 28], ["sneezing", "DISEASE", 33, 41], ["spasmodic", "DISEASE", 46, 55], ["coughing", "PROBLEM", 20, 28], ["sneezing", "PROBLEM", 33, 41], ["spasmodic events", "PROBLEM", 46, 62], ["multiphase dynamical phenomena", "PROBLEM", 67, 97], ["coughing", "OBSERVATION", 20, 28], ["dynamical phenomena", "OBSERVATION", 78, 97]]], ["4 While expelling the respiratory liquid, the bulk fluid is converted into several polydisperse droplets 5 via multiple intermediate processes.", [["the respiratory liquid", "PROBLEM", 18, 40], ["the bulk fluid", "TEST", 42, 56], ["several polydisperse droplets", "TREATMENT", 75, 104], ["respiratory liquid", "OBSERVATION", 22, 40], ["polydisperse droplets", "OBSERVATION", 83, 104], ["intermediate processes", "OBSERVATION", 120, 142]]], ["The occurrence of these events is analogous to that of liquid atomization processes.", [["these events", "PROBLEM", 18, 30], ["liquid atomization processes", "TREATMENT", 55, 83]]], ["6 Talking loudly, 7 coughing, and sneezing, 8 cause a significant increase in pressure in the nasal cavity that tends to expel a cloud of respiratory liquid to the ambient air from the mouth within a microsecond.", [["nasal cavity", "ANATOMY", 94, 106], ["mouth", "ANATOMY", 185, 190], ["coughing", "DISEASE", 20, 28], ["sneezing", "DISEASE", 34, 42], ["nasal cavity", "ORGANISM_SUBDIVISION", 94, 106], ["mouth", "ORGANISM_SUBDIVISION", 185, 190], ["coughing", "PROBLEM", 20, 28], ["sneezing", "PROBLEM", 34, 42], ["a significant increase in pressure in the nasal cavity", "PROBLEM", 52, 106], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["pressure", "OBSERVATION_MODIFIER", 78, 86], ["nasal cavity", "ANATOMY", 94, 106], ["respiratory liquid", "OBSERVATION", 138, 156], ["mouth", "ANATOMY", 185, 190]]], ["This dynamic event is accompanied by the combined occurrence of Kelvin-Helmholtz (K-H) and Rayleigh-Taylor (R-T) instabilities due to the generation of axial relative velocity and an acceleration field, respectively.", [["K", "CHEMICAL", 82, 83], ["Kelvin", "TEST", 64, 70], ["Rayleigh", "TEST", 91, 99], ["instabilities", "PROBLEM", 113, 126], ["the generation of axial relative velocity", "PROBLEM", 134, 175], ["velocity", "OBSERVATION_MODIFIER", 167, 175], ["acceleration", "OBSERVATION_MODIFIER", 183, 195], ["field", "OBSERVATION_MODIFIER", 196, 201]]], ["Thus, the expelled respiratory liquid, in particular, coughing and sneezing, is a case where both the instabilities could occur.", [["coughing", "DISEASE", 54, 62], ["sneezing", "DISEASE", 67, 75], ["the expelled respiratory liquid", "PROBLEM", 6, 37], ["coughing", "PROBLEM", 54, 62], ["sneezing", "PROBLEM", 67, 75], ["respiratory liquid", "OBSERVATION", 19, 37]]], ["Therefore, it presents itself as a prominent example of the classical primary liquid atomization problem.", [["the classical primary liquid atomization problem", "PROBLEM", 56, 104], ["primary", "OBSERVATION_MODIFIER", 70, 77], ["liquid atomization", "OBSERVATION", 78, 96]]], ["9 The expelled respiratory liquid cloud is further ruptured into ligamentsARTICLEscitation.org/journal/phf and drops, signifying the secondary atomization.", [["ligaments", "ANATOMY", 65, 74], ["ligaments", "TISSUE", 65, 74], ["The expelled respiratory liquid cloud", "PROBLEM", 2, 39], ["further ruptured into ligamentsARTICLEscitation", "PROBLEM", 43, 90], ["phf", "PROBLEM", 103, 106], ["drops", "TREATMENT", 111, 116], ["the secondary atomization", "PROBLEM", 129, 154], ["expelled", "OBSERVATION_MODIFIER", 6, 14], ["respiratory", "OBSERVATION", 15, 26], ["liquid cloud", "OBSERVATION", 27, 39], ["ruptured", "OBSERVATION", 51, 59], ["ligamentsARTICLEscitation", "OBSERVATION", 65, 90], ["secondary atomization", "OBSERVATION", 133, 154]]], ["The droplets generated out of the expelled respiratory liquid process are polydisperse in nature.", [["The droplets", "TREATMENT", 0, 12], ["the expelled respiratory liquid process", "TREATMENT", 30, 69], ["expelled", "OBSERVATION_MODIFIER", 34, 42], ["respiratory", "OBSERVATION", 43, 54], ["liquid process", "OBSERVATION", 55, 69], ["polydisperse", "OBSERVATION_MODIFIER", 74, 86]]], ["10 These droplet ranges from sub-micron to hundreds of micrometers are the primary factor in airborne disease transmission.", [["These droplet ranges", "TEST", 3, 23], ["airborne disease transmission", "PROBLEM", 93, 122], ["airborne disease", "OBSERVATION", 93, 109]]], ["These respiratory droplets can act as a carrier of pathogens and allow them to transport in the air medium.", [["respiratory droplets", "ANATOMY", 6, 26], ["These respiratory droplets", "PROBLEM", 0, 26], ["pathogens", "PROBLEM", 51, 60], ["respiratory droplets", "OBSERVATION", 6, 26]]], ["The pathogens can stay alive inside the droplets, suspend in the ambient air for a long time, and spread the infections via this route.ARTICLEDespite several studies that have attempted to uncover the dynamics involved in creating expelled respiratory droplets, little attention has been devoted to understanding the instabilities associated with these events, which are multiphysics in nature.", [["respiratory droplets", "ANATOMY", 240, 260], ["infections", "DISEASE", 109, 119], ["the infections", "PROBLEM", 105, 119], ["several studies", "TEST", 150, 165], ["expelled respiratory droplets", "PROBLEM", 231, 260], ["the instabilities", "PROBLEM", 313, 330], ["infections", "OBSERVATION", 109, 119], ["respiratory droplets", "OBSERVATION", 240, 260]]], ["Recent effort includes a realistic modeling of the characteristics of droplets originated from a human sneeze 11 and their control strategies, 12, 13 survival of pathogens in the droplets deposited on surfaces, 14 dispersion mechanism, 15 and the effect of the respiratory droplets under different ambient conditions.", [["respiratory droplets", "ANATOMY", 261, 281], ["human", "ORGANISM", 97, 102], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["droplets", "PROBLEM", 70, 78], ["a human sneeze", "TREATMENT", 95, 109], ["pathogens", "PROBLEM", 162, 171], ["the respiratory droplets", "TREATMENT", 257, 281], ["different ambient conditions", "TREATMENT", 288, 316], ["respiratory droplets", "OBSERVATION", 261, 281]]], ["16 However, the mechanism by which the droplets are formed close to the mouth has not been studied.", [["droplets", "ANATOMY", 39, 47], ["mouth", "ANATOMY", 72, 77], ["mouth", "ORGAN", 72, 77]]], ["Hence, there is a rising concern among researchers to unravel the entire dynamics with the aid of fluid mechanics tools, especially high-speed imaging.", [["fluid", "ANATOMY", 98, 103], ["fluid mechanics tools", "TEST", 98, 119], ["high-speed imaging", "TEST", 132, 150], ["fluid", "OBSERVATION", 98, 103]]], ["17, 18 Lately, high-speed imaging has contributed to extending the knowledge on many scientific questions by revealing the intermediate events that happen during such spasmodic events.", [["spasmodic", "DISEASE", 167, 176], ["high-speed imaging", "TEST", 15, 33], ["the intermediate events", "PROBLEM", 119, 142], ["such spasmodic events", "PROBLEM", 162, 183]]], ["Therefore, the present work proposes an experiment with a soap film and air to visualize the dynamics of the expelled respiratory liquid sputum from a human and the associated mechanisms that govern the breakup process.", [["human", "ORGANISM", 151, 156], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 151, 156], ["a soap film", "TEST", 56, 67], ["the expelled respiratory liquid sputum", "PROBLEM", 105, 143], ["the breakup process", "PROBLEM", 199, 218], ["respiratory", "ANATOMY", 118, 129], ["liquid sputum", "OBSERVATION", 130, 143]]], ["From this standpoint, the breakup instability in the soap film serves as the simplified model of the respiratory liquid sheet to understand its dynamics.", [["the breakup instability", "PROBLEM", 22, 45], ["the soap film", "TEST", 49, 62], ["the respiratory liquid sheet", "TREATMENT", 97, 125]]], ["A simple and controlled experiment with the soap solution and air, although it is not performed on the exact geometry, captures the intermediate physical events that would occur during the destabilization of the respiratory liquid.", [["the soap solution", "TREATMENT", 40, 57], ["the respiratory liquid", "PROBLEM", 208, 230], ["simple", "OBSERVATION_MODIFIER", 2, 8], ["air", "OBSERVATION", 62, 65], ["respiratory liquid", "OBSERVATION", 212, 230]]], ["This understanding is essential to elucidate the salient features of the respiratory expelled liquid and impervious airborne disease transmission.ARTICLEDuring the process of expelling a respiratory liquid, a thin liquid jet or sheet of sputum is ejected out from the mouth to the ambient air resulting in ligaments.", [["sputum", "ANATOMY", 237, 243], ["mouth", "ANATOMY", 268, 273], ["ligaments", "ANATOMY", 306, 315], ["mouth", "ORGANISM_SUBDIVISION", 268, 273], ["ligaments", "TISSUE", 306, 315], ["the respiratory expelled liquid", "PROBLEM", 69, 100], ["impervious airborne disease transmission", "PROBLEM", 105, 145], ["a respiratory liquid", "PROBLEM", 185, 205], ["a thin liquid jet", "TREATMENT", 207, 224], ["sputum", "PROBLEM", 237, 243], ["respiratory", "ANATOMY", 73, 84], ["airborne disease", "OBSERVATION", 116, 132], ["respiratory liquid", "OBSERVATION", 187, 205], ["sputum", "OBSERVATION", 237, 243], ["mouth", "ANATOMY", 268, 273], ["ambient air", "OBSERVATION", 281, 292], ["ligaments", "ANATOMY", 306, 315]]], ["The ligaments will undergo a \"film burst\" process leading to the formation of a multitude of smaller fragments of varying sizes.", [["ligaments", "ANATOMY", 4, 13], ["fragments", "ANATOMY", 101, 110], ["ligaments", "TISSUE", 4, 13], ["a \"film burst\" process", "PROBLEM", 27, 49], ["smaller fragments of varying sizes", "PROBLEM", 93, 127], ["ligaments", "ANATOMY", 4, 13], ["multitude", "OBSERVATION_MODIFIER", 80, 89], ["smaller", "OBSERVATION_MODIFIER", 93, 100], ["fragments", "OBSERVATION", 101, 110], ["varying", "OBSERVATION_MODIFIER", 114, 121], ["sizes", "OBSERVATION_MODIFIER", 122, 127]]], ["The above process is very similar to the destabilization of the flapping liquid sheet, as illustrated in Fig. 1 .", [["the flapping liquid sheet", "TREATMENT", 60, 85]]], ["The dynamics of a flapping sheet and its downstream processes have been extensively documented for the application of gas turbine atomizers.", [["a flapping sheet", "TREATMENT", 16, 32], ["gas turbine atomizers", "TREATMENT", 118, 139], ["gas turbine", "OBSERVATION", 118, 129]]], ["[19] [20] [21] It should be mentioned that the breakup of thin liquid sheets 22 is analogous to bursting the soap film.", [["[19] [20] [21", "SIMPLE_CHEMICAL", 0, 13], ["the soap film", "TEST", 105, 118]]], ["23, 24 The expelled respiratory liquid as a ligament in the air stream will eventually burst 25 or break up 26 into smaller fragments.", [["ligament", "ANATOMY", 44, 52], ["fragments", "ANATOMY", 124, 133], ["ligament", "TISSUE", 44, 52], ["The expelled respiratory liquid", "PROBLEM", 7, 38], ["a ligament in the air stream", "PROBLEM", 42, 70], ["expelled", "OBSERVATION_MODIFIER", 11, 19], ["respiratory liquid", "OBSERVATION", 20, 38], ["ligament", "ANATOMY", 44, 52], ["air", "ANATOMY", 60, 63], ["smaller", "OBSERVATION_MODIFIER", 116, 123], ["fragments", "OBSERVATION", 124, 133]]], ["In particular, the intermediate processes that occur between the formation of a thin liquid sheet and the bubbles fragmenting into smaller drops are of current interest.ARTICLEThe events mentioned above, in general, occur either independently or sequentially in different systems.", [["a thin liquid sheet", "TREATMENT", 78, 97], ["the bubbles fragmenting", "PROBLEM", 102, 125], ["ARTICLEThe events", "PROBLEM", 169, 186], ["intermediate processes", "OBSERVATION", 19, 41], ["bubbles", "OBSERVATION_MODIFIER", 106, 113], ["fragmenting", "OBSERVATION_MODIFIER", 114, 125], ["smaller", "OBSERVATION_MODIFIER", 131, 138], ["drops", "OBSERVATION_MODIFIER", 139, 144]]], ["The one striking feature from the present study is to show all these existing events during the process of expelling a respiratory liquid with a model system and characterize them for limited flow conditions.ARTICLEWe propose a simplified experimental model to investigate the intermediate physical events associated with expelling the respiratory liquid via flapping liquid sheets-these events resulting in numerous smaller fragments.", [["fragments", "ANATOMY", 425, 434], ["the present study", "TEST", 30, 47], ["a respiratory liquid", "TREATMENT", 117, 137], ["limited flow conditions", "PROBLEM", 184, 207], ["the respiratory liquid via flapping liquid sheets", "PROBLEM", 332, 381], ["these events", "PROBLEM", 382, 394], ["numerous smaller fragments", "PROBLEM", 408, 434], ["respiratory", "ANATOMY", 336, 347], ["numerous", "OBSERVATION_MODIFIER", 408, 416], ["smaller", "OBSERVATION_MODIFIER", 417, 424], ["fragments", "OBSERVATION", 425, 434]]], ["We study the underlying dynamics using a model of the soap film while the air impinges on it.", [["the soap film", "TEST", 50, 63], ["the air impinges", "PROBLEM", 70, 86], ["air impinges", "OBSERVATION", 74, 86]]], ["The velocity gradients between the air and the soap film initiate the K-H instability and make the sheet flap.", [["The velocity gradients", "TEST", 0, 22], ["the soap film", "TEST", 43, 56], ["the K-H instability", "PROBLEM", 66, 85], ["the sheet flap", "TREATMENT", 95, 109], ["velocity", "OBSERVATION_MODIFIER", 4, 12], ["gradients", "OBSERVATION_MODIFIER", 13, 22], ["air", "OBSERVATION_MODIFIER", 35, 38], ["instability", "OBSERVATION", 74, 85], ["flap", "OBSERVATION", 105, 109]]], ["Eventually, flapping induces the R-T instability that initiates the breakup.", [["R-T", "GENE_OR_GENE_PRODUCT", 33, 36], ["the R-T instability", "PROBLEM", 29, 48], ["the breakup", "PROBLEM", 64, 75], ["instability", "OBSERVATION", 37, 48]]], ["We hope that this study helps understand the ubiquitous phenomenon in a better way.", [["this study", "TEST", 13, 23], ["the ubiquitous phenomenon", "PROBLEM", 41, 66]]], ["This paper reports high-speed imaging in a simple laboratory experimental setup aimed at delineating the different mechanisms and quantifying their effects.ARTICLEThis paper is streamlined as follows: In Sec.", [["speed imaging", "TEST", 24, 37]]], ["II, the experimental setup used for this study is presented.", [["the experimental setup", "TEST", 4, 26], ["this study", "TEST", 36, 46], ["experimental setup", "OBSERVATION", 8, 26]]], ["The behavior of the flow system and scaling are presented in Secs.", [["Secs", "PROTEIN", 61, 65], ["flow system", "OBSERVATION", 20, 31], ["scaling", "OBSERVATION_MODIFIER", 36, 43]]], ["V and summarized in Sec.", [["V", "GENE_OR_GENE_PRODUCT", 0, 1]]], ["VI.II. EXPERIMENTAL SETUP-CONCEPT AND DETAILSA test rig capable of generating a cylindrical column of the bubble was designed and assembled.", [["II", "CHEMICAL", 3, 5], ["VI", "GENE_OR_GENE_PRODUCT", 0, 2], ["DETAILSA test rig", "TEST", 38, 55], ["bubble", "OBSERVATION", 106, 112]]], ["The rig consists of a circular frame and an air supply unit.", [["a circular frame", "TREATMENT", 20, 36], ["an air supply unit", "TREATMENT", 41, 59], ["circular frame", "OBSERVATION", 22, 36], ["air supply", "OBSERVATION", 44, 54]]], ["A schematic of the experimental setup, along with a high-speed imaging setup, is shown in Fig. 2 .", [["the experimental setup", "TREATMENT", 15, 37], ["a high-speed imaging setup", "TREATMENT", 50, 76]]], ["The soap solution was prepared using 5% of liquid (Ivory) washing solution and 95% of distilled water by volume.", [["The soap solution", "TREATMENT", 0, 17], ["liquid (Ivory) washing solution", "TREATMENT", 43, 74]]], ["The solution was well maintained below the critical micellar concentration.", [["The solution", "TREATMENT", 0, 12], ["the critical micellar concentration", "TREATMENT", 39, 74], ["micellar concentration", "OBSERVATION", 52, 74]]], ["The same solution concentration was used for all the experiments.", [["The same solution concentration", "TREATMENT", 0, 31]]], ["The surface tension of the solution was measured using the pendant drop method and a tensiometer test.", [["surface", "ANATOMY", 4, 11], ["The surface tension of the solution", "TREATMENT", 0, 35], ["the pendant drop method", "TREATMENT", 55, 78], ["a tensiometer test", "TEST", 83, 101], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["tension", "OBSERVATION_MODIFIER", 12, 19]]], ["The surface tension of the solution is \u22480.025 N/m.", [["surface", "ANATOMY", 4, 11], ["The surface tension of the solution", "TREATMENT", 0, 35], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["tension", "OBSERVATION_MODIFIER", 12, 19]]], ["The other properties of the solution, such as density and kinematic viscosity, are assumed to be 1.23 kg/m 3 and 10 \u22126 m 2 /s, respectively.", [["the solution", "TREATMENT", 24, 36], ["density", "OBSERVATION", 46, 53], ["kinematic viscosity", "OBSERVATION", 58, 77]]], ["A circular frame with a diameter of 200 mm was used to hold a soap solution as a thin film.", [["a soap solution", "TREATMENT", 60, 75], ["a thin film", "TEST", 79, 90], ["circular", "OBSERVATION_MODIFIER", 2, 10], ["diameter", "OBSERVATION_MODIFIER", 24, 32], ["200 mm", "OBSERVATION_MODIFIER", 36, 42]]], ["The thin soap film was generated by immersing the circular frame into the soap solution and pulled out gently.", [["The thin soap film", "TEST", 0, 18], ["the soap solution", "TREATMENT", 70, 87]]], ["The generated soap film was placed horizontally in the gravity field.", [["The generated soap film", "TREATMENT", 0, 23]]], ["We ensured that the soap film was stable, and there were no gradients in the radial direction.", [["radial", "ANATOMY", 77, 83], ["the soap film", "TEST", 16, 29], ["gradients in the radial direction", "PROBLEM", 60, 93], ["stable", "OBSERVATION_MODIFIER", 34, 40], ["no", "UNCERTAINTY", 57, 59], ["gradients", "OBSERVATION_MODIFIER", 60, 69], ["radial", "ANATOMY_MODIFIER", 77, 83]]], ["The entire experiments were conducted in the vapor saturated environment to avoid liquid evaporation.Physics of FluidsA plane orifice nozzle with an exit diameter of 8 mm was used to create a high-velocity air jet.", [["the vapor saturated environment", "TREATMENT", 41, 72], ["liquid evaporation", "TREATMENT", 82, 100], ["FluidsA plane orifice nozzle", "TREATMENT", 112, 140], ["a high-velocity air jet", "PROBLEM", 190, 213], ["Fluids", "OBSERVATION", 112, 118], ["diameter", "OBSERVATION_MODIFIER", 154, 162], ["8 mm", "OBSERVATION_MODIFIER", 166, 170], ["high", "OBSERVATION_MODIFIER", 192, 196], ["velocity", "OBSERVATION_MODIFIER", 197, 205], ["air jet", "OBSERVATION", 206, 213]]], ["The nozzle was located 10 mm below the circular frame.", [["circular frame", "DNA", 39, 53], ["The nozzle", "TREATMENT", 0, 10], ["nozzle", "OBSERVATION_MODIFIER", 4, 10], ["10 mm", "OBSERVATION_MODIFIER", 23, 28], ["circular frame", "OBSERVATION", 39, 53]]], ["The high-pressure air cylinder was used to supply the air to the nozzle.", [["The high-pressure air cylinder", "TREATMENT", 0, 30], ["high", "OBSERVATION_MODIFIER", 4, 8], ["pressure", "OBSERVATION_MODIFIER", 9, 17], ["air cylinder", "OBSERVATION", 18, 30], ["air", "ANATOMY", 54, 57]]], ["A high precision pressure regulator controls the airflow, and the flow rate was maintained.", [["A high precision pressure regulator", "TREATMENT", 0, 35], ["the flow rate", "TEST", 62, 75], ["airflow", "OBSERVATION_MODIFIER", 49, 56], ["flow rate", "OBSERVATION", 66, 75]]], ["The jet velocity was measured using a pitot tube with an estimated accuracy of 2%.", [["pitot tube", "TISSUE", 38, 48], ["The jet velocity", "TEST", 0, 16], ["a pitot tube", "TREATMENT", 36, 48], ["an estimated accuracy", "TEST", 54, 75], ["jet", "OBSERVATION_MODIFIER", 4, 7], ["velocity", "OBSERVATION_MODIFIER", 8, 16], ["pitot tube", "OBSERVATION", 38, 48]]], ["A steady flow of the air jet is placed below the circular frame to impinge high-velocity air perpendicular to the center of the thin film in the upward direction against gravity to produce a cylindrical column of the bubble.Physics of FluidsTo study the breakup behavior of the bubble column, a highspeed shadowgraphy technique was used.", [["the air jet", "TREATMENT", 17, 28], ["the thin film", "TEST", 124, 137], ["a highspeed shadowgraphy technique", "TREATMENT", 293, 327], ["steady", "OBSERVATION_MODIFIER", 2, 8], ["flow", "OBSERVATION", 9, 13], ["air jet", "OBSERVATION", 21, 28], ["circular", "OBSERVATION_MODIFIER", 49, 57], ["high", "OBSERVATION_MODIFIER", 75, 79], ["velocity", "OBSERVATION_MODIFIER", 80, 88], ["air perpendicular", "OBSERVATION", 89, 106], ["thin", "OBSERVATION_MODIFIER", 128, 132], ["film", "OBSERVATION_MODIFIER", 133, 137], ["upward", "OBSERVATION_MODIFIER", 145, 151], ["gravity", "OBSERVATION", 170, 177], ["cylindrical", "OBSERVATION_MODIFIER", 191, 202], ["column", "OBSERVATION_MODIFIER", 203, 209], ["bubble", "OBSERVATION_MODIFIER", 217, 223], ["Fluids", "OBSERVATION_MODIFIER", 235, 241], ["bubble column", "OBSERVATION", 278, 291]]], ["A bright field was created by illuminating the background with a high power LED light source.", [["bright", "OBSERVATION_MODIFIER", 2, 8]]], ["The diffuser sheet placed between the light source and the object helps produce the uniform light distribution.", [["The diffuser sheet", "TREATMENT", 0, 18], ["diffuser", "OBSERVATION_MODIFIER", 4, 12], ["uniform", "OBSERVATION_MODIFIER", 84, 91], ["light distribution", "OBSERVATION", 92, 110]]], ["A Photron FastCam TM high-speed imaging camera was used to capture the instantaneous images in shadowgraphy mode.", [["A Photron FastCam TM", "TREATMENT", 0, 20], ["the instantaneous images", "TEST", 67, 91]]], ["To avoid streaks in the images, the light source was synchronized with the high-speed camera.", [["streaks in the images", "PROBLEM", 9, 30], ["the high-speed camera", "TREATMENT", 71, 92], ["streaks", "OBSERVATION", 9, 16]]], ["The entire breakup events of the bubble column were captured at 10 000 f.p.s with an exposure time of 1/20 000 s, and its image resolution is 512 \u00d7 768 pixels.", [["the bubble column", "PROBLEM", 29, 46], ["entire", "OBSERVATION_MODIFIER", 4, 10], ["breakup", "OBSERVATION_MODIFIER", 11, 18], ["bubble column", "OBSERVATION", 33, 46]]], ["To capture the number of ligaments generated from the bubble burst, we captured the magnified events at 3600 f.p.s with an exposure time of 1/50 000 s, and its image resolution is 1024 \u00d7 1024 pixels.", [["ligaments", "ANATOMY", 25, 34], ["ligaments", "TISSUE", 25, 34], ["ligaments", "ANATOMY", 25, 34], ["bubble burst", "OBSERVATION", 54, 66]]], ["Special care was taken to enhance the reproducibility and quality of the experiments.", [["Special care", "TREATMENT", 0, 12]]], ["Throughout the experiments, it was made sure that the soap film was steady and had a constant thickness initially.III. OBSERVATIONS-CHRONOLOGY OF THE FLOW SYSTEMWe performed the experiments with the setup discussed in Sec.", [["the soap film", "TEST", 50, 63], ["the setup", "TREATMENT", 195, 204]]], ["II, and the chronology of the expelling respiratory liquid is described here.", [["II", "CHEMICAL", 0, 2], ["respiratory liquid", "OBSERVATION", 40, 58]]], ["The sequential behavior can be seen from Fig. 3 and is as follows: (a) flapping liquid sheet, (b) continuous formation of bubbles, (c) hole formation at a point, (d) rupture of the liquid sheet, (e) multiple bursts, and (f) the formation of ligaments.", [["ligaments", "ANATOMY", 241, 250], ["ligaments", "TISSUE", 241, 250], ["a) flapping liquid sheet", "TREATMENT", 68, 92], ["bubbles, (c) hole formation", "PROBLEM", 122, 149], ["rupture of the liquid sheet", "PROBLEM", 166, 193], ["multiple bursts, and (f) the formation of ligaments", "PROBLEM", 199, 250], ["bubbles", "OBSERVATION", 122, 129], ["rupture", "OBSERVATION", 166, 173], ["ligaments", "ANATOMY", 241, 250]]], ["The bubbles pinch off from the flapping sheet by their own weight, as shown in Fig. 3(b) .", [["The bubbles pinch", "TREATMENT", 0, 17], ["the flapping sheet", "TREATMENT", 27, 45], ["bubbles", "OBSERVATION_MODIFIER", 4, 11], ["pinch", "OBSERVATION_MODIFIER", 12, 17]]], ["The rupturing and bursting process can be noted from Figs.", [["The rupturing and bursting process", "PROBLEM", 0, 34], ["rupturing", "OBSERVATION", 4, 13], ["bursting process", "OBSERVATION", 18, 34]]], ["The ligament formation is shown in Fig. 3 (f).", [["ligament", "ANATOMY", 4, 12], ["ligament", "TISSUE", 4, 12], ["ligament", "ANATOMY", 4, 12]]], ["Note that, in this sequence shown in Fig. 3 , the time interval between two consecutive frames is not equal.", [["not", "UNCERTAINTY", 98, 101], ["equal", "OBSERVATION_MODIFIER", 102, 107]]], ["The present study is an attempt to characterize each event in detail.III. OBSERVATIONS-CHRONOLOGY OF THE FLOW SYSTEMWe will classify the behavior of the flow system into four major events, as observed in the destabilization process of the cylindrical liquid sheet.", [["The present study", "TEST", 0, 17], ["THE FLOW SYSTEMWe", "TEST", 101, 118], ["the cylindrical liquid sheet", "TREATMENT", 235, 263]]], ["The liquid sheet undergoes different stages such as (A) flapping, (B) rupture, (C) ligament, and (D) droplet formation before it forms as a stable droplet.", [["rupture", "DISEASE", 70, 77], ["The liquid sheet", "TREATMENT", 0, 16], ["A) flapping, (B) rupture, (C) ligament, and (D) droplet formation", "PROBLEM", 53, 118], ["different stages", "OBSERVATION_MODIFIER", 27, 43], ["rupture", "OBSERVATION", 70, 77], ["ligament", "ANATOMY", 83, 91], ["stable", "OBSERVATION_MODIFIER", 140, 146]]], ["The processes that lead to the sequential events will be discussed here with a few physical arguments.III. OBSERVATIONS-CHRONOLOGY OF THE FLOW SYSTEMIn order to create a gas centered co-annular (cylindrical) liquid sheet, the air jet is allowed to impinge on the soap film.", [["the sequential events", "PROBLEM", 27, 48], ["a gas centered co-annular (cylindrical) liquid sheet", "TREATMENT", 168, 220], ["the air jet", "TREATMENT", 222, 233], ["the soap film", "TEST", 259, 272], ["air jet", "OBSERVATION", 226, 233]]], ["On a continuous supply of the air at the bottom surface of the soap film, the soap film expands both in axial and radial directions.", [["the soap film", "TEST", 59, 72], ["the soap film", "TEST", 74, 87], ["air", "OBSERVATION", 30, 33], ["axial", "ANATOMY_MODIFIER", 104, 109], ["radial", "ANATOMY_MODIFIER", 114, 120]]], ["Due to the airflow, the bubble expands in the axial direction.", [["the airflow", "PROBLEM", 7, 18], ["airflow", "OBSERVATION", 11, 18], ["bubble", "OBSERVATION_MODIFIER", 24, 30], ["axial", "ANATOMY_MODIFIER", 46, 51]]], ["The interfacial area of the soap film increases, and the expansion is opposed by the surface tension force acting on the interface.", [["surface", "ANATOMY", 85, 92], ["the soap film", "TEST", 24, 37], ["interfacial", "OBSERVATION_MODIFIER", 4, 15], ["area", "OBSERVATION_MODIFIER", 16, 20], ["soap", "OBSERVATION_MODIFIER", 28, 32], ["film", "OBSERVATION_MODIFIER", 33, 37], ["increases", "OBSERVATION_MODIFIER", 38, 47], ["expansion", "OBSERVATION_MODIFIER", 57, 66], ["surface", "OBSERVATION_MODIFIER", 85, 92], ["tension", "OBSERVATION_MODIFIER", 93, 100], ["force", "OBSERVATION_MODIFIER", 101, 106]]], ["In contrast, the expansion in the radial direction is limited by the frame edge.", [["expansion", "OBSERVATION_MODIFIER", 17, 26], ["radial", "ANATOMY_MODIFIER", 34, 40], ["frame edge", "OBSERVATION", 69, 79]]], ["Note that the diameter of the bubble column is controlled by the diameter of the gas (air) jet.III. OBSERVATIONS-CHRONOLOGY OF THE FLOW SYSTEMThe continuous domination of the airflow assists the cylindrical liquid (bubble) column to grow in the axial direction, as shown in Fig. 3(a) .", [["the cylindrical liquid (bubble) column", "TREATMENT", 191, 229], ["diameter", "OBSERVATION_MODIFIER", 14, 22], ["bubble", "OBSERVATION_MODIFIER", 30, 36], ["column", "OBSERVATION_MODIFIER", 37, 43], ["diameter", "OBSERVATION_MODIFIER", 65, 73], ["gas", "OBSERVATION", 81, 84], ["jet", "OBSERVATION_MODIFIER", 91, 94], ["airflow", "ANATOMY", 175, 182]]], ["Due to the continuous co-flowing air stream, the stable bubble column will tend to destabilize by generating waves on its surface.", [["surface", "ANATOMY", 122, 129], ["surface", "CELLULAR_COMPONENT", 122, 129], ["the continuous co-flowing air stream", "PROBLEM", 7, 43], ["the stable bubble column", "PROBLEM", 45, 69], ["air stream", "OBSERVATION", 33, 43], ["stable", "OBSERVATION_MODIFIER", 49, 55], ["bubble column", "OBSERVATION", 56, 69], ["waves", "OBSERVATION_MODIFIER", 109, 114], ["surface", "OBSERVATION_MODIFIER", 122, 129]]], ["The waves move toward the direction of the airflow, thus resulting in flapping.", [["airflow", "OBSERVATION", 43, 50], ["flapping", "OBSERVATION_MODIFIER", 70, 78]]], ["The flapping is due to the velocity difference between the interfaces.III. OBSERVATIONS-CHRONOLOGY OF THE FLOW SYSTEMThe next event is addressed as rupturing the soap film, and it can be summarized as follows: Due to gravity or capillary suction, the liquid flows down in the bubble cap, leading to a thinner film.", [["capillary", "ANATOMY", 228, 237], ["capillary", "TISSUE", 228, 237], ["the velocity difference between the interfaces", "PROBLEM", 23, 69], ["the soap film", "TEST", 158, 171], ["gravity or capillary suction", "TREATMENT", 217, 245], ["the liquid flows", "TREATMENT", 247, 263], ["the bubble cap", "TREATMENT", 272, 286], ["a thinner film", "TEST", 299, 313], ["flapping", "OBSERVATION_MODIFIER", 4, 12], ["velocity", "OBSERVATION_MODIFIER", 27, 35], ["difference", "OBSERVATION", 36, 46], ["gravity", "OBSERVATION", 217, 224], ["capillary suction", "OBSERVATION", 228, 245], ["liquid flows", "OBSERVATION", 251, 263], ["bubble cap", "OBSERVATION", 276, 286]]], ["A hole eventually nucleates at any point in the film, and the hole expands.", [["A hole", "TREATMENT", 0, 6], ["the film", "TEST", 44, 52], ["hole", "OBSERVATION_MODIFIER", 2, 6], ["hole", "OBSERVATION", 62, 66]]], ["However, the point where the rupture happens is beyond the scope of the present study.III. OBSERVATIONS-CHRONOLOGY OF THE FLOW SYSTEMThe corresponding event is bursting.", [["rupture", "DISEASE", 29, 36], ["the rupture", "PROBLEM", 25, 36], ["the present study", "TEST", 68, 85], ["rupture", "OBSERVATION", 29, 36], ["FLOW SYSTEMThe", "OBSERVATION", 122, 136]]], ["This bursting is observed in two cases: (i) the bubble which is pinched off from the liquid sheet ruptures and tends to burst and (ii) the continuous sheet attached with the circular frame bursts continuously until all the mass of the soap film ruptures.", [["the liquid sheet ruptures", "TREATMENT", 81, 106], ["the continuous sheet", "TREATMENT", 135, 155], ["the circular frame bursts", "TREATMENT", 170, 195], ["the soap film ruptures", "PROBLEM", 231, 253], ["bubble", "OBSERVATION", 48, 54], ["pinched", "OBSERVATION_MODIFIER", 64, 71], ["liquid sheet", "OBSERVATION", 85, 97], ["ruptures", "OBSERVATION", 98, 106], ["mass", "OBSERVATION", 223, 227], ["ruptures", "OBSERVATION", 245, 253]]], ["The former is similar to the drop breakup when it is suddenly exposed to the high stream of air, and the latter is analogous to the flapping liquid sheet resulting in the formation of ligaments that eventually break up into smaller droplets.", [["ligaments", "ANATOMY", 184, 193], ["ligaments", "TISSUE", 184, 193], ["the flapping liquid sheet", "TREATMENT", 128, 153], ["the formation of ligaments", "PROBLEM", 167, 193], ["high", "OBSERVATION_MODIFIER", 77, 81], ["stream", "OBSERVATION_MODIFIER", 82, 88], ["air", "OBSERVATION", 92, 95], ["ligaments", "ANATOMY", 184, 193], ["smaller", "OBSERVATION_MODIFIER", 224, 231], ["droplets", "OBSERVATION_MODIFIER", 232, 240]]], ["The last event is the origination of tiny drops from the ligaments.", [["ligaments", "ANATOMY", 57, 66], ["ligaments", "TISSUE", 57, 66], ["tiny", "OBSERVATION_MODIFIER", 37, 41], ["drops", "OBSERVATION", 42, 47], ["ligaments", "ANATOMY", 57, 66]]], ["IV, the above-discussed events will be presented in detail.A. Flapping and breakup lengthIn this section, we will discuss the flapping motion of the cylindrical liquid sheet, and it is shown in Fig. 3(a) .", [["IV", "TREATMENT", 0, 2], ["the cylindrical liquid sheet", "TREATMENT", 145, 173], ["Flapping", "OBSERVATION_MODIFIER", 62, 70], ["breakup", "OBSERVATION_MODIFIER", 75, 82], ["length", "OBSERVATION_MODIFIER", 83, 89]]], ["The liquid sheet flapping is associated with a velocity difference across the thin sheet, and it is the manifestation of the K-H instability.", [["The liquid sheet flapping", "TREATMENT", 0, 25], ["a velocity difference across the thin sheet", "PROBLEM", 45, 88], ["the K-H instability", "PROBLEM", 121, 140], ["liquid sheet flapping", "OBSERVATION", 4, 25], ["velocity", "OBSERVATION_MODIFIER", 47, 55], ["difference", "OBSERVATION", 56, 66], ["instability", "OBSERVATION", 129, 140]]], ["27 A liquid sheet on the still surrounding air is balanced by surface tension and modulated by the Bernoulli effect.A. Flapping and breakup lengthFlapping motion causes the annular liquid sheet to expand and contract in symmetric mode.", [["surface", "ANATOMY", 62, 69], ["A liquid sheet", "TREATMENT", 3, 17], ["breakup lengthFlapping motion", "PROBLEM", 132, 161], ["the annular liquid sheet", "TREATMENT", 169, 193], ["liquid sheet", "OBSERVATION", 5, 17], ["air", "OBSERVATION", 43, 46], ["surface tension", "OBSERVATION", 62, 77], ["Bernoulli effect", "OBSERVATION", 99, 115], ["Flapping", "OBSERVATION_MODIFIER", 119, 127], ["annular", "OBSERVATION_MODIFIER", 173, 180], ["liquid sheet", "OBSERVATION", 181, 193]]], ["As the surface wave propagates, the amplitude of oscillation increases and results in liquid sheet necking.", [["surface", "ANATOMY", 7, 14], ["surface", "CELLULAR_COMPONENT", 7, 14], ["liquid sheet necking", "TREATMENT", 86, 106], ["surface", "OBSERVATION_MODIFIER", 7, 14], ["amplitude", "OBSERVATION_MODIFIER", 36, 45], ["oscillation", "OBSERVATION_MODIFIER", 49, 60], ["increases", "OBSERVATION_MODIFIER", 61, 70]]], ["Air at low impact velocity on a soap film causes the spherical bubbles to pinch off from the annular liquid sheet continuously.", [["Air at low impact velocity", "PROBLEM", 0, 26], ["a soap film", "TREATMENT", 30, 41], ["the spherical bubbles", "PROBLEM", 49, 70], ["the annular liquid sheet", "TREATMENT", 89, 113], ["low impact", "OBSERVATION_MODIFIER", 7, 17], ["velocity", "OBSERVATION_MODIFIER", 18, 26], ["spherical bubbles", "OBSERVATION", 53, 70], ["pinch", "OBSERVATION_MODIFIER", 74, 79], ["annular", "ANATOMY_MODIFIER", 93, 100]]], ["Figures 3(b) -3(e) depict the various time instants at which bubbles pinch off from the liquid sheet.", [["Figures", "TEST", 0, 7]]], ["One of the most striking features visible from these images is the breakup length.", [["these images", "TEST", 47, 59], ["most striking", "OBSERVATION_MODIFIER", 11, 24], ["breakup", "OBSERVATION_MODIFIER", 67, 74], ["length", "OBSERVATION_MODIFIER", 75, 81]]], ["Here, the breakup length is defined as the length of the intact liquid sheet.", [["the intact liquid sheet", "TREATMENT", 53, 76], ["breakup", "OBSERVATION_MODIFIER", 10, 17], ["length", "OBSERVATION_MODIFIER", 18, 24], ["intact", "OBSERVATION", 57, 63]]], ["Similar to Fig. 3 , the breakup length was observed for other flow conditions as well, and it is shown in Fig. 4 .", [["the breakup length", "TEST", 20, 38], ["other flow conditions", "PROBLEM", 56, 77], ["Fig", "OBSERVATION_MODIFIER", 11, 14], ["breakup", "OBSERVATION_MODIFIER", 24, 31], ["length", "OBSERVATION_MODIFIER", 32, 38], ["flow conditions", "OBSERVATION", 62, 77]]], ["Here, the images are presented for four different operating conditions.", [["the images", "TEST", 6, 16]]], ["As can be noted, the breakup length decreases as the Weber number (velocity of the gas jet) increases.", [["the breakup length", "PROBLEM", 17, 35], ["the gas jet", "TEST", 79, 90], ["breakup", "OBSERVATION_MODIFIER", 21, 28], ["length", "OBSERVATION_MODIFIER", 29, 35], ["gas jet", "OBSERVATION", 83, 90]]], ["It can be observed that the diameter of the cylindrical sheet is approximately the same for all the conditions.", [["diameter", "OBSERVATION_MODIFIER", 28, 36], ["cylindrical", "OBSERVATION_MODIFIER", 44, 55], ["approximately", "OBSERVATION_MODIFIER", 65, 78]]], ["This implies that the diameter of the cylindrical sheet depends only on the diameter of the air nozzle exit orifice.A. Flapping and breakup lengthThe other factor is that the number of bubbles pinching off from the liquid sheet decreases as velocity increases.", [["diameter", "OBSERVATION_MODIFIER", 22, 30], ["cylindrical", "OBSERVATION_MODIFIER", 38, 49], ["sheet", "OBSERVATION_MODIFIER", 50, 55], ["diameter", "OBSERVATION_MODIFIER", 76, 84], ["air nozzle", "OBSERVATION", 92, 102], ["orifice", "OBSERVATION_MODIFIER", 108, 115], ["Flapping", "OBSERVATION_MODIFIER", 119, 127], ["breakup", "OBSERVATION_MODIFIER", 132, 139], ["length", "OBSERVATION_MODIFIER", 140, 146], ["bubbles", "OBSERVATION_MODIFIER", 185, 192], ["pinching", "OBSERVATION_MODIFIER", 193, 201], ["velocity", "OBSERVATION_MODIFIER", 241, 249], ["increases", "OBSERVATION_MODIFIER", 250, 259]]], ["However, the numbers are not consistent, and it cannot be quantified.", [["not consistent", "UNCERTAINTY", 25, 39]]], ["In other words, it can be observed while performing experiments that for the case of low Weber numbers, the number of bubbles pinching off is more, whereas for the high velocity, the number of bubbles pinching off is less or sometimes, the air jet ruptures even before the formation of bubbles.", [["the high velocity", "PROBLEM", 160, 177], ["the air jet ruptures", "PROBLEM", 236, 256], ["bubbles", "OBSERVATION", 118, 125], ["high velocity", "OBSERVATION_MODIFIER", 164, 177], ["bubbles", "OBSERVATION_MODIFIER", 193, 200], ["pinching", "OBSERVATION_MODIFIER", 201, 209], ["air jet", "OBSERVATION", 240, 247], ["ruptures", "OBSERVATION", 248, 256], ["bubbles", "OBSERVATION", 286, 293]]], ["As can be noted from Fig. 3 , the average number of bubbles formed are 4, 3, 2, and 1 for We = 79, We = 177, We = 315, and We = 492, respectively.", [["average", "OBSERVATION_MODIFIER", 34, 41], ["number", "OBSERVATION_MODIFIER", 42, 48], ["bubbles", "OBSERVATION_MODIFIER", 52, 59]]], ["In this study, the Weber number is defined by, We =Physics of Fluidswhere \u03c1g and Vg denote the density and velocity of the gas (air) jet, R denotes the radius of the gas jet, and \u03c3 denotes the surface tension.", [["surface", "ANATOMY", 193, 200], ["surface", "CELLULAR_COMPONENT", 193, 200], ["Vg", "PROTEIN", 81, 83], ["\u03c3", "PROTEIN", 179, 180], ["this study", "TEST", 3, 13], ["the gas (air) jet", "TEST", 119, 136], ["the surface tension", "PROBLEM", 189, 208], ["density", "OBSERVATION", 95, 102], ["velocity", "OBSERVATION_MODIFIER", 107, 115], ["gas", "OBSERVATION_MODIFIER", 123, 126], ["radius", "ANATOMY_MODIFIER", 152, 158], ["gas jet", "OBSERVATION", 166, 173], ["surface", "OBSERVATION_MODIFIER", 193, 200], ["tension", "OBSERVATION_MODIFIER", 201, 208]]], ["Here, l b is defined by the dimensional breakup length (l \u2032 b ) normalized by the radius of the gas jet (R), indi-Physics of FluidsR .", [["FluidsR", "PROTEIN", 125, 132], ["the dimensional breakup length", "TEST", 24, 54], ["length", "OBSERVATION_MODIFIER", 48, 54], ["radius", "ANATOMY_MODIFIER", 82, 88], ["gas jet", "OBSERVATION", 96, 103]]], ["The plot also shows that l b decreases with an increase in We.", [["The plot", "TEST", 0, 8], ["l b decreases", "PROBLEM", 25, 38], ["l b", "OBSERVATION_MODIFIER", 25, 28], ["decreases", "OBSERVATION_MODIFIER", 29, 38], ["increase", "OBSERVATION_MODIFIER", 47, 55]]], ["It is due to the fact that inertial forces dominating the surface tension forces result in a decrease in l b while increasing We.", [["surface", "ANATOMY", 58, 65], ["inertial forces", "PROBLEM", 27, 42], ["the surface tension forces", "TREATMENT", 54, 80], ["a decrease in l b", "PROBLEM", 91, 108], ["inertial forces", "OBSERVATION", 27, 42], ["surface", "OBSERVATION_MODIFIER", 58, 65], ["tension forces", "OBSERVATION", 66, 80], ["decrease", "OBSERVATION_MODIFIER", 93, 101], ["l", "ANATOMY_MODIFIER", 105, 106]]], ["The mean wavelength of the oscillations is observed to be the same for a range of We, henceforth, resulting in bubble formation of similar sizes.", [["mean", "OBSERVATION_MODIFIER", 4, 8], ["wavelength", "OBSERVATION_MODIFIER", 9, 19], ["oscillations", "OBSERVATION", 27, 39], ["bubble formation", "OBSERVATION", 111, 127], ["similar", "OBSERVATION_MODIFIER", 131, 138], ["sizes", "OBSERVATION_MODIFIER", 139, 144]]], ["The size of the bubble is found to be around 20 mm from the images.", [["the images", "TEST", 56, 66], ["size", "OBSERVATION_MODIFIER", 4, 8], ["bubble", "OBSERVATION_MODIFIER", 16, 22], ["20 mm", "OBSERVATION_MODIFIER", 45, 50]]], ["It indicates that the increase in We (velocity of the gas jet) influences l b , and the pinched-off bubble size remains the same.", [["l b", "GENE_OR_GENE_PRODUCT", 74, 77], ["the gas jet", "TEST", 50, 61], ["increase", "OBSERVATION_MODIFIER", 22, 30], ["gas jet", "OBSERVATION", 54, 61], ["pinched", "OBSERVATION_MODIFIER", 88, 95], ["off bubble", "OBSERVATION", 96, 106], ["size", "OBSERVATION_MODIFIER", 107, 111]]], ["28B.", [["28B", "GENE_OR_GENE_PRODUCT", 0, 3], ["28B", "PROTEIN", 0, 3]]], ["RuptureThe complete sequential behavior of rupture on a cylindrical liquid sheet is shown in Fig. 6 .", [["Rupture", "DISEASE", 0, 7], ["rupture", "DISEASE", 43, 50], ["Rupture", "PROBLEM", 0, 7], ["rupture", "PROBLEM", 43, 50], ["a cylindrical liquid sheet", "TREATMENT", 54, 80], ["rupture", "OBSERVATION", 43, 50]]], ["These instantaneous images were captured at 3600 f.p.s with an exposure time of 500 \u03bcs.", [["These instantaneous images", "TEST", 0, 26]]], ["The inception of rupture occurs at a point in the liquid sheet where the sheet thickness tends to zero.", [["rupture", "DISEASE", 17, 24], ["rupture", "PROBLEM", 17, 24], ["the liquid sheet", "TREATMENT", 46, 62], ["the sheet thickness", "TREATMENT", 69, 88], ["rupture", "OBSERVATION", 17, 24]]], ["In other words, the thin film's initial puncture is localized preferentially at the point where the normal stresses are large.", [["the thin film's initial puncture", "TEST", 16, 48], ["normal stresses", "OBSERVATION", 100, 115], ["large", "OBSERVATION_MODIFIER", 120, 125]]], ["The rupture also occurs individually on each bubble disintegrated from the liquid sheet.", [["rupture", "DISEASE", 4, 11], ["The rupture", "PROBLEM", 0, 11], ["rupture", "OBSERVATION", 4, 11]]], ["The bubble diameter is equivalent to the wavelength of the liquid sheet as a result of K-H instability.", [["K-H", "SIMPLE_CHEMICAL", 87, 90], ["the liquid sheet", "TREATMENT", 55, 71], ["K-H instability", "PROBLEM", 87, 102], ["bubble", "OBSERVATION_MODIFIER", 4, 10], ["diameter", "OBSERVATION_MODIFIER", 11, 19], ["equivalent", "OBSERVATION_MODIFIER", 23, 33], ["wavelength", "OBSERVATION_MODIFIER", 41, 51], ["instability", "OBSERVATION", 91, 102]]], ["The rupture event continues until the whole liquid sheet deforms.B. RuptureOn continuous impingement of air, the soap film ruptures at some critical point without any external disturbances by forming a small hole (internal pressure will be enough to break the bubble, causing it to burst).", [["rupture", "DISEASE", 4, 11], ["impingement", "DISEASE", 89, 100], ["ruptures", "DISEASE", 123, 131], ["The rupture event", "PROBLEM", 0, 17], ["the whole liquid sheet deforms", "TREATMENT", 34, 64], ["continuous impingement of air", "PROBLEM", 78, 107], ["the soap film ruptures", "TREATMENT", 109, 131], ["any external disturbances", "PROBLEM", 163, 188], ["a small hole", "TREATMENT", 200, 212], ["internal pressure", "TREATMENT", 214, 231], ["rupture", "OBSERVATION", 4, 11], ["impingement", "OBSERVATION", 89, 100], ["air", "OBSERVATION", 104, 107], ["ruptures", "OBSERVATION", 123, 131], ["disturbances", "OBSERVATION", 176, 188], ["small", "OBSERVATION_MODIFIER", 202, 207], ["hole", "OBSERVATION", 208, 212], ["bubble", "OBSERVATION", 260, 266]]], ["It is worth mentioning that the rupture may happen at multiple points simultaneously, leading to multiple bursts.", [["rupture", "DISEASE", 32, 39], ["the rupture", "PROBLEM", 28, 39], ["rupture", "OBSERVATION", 32, 39], ["multiple", "OBSERVATION_MODIFIER", 97, 105], ["bursts", "OBSERVATION_MODIFIER", 106, 112]]], ["Note that the images were captured using a high-speed cameraARTICLE scitation.org/journal/phfrepresenting two-dimensional projections of the three-dimensional motion; only bubbles with axisymmetric oscillations were selected for the data analysis.", [["the images", "TEST", 10, 20], ["a high-speed cameraARTICLE scitation", "TREATMENT", 41, 77], ["axisymmetric oscillations", "TEST", 185, 210], ["the data analysis", "TEST", 229, 246], ["bubbles", "OBSERVATION", 172, 179], ["axisymmetric oscillations", "OBSERVATION", 185, 210]]], ["The rupture that can be visualized from the image was only considered and reported.", [["rupture", "DISEASE", 4, 11], ["The rupture", "PROBLEM", 0, 11], ["the image", "TEST", 40, 49], ["rupture", "OBSERVATION", 4, 11]]], ["First, the bubble is in the form of a spherical shape and would like to retain its shape.", [["bubble", "OBSERVATION_MODIFIER", 11, 17], ["spherical shape", "OBSERVATION", 38, 53], ["shape", "OBSERVATION_MODIFIER", 83, 88]]], ["The puncture or rupture happens from the upstream or downstream.", [["rupture", "DISEASE", 16, 23], ["upstream or downstream", "DNA", 41, 63], ["The puncture", "PROBLEM", 0, 12], ["rupture", "PROBLEM", 16, 23], ["puncture", "OBSERVATION", 4, 12], ["rupture", "OBSERVATION", 16, 23]]], ["It is common that whenever a bubble ruptures, the droplet or fragments are formed by the retraction of the thin film, as shown in Fig. 6 .", [["fragments", "ANATOMY", 61, 70], ["a bubble ruptures", "PROBLEM", 27, 44], ["the droplet or fragments", "PROBLEM", 46, 70], ["the thin film", "TEST", 103, 116], ["bubble", "OBSERVATION_MODIFIER", 29, 35], ["ruptures", "OBSERVATION", 36, 44], ["droplet", "OBSERVATION_MODIFIER", 50, 57], ["fragments", "OBSERVATION_MODIFIER", 61, 70], ["retraction", "OBSERVATION_MODIFIER", 89, 99]]], ["The sheet retraction caused by the rupture differs depending upon the velocity conditions.", [["rupture", "DISEASE", 35, 42], ["The sheet retraction", "TREATMENT", 0, 20], ["the rupture differs", "PROBLEM", 31, 50], ["retraction", "OBSERVATION", 10, 20], ["rupture", "OBSERVATION", 35, 42]]], ["Followed by these events, there will be a formation of ligaments, leading to the formation of other sets of droplets [Figs.", [["ligaments", "ANATOMY", 55, 64], ["ligaments", "TISSUE", 55, 64], ["a formation of ligaments", "PROBLEM", 40, 64], ["ligaments", "ANATOMY", 55, 64]]], ["During the course, the retracting sheet flattens the bubble-like pancake shape and then spirals up to shatter the liquid sheet into smaller fragments, 25, 26, 29, 30 as shown in Figs.", [["fragments", "ANATOMY", 140, 149], ["the retracting sheet", "TEST", 19, 39], ["pancake shape", "PROBLEM", 65, 78], ["retracting", "OBSERVATION_MODIFIER", 23, 33], ["bubble", "OBSERVATION_MODIFIER", 53, 59], ["pancake", "OBSERVATION_MODIFIER", 65, 72], ["shape", "OBSERVATION_MODIFIER", 73, 78], ["smaller", "OBSERVATION_MODIFIER", 132, 139], ["fragments", "OBSERVATION", 140, 149]]], ["6(e)-6(h).C. Ligament formationThe event of rupturing or bursting a spherical bubble leads to the formation of ligaments.", [["Ligament", "ANATOMY", 13, 21], ["ligaments", "ANATOMY", 111, 120], ["ligaments", "TISSUE", 111, 120], ["C.", "SPECIES", 10, 12], ["C.", "SPECIES", 10, 12], ["Ligament formation", "PROBLEM", 13, 31], ["rupturing", "PROBLEM", 44, 53], ["bursting a spherical bubble", "PROBLEM", 57, 84], ["rupturing", "OBSERVATION", 44, 53], ["bursting", "OBSERVATION_MODIFIER", 57, 65], ["spherical bubble", "OBSERVATION", 68, 84], ["ligaments", "ANATOMY", 111, 120]]], ["The number of ligaments depends upon the acceleration experienced by the spherical bubble while rupturing.", [["ligaments", "ANATOMY", 14, 23], ["ligaments", "TISSUE", 14, 23], ["rupturing", "PROBLEM", 96, 105], ["number", "OBSERVATION_MODIFIER", 4, 10], ["ligaments", "ANATOMY", 14, 23], ["acceleration", "OBSERVATION_MODIFIER", 41, 53], ["spherical bubble", "OBSERVATION", 73, 89], ["rupturing", "OBSERVATION", 96, 105]]], ["Ligament formation\u03c3 .", [["Ligament", "ANATOMY", 0, 8], ["\u03c3", "DNA", 18, 19], ["Ligament formation", "PROBLEM", 0, 18]]], ["In addition, R b represents the radius of the bubble.", [["R b", "GENE_OR_GENE_PRODUCT", 13, 16], ["R b", "PROTEIN", 13, 16], ["radius", "ANATOMY_MODIFIER", 32, 38], ["bubble", "OBSERVATION", 46, 52]]], ["Both A and We increase because the gas (air) velocity increases.", [["the gas (air) velocity", "TEST", 31, 53], ["gas", "OBSERVATION", 35, 38]]], ["R-T instability occurs in a spherical bubble 31 that leads to the formation of ligaments in several instances, which includes breakup either due to viscous drainage 32 or destabilized by a laser source 33 or by a combustion source.", [["ligaments", "ANATOMY", 79, 88], ["R-T", "GENE_OR_GENE_PRODUCT", 0, 3], ["ligaments", "TISSUE", 79, 88], ["R-T instability", "PROBLEM", 0, 15], ["breakup", "PROBLEM", 126, 133], ["viscous drainage", "PROBLEM", 148, 164], ["T instability", "OBSERVATION", 2, 15], ["ligaments", "ANATOMY", 79, 88], ["several", "OBSERVATION_MODIFIER", 92, 99], ["instances", "OBSERVATION", 100, 109], ["viscous", "OBSERVATION_MODIFIER", 148, 155], ["drainage", "OBSERVATION", 156, 164]]], ["34 We confirmed and stated that it yields the same number of ligaments irrespective of their sources.", [["ligaments", "ANATOMY", 61, 70], ["ligaments", "TISSUE", 61, 70], ["ligaments", "ANATOMY", 61, 70]]], ["With this, we also characterize the number of formation of ligaments (N) for the wide range of Bond numbers (Bo), as shown in Fig. 7(b) .", [["ligaments", "ANATOMY", 59, 68], ["ligaments", "TISSUE", 59, 68], ["ligaments", "ANATOMY", 59, 68]]], ["As can be seen, increasing the value of Bo tends to increase N. It is due to the dominance of inertial forces driven by acceleration over the surface tension forces.", [["surface", "ANATOMY", 142, 149], ["inertial forces", "PROBLEM", 94, 109], ["increasing", "OBSERVATION_MODIFIER", 16, 26], ["inertial forces", "OBSERVATION", 94, 109]]], ["Note that the trend observed for a cylindrical thin liquid sheet (N \u223c \u221a Bo) is consistent with the aforementioned earlier studies.", [["a cylindrical thin liquid sheet", "TREATMENT", 33, 64], ["consistent with", "UNCERTAINTY", 79, 94]]], ["31C.", [["31C", "CELL_LINE", 0, 3]]], ["Ligament formationEach ligament breaks into tiny drops due to the influence of the P-R instability.", [["Ligament", "ANATOMY", 0, 8], ["ligament", "ANATOMY", 23, 31], ["Ligament", "TISSUE", 0, 8], ["ligament", "TISSUE", 23, 31], ["P", "DNA", 83, 84], ["Ligament formation", "PROBLEM", 0, 18], ["ligament breaks into tiny drops", "PROBLEM", 23, 54], ["the P-R instability", "PROBLEM", 79, 98], ["ligament breaks", "OBSERVATION", 23, 38], ["tiny", "OBSERVATION_MODIFIER", 44, 48], ["drops", "OBSERVATION", 49, 54], ["instability", "OBSERVATION", 87, 98]]], ["Note that t l \u223c We \u22120.5 .D. Drop formationIt is well known that each ligament will tend to break up further into drops.", [["ligament", "ANATOMY", 69, 77], ["ligament", "TISSUE", 69, 77], ["ligament", "ANATOMY", 69, 77]]], ["It is due to the Plateau-Rayleigh (P-R) instability.", [["the Plateau", "TEST", 13, 24], ["Rayleigh (P-R) instability", "PROBLEM", 25, 51], ["Plateau", "OBSERVATION_MODIFIER", 17, 24], ["Rayleigh", "OBSERVATION_MODIFIER", 25, 33], ["instability", "OBSERVATION", 40, 51]]], ["Here, we discuss the thickness (t l ) of each ligament that is formed.", [["ligament", "ANATOMY", 46, 54], ["ligament", "TISSUE", 46, 54], ["the thickness (t l ) of each ligament", "TREATMENT", 17, 54], ["each ligament", "ANATOMY", 41, 54]]], ["Figure 8 shows the thickness of the ligament (t l ) as a function of Weber number (We).", [["ligament", "ANATOMY", 36, 44], ["ligament", "TISSUE", 36, 44], ["Figure", "TEST", 0, 6], ["thickness", "OBSERVATION_MODIFIER", 19, 28], ["ligament", "ANATOMY", 36, 44]]], ["Here, t l is normalized as t l = \u03c0D b NR , where D b refers to the diameter of the bubble before rupturing.", [["D b", "GENE_OR_GENE_PRODUCT", 49, 52], ["t l", "DNA", 6, 9], ["rupturing", "PROBLEM", 97, 106], ["diameter", "OBSERVATION_MODIFIER", 67, 75], ["bubble", "OBSERVATION_MODIFIER", 83, 89], ["rupturing", "OBSERVATION", 97, 106]]], ["Note that each ligament thickness reduces due to an increase in the number of ligaments.", [["ligament", "ANATOMY", 15, 23], ["ligaments", "ANATOMY", 78, 87], ["ligament", "TISSUE", 15, 23], ["ligaments", "TISSUE", 78, 87], ["an increase in the number of ligaments", "PROBLEM", 49, 87], ["ligament", "ANATOMY", 15, 23], ["thickness", "OBSERVATION_MODIFIER", 24, 33], ["increase", "OBSERVATION_MODIFIER", 52, 60], ["number", "OBSERVATION_MODIFIER", 68, 74], ["ligaments", "ANATOMY", 78, 87]]], ["An increase in We of the flow increases the number of ligaments formed (N), resulting in thinner ligaments.", [["ligaments", "ANATOMY", 54, 63], ["ligaments", "ANATOMY", 97, 106], ["ligaments", "TISSUE", 54, 63], ["ligaments", "TISSUE", 97, 106], ["the flow", "TEST", 21, 29], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["flow", "OBSERVATION_MODIFIER", 25, 29], ["increases", "OBSERVATION_MODIFIER", 30, 39], ["number", "OBSERVATION_MODIFIER", 44, 50], ["ligaments", "ANATOMY", 54, 63], ["thinner ligaments", "ANATOMY", 89, 106]]], ["In other words, increasing We leads to thinner ligaments.", [["ligaments", "ANATOMY", 47, 56], ["ligaments", "TISSUE", 47, 56], ["thinner ligaments", "ANATOMY", 39, 56]]], ["Therefore, the trend of t l decreases as an increase in We is quite a common factor.", [["increase", "OBSERVATION_MODIFIER", 44, 52]]], ["Later, each ligament will end up in smaller drops due to the P-R instability.V. DISCUSSIONIn the present work, we have delineated the instabilities associated with expelling the respiratory liquid by a human by the idealization of destabilizing a thin liquid sheet.", [["ligament", "ANATOMY", 12, 20], ["ligament", "TISSUE", 12, 20], ["human", "ORGANISM", 202, 207], ["P", "DNA", 61, 62], ["human", "SPECIES", 202, 207], ["human", "SPECIES", 202, 207], ["the P-R instability", "PROBLEM", 57, 76], ["the instabilities", "PROBLEM", 130, 147], ["the respiratory liquid", "PROBLEM", 174, 196], ["a thin liquid sheet", "TREATMENT", 245, 264], ["ligament", "ANATOMY", 12, 20], ["instability", "OBSERVATION", 65, 76]]], ["We show that the event is governed by three instability mechanisms, namely, Kelvin-Helmholtz instability, Rayleigh-Taylor instability, and Plateau-Rayleigh instability.", [["Helmholtz instability", "PROBLEM", 83, 104], ["Taylor instability", "PROBLEM", 115, 133], ["Rayleigh instability", "PROBLEM", 147, 167], ["Taylor instability", "OBSERVATION", 115, 133], ["Plateau", "ANATOMY", 139, 146], ["Rayleigh instability", "OBSERVATION", 147, 167]]], ["With careful experiments, we also confirm that the K-H instability only provides a mechanism for the thin sheet to flap and form as a rim at the edge, while rupturing the rim is by thinning a liquid sheet, followed by destabilization of the liquid sheet edge, which involves both R-T and P-R instability mechanisms.", [["flap", "ANATOMY", 115, 119], ["K-H", "CHEMICAL", 51, 54], ["R-T", "GENE_OR_GENE_PRODUCT", 280, 283], ["the K-H instability", "PROBLEM", 47, 66], ["the thin sheet to flap", "TREATMENT", 97, 119], ["thinning a liquid sheet", "TREATMENT", 181, 204], ["the liquid sheet edge", "TREATMENT", 237, 258], ["R instability mechanisms", "PROBLEM", 290, 314], ["flap", "OBSERVATION", 115, 119], ["rupturing", "OBSERVATION", 157, 166], ["rim", "OBSERVATION_MODIFIER", 171, 174]]], ["The present work indicates that the axially long cylindrical liquid sheet of 20 mm of diameter with a thickness of 1 mm would break into a 10 mm bubble (drop) due to the K-H instability.", [["the axially long cylindrical liquid sheet", "TREATMENT", 32, 73], ["a 10 mm bubble (drop)", "PROBLEM", 137, 158], ["the K-H instability", "PROBLEM", 166, 185], ["20 mm", "OBSERVATION_MODIFIER", 77, 82], ["1 mm", "OBSERVATION_MODIFIER", 115, 119], ["10 mm", "OBSERVATION_MODIFIER", 139, 144], ["instability", "OBSERVATION", 174, 185]]], ["The bubble further ruptures into a 1 mm thickness of the ligament due to the R-T instability.", [["ligament", "ANATOMY", 57, 65], ["ligament", "TISSUE", 57, 65], ["R-T", "GENE_OR_GENE_PRODUCT", 77, 80], ["The bubble further ruptures", "PROBLEM", 0, 27], ["the R-T instability", "PROBLEM", 73, 92], ["bubble", "OBSERVATION_MODIFIER", 4, 10], ["ruptures", "OBSERVATION", 19, 27], ["1 mm", "OBSERVATION_MODIFIER", 35, 39], ["thickness", "OBSERVATION_MODIFIER", 40, 49], ["ligament", "ANATOMY", 57, 65], ["instability", "OBSERVATION", 81, 92]]], ["This ligament tends to tiny drops in the order of 10 \u03bcm obeying the P-R instability.", [["ligament", "ANATOMY", 5, 13], ["ligament", "TISSUE", 5, 13], ["P", "DNA", 68, 69], ["ligament", "ANATOMY", 5, 13], ["tiny", "OBSERVATION_MODIFIER", 23, 27], ["drops", "OBSERVATION", 28, 33], ["instability", "OBSERVATION", 72, 83]]], ["It is to be noted that our experiments are within a low viscous regime, where surface tension dominates any viscous effects.", [["surface", "ANATOMY", 78, 85], ["a low viscous regime", "TREATMENT", 50, 70], ["surface tension", "PROBLEM", 78, 93], ["low viscous regime", "OBSERVATION_MODIFIER", 52, 70], ["surface tension", "OBSERVATION", 78, 93], ["viscous effects", "OBSERVATION", 108, 123]]], ["In addition, it provides the platform to showcase the influence of K-H and R-T instabilities with surfaceARTICLEscitation.org/journal/phf tension in the absence of viscous effects.", [["K", "CHEMICAL", 67, 68], ["K-H", "CHEMICAL", 67, 70], ["K-H", "SIMPLE_CHEMICAL", 67, 70], ["K", "TEST", 67, 68], ["R-T instabilities", "PROBLEM", 75, 92], ["surfaceARTICLEscitation", "TREATMENT", 98, 121], ["phf tension", "PROBLEM", 134, 145], ["viscous effects", "PROBLEM", 164, 179], ["phf tension", "OBSERVATION", 134, 145], ["viscous effects", "OBSERVATION", 164, 179]]], ["Furthermore, the dynamics of these drops and their transmission routes could be altered depending upon the conditions such as wind speed, temperature, and humidity.", [["these drops", "TREATMENT", 29, 40]]], ["[37] [38] [39] This study also complements the work of blowing the soap film 40 as well as other exhaustive experiments on coaxial atomizers.", [["This study", "TEST", 15, 25], ["blowing the soap film", "TEST", 55, 76]]], ["28, 32, 41, 42 The experimental setup considered in the present study gives glimpses into the dynamics of sneezing and lends itself well for quantitative analysis.", [["The experimental setup", "TEST", 15, 37], ["sneezing", "PROBLEM", 106, 114], ["quantitative analysis", "TEST", 141, 162]]], ["Although this has widened the understanding of sneezing for the limited flow conditions, we are aware that the present study also proposes more exciting questions.", [["sneezing", "DISEASE", 47, 55], ["sneezing", "PROBLEM", 47, 55], ["the limited flow conditions", "PROBLEM", 60, 87], ["the present study", "TEST", 107, 124], ["widened", "OBSERVATION_MODIFIER", 18, 25]]], ["It is worthwhile to mention that comparisons with the existing literature for sneezing could not be performed because the parameters that govern the event are rather different.", [["sneezing", "DISEASE", 78, 86], ["sneezing", "PROBLEM", 78, 86]]], ["The complete morphology of sneezing phenomena can be understood only by conducting experiments with a fluid with similar properties as saliva and mucus, which generally exhibit non-Newtonian behavior.", [["fluid", "ANATOMY", 102, 107], ["mucus", "ANATOMY", 146, 151], ["saliva", "ORGANISM_SUBSTANCE", 135, 141], ["mucus", "ORGANISM_SUBSTANCE", 146, 151], ["sneezing phenomena", "PROBLEM", 27, 45], ["non-Newtonian behavior", "PROBLEM", 177, 199], ["sneezing phenomena", "OBSERVATION", 27, 45], ["fluid", "OBSERVATION", 102, 107], ["non-Newtonian behavior", "OBSERVATION", 177, 199]]], ["In general, the typical velocity of the cough or sneeze is not well documented, even for a healthy person.", [["cough", "DISEASE", 40, 45], ["sneeze", "DISEASE", 49, 55], ["person", "SPECIES", 99, 105], ["the cough", "PROBLEM", 36, 45], ["velocity", "OBSERVATION_MODIFIER", 24, 32], ["cough", "OBSERVATION", 40, 45]]], ["To date, such data for an infected person are still in the scientific perusal stage.ARTICLEOn the other hand, there are enough possibilities by which one can generate a droplet cloud while talking loudly or singing.", [["person", "SPECIES", 35, 41], ["an infected person", "PROBLEM", 23, 41], ["a droplet cloud", "PROBLEM", 167, 182], ["infected", "OBSERVATION", 26, 34]]], ["In such instances, the dynamics could be entirely different because multiple ejections happen at very low velocities.", [["multiple ejections", "PROBLEM", 68, 86]]], ["These complexities suggest that current researchers include multiple hydrodynamic instabilities and develop a holistic combined model.", [["multiple hydrodynamic instabilities", "PROBLEM", 60, 95], ["multiple", "OBSERVATION_MODIFIER", 60, 68], ["hydrodynamic instabilities", "OBSERVATION", 69, 95]]], ["For example, if aerosol generation by sneezing is the outcome of the simultaneous effect of both K-H and R-T instabilities, a flow system that mimics both mechanisms is cumbersome and even harder to perform in situ measurements.", [["sneezing", "DISEASE", 38, 46], ["K-H", "CHEMICAL", 97, 100], ["K-H", "SIMPLE_CHEMICAL", 97, 100], ["R-T", "GENE_OR_GENE_PRODUCT", 105, 108], ["sneezing", "PROBLEM", 38, 46], ["K-H", "TEST", 97, 100], ["R-T instabilities", "PROBLEM", 105, 122], ["a flow system", "TEST", 124, 137]]], ["However, a detailed comparison between the theoretical predictions 35, 36, 43 of both mechanisms and the observations from the real condition experiments deserves an independent study in the near future.VI. SUMMARYThe present study highlights the role of hydrodynamic instabilities in atomizing expelled respiratory human liquids.", [["human", "ORGANISM", 316, 321], ["human", "SPECIES", 316, 321], ["human", "SPECIES", 316, 321], ["the theoretical predictions", "TEST", 39, 66], ["an independent study", "TEST", 163, 183], ["The present study", "TEST", 214, 231], ["hydrodynamic instabilities", "PROBLEM", 255, 281], ["expelled respiratory human liquids", "TREATMENT", 295, 329], ["hydrodynamic instabilities", "OBSERVATION", 255, 281], ["respiratory human liquids", "OBSERVATION", 304, 329]]], ["To achieve this purpose, we have idealized a sneeze or any other expelling respiratory event by a flow system comprising a soap film and an air jet.", [["a sneeze", "PROBLEM", 43, 51], ["any other expelling respiratory event", "PROBLEM", 55, 92], ["a soap film", "TEST", 121, 132], ["an air jet", "PROBLEM", 137, 147], ["air jet", "OBSERVATION", 140, 147]]], ["We have identified the various intermediate events encountered by the annular liquid sheet to form stable droplets.", [["the annular liquid sheet", "TREATMENT", 66, 90], ["stable", "OBSERVATION_MODIFIER", 99, 105], ["droplets", "OBSERVATION", 106, 114]]], ["We observed various hydrodynamic instabilities that are responsible for each event with the aid of high-speed imaging.", [["various hydrodynamic instabilities", "PROBLEM", 12, 46], ["high-speed imaging", "TEST", 99, 117], ["various", "OBSERVATION_MODIFIER", 12, 19], ["hydrodynamic instabilities", "OBSERVATION", 20, 46]]], ["We observed that the cylindrical liquid sheet undergoes flapping, rupture, ligament, and droplet formation.", [["ligament", "ANATOMY", 75, 83], ["droplet", "ANATOMY", 89, 96], ["rupture", "DISEASE", 66, 73], ["ligament", "TISSUE", 75, 83], ["the cylindrical liquid sheet", "TREATMENT", 17, 45], ["rupture, ligament, and droplet formation", "PROBLEM", 66, 106], ["cylindrical liquid", "OBSERVATION", 21, 39], ["flapping", "OBSERVATION_MODIFIER", 56, 64], ["rupture", "OBSERVATION", 66, 73], ["ligament", "ANATOMY", 75, 83], ["droplet formation", "OBSERVATION", 89, 106]]], ["We quantified the dynamics of a thin annular liquid sheet for a range of Weber and Bond numbers.", [["a thin annular liquid sheet", "TREATMENT", 30, 57]]], ["In this context, we showed that the dimensionless breakup length of the expelled respiratory liquid film scales as a function of Weber number, l b \u223c We \u22120.17 , while the number of ligaments scales as a function of Bond number, N \u223c \u221aVI.", [["ligaments", "ANATOMY", 180, 189], ["ligaments", "TISSUE", 180, 189], ["the expelled respiratory liquid film scales", "TREATMENT", 68, 111], ["ligaments", "ANATOMY", 180, 189]]], ["In addition, we also showed that the thickness of the ligament (t l ) is a strong function of the Weber number.", [["ligament", "ANATOMY", 54, 62], ["ligament", "TISSUE", 54, 62], ["thickness", "OBSERVATION_MODIFIER", 37, 46], ["ligament", "ANATOMY", 54, 62]]], ["Finally, we hope that the present study would help the current researchers gain momentum to explore hydrodynamic instabilities during sneezing.", [["sneezing", "DISEASE", 134, 142], ["the present study", "TEST", 22, 39], ["hydrodynamic instabilities", "PROBLEM", 100, 126], ["sneezing", "PROBLEM", 134, 142], ["hydrodynamic instabilities", "OBSERVATION", 100, 126]]], ["This understanding is crucial to elucidate the aerosol formation and to mitigate disease transmission through expelled respiratory droplets.", [["respiratory droplets", "ANATOMY", 119, 139], ["the aerosol formation", "TREATMENT", 43, 64], ["disease transmission", "PROBLEM", 81, 101], ["expelled respiratory droplets", "PROBLEM", 110, 139], ["respiratory droplets", "OBSERVATION", 119, 139]]]], "9d7e3fb4846e14ad352844fda91915404a43338e": [["Introduction.The COVID-19 global pandemic caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented a major public health challenge.", [["infection", "DISEASE", 52, 61], ["acute respiratory syndrome coronavirus", "DISEASE", 74, 112], ["SARS-CoV-2", "CHEMICAL", 116, 126], ["SARS-CoV-2", "ORGANISM", 116, 126], ["severe acute respiratory syndrome coronavirus", "SPECIES", 67, 112], ["SARS-CoV-2", "SPECIES", 116, 126], ["The COVID", "TEST", 13, 22], ["infection", "PROBLEM", 52, 61], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 67, 112], ["infection", "OBSERVATION", 52, 61], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["respiratory syndrome", "OBSERVATION", 80, 100]]], ["For reasons that are not completely understood, the per-capita mortality from COVID-19 varies by several orders of magnitude between countries.", [["COVID", "TEST", 78, 83]]], ["1 Numerous sources of heterogeneity have been hypothesized.", [["heterogeneity", "PROBLEM", 22, 35], ["Numerous", "OBSERVATION_MODIFIER", 2, 10], ["heterogeneity", "OBSERVATION", 22, 35]]], ["Higher mortality has been observed in older populations and in men.", [["men", "ORGANISM", 63, 66], ["men", "SPECIES", 63, 66]]], ["2, 3 Patient-level behaviors, such as smoking, might also have an impact.", [["smoking", "CHEMICAL", 38, 45], ["impact", "OBSERVATION", 66, 72]]], ["3 Other potentially relevant factors include economic activity, and environmental variation, such as temperature.", [["economic activity", "PROBLEM", 45, 62], ["economic activity", "OBSERVATION", 45, 62]]], ["4 More urban settings and increased population density would be expected to enhance viral transmission.", [["increased population density", "PROBLEM", 26, 54], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["population", "OBSERVATION_MODIFIER", 36, 46], ["density", "OBSERVATION", 47, 54], ["viral", "OBSERVATION", 84, 89]]], ["5 In addition, public health responses to the COVID-19 pandemic may influence per-capita mortality.", [["the COVID", "TEST", 42, 51]]], ["Various strategies have been implemented, ranging from robust testing programs to lockdown or stay-at-home orders, to mandates regarding social distancing and face mask usage.", [["face mask usage", "TREATMENT", 159, 174]]], ["Practices with theoretical benefit, such as social distancing, stay-at-home orders, and implementation of mandates regarding use of masks in public spaces, must be assessed quickly, as implementation has the potential to reduce morbidity and mortality.Introduction.Mask usage by the public is postulated to decrease infection by blocking the spread of respiratory droplets, 1 and was successfully implemented during other coronavirus outbreaks (i.e. SARS and MERS).", [["respiratory droplets", "ANATOMY", 352, 372], ["infection", "DISEASE", 316, 325], ["coronavirus", "DISEASE", 422, 433], ["SARS", "DISEASE", 450, 454], ["morbidity", "PROBLEM", 228, 237], ["Mask usage", "TREATMENT", 265, 275], ["decrease infection", "PROBLEM", 307, 325], ["respiratory droplets", "TREATMENT", 352, 372], ["other coronavirus outbreaks", "PROBLEM", 416, 443], ["decrease", "OBSERVATION_MODIFIER", 307, 315], ["infection", "OBSERVATION", 316, 325], ["respiratory droplets", "OBSERVATION", 352, 372]]], ["6 In the context of the ongoing pandemic, we assessed the impact of masks on per-capita COVID-19-related mortality, controlling for the aforementioned factors.", [["per-capita COVID", "TEST", 77, 93], ["pandemic", "OBSERVATION", 32, 40]]], ["We hypothesized that in countries where mask use was either an accepted cultural norm or favored by government policies on a national level, the per-capita mortality might be reduced, as compared with remaining countries.Introduction.Methods.Data acquisition.Data from 183 countries for which coronavirus mortality and testing data were available were retrieved from a publicly available source on May 9, 2020.", [["coronavirus", "ORGANISM", 293, 304], ["coronavirus", "SPECIES", 293, 304], ["Data acquisition", "TEST", 242, 258], ["coronavirus mortality", "TEST", 293, 314], ["testing data", "TEST", 319, 331], ["reduced", "OBSERVATION_MODIFIER", 175, 182]]], ["7 Archived testing data for April were also downloaded.", [["Archived testing data", "TEST", 2, 23]]], ["8 The date of the country's first reported infection and first death were obtained from the European Centre for Disease Prevention and Control.", [["infection", "DISEASE", 43, 52], ["death", "DISEASE", 63, 68], ["infection", "PROBLEM", 43, 52], ["first death", "PROBLEM", 57, 68], ["Disease Prevention", "TREATMENT", 112, 130], ["infection", "OBSERVATION", 43, 52]]], ["9 Mean temperature in each country during the pandemic was estimated using the average monthly temperature in the country's largest city from public sources.", [["Mean temperature", "TEST", 2, 18]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Data acquisition.The copyright holder for this preprint this version posted May 25, 2020. . https://doi.org/10.1101/2020.05.22.20109231 doi: medRxiv preprint national government mandated or recommended mask-wearing by the public before April 16, 2020.Data acquisition.Population, 12 fraction of the population age 60 years and over, and age 14 and under, male: female ratio per country, 13 surface area, 12,13 gross domestic product per capita, 14 percent urbanization, 12,15 and adult smoking prevalence [16] [17] [18] [19] were obtained from publicly-available databases.", [["surface area", "ANATOMY", 592, 604], ["CC", "CHEMICAL", 0, 2], ["smoking", "CHEMICAL", 688, 695], ["ND", "PROBLEM", 9, 11], ["Data acquisition", "TEST", 202, 218], ["The copyright holder", "TREATMENT", 219, 239], ["mask", "TREATMENT", 404, 408], ["Data acquisition", "TEST", 453, 469], ["med", "ANATOMY", 105, 108], ["12 fraction", "OBSERVATION_MODIFIER", 482, 493]]], ["Whether a nation was an isolated political entity on an island was also recorded.Statistical analysis.The prevalence of an infectious process subject to exponential growth (or decay) appears linear over time when graphed on a logarithmic scale.", [["an isolated political entity", "PROBLEM", 21, 49], ["Statistical analysis", "TEST", 81, 101], ["an infectious process", "PROBLEM", 120, 141], ["exponential growth", "PROBLEM", 153, 171], ["a logarithmic scale", "TREATMENT", 224, 243], ["isolated", "OBSERVATION_MODIFIER", 24, 32], ["political", "OBSERVATION_MODIFIER", 33, 42], ["infectious", "OBSERVATION", 123, 133], ["exponential", "OBSERVATION_MODIFIER", 153, 164], ["growth", "OBSERVATION_MODIFIER", 165, 171], ["linear", "OBSERVATION_MODIFIER", 191, 197]]], ["1 Therefore, we postulated that the logarithm of the country-wide infection prevalence would be linearly related with the duration of the infection in each country.", [["infection", "DISEASE", 66, 75], ["infection", "DISEASE", 138, 147], ["wide infection prevalence", "PROBLEM", 61, 86], ["the infection", "PROBLEM", 134, 147], ["wide", "OBSERVATION_MODIFIER", 61, 65], ["infection", "OBSERVATION", 66, 75], ["infection", "OBSERVATION", 138, 147]]], ["In addition, our analysis postulated that deaths from coronavirus would follow infections with some delay.Statistical analysis.On average, the time from infection with the coronavirus to onset of symptoms is 5.1 days, 20 and the time from symptom onset to death is on average 17.8 days.", [["deaths", "DISEASE", 42, 48], ["coronavirus", "DISEASE", 54, 65], ["infections", "DISEASE", 79, 89], ["infection", "DISEASE", 153, 162], ["coronavirus", "DISEASE", 172, 183], ["death", "DISEASE", 256, 261], ["coronavirus", "ORGANISM", 54, 65], ["coronavirus", "ORGANISM", 172, 183], ["our analysis", "TEST", 13, 25], ["coronavirus", "PROBLEM", 54, 65], ["some delay", "PROBLEM", 95, 105], ["Statistical analysis", "TEST", 106, 126], ["infection", "PROBLEM", 153, 162], ["the coronavirus", "PROBLEM", 168, 183], ["symptoms", "PROBLEM", 196, 204], ["death", "PROBLEM", 256, 261], ["infection", "OBSERVATION", 153, 162]]], ["21 Therefore, the time from infection to death is expected to be 23 days.", [["infection", "DISEASE", 28, 37], ["death", "DISEASE", 41, 46], ["infection", "PROBLEM", 28, 37], ["death", "PROBLEM", 41, 46], ["infection", "OBSERVATION", 28, 37]]], ["1, 22 These incubation and mortality times were prespecified.", [["These incubation", "TREATMENT", 6, 22]]], ["1, 22 Therefore, the date of each country's initial infection was estimated as the earlier of: 5 days before the first reported infection, or 23 days before the first death.", [["infection", "DISEASE", 52, 61], ["infection", "DISEASE", 128, 137], ["death", "DISEASE", 167, 172], ["initial infection", "PROBLEM", 44, 61], ["the first reported infection", "PROBLEM", 109, 137], ["infection", "OBSERVATION", 52, 61], ["infection", "OBSERVATION", 128, 137]]], ["8, 9, 23 Deaths by May 9, 2020 would typically reflect infections beginning 23 days previously (by April 16) .", [["infections", "DISEASE", 55, 65], ["infections", "PROBLEM", 55, 65], ["infections", "OBSERVATION", 55, 65]]], ["Therefore, we recorded the time from the first infection in a country until April 16.", [["infection", "DISEASE", 47, 56], ["infection", "OBSERVATION", 47, 56]]], ["We also recorded the period of the outbreak: 1) from the mandating of activity restrictions until April 16, and 2) from when public mask-wearing was recommended until April 16.Statistical analysis.In univariate analysis, characteristics of countries with above-median per-capita mortality were compared with the remaining (lower mortality) countries by the two-group t-test.", [["public mask", "TREATMENT", 125, 136], ["Statistical analysis", "TEST", 176, 196], ["univariate analysis", "TEST", 200, 219], ["the two-group t-test", "TEST", 353, 373]]], ["The odds ratio for being in the high-mortality group was calculated by logistic regression.Statistical analysis.Significant predictors of per-capita coronavirus mortality in the univariate analysis were analyzed by stepwise backwards multivariable linear regression analysis.", [["coronavirus", "ORGANISM", 149, 160], ["per-capita coronavirus", "SPECIES", 138, 160], ["The odds ratio", "TEST", 0, 14], ["Statistical analysis", "TEST", 91, 111], ["per-capita coronavirus mortality", "PROBLEM", 138, 170], ["the univariate analysis", "TEST", 174, 197], ["multivariable linear regression analysis", "TEST", 234, 274], ["per-capita coronavirus", "OBSERVATION", 138, 160]]], ["The dependent variable was the logarithm (base 10) of per-capita coronavirus-related mortality.", [["coronavirus", "DISEASE", 65, 76], ["coronavirus", "ORGANISM", 65, 76], ["per-capita coronavirus", "SPECIES", 54, 76], ["per-capita coronavirus", "PROBLEM", 54, 76], ["dependent", "OBSERVATION_MODIFIER", 4, 13], ["variable", "OBSERVATION_MODIFIER", 14, 22], ["per-capita coronavirus", "OBSERVATION", 54, 76]]], ["Because of the importance relative to public health, the weeks the country spent in lockdown and using masks, and per-capita testing levels, were all retained in the model.", [["masks", "TREATMENT", 103, 108], ["per-capita testing levels", "TEST", 114, 139]]], ["Statistical analysis was performed with xlstat 2020.1 (Addinsoft, New York).", [["Statistical analysis", "TEST", 0, 20]]], ["An alpha (p value) of 0.05 was deemed to be statistically significant.", [["An alpha (p value", "TEST", 0, 17], ["alpha", "OBSERVATION_MODIFIER", 3, 8]]], ["The study was approved by the Virginia Commonwealth University Office of Research Subjects Protection.Statistical analysis..", [["The study", "TEST", 0, 9], ["Statistical analysis", "TEST", 102, 122]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Statistical analysis.The copyright holder for this preprint this version posted May 25, 2020. . https://doi.org/10.1101/2020.05.22.20109231 doi: medRxiv preprintResults.A total of 183 countries reported coronavirus mortality and testing data by May 9, 2020.", [["CC", "CHEMICAL", 0, 2], ["coronavirus", "ORGANISM", 405, 416], ["ND", "PROBLEM", 9, 11], ["Statistical analysis", "TEST", 202, 222], ["The copyright holder", "TREATMENT", 223, 243], ["medRxiv preprintResults", "TREATMENT", 347, 370], ["coronavirus mortality", "TEST", 405, 426], ["testing data", "TEST", 431, 443], ["med", "ANATOMY", 105, 108]]], ["The 91 lower-mortality countries had 1.1 deaths per million population, in contrast with an average of 101.0 deaths per million population in the 92 highermortality countries (p<0.001, Table 1 ).", [["deaths", "DISEASE", 41, 47], ["deaths", "DISEASE", 109, 115]]], ["The median value was 4.7 deaths per million population.Results.We assumed that island nations might find it less challenging to isolate and protect their populations.", [["deaths", "DISEASE", 25, 31]]], ["Country surface area and population were not associated with coronavirus mortality (Table 1) . .", [["surface area", "ANATOMY", 8, 20], ["coronavirus", "DISEASE", 61, 72], ["coronavirus mortality", "PROBLEM", 61, 82], ["not associated with", "UNCERTAINTY", 41, 60]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 25, 2020. . https://doi.org/10.1101/2020.05.22.20109231 doi: medRxiv preprintDemographics.Countries with older populations suffered higher coronavirus mortality.", [["CC", "CHEMICAL", 0, 2], ["coronavirus", "DISEASE", 403, 414], ["coronavirus", "ORGANISM", 403, 414], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprintDemographics", "TREATMENT", 325, 353], ["higher coronavirus mortality", "PROBLEM", 396, 424], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["higher coronavirus mortality", "OBSERVATION", 396, 424]]], ["Countries with low mortality had on average 9.3% of their population over age 60, as compared with 18.9% in the high-mortality countries (Table 1) .", [["low mortality", "PROBLEM", 15, 28]]], ["Smoking prevalence was on average 14.0% in low mortality countries and 18.7% in high-mortality countries (p<0.001, Table 1 ).Temperature.Colder countries were associated with higher coronavirus mortality in univariate analysis.", [["Smoking", "DISEASE", 0, 7], ["coronavirus", "ORGANISM", 182, 193], ["Temperature", "TEST", 125, 136], ["higher coronavirus mortality", "PROBLEM", 175, 203], ["univariate analysis", "TEST", 207, 226]]], ["The mean temperature was 21.7 C (SD 7.5 C) in the low-mortality countries, and 13.4 C (SD 9.1 C) in the high-mortality countries (p<0.001, Table 1 ).Economics.Urbanization was associated with coronavirus mortality.", [["Urbanization", "DISEASE", 159, 171], ["coronavirus", "ORGANISM", 192, 203], ["The mean temperature", "TEST", 0, 20], ["coronavirus mortality", "PROBLEM", 192, 213], ["coronavirus mortality", "OBSERVATION", 192, 213]]], ["In low-mortality countries, on average 55% of the population was urban, as compared with 70% of the population in the high-mortality countries (p<0.001, Table 1 ).", [["low-mortality", "OBSERVATION_MODIFIER", 3, 16]]], ["Richer countries suffered a higher coronavirus related mortality.", [["coronavirus", "DISEASE", 35, 46], ["coronavirus", "ORGANISM", 35, 46], ["a higher coronavirus related mortality", "PROBLEM", 26, 64], ["higher coronavirus", "OBSERVATION", 28, 46]]], ["The mean GDP per capita was $10,570 in the low-mortality countries, and was $27,600 in the high-mortality countries (Table 1 , p<0.001).Masks.In some Asian countries, masks were used extensively by the public, essentially from the beginning of the outbreak, 1,24 including: Thailand, 25 Japan, 24, 26 South Korea, 24, 27 Taiwan, 28 Hong Kong, 24, 29, 30 Vietnam, 31 Malaysia, 32 Cambodia, 33, 34 and the Philippines 35 (Table 2 ).", [["GDP", "CHEMICAL", 9, 12], ["GDP", "SIMPLE_CHEMICAL", 9, 12], ["Cambodia", "TEST", 379, 387]]], ["Despite the fact that the outbreak tended to appear in these 11 countries quite early, the countries had experienced a low per-capita coronavirus mortality by May 9 (mean 1.9 per million, SD 2.5, Table 2 ).Masks.The World Health Organization initially advised against widespread mask wearing by the public, as did the United States CDC.", [["coronavirus", "DISEASE", 134, 145], ["a low per-capita coronavirus mortality", "PROBLEM", 117, 155]]], ["1, 24 Nonetheless, some Western governments mandated or recommended wearing of masks by the general public during March 2020.", [["masks", "TREATMENT", 79, 84]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 25, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["24 South Korea Jan. 20 5.0 Use of masks is traditional.", [["masks", "TREATMENT", 34, 39]]], ["24 South Korea initially had trouble obtaining enough masks, but at the end of February the government began to control the distribution of masks to the public.", [["public", "ANATOMY", 153, 159]]], ["21 0.3 Use of masks is traditional.", [["masks", "TREATMENT", 14, 19]]], ["23 29 0.5 Surgical masks were traditionally used, and also were recommended on public transport and in crowded places, on January 24, 2020.", [["Surgical masks", "TREATMENT", 10, 24]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 25, 2020.Multivariable analysis.By multivariable linear regression, significant predictors of the logarithm of each country's per-capita coronavirus mortality included: duration of infection in the country, duration of wearing masks, percentage of the population over age 60 , and urbanization (all p<0.001, Table 3 ).", [["CC", "CHEMICAL", 0, 2], ["coronavirus", "DISEASE", 401, 412], ["infection", "DISEASE", 445, 454], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["Multivariable analysis", "TEST", 273, 295], ["multivariable linear regression", "PROBLEM", 299, 330], ["infection", "PROBLEM", 445, 454], ["wearing masks", "TREATMENT", 483, 496], ["med", "ANATOMY", 105, 108], ["linear", "OBSERVATION_MODIFIER", 313, 319], ["regression", "OBSERVATION_MODIFIER", 320, 330], ["significant", "OBSERVATION_MODIFIER", 332, 343], ["infection", "OBSERVATION", 445, 454]]], ["With the duration of infection in the country controlled for, there was a trend for time in lockdown to be negatively associated with mortality, and for percapita testing to be positively associated with mortality, though neither association was significant (Table 3 ).", [["infection", "DISEASE", 21, 30], ["infection", "PROBLEM", 21, 30], ["percapita testing", "TEST", 153, 170], ["infection", "OBSERVATION", 21, 30]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 25, 2020. . https://doi.org/10.1101/2020.05.22.20109231 doi: medRxiv preprint A country with 10% more of its population living in an urban environment than another country will tend to suffer a mortality 21% higher (10 0.0838 = 1.21).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["A country in which the percentage of the population age 60 or over is 10% higher than in another country will tend to suffer mortality 231% higher (10 0.52 = 3.31, Table 3 ).(which was not certified by peer review)The trend towards a positive association with testing by May 9 probably reflects the greater recognition of coronavirus-related mortality with more testing, as well as the increased incentive countries have to test when they suffer a more intense outbreak.Testing.As noted above, testing was positively associated with mortality.", [["coronavirus", "DISEASE", 322, 333], ["coronavirus", "ORGANISM", 322, 333], ["mortality", "TEST", 125, 134], ["testing", "TEST", 260, 267], ["coronavirus", "PROBLEM", 322, 333], ["Testing", "TEST", 470, 477], ["testing", "TEST", 494, 501], ["mortality", "PROBLEM", 533, 542], ["percentage", "OBSERVATION_MODIFIER", 23, 33], ["intense", "OBSERVATION_MODIFIER", 453, 460]]], ["Presumably, testing performed early on would better help to contain the outbreak.", [["testing", "TEST", 12, 19]]], ["By April 4 (the earliest testing data archived), lowmortality countries had tested 1 in 63,300 in the population, as compared with 1 in 1,710 in the high-mortality countries (p<0.001, Table 1 ).", [["the earliest testing data", "TEST", 12, 37]]], ["However, when (log) per-capita testing on April 4, 2020 was included in the model in Table 3 (which also includes later testing), early testing was not inversely related to mortality (coefficient = 0.01, p=0.83).", [["early testing", "TEST", 130, 143], ["coefficient", "TEST", 184, 195]]], ["Likewise, when (log) per-capita testing on April 16, 2020 was included in the model in Table 3 , early testing still tended not to be inversely related to coronavirus mortality (coefficient = 0.21, p=0.11).Testing.Only 5 countries had performed over 1 test for every 10 people in the country by May 9, 2020 (in order of most testing to least): the Faeroe Islands, Iceland, the Falkland Islands, the UAE, and Bahrain.", [["coronavirus", "DISEASE", 155, 166], ["coronavirus", "ORGANISM", 155, 166], ["people", "ORGANISM", 270, 276], ["people", "SPECIES", 270, 276], ["per-capita testing", "TEST", 21, 39], ["early testing", "TEST", 97, 110], ["coronavirus mortality", "PROBLEM", 155, 176], ["coefficient", "TEST", 178, 189], ["Testing", "TEST", 206, 213]]], ["The Faeroe and Falkland Islands reported no coronavirus-related deaths.", [["coronavirus", "DISEASE", 44, 55], ["deaths", "DISEASE", 64, 70], ["coronavirus", "ORGANISM", 44, 55], ["coronavirus", "PROBLEM", 44, 55], ["no", "UNCERTAINTY", 41, 43], ["coronavirus", "OBSERVATION", 44, 55]]], ["The highest per-capita mortality among this group was 29.0 per million population (or 1 in 34,480 people), seen in Iceland.Testing..", [["people", "ORGANISM", 98, 104], ["people", "SPECIES", 98, 104], ["Testing", "TEST", 123, 130], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["per-capita", "OBSERVATION_MODIFIER", 12, 22]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 25, 2020. .Discussion.These results confirm that over 4 months since the appearance of COVID-19 in late 2019, there remains a great deal of variation between countries in related mortality.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["COVID", "TEST", 351, 356], ["med", "ANATOMY", 105, 108], ["great", "OBSERVATION_MODIFIER", 390, 395]]], ["Countries in the lower half of mortality have experienced an average COVID-19-related per-capita mortality of 1.1 deaths per million population, in contrast with an average of 101 deaths per million in the remaining countries.", [["deaths", "DISEASE", 114, 120], ["deaths", "DISEASE", 180, 186]]], ["Independent predictors of mortality included urbanization, fraction of the population age 60 years or over, duration of the outbreak in the country, and the period of outbreak subject to cultural norms or government policies favoring mask-wearing by the public.Discussion.These results support the universal wearing of masks by the public to suppress the spread of the coronavirus.", [["coronavirus", "DISEASE", 369, 380], ["coronavirus", "ORGANISM", 369, 380], ["mask", "TREATMENT", 234, 238], ["masks", "TREATMENT", 319, 324], ["the coronavirus", "PROBLEM", 365, 380], ["coronavirus", "OBSERVATION", 369, 380]]], ["1 Given the low levels of coronavirus mortality seen in the Asian countries which adopted widespread public mask usage early in the outbreak, it seems highly unlikely that masks are harmful.", [["coronavirus mortality", "DISEASE", 26, 47], ["coronavirus", "ORGANISM", 26, 37], ["coronavirus mortality", "PROBLEM", 26, 47], ["coronavirus mortality", "OBSERVATION", 26, 47], ["widespread", "OBSERVATION_MODIFIER", 90, 100], ["public mask", "OBSERVATION", 101, 112], ["seems highly unlikely", "UNCERTAINTY", 145, 166]]], ["One major limitation is that evidence concerning the actual levels of mask-wearing by the public are not available for most countries.", [["mask", "TREATMENT", 70, 74]]], ["Particularly in Western countries which only recommended (rather than mandated) mask-wearing by the public, such as the United States, the practice has been steadily increasing, but change has not occurred overnight.", [["mask", "TREATMENT", 80, 84], ["steadily", "OBSERVATION_MODIFIER", 157, 165], ["increasing", "OBSERVATION_MODIFIER", 166, 176]]], ["Our analysis based on norms and policies can be compared with \"intention-to-treat\" analysis in a clinical trial.Discussion.Much of the randomized controlled data on the effect of mask-wearing on the spread of respiratory viruses relates to influenza.", [["respiratory viruses", "DISEASE", 209, 228], ["influenza", "DISEASE", 240, 249], ["Our analysis", "TEST", 0, 12], ["mask", "TREATMENT", 179, 183], ["respiratory viruses", "PROBLEM", 209, 228], ["influenza", "PROBLEM", 240, 249], ["respiratory viruses", "OBSERVATION", 209, 228], ["influenza", "OBSERVATION", 240, 249]]], ["One recent meta-analysis of 10 trials in families, students, or religious pilgrims found that the relative risk for influenza with the use of face masks was 0.78, a 22% reduction, though the findings were not statistically significant.", [["influenza", "DISEASE", 116, 125], ["influenza", "PROBLEM", 116, 125], ["face masks", "TREATMENT", 142, 152], ["a 22% reduction", "TREATMENT", 163, 178], ["influenza", "OBSERVATION", 116, 125]]], ["48 Combining all the trials, there were 29 cases in groups assigned to wear masks, compared with 51 cases in control groups.", [["masks", "TREATMENT", 76, 81]]], ["48 The direct applicability of these results to mask-wearing at the population level is uncertain.", [["mask", "TREATMENT", 48, 52]]], ["For instance, there was some heterogeneity in methods of the component trials, with one trial assigning mask wearing to the person with a respiratory illness, another to his close contacts, and the remainder to both the ill and their contacts.", [["respiratory", "ANATOMY", 138, 149], ["respiratory illness", "DISEASE", 138, 157], ["person", "SPECIES", 124, 130], ["the component trials", "TREATMENT", 57, 77], ["a respiratory illness", "PROBLEM", 136, 157], ["some", "OBSERVATION_MODIFIER", 24, 28], ["heterogeneity", "OBSERVATION_MODIFIER", 29, 42], ["component", "OBSERVATION_MODIFIER", 61, 70]]], ["The groups living together could not wear a mask when bathing, sleeping, eating, or brushing teeth.", [["teeth", "ANATOMY", 93, 98], ["teeth", "ORGAN", 93, 98], ["a mask", "TREATMENT", 42, 48], ["brushing teeth", "PROBLEM", 84, 98]]], ["51 In a different trial, students were asked to wear a mask in their residence hall for at least 6 hours daily (rather than all the time).", [["a mask", "TREATMENT", 53, 59]]], ["49 The bottom line is that it is nearly impossible for people to constantly maintain mask wear around the people with whom they live.", [["people", "ORGANISM", 55, 61], ["people", "ORGANISM", 106, 112], ["people", "SPECIES", 55, 61], ["people", "SPECIES", 106, 112], ["The bottom line", "TREATMENT", 3, 18], ["bottom line", "OBSERVATION", 7, 18]]], ["In contrast, wearing a mask when on public transit or shopping is quite feasible.", [["a mask", "TREATMENT", 21, 27], ["public transit", "TREATMENT", 36, 50]]], ["In addition, as an infection propagates through multiple generations in the population, the benefits multiply exponentially.", [["infection", "DISEASE", 19, 28], ["an infection", "PROBLEM", 16, 28], ["infection", "OBSERVATION", 19, 28], ["multiple", "OBSERVATION_MODIFIER", 48, 56], ["generations", "OBSERVATION_MODIFIER", 57, 68]]], ["Even if one accepts that masks would only reduce transmissions by 22%, then after 10 cycles of the infection, mask-wearing would reduce the level of infection in the population by 91.7%, as compared with a non-mask wearing population (because 0.78 10 = 0.083).", [["infection", "DISEASE", 99, 108], ["infection", "DISEASE", 149, 158], ["the infection", "PROBLEM", 95, 108], ["mask", "TREATMENT", 110, 114], ["infection", "PROBLEM", 149, 158], ["infection", "OBSERVATION", 99, 108], ["infection", "OBSERVATION", 149, 158]]], ["It is highly unlikely that anyone will ever randomize entire .", [["highly unlikely", "UNCERTAINTY", 6, 21]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 25, 2020. .1countries or populations to either wear, or not wear, masks.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Public policies can only be formulated based on the best evidence available.1A recent study demonstrated that in 4 patients infected with SARS-CoV-2 who were asked to cough without and with a cloth mask, the viral load on a nearby petri dish was reduced with the cloth mask in all patients, and in half was not detectable with the cloth mask.", [["SARS", "DISEASE", 138, 142], ["cough", "DISEASE", 167, 172], ["patients", "ORGANISM", 115, 123], ["SARS-CoV-2", "ORGANISM", 138, 148], ["patients", "ORGANISM", 281, 289], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 281, 289], ["SARS-CoV-2", "SPECIES", 138, 148], ["Public policies", "TREATMENT", 0, 15], ["A recent study", "TEST", 77, 91], ["cough", "PROBLEM", 167, 172], ["a cloth mask", "TREATMENT", 190, 202], ["the viral load", "PROBLEM", 204, 218], ["a nearby petri dish", "PROBLEM", 222, 241], ["the cloth mask", "TREATMENT", 259, 273], ["the cloth mask", "TREATMENT", 327, 341], ["viral load", "OBSERVATION", 208, 218], ["petri dish", "OBSERVATION", 231, 241]]], ["The adoption of numerous public health policies at the same time can make it difficult to tease out the relative importance of each.1Colder average monthly temperature was associated with higher levels of COVID-19 mortality in univariate analysis, but not when accounting for other independent variables.", [["COVID", "TEST", 205, 210], ["univariate analysis", "TEST", 227, 246]]], ["Nonetheless, environmental factors which could influence either human behavior or the stability and spread of virus particles are worthy of further study.1Per-capita testing both early (April 4, 16) and later (May 9) were positively associated with reported coronavirus-related mortality.", [["coronavirus", "DISEASE", 258, 269], ["human", "ORGANISM", 64, 69], ["coronavirus", "ORGANISM", 258, 269], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["environmental factors", "PROBLEM", 13, 34], ["virus particles", "PROBLEM", 110, 125], ["further study", "TEST", 140, 153], ["capita testing", "TEST", 159, 173], ["coronavirus", "PROBLEM", 258, 269], ["coronavirus", "OBSERVATION", 258, 269]]], ["It seems likely that countries which test at a low level are missing many cases.", [["seems likely", "UNCERTAINTY", 3, 15]]], ["All 5 countries had a mortality of 29 per million (1 in 34,480 people) or less.", [["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69]]], ["The degree to which these results would apply to larger, less isolated, or less wealthy countries is unknown.", [["larger", "OBSERVATION_MODIFIER", 49, 55], ["less isolated", "OBSERVATION_MODIFIER", 57, 70]]], ["Statistical support for benefit of high levels of testing might be demonstrated if additional and more diverse countries are able to test at this level.1One limitation of our study is that the ultimate source of mortality data is often from governments which may not have the resources to provide a full accounting of their public health crises, or an interest in doing so.1In summary, older age of the population, urbanization, and longer duration of the outbreak in a country were independently associated with higher country-wide percapita coronavirus mortality.", [["coronavirus", "DISEASE", 543, 554], ["percapita coronavirus", "ORGANISM", 533, 554], ["percapita coronavirus", "SPECIES", 533, 554], ["high levels of testing", "TEST", 35, 57], ["our study", "TEST", 171, 180], ["wide percapita coronavirus mortality", "PROBLEM", 528, 564]]], ["Lockdowns and the amount of viral testing were not statistically significant predictors of country-wide coronavirus mortality, after controlling for other variables.", [["coronavirus", "DISEASE", 104, 115], ["coronavirus", "ORGANISM", 104, 115], ["viral testing", "TEST", 28, 41], ["wide coronavirus mortality", "PROBLEM", 99, 125]]], ["The use of masks in public is an important and readily modifiable public health measure.", [["masks", "TREATMENT", 11, 16]]], ["Societal norms and government policies supporting maskwearing by the public were independently associated with lower per-capita mortality from COVID-19.1.", [["COVID", "TEST", 143, 148]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)1The copyright holder for this preprint this version posted May 25, 2020. .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 203, 223], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)1The copyright holder for this preprint this version posted May 25, 2020. . https://doi.org/10.1101/2020.05.22.20109231 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 203, 223], ["medRxiv", "TREATMENT", 327, 334], ["med", "ANATOMY", 105, 108]]]], "79c71b4eb06fe515bea19db4aadbba835b63a1d5": [["In December 2019, some cases of pneumonia caused by an unknown pathogen were found in Wuhan, the capital city of Hubei, which is located in central China [1] .", [["pneumonia", "DISEASE", 32, 41], ["pneumonia", "PROBLEM", 32, 41], ["an unknown pathogen", "PROBLEM", 52, 71], ["pneumonia", "OBSERVATION", 32, 41], ["central", "ANATOMY_MODIFIER", 140, 147]]], ["After active etiological investigation, on January 7, 2020, the causative pathogen was identified as a novel coronavirus.", [["coronavirus", "DISEASE", 109, 120], ["coronavirus", "ORGANISM", 109, 120], ["the causative pathogen", "PROBLEM", 60, 82], ["a novel coronavirus", "PROBLEM", 101, 120]]], ["On February 11, 2020, the International Committee on Virus Classification announced that this type of virus was officially named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and on the same day WHO announced that the official name of the disease caused by this virus was COVID-19.", [["acute respiratory syndrome coronavirus", "DISEASE", 136, 174], ["SARS-CoV-2", "ORGANISM", 178, 188], ["severe acute respiratory syndrome coronavirus", "SPECIES", 129, 174], ["SARS-CoV-2", "SPECIES", 178, 188], ["virus", "PROBLEM", 102, 107], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 129, 174], ["SARS-CoV", "TEST", 178, 186], ["the disease", "PROBLEM", 251, 262], ["this virus", "PROBLEM", 273, 283], ["COVID", "TEST", 288, 293], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["acute", "OBSERVATION_MODIFIER", 136, 141], ["respiratory syndrome", "OBSERVATION", 142, 162], ["disease", "OBSERVATION", 255, 262]]], ["The proportion of children in COVID-19 patients is significantly lower than that in adults.", [["children", "ORGANISM", 18, 26], ["patients", "ORGANISM", 39, 47], ["children", "SPECIES", 18, 26], ["patients", "SPECIES", 39, 47]]], ["The literature has reported the clinical characteristics and outcomes of the population with a history of tumors in adult COVID-19 patients [2, 3] .", [["tumors", "ANATOMY", 106, 112], ["tumors", "DISEASE", 106, 112], ["tumors", "CANCER", 106, 112], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["tumors", "PROBLEM", 106, 112], ["tumors", "OBSERVATION", 106, 112]]], ["However, there are few reports on COVID-19 in pediatric cancer patients.", [["cancer", "ANATOMY", 56, 62], ["COVID-19", "CHEMICAL", 34, 42], ["cancer", "DISEASE", 56, 62], ["COVID-19", "GENE_OR_GENE_PRODUCT", 34, 42], ["cancer", "CANCER", 56, 62], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["COVID", "TEST", 34, 39], ["few", "OBSERVATION_MODIFIER", 19, 22], ["cancer", "OBSERVATION", 56, 62]]], ["In order to investigate the prevalence rate of COVID-19 in pediatric hemato-oncological patients in the epidemic centers of this outbreak, we selected three representative pediatric hematological cancer centers, which were the Pediatric Hematology and Oncology Department of Wuhan Tongji Hospital, Wuhan Children's Hospital, and Xiangyang Central Hospital.", [["hematological cancer", "ANATOMY", 182, 202], ["COVID-19", "CHEMICAL", 47, 55], ["hematological cancer", "DISEASE", 182, 202], ["patients", "ORGANISM", 88, 96], ["hematological cancer", "CANCER", 182, 202], ["patients", "SPECIES", 88, 96], ["COVID", "TEST", 47, 52], ["cancer", "OBSERVATION", 196, 202]]], ["Then we conducted a relevant survey of SARS-CoV-2 infection of the hospitalized children in the Department of Pediatric Hemato-oncology of the three hospitals in Hubei Province.Study Design and ParticipantsA cross-sectional study was performed to inves-tigate the SARS-CoV-2 infection status of children with hemato-oncological diseases hospitalized in three medical institutions from January 23 to April 24, 2020.Study MethodsThe clinical data of all enrolled children were collected, including general information, diagnosis, high-resolution CT examination results of the lungs, and whether serious clinical events occurred.", [["lungs", "ANATOMY", 574, 579], ["SARS-CoV-2 infection", "DISEASE", 39, 59], ["SARS", "DISEASE", 264, 268], ["infection", "DISEASE", 275, 284], ["hemato-oncological diseases", "DISEASE", 309, 336], ["SARS-CoV-2", "ORGANISM", 39, 49], ["children", "ORGANISM", 80, 88], ["children", "ORGANISM", 295, 303], ["children", "ORGANISM", 461, 469], ["lungs", "ORGAN", 574, 579], ["children", "SPECIES", 80, 88], ["children", "SPECIES", 295, 303], ["children", "SPECIES", 461, 469], ["SARS-CoV-2", "SPECIES", 39, 49], ["SARS", "PROBLEM", 39, 43], ["A cross-sectional study", "TEST", 206, 229], ["inves", "TEST", 247, 252], ["the SARS", "PROBLEM", 260, 268], ["hemato-oncological diseases", "PROBLEM", 309, 336], ["high-resolution CT examination", "TEST", 528, 558], ["serious clinical events", "PROBLEM", 593, 616], ["oncological diseases", "OBSERVATION", 316, 336], ["lungs", "ANATOMY", 574, 579]]], ["SARS-CoV-2 serological antibodies (IgG and IgM) were detected by magnetic particle chemiluminescence.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["IgG", "GENE_OR_GENE_PRODUCT", 35, 38], ["IgM", "GENE_OR_GENE_PRODUCT", 43, 46], ["SARS-CoV-2 serological antibodies", "PROTEIN", 0, 33], ["IgG", "PROTEIN", 35, 38], ["IgM", "PROTEIN", 43, 46], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["serological antibodies", "TEST", 11, 33], ["IgG", "TEST", 35, 38], ["IgM", "TEST", 43, 46]]], ["Nasal swabs, pharyngeal swabs, and anal swabs were collected to detect SARS-CoV-2 nucleic acid by reverse transcriptionpolymerase chain reaction (RT-PCR).", [["Nasal swabs", "ANATOMY", 0, 11], ["pharyngeal swabs", "ANATOMY", 13, 29], ["anal swabs", "ANATOMY", 35, 45], ["nucleic acid", "CHEMICAL", 82, 94], ["Nasal swabs", "MULTI-TISSUE_STRUCTURE", 0, 11], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 13, 29], ["anal swabs", "ORGANISM_SUBSTANCE", 35, 45], ["SARS-CoV", "SPECIES", 71, 79], ["Nasal swabs", "TEST", 0, 11], ["pharyngeal swabs", "TEST", 13, 29], ["anal swabs", "TEST", 35, 45], ["SARS", "TEST", 71, 75], ["CoV", "TEST", 76, 79], ["nucleic acid", "TEST", 82, 94], ["reverse transcriptionpolymerase chain reaction", "PROBLEM", 98, 144], ["RT-PCR", "TEST", 146, 152], ["pharyngeal swabs", "ANATOMY", 13, 29], ["anal", "ANATOMY", 35, 39]]], ["COVID-19 was diagnosed based on the 5th trial of the New Coronavirus Pneumonia Diagnosis and Treatment Program issued by the Health Commission of China.", [["Pneumonia", "DISEASE", 69, 78], ["COVID", "TEST", 0, 5], ["the New Coronavirus Pneumonia", "PROBLEM", 49, 78], ["New", "OBSERVATION_MODIFIER", 53, 56], ["Coronavirus", "OBSERVATION_MODIFIER", 57, 68], ["Pneumonia", "OBSERVATION", 69, 78]]], ["Serious clinical events were defined as conditions requiring admission to pediatric intensive care unit (PICU).Statistical AnalysisThe COVID-19 prevalence rate was calculated as the number of all patients diagnosed in the time period/ the number of all enrolled patients in this period.General Clinical CharacteristicsA total of 299 children were enrolled, including 176 males (58.9%) and 123 females (41.1%), aged from 2 months to 16 years, with a median age of 5 years and 2 months old.", [["patients", "ORGANISM", 196, 204], ["patients", "ORGANISM", 262, 270], ["children", "ORGANISM", 333, 341], ["patients", "SPECIES", 196, 204], ["patients", "SPECIES", 262, 270], ["children", "SPECIES", 333, 341], ["Serious clinical events", "PROBLEM", 0, 23], ["Statistical Analysis", "TEST", 111, 131], ["The COVID", "TEST", 131, 140], ["prevalence rate", "TEST", 144, 159]]], ["The distribution of primary diseases were as follows: leukemia (n=160, 53.5%), solid tumors (n= 31, 10.4%), aplastic anemia (n=21, 7.0%), lymphoma (n=18, 6.0%), Langerhans cell histiocytosis (n=14, 4.7%), hemophagocytic syndrome (n=6, 2.0%), myelodysplastic syndrome (n=5, 1.7%), other nonneoplastic diseases (n=44, 14.7%).", [["leukemia", "ANATOMY", 54, 62], ["solid tumors", "ANATOMY", 79, 91], ["lymphoma", "ANATOMY", 138, 146], ["Langerhans cell histiocytosis", "ANATOMY", 161, 190], ["nonneoplastic", "ANATOMY", 286, 299], ["primary diseases", "DISEASE", 20, 36], ["leukemia", "DISEASE", 54, 62], ["tumors", "DISEASE", 85, 91], ["aplastic anemia", "DISEASE", 108, 123], ["lymphoma", "DISEASE", 138, 146], ["Langerhans cell histiocytosis", "DISEASE", 161, 190], ["hemophagocytic syndrome", "DISEASE", 205, 228], ["myelodysplastic syndrome", "DISEASE", 242, 266], ["nonneoplastic diseases", "DISEASE", 286, 308], ["leukemia", "CANCER", 54, 62], ["solid tumors", "CANCER", 79, 91], ["lymphoma", "CANCER", 138, 146], ["Langerhans cell histiocytosis", "CANCER", 161, 190], ["primary diseases", "PROBLEM", 20, 36], ["leukemia", "PROBLEM", 54, 62], ["solid tumors", "PROBLEM", 79, 91], ["aplastic anemia", "PROBLEM", 108, 123], ["lymphoma", "PROBLEM", 138, 146], ["Langerhans cell histiocytosis", "PROBLEM", 161, 190], ["hemophagocytic syndrome", "PROBLEM", 205, 228], ["myelodysplastic syndrome", "PROBLEM", 242, 266], ["other nonneoplastic diseases", "PROBLEM", 280, 308], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["primary diseases", "OBSERVATION", 20, 36], ["leukemia", "OBSERVATION", 54, 62], ["tumors", "OBSERVATION", 85, 91], ["aplastic", "OBSERVATION_MODIFIER", 108, 116], ["anemia", "OBSERVATION", 117, 123], ["lymphoma", "OBSERVATION", 138, 146], ["Langerhans cell histiocytosis", "OBSERVATION", 161, 190], ["hemophagocytic syndrome", "OBSERVATION", 205, 228], ["myelodysplastic syndrome", "OBSERVATION", 242, 266], ["nonneoplastic", "OBSERVATION_MODIFIER", 286, 299], ["diseases", "OBSERVATION", 300, 308]]], ["255 cases (85.3%) received chemotherapy or immunosuppressive agents.", [["chemotherapy", "TREATMENT", 27, 39], ["immunosuppressive agents", "TREATMENT", 43, 67]]], ["Four patients (1.3%) had a history of close contact with COVID-19 patients (table 1).Laboratory and Radiologic FindingsThe number of children who completed the nucleic acid test was 258 (86.3%), including 257 negative cases (99.6%), and 1 positive case (0.4%).", [["nucleic acid", "CHEMICAL", 160, 172], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 66, 74], ["children", "ORGANISM", 133, 141], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 66, 74], ["children", "SPECIES", 133, 141], ["the nucleic acid test", "TEST", 156, 177]]], ["There were 50 patients (19.4%) with multi-site testing, and 208 patients (80.6%) with single-site testing.", [["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 64, 72], ["multi-site testing", "TEST", 36, 54], ["single-site testing", "TEST", 86, 105]]], ["163 cases (54.5%) were tested for serum antibodies (IgG and IgM), and all were negative.Laboratory and Radiologic FindingsOf 247 children (82.6%) receiving high-resolution CT examination of the lungs, 107 (43.3%) showed infectious changes: patchy shadows in 48 patients, residual fiber strips in 21 cases, ground glass opacity in 11 cases, consolidation in 3 cases, diffused interstitial lesions in 2 cases, others (thickening of the pleura, pleural effusion, atelectasis, etc.) in 22 cases.", [["serum", "ANATOMY", 34, 39], ["lungs", "ANATOMY", 194, 199], ["interstitial lesions", "ANATOMY", 375, 395], ["pleura", "ANATOMY", 434, 440], ["pleural", "ANATOMY", 442, 449], ["interstitial lesions", "DISEASE", 375, 395], ["pleural effusion", "DISEASE", 442, 458], ["atelectasis", "DISEASE", 460, 471], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["IgG", "GENE_OR_GENE_PRODUCT", 52, 55], ["IgM", "GENE_OR_GENE_PRODUCT", 60, 63], ["children", "ORGANISM", 129, 137], ["lungs", "ORGAN", 194, 199], ["patients", "ORGANISM", 261, 269], ["interstitial lesions", "PATHOLOGICAL_FORMATION", 375, 395], ["pleura", "MULTI-TISSUE_STRUCTURE", 434, 440], ["pleural", "ORGAN", 442, 449], ["serum antibodies", "PROTEIN", 34, 50], ["IgG", "PROTEIN", 52, 55], ["IgM", "PROTEIN", 60, 63], ["children", "SPECIES", 129, 137], ["patients", "SPECIES", 261, 269], ["cases", "TEST", 4, 9], ["serum antibodies", "TEST", 34, 50], ["IgG", "TEST", 52, 55], ["IgM", "TEST", 60, 63], ["high-resolution CT examination of the lungs", "TEST", 156, 199], ["infectious changes", "PROBLEM", 220, 238], ["patchy shadows", "PROBLEM", 240, 254], ["residual fiber strips", "TREATMENT", 271, 292], ["ground glass opacity in 11 cases", "PROBLEM", 306, 338], ["consolidation in 3 cases", "PROBLEM", 340, 364], ["diffused interstitial lesions in 2 cases", "PROBLEM", 366, 406], ["thickening of the pleura", "PROBLEM", 416, 440], ["pleural effusion", "PROBLEM", 442, 458], ["atelectasis", "PROBLEM", 460, 471], ["negative", "OBSERVATION", 79, 87], ["lungs", "ANATOMY", 194, 199], ["infectious", "OBSERVATION", 220, 230], ["patchy", "OBSERVATION_MODIFIER", 240, 246], ["shadows", "OBSERVATION_MODIFIER", 247, 254], ["48 patients", "OBSERVATION_MODIFIER", 258, 269], ["fiber strips", "OBSERVATION", 280, 292], ["ground glass opacity", "OBSERVATION", 306, 326], ["11 cases", "OBSERVATION_MODIFIER", 330, 338], ["consolidation", "OBSERVATION", 340, 353], ["diffused", "OBSERVATION_MODIFIER", 366, 374], ["interstitial", "OBSERVATION_MODIFIER", 375, 387], ["lesions", "OBSERVATION", 388, 395], ["thickening", "OBSERVATION_MODIFIER", 416, 426], ["pleura", "ANATOMY", 434, 440], ["pleural", "ANATOMY", 442, 449], ["effusion", "OBSERVATION", 450, 458], ["atelectasis", "OBSERVATION", 460, 471]]], ["Among the 107 children with abnormal imaging, 24 had fever symptoms, 18 had cough symptoms, and 3 had diarrhea symptoms (table 2).Prevalence Rate of COVID-19 and Clinical Analysis of Child with COVID-19Only one case of COVID-19 was diagnosed in the group.", [["fever", "DISEASE", 53, 58], ["cough symptoms", "DISEASE", 76, 90], ["diarrhea", "DISEASE", 102, 110], ["children", "ORGANISM", 14, 22], ["children", "SPECIES", 14, 22], ["abnormal imaging", "TEST", 28, 44], ["fever symptoms", "PROBLEM", 53, 67], ["cough symptoms", "PROBLEM", 76, 90], ["diarrhea symptoms", "PROBLEM", 102, 119], ["COVID", "TEST", 149, 154], ["COVID", "TREATMENT", 194, 199], ["COVID", "TEST", 219, 224]]], ["The prevalence rate of COVID-19 in enrolled children with hemato-oncological diseases was 0.33%.", [["COVID-19", "CHEMICAL", 23, 31], ["hemato-oncological diseases", "DISEASE", 58, 85], ["children", "ORGANISM", 44, 52], ["children", "SPECIES", 44, 52], ["COVID", "TREATMENT", 23, 28], ["hemato-oncological diseases", "PROBLEM", 58, 85], ["oncological diseases", "OBSERVATION", 65, 85]]], ["The COVID-19 child was an 8-year-old boy who had lived in Wuhan for a long time with his parents.", [["boy", "ORGANISM", 37, 40], ["boy", "SPECIES", 37, 40]]], ["He was diagnosed with acute lymphoblastic leukemia (T-lineage, high risk) more than 1 year ago.", [["acute lymphoblastic leukemia", "ANATOMY", 22, 50], ["T-lineage", "ANATOMY", 52, 61], ["acute lymphoblastic leukemia", "DISEASE", 22, 50], ["acute lymphoblastic leukemia", "CANCER", 22, 50], ["T-lineage", "CELL", 52, 61], ["acute lymphoblastic leukemia", "PROBLEM", 22, 50], ["acute", "OBSERVATION_MODIFIER", 22, 27], ["lymphoblastic leukemia", "OBSERVATION", 28, 50]]], ["After more than one year of systemic chemotherapy, he obtained complete remission in his bone marrow and his treatment was in maintenance stage.", [["bone marrow", "ANATOMY", 89, 100], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 89, 100], ["systemic chemotherapy", "TREATMENT", 28, 49], ["his bone marrow", "TEST", 85, 100], ["his treatment", "TREATMENT", 105, 118], ["bone marrow", "ANATOMY", 89, 100]]], ["The child was admitted to hospital without any clinical symptoms, then he received the maintenance phase CA regimen chemotherapy (cyclophosphamide 300 mg/m 2 /day+Cytarabine 300 mg/m 2 /day).", [["cyclophosphamide", "CHEMICAL", 130, 146], ["Cytarabine", "CHEMICAL", 163, 173], ["cyclophosphamide", "CHEMICAL", 130, 146], ["Cytarabine", "CHEMICAL", 163, 173], ["child", "ORGANISM", 4, 9], ["cyclophosphamide", "SIMPLE_CHEMICAL", 130, 146], ["Cytarabine", "SIMPLE_CHEMICAL", 163, 173], ["any clinical symptoms", "PROBLEM", 43, 64], ["the maintenance phase CA regimen chemotherapy", "TREATMENT", 83, 128], ["cyclophosphamide", "TREATMENT", 130, 146], ["Cytarabine", "TREATMENT", 163, 173]]], ["On day 6 after chemotherapy, his myelosuppressive phase was coming with neutropenia (a neutrophil count of 0.35\u00d710 9 /L), lymphopenia (a lymphocyte count of 0.18\u00d710 9 /L), moderate anemia (hemoglobin 67 g/L), and thrombocytopenia (a platelet count of 14\u00d710 9 /L).", [["neutrophil", "ANATOMY", 87, 97], ["lymphocyte", "ANATOMY", 137, 147], ["platelet", "ANATOMY", 233, 241], ["neutropenia", "DISEASE", 72, 83], ["lymphopenia", "DISEASE", 122, 133], ["anemia", "DISEASE", 181, 187], ["thrombocytopenia", "DISEASE", 213, 229], ["neutrophil", "CELL", 87, 97], ["lymphocyte", "CELL", 137, 147], ["platelet", "CELL", 233, 241], ["hemoglobin", "PROTEIN", 189, 199], ["chemotherapy", "TREATMENT", 15, 27], ["his myelosuppressive phase", "PROBLEM", 29, 55], ["neutropenia", "PROBLEM", 72, 83], ["a neutrophil count", "TEST", 85, 103], ["lymphopenia", "PROBLEM", 122, 133], ["a lymphocyte count", "TEST", 135, 153], ["moderate anemia", "PROBLEM", 172, 187], ["hemoglobin", "TEST", 189, 199], ["thrombocytopenia", "PROBLEM", 213, 229], ["a platelet count", "TEST", 231, 247], ["myelosuppressive phase", "OBSERVATION_MODIFIER", 33, 55], ["lymphopenia", "OBSERVATION", 122, 133], ["moderate", "OBSERVATION_MODIFIER", 172, 180], ["anemia", "OBSERVATION", 181, 187], ["thrombocytopenia", "OBSERVATION", 213, 229]]], ["Two days later, he began to have symptoms of low fever and cough.", [["low fever", "DISEASE", 45, 54], ["cough", "DISEASE", 59, 64], ["symptoms", "PROBLEM", 33, 41], ["low fever", "PROBLEM", 45, 54], ["cough", "PROBLEM", 59, 64], ["low", "OBSERVATION_MODIFIER", 45, 48], ["fever", "OBSERVATION", 49, 54], ["cough", "OBSERVATION", 59, 64]]], ["Physical examination showed only pharyngeal congestion without other positive signs.", [["pharyngeal", "ANATOMY", 33, 43], ["pharyngeal congestion", "DISEASE", 33, 54], ["pharyngeal", "ORGAN", 33, 43], ["Physical examination", "TEST", 0, 20], ["pharyngeal congestion", "PROBLEM", 33, 54], ["other positive signs", "PROBLEM", 63, 83], ["pharyngeal", "ANATOMY", 33, 43], ["congestion", "OBSERVATION", 44, 54]]], ["CT scan of the lungs showed consolidation of the left lower lobe and thickening of the local pleura in the right lung.Prevalence Rate of COVID-19 and Clinical Analysis of Child with COVID-19Only influenza virus A antigen was positive for multiple pathogenic examinations.", [["lungs", "ANATOMY", 15, 20], ["left lower lobe", "ANATOMY", 49, 64], ["pleura", "ANATOMY", 93, 99], ["right lung", "ANATOMY", 107, 117], ["lungs", "ORGAN", 15, 20], ["lower lobe", "ORGAN", 54, 64], ["pleura", "ORGAN", 93, 99], ["lung", "ORGAN", 113, 117], ["COVID-19Only influenza virus A antigen", "GENE_OR_GENE_PRODUCT", 182, 220], ["19Only influenza virus", "SPECIES", 188, 210], ["COVID-19Only influenza virus A", "SPECIES", 182, 212], ["CT scan of the lungs", "TEST", 0, 20], ["consolidation of the left lower lobe", "PROBLEM", 28, 64], ["thickening of the local pleura in the right lung", "PROBLEM", 69, 117], ["COVID", "TEST", 137, 142], ["Clinical Analysis", "TEST", 150, 167], ["COVID", "TEST", 182, 187], ["influenza virus A antigen", "TEST", 195, 220], ["multiple pathogenic examinations", "TEST", 238, 270], ["lungs", "ANATOMY", 15, 20], ["consolidation", "OBSERVATION", 28, 41], ["left lower lobe", "ANATOMY", 49, 64], ["thickening", "OBSERVATION", 69, 79], ["local", "ANATOMY_MODIFIER", 87, 92], ["pleura", "ANATOMY", 93, 99], ["right", "ANATOMY_MODIFIER", 107, 112], ["lung", "ANATOMY", 113, 117]]], ["Despite receiving strong antiinfection and immune support treatment, the child still suffered repeated high fever and paroxysmal dry cough.", [["fever", "DISEASE", 108, 113], ["paroxysmal dry cough", "DISEASE", 118, 138], ["child", "ORGANISM", 73, 78], ["strong antiinfection", "TREATMENT", 18, 38], ["immune support treatment", "TREATMENT", 43, 67], ["repeated high fever", "PROBLEM", 94, 113], ["paroxysmal dry cough", "PROBLEM", 118, 138], ["cough", "OBSERVATION", 133, 138]]], ["Re-scan of lung CT on day 10 after fever showed patchy flocculent increased density shadow and a small amount of pleural effusion.", [["lung", "ANATOMY", 11, 15], ["pleural effusion", "ANATOMY", 113, 129], ["fever", "DISEASE", 35, 40], ["pleural effusion", "DISEASE", 113, 129], ["lung", "ORGAN", 11, 15], ["pleural effusion", "PATHOLOGICAL_FORMATION", 113, 129], ["lung CT", "TEST", 11, 18], ["fever", "PROBLEM", 35, 40], ["patchy flocculent increased density shadow", "PROBLEM", 48, 90], ["a small amount of pleural effusion", "PROBLEM", 95, 129], ["lung", "ANATOMY", 11, 15], ["patchy", "OBSERVATION_MODIFIER", 48, 54], ["flocculent", "OBSERVATION_MODIFIER", 55, 65], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["density shadow", "OBSERVATION", 76, 90], ["small", "OBSERVATION_MODIFIER", 97, 102], ["amount", "OBSERVATION_MODIFIER", 103, 109], ["pleural", "ANATOMY", 113, 120], ["effusion", "OBSERVATION", 121, 129]]], ["SARS-CoV-2 nucleic acid test was performed on the day 12 after fever and the result was positive.", [["SARS-CoV-2 nucleic acid", "CHEMICAL", 0, 23], ["fever", "DISEASE", 63, 68], ["SARS-CoV-2 nucleic acid test", "TEST", 0, 28], ["fever", "PROBLEM", 63, 68]]], ["The child was immediately transferred to the negative pressure isolation ward.", [["child", "ORGANISM", 4, 9], ["child", "SPECIES", 4, 9]]], ["The screening results were normal.", [["The screening", "TEST", 0, 13], ["normal", "OBSERVATION", 27, 33]]], ["On the 23rd day of the disease course, the child developed respiratory failure and was transferred to the PICU for treatment.", [["respiratory", "ANATOMY", 59, 70], ["respiratory failure", "DISEASE", 59, 78], ["child", "ORGANISM", 43, 48], ["respiratory failure", "PROBLEM", 59, 78], ["treatment", "TREATMENT", 115, 124], ["respiratory failure", "OBSERVATION", 59, 78]]], ["During the course of the disease, multiple pharyngeal swabs were positive for nucleic acid, and antibodies remained negative.", [["pharyngeal swabs", "ANATOMY", 43, 59], ["nucleic acid", "CHEMICAL", 78, 90], ["pharyngeal swabs", "ORGAN", 43, 59], ["nucleic acid", "SIMPLE_CHEMICAL", 78, 90], ["antibodies", "PROTEIN", 96, 106], ["the disease", "PROBLEM", 21, 32], ["multiple pharyngeal swabs", "TEST", 34, 59], ["nucleic acid", "TEST", 78, 90], ["antibodies", "TEST", 96, 106], ["pharyngeal swabs", "ANATOMY", 43, 59]]], ["The patient's clinical classification was severe.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["severe", "PROBLEM", 42, 48], ["severe", "OBSERVATION_MODIFIER", 42, 48]]], ["At last his pulmonary infection was recovered after comprehensive treatment, and then he was discharged.Treatment and ComplicationsFour cases had serious clinical events, manifesting as severe pneumonia and acute respiratory distress syndrome (ARDS).", [["pulmonary", "ANATOMY", 12, 21], ["respiratory", "ANATOMY", 213, 224], ["pulmonary infection", "DISEASE", 12, 31], ["pneumonia", "DISEASE", 193, 202], ["acute respiratory distress syndrome", "DISEASE", 207, 242], ["ARDS", "DISEASE", 244, 248], ["pulmonary", "ORGAN", 12, 21], ["his pulmonary infection", "PROBLEM", 8, 31], ["comprehensive treatment", "TREATMENT", 52, 75], ["Treatment", "TREATMENT", 104, 113], ["serious clinical events", "PROBLEM", 146, 169], ["severe pneumonia", "PROBLEM", 186, 202], ["acute respiratory distress syndrome", "PROBLEM", 207, 242], ["ARDS", "PROBLEM", 244, 248], ["pulmonary", "ANATOMY", 12, 21], ["infection", "OBSERVATION", 22, 31], ["severe", "OBSERVATION_MODIFIER", 186, 192], ["pneumonia", "OBSERVATION", 193, 202], ["acute", "OBSERVATION_MODIFIER", 207, 212], ["respiratory distress syndrome", "OBSERVATION", 213, 242]]], ["The etiological evidence showed that there was one case of SARS-CoV-2 infection, two cases of invasive fungal infection, and no pathogen was found in the last one.", [["SARS-CoV-2 infection", "DISEASE", 59, 79], ["fungal infection", "DISEASE", 103, 119], ["SARS-CoV-2", "ORGANISM", 59, 69], ["SARS-CoV", "SPECIES", 59, 67], ["SARS", "PROBLEM", 59, 63], ["CoV-2 infection", "PROBLEM", 64, 79], ["invasive fungal infection", "PROBLEM", 94, 119], ["pathogen", "PROBLEM", 128, 136], ["SARS", "OBSERVATION", 59, 63], ["infection", "OBSERVATION", 70, 79], ["invasive", "OBSERVATION_MODIFIER", 94, 102], ["fungal", "OBSERVATION_MODIFIER", 103, 109], ["infection", "OBSERVATION", 110, 119], ["no", "UNCERTAINTY", 125, 127], ["pathogen", "OBSERVATION", 128, 136]]], ["Including the COVID-19 case, three of them received tracheal intubation mechanical ventilation.", [["tracheal", "ANATOMY", 52, 60], ["tracheal", "ORGAN", 52, 60], ["tracheal intubation mechanical ventilation", "TREATMENT", 52, 94], ["tracheal", "ANATOMY", 52, 60], ["intubation", "OBSERVATION", 61, 71], ["mechanical ventilation", "OBSERVATION", 72, 94]]], ["The last one complicated with acute heart failure received non-invasive ventilation assistance.", [["heart", "ANATOMY", 36, 41], ["heart failure", "DISEASE", 36, 49], ["heart", "ORGAN", 36, 41], ["acute heart failure", "PROBLEM", 30, 49], ["non-invasive ventilation assistance", "TREATMENT", 59, 94], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["heart", "ANATOMY", 36, 41], ["failure", "OBSERVATION", 42, 49], ["non-invasive ventilation", "OBSERVATION", 59, 83]]], ["All 4 patients had recovered from pulmonary infection (table 3) .pandemic.", [["pulmonary", "ANATOMY", 34, 43], ["pulmonary infection", "DISEASE", 34, 53], ["patients", "ORGANISM", 6, 14], ["pulmonary", "ORGAN", 34, 43], ["patients", "SPECIES", 6, 14], ["pulmonary infection", "PROBLEM", 34, 53], ["pulmonary", "ANATOMY", 34, 43], ["infection", "OBSERVATION", 44, 53]]], ["The epidemiological characteristics of COVID-19 reported by Chinese Center for DiseaseControl and Prevention showed that the proportion of COVID-19 patients under 20 years of old reported in mainland China was 2.1% [4] .pandemic.", [["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["COVID", "TEST", 39, 44], ["DiseaseControl", "TREATMENT", 79, 93], ["COVID", "TEST", 139, 144]]], ["The epidemiological characteristics of COVID-19 reported by Chinese Center for DiseaseThe proportion of patients under 18 years of old reported by the US CDC was 1.7% [5] .", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["COVID", "TEST", 39, 44], ["Disease", "PROBLEM", 79, 86], ["the US CDC", "TEST", 147, 157]]], ["Compared with adults, most pediatric patients generally had less severe infection, and a few cases were completely asymptomatic.", [["infection", "DISEASE", 72, 81], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["less severe infection", "PROBLEM", 60, 81], ["less", "OBSERVATION_MODIFIER", 60, 64], ["severe", "OBSERVATION_MODIFIER", 65, 71], ["infection", "OBSERVATION", 72, 81]]], ["SARS-CoV-2 is mainly transmitted by respiratory droplets and close contact [7] .", [["respiratory droplets", "ANATOMY", 36, 56], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["respiratory droplets", "OBSERVATION", 36, 56]]], ["Close contact with COVID-19 infected individuals is the main route of transmission in children [8] .", [["COVID-19", "CHEMICAL", 19, 27], ["COVID-19", "ORGANISM", 19, 27], ["individuals", "ORGANISM", 37, 48], ["children", "ORGANISM", 86, 94], ["children", "SPECIES", 86, 94]]], ["In this study, only one patient was diagnosed.", [["patient", "ORGANISM", 24, 31], ["patient", "SPECIES", 24, 31], ["this study", "TEST", 3, 13]]], ["The patient denied the history of close contact with SARS-CoV-2 within 2 weeks.", [["SARS", "DISEASE", 53, 57], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["The family members of the child, the patients who stayed in the same period, and the medical staff had normal COVID-19 examinations.", [["child", "ORGANISM", 26, 31], ["patients", "ORGANISM", 37, 45], ["child", "SPECIES", 26, 31], ["patients", "SPECIES", 37, 45]]], ["Therefore, it was speculated that the patient may be in the incubation period at admission.pandemic.", [["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["pandemic", "PROBLEM", 91, 99]]], ["The epidemiological characteristics of COVID-19 reported by Chinese Center for DiseaseChildren with hematological malignancies are immunosuppressed due to their own disease and related treatments, which are a highly vulnerable group for SARS-CoV-2 infection.", [["hematological malignancies", "ANATOMY", 100, 126], ["hematological malignancies", "DISEASE", 100, 126], ["SARS-CoV-2 infection", "DISEASE", 237, 257], ["hematological malignancies", "CANCER", 100, 126], ["SARS-CoV-2", "ORGANISM", 237, 247], ["SARS-CoV", "SPECIES", 237, 245], ["COVID", "TEST", 39, 44], ["hematological malignancies", "PROBLEM", 100, 126], ["immunosuppressed", "PROBLEM", 131, 147], ["their own disease", "PROBLEM", 155, 172], ["related treatments", "TREATMENT", 177, 195], ["SARS", "PROBLEM", 237, 241], ["CoV-2 infection", "PROBLEM", 242, 257], ["hematological", "ANATOMY", 100, 113], ["malignancies", "OBSERVATION", 114, 126], ["infection", "OBSERVATION", 248, 257]]], ["Studies have found that viral infections, including other human coronaviruses, are associated with increased morbidity and mortality of immunodeficient children [9] .", [["viral infections", "DISEASE", 24, 40], ["human", "ORGANISM", 58, 63], ["children", "ORGANISM", 152, 160], ["human", "SPECIES", 58, 63], ["children", "SPECIES", 152, 160], ["human coronaviruses", "SPECIES", 58, 77], ["Studies", "TEST", 0, 7], ["viral infections", "PROBLEM", 24, 40], ["other human coronaviruses", "PROBLEM", 52, 77], ["increased morbidity", "PROBLEM", 99, 118], ["viral", "OBSERVATION_MODIFIER", 24, 29], ["infections", "OBSERVATION", 30, 40], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["morbidity", "OBSERVATION", 109, 118]]], ["Recently, it has been reported that among COVID-19 patients, the proportion of patients with tumors reached 1% [2] .", [["tumors", "ANATOMY", 93, 99], ["tumors", "DISEASE", 93, 99], ["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 79, 87], ["tumors", "CANCER", 93, 99], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 79, 87], ["tumors", "PROBLEM", 93, 99], ["tumors", "OBSERVATION", 93, 99]]], ["The findings of this study showed that the SARS-CoV-2 infection rate in enrolled children with hematological malignancies was 0.33%.", [["hematological malignancies", "ANATOMY", 95, 121], ["SARS", "DISEASE", 43, 47], ["infection", "DISEASE", 54, 63], ["hematological malignancies", "DISEASE", 95, 121], ["SARS-CoV-2", "ORGANISM", 43, 53], ["children", "ORGANISM", 81, 89], ["hematological malignancies", "CANCER", 95, 121], ["children", "SPECIES", 81, 89], ["SARS-CoV", "SPECIES", 43, 51], ["this study", "TEST", 16, 26], ["the SARS", "TEST", 39, 47], ["CoV", "TEST", 48, 51], ["2 infection rate", "PROBLEM", 52, 68], ["hematological malignancies", "PROBLEM", 95, 121], ["hematological", "ANATOMY", 95, 108], ["malignancies", "OBSERVATION", 109, 121]]], ["It may be related to the following reasons: on one hand, children and their families have a strong protective awareness, such as strict home isolation, maintaining safe social distance in public places, and wearing masks for a long time; on the other hand, the hospital has a strict control of nosocomial infection, such as strict COVID-19 screening for admitted children and attendants (positive diversion to designated hospitals for treatment, negative admission arranged to buffer ward for single isolation), active prevention and treatment of agranulocytosis and other measures.pandemic.", [["nosocomial infection", "DISEASE", 294, 314], ["agranulocytosis", "DISEASE", 547, 562], ["children", "ORGANISM", 57, 65], ["children", "ORGANISM", 363, 371], ["children", "SPECIES", 57, 65], ["children", "SPECIES", 363, 371], ["strict home isolation", "TREATMENT", 129, 150], ["nosocomial infection", "PROBLEM", 294, 314], ["treatment", "TREATMENT", 435, 444], ["single isolation", "TREATMENT", 493, 509], ["active prevention", "TREATMENT", 512, 529], ["treatment", "TREATMENT", 534, 543], ["agranulocytosis", "PROBLEM", 547, 562], ["other measures", "TREATMENT", 567, 581], ["pandemic", "PROBLEM", 582, 590], ["infection", "OBSERVATION", 305, 314], ["agranulocytosis", "OBSERVATION", 547, 562]]], ["The epidemiological characteristics of COVID-19 reported by Chinese Center for DiseaseImmunodeficient children are prone to develop into severe cases after being infected with SARS-CoV-2.", [["SARS", "DISEASE", 176, 180], ["children", "ORGANISM", 102, 110], ["SARS-CoV-2", "ORGANISM", 176, 186], ["children", "SPECIES", 102, 110], ["SARS-CoV", "SPECIES", 176, 184], ["COVID", "TEST", 39, 44]]], ["Zhang [3] reported that 53.6% of COVID-19infected cancer patients had serious clinical events, with a mortality rate of 28.6%.", [["cancer", "ANATOMY", 50, 56], ["cancer", "DISEASE", 50, 56], ["COVID-19infected cancer", "CANCER", 33, 56], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["19infected cancer", "PROBLEM", 39, 56], ["serious clinical events", "PROBLEM", 70, 93], ["a mortality rate", "TEST", 100, 116], ["cancer", "OBSERVATION", 50, 56]]], ["The child with COVID-19 in this study was clinically classified as severe.", [["child", "ORGANISM", 4, 9], ["child", "SPECIES", 4, 9], ["COVID", "TEST", 15, 20], ["this study", "TEST", 27, 37], ["severe", "OBSERVATION_MODIFIER", 67, 73]]], ["On the 23rd day of the disease course, the child suffered a serious clinical event.", [["child", "ORGANISM", 43, 48], ["a serious clinical event", "PROBLEM", 58, 82]]], ["His SARS-CoV-2 nucleic acid test had been persistently positive for more than 2 months, along with persistently negative SARS-CoV-2 antibodies (IgM and IgG) for more than 2 weeks,DISCUSSIONCOVID-19 has rapidly escalated into a global which may be related to the weak ability to clear the virus and the inability to produce antibodies due to humoral immunosuppression.", [["SARS-CoV-2 nucleic acid", "CHEMICAL", 4, 27], ["SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 121, 142], ["IgM", "GENE_OR_GENE_PRODUCT", 144, 147], ["IgG", "GENE_OR_GENE_PRODUCT", 152, 155], ["persistently negative SARS-CoV-2 antibodies", "PROTEIN", 99, 142], ["IgM", "PROTEIN", 144, 147], ["IgG", "PROTEIN", 152, 155], ["antibodies", "PROTEIN", 323, 333], ["His SARS", "TEST", 0, 8], ["CoV-2 nucleic acid test", "TEST", 9, 32], ["persistently positive", "PROBLEM", 42, 63], ["SARS", "TEST", 121, 125], ["CoV", "TEST", 126, 129], ["antibodies", "TEST", 132, 142], ["IgM", "TEST", 144, 147], ["IgG", "TEST", 152, 155], ["DISCUSSIONCOVID", "TEST", 179, 194], ["the weak ability", "PROBLEM", 258, 274], ["the virus", "PROBLEM", 284, 293], ["the inability to produce antibodies", "PROBLEM", 298, 333], ["humoral immunosuppression", "TREATMENT", 341, 366]]], ["Therefore, for patients with hematological malignancies, the possibility of COVID-19 cannot be ruled out by negative antibody detection, which needs to be combined with multiple nucleic acid test, epidemiological history, and lung imaging to assist in the diagnosis.", [["hematological malignancies", "ANATOMY", 29, 55], ["lung", "ANATOMY", 226, 230], ["hematological malignancies", "DISEASE", 29, 55], ["patients", "ORGANISM", 15, 23], ["hematological malignancies", "CANCER", 29, 55], ["lung", "ORGAN", 226, 230], ["patients", "SPECIES", 15, 23], ["hematological malignancies", "PROBLEM", 29, 55], ["COVID", "TEST", 76, 81], ["negative antibody detection", "PROBLEM", 108, 135], ["multiple nucleic acid test", "TEST", 169, 195], ["lung imaging", "TEST", 226, 238], ["lung", "ANATOMY", 226, 230]]], ["Chest CT imaging can be used to investigate pulmonary infection, but COVID-19 cannot be diagnosed only with typical CT features.", [["pulmonary", "ANATOMY", 44, 53], ["pulmonary infection", "DISEASE", 44, 63], ["pulmonary", "ORGAN", 44, 53], ["Chest CT imaging", "TEST", 0, 16], ["pulmonary infection", "PROBLEM", 44, 63], ["COVID", "TEST", 69, 74], ["typical CT features", "TEST", 108, 127], ["pulmonary", "ANATOMY", 44, 53], ["infection", "OBSERVATION", 54, 63]]], ["A multicenter study on clinical and imaging lesions of COVID-19 showed that the typical pulmonary imaging lesions of COVID-19 patients were ground glass lesions (86.1%) or ground-glass lesions combined with consolidation (64.4%) [10] .", [["lesions", "ANATOMY", 44, 51], ["pulmonary imaging lesions", "ANATOMY", 88, 113], ["lesions", "ANATOMY", 153, 160], ["lesions", "ANATOMY", 185, 192], ["lesions", "PATHOLOGICAL_FORMATION", 44, 51], ["pulmonary imaging lesions", "CANCER", 88, 113], ["patients", "ORGANISM", 126, 134], ["ground glass lesions", "CANCER", 140, 160], ["ground-glass lesions", "CANCER", 172, 192], ["patients", "SPECIES", 126, 134], ["A multicenter study", "TEST", 0, 19], ["imaging lesions", "TEST", 36, 51], ["COVID", "TEST", 55, 60], ["the typical pulmonary imaging lesions", "PROBLEM", 76, 113], ["COVID", "TEST", 117, 122], ["ground glass lesions", "PROBLEM", 140, 160], ["ground-glass lesions", "PROBLEM", 172, 192], ["consolidation", "PROBLEM", 207, 220], ["pulmonary", "ANATOMY", 88, 97], ["lesions", "OBSERVATION", 106, 113], ["ground glass lesions", "OBSERVATION", 140, 160], ["ground", "OBSERVATION_MODIFIER", 172, 178], ["glass lesions", "OBSERVATION", 179, 192], ["consolidation", "OBSERVATION", 207, 220]]], ["The proportion of abnormal pulmonary CT findings in this study suggested that pulmonary infection was common in children with hematological malignancies, which is consistent with previous imaging studies of infection in children and adolescents with cancer reported by Sue et al [11] .", [["pulmonary", "ANATOMY", 27, 36], ["pulmonary", "ANATOMY", 78, 87], ["hematological malignancies", "ANATOMY", 126, 152], ["cancer", "ANATOMY", 250, 256], ["pulmonary infection", "DISEASE", 78, 97], ["hematological malignancies", "DISEASE", 126, 152], ["infection", "DISEASE", 207, 216], ["cancer", "DISEASE", 250, 256], ["pulmonary", "ORGAN", 27, 36], ["pulmonary", "ORGAN", 78, 87], ["children", "ORGANISM", 112, 120], ["hematological malignancies", "CANCER", 126, 152], ["children", "ORGANISM", 220, 228], ["cancer", "CANCER", 250, 256], ["children", "SPECIES", 112, 120], ["children", "SPECIES", 220, 228], ["abnormal pulmonary CT findings", "PROBLEM", 18, 48], ["this study", "TEST", 52, 62], ["pulmonary infection", "PROBLEM", 78, 97], ["hematological malignancies", "PROBLEM", 126, 152], ["previous imaging studies", "TEST", 179, 203], ["infection", "PROBLEM", 207, 216], ["cancer", "PROBLEM", 250, 256], ["abnormal", "OBSERVATION_MODIFIER", 18, 26], ["pulmonary", "ANATOMY", 27, 36], ["pulmonary", "ANATOMY", 78, 87], ["infection", "OBSERVATION", 88, 97], ["malignancies", "OBSERVATION", 140, 152], ["consistent with", "UNCERTAINTY", 163, 178], ["infection", "OBSERVATION", 207, 216]]], ["Among 107 patients with abnormal lung imaging, most of them had no such COVID-19 similar symptoms, and it is likely that some of them are not fully recovered from the pneumonia caused by chemotherapy.", [["lung", "ANATOMY", 33, 37], ["pneumonia", "DISEASE", 167, 176], ["patients", "ORGANISM", 10, 18], ["lung", "ORGAN", 33, 37], ["patients", "SPECIES", 10, 18], ["abnormal lung imaging", "PROBLEM", 24, 45], ["such COVID", "PROBLEM", 67, 77], ["similar symptoms", "PROBLEM", 81, 97], ["the pneumonia", "PROBLEM", 163, 176], ["chemotherapy", "TREATMENT", 187, 199], ["lung", "ANATOMY", 33, 37], ["pneumonia", "OBSERVATION", 167, 176]]], ["Fourteen cases showed typical ground-glass lesions and consolidation in pulmonary high-resolution CT.", [["pulmonary", "ANATOMY", 72, 81], ["pulmonary", "ORGAN", 72, 81], ["Fourteen cases", "TEST", 0, 14], ["typical ground-glass lesions", "PROBLEM", 22, 50], ["consolidation", "PROBLEM", 55, 68], ["pulmonary high-resolution CT", "TEST", 72, 100], ["typical", "OBSERVATION_MODIFIER", 22, 29], ["ground", "OBSERVATION_MODIFIER", 30, 36], ["glass lesions", "OBSERVATION", 37, 50], ["consolidation", "OBSERVATION", 55, 68], ["pulmonary", "ANATOMY", 72, 81], ["high", "OBSERVATION_MODIFIER", 82, 86]]], ["However, only one case was finally diagnosed as COVID-19.", [["COVID", "TEST", 48, 53]]], ["The rest 13 children had negative multiple nucleic acid test and antibody test, of which 4 cases of severe pneumonia had pathogen detections: 1 case of COVID-19, 2 cases of invasive pulmonary fungal infection, and 1 case of unknown pathogen.", [["pulmonary", "ANATOMY", 182, 191], ["nucleic acid", "CHEMICAL", 43, 55], ["pneumonia", "DISEASE", 107, 116], ["pulmonary fungal infection", "DISEASE", 182, 208], ["children", "ORGANISM", 12, 20], ["children", "SPECIES", 12, 20], ["multiple nucleic acid test", "TEST", 34, 60], ["antibody test", "TEST", 65, 78], ["severe pneumonia", "PROBLEM", 100, 116], ["COVID", "TEST", 152, 157], ["invasive pulmonary fungal infection", "PROBLEM", 173, 208], ["unknown pathogen", "PROBLEM", 224, 240], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["pneumonia", "OBSERVATION", 107, 116], ["invasive", "OBSERVATION_MODIFIER", 173, 181], ["pulmonary", "ANATOMY", 182, 191], ["fungal infection", "OBSERVATION", 192, 208], ["pathogen", "OBSERVATION", 232, 240]]], ["Their clinical symptoms and pulmonary imaging were significantly improved after targeted treatment.", [["pulmonary", "ANATOMY", 28, 37], ["pulmonary", "ORGAN", 28, 37], ["Their clinical symptoms", "PROBLEM", 0, 23], ["pulmonary imaging", "TEST", 28, 45], ["targeted treatment", "TREATMENT", 80, 98], ["pulmonary", "ANATOMY", 28, 37]]], ["Lung imaging lesions in immunodeficiency children were not specific, and a variety of pathogens can lead to similar imaging changes of viral pneumonia.", [["Lung", "ANATOMY", 0, 4], ["lesions", "ANATOMY", 13, 20], ["immunodeficiency", "DISEASE", 24, 40], ["viral pneumonia", "DISEASE", 135, 150], ["Lung", "ORGAN", 0, 4], ["children", "ORGANISM", 41, 49], ["children", "SPECIES", 41, 49], ["Lung imaging lesions in immunodeficiency children", "PROBLEM", 0, 49], ["pathogens", "PROBLEM", 86, 95], ["viral pneumonia", "PROBLEM", 135, 150], ["lesions", "OBSERVATION", 13, 20], ["immunodeficiency", "OBSERVATION", 24, 40], ["viral", "OBSERVATION_MODIFIER", 135, 140], ["pneumonia", "OBSERVATION", 141, 150]]], ["Therefore, multiple etiological examinations should be recommended to assist in the diagnosis.DISCUSSIONMultiple multi-site nucleic acid tests are a better choice for SARS-CoV-2 screening in children with hematological malignancies.", [["hematological malignancies", "ANATOMY", 205, 231], ["nucleic acid", "CHEMICAL", 124, 136], ["hematological malignancies", "DISEASE", 205, 231], ["children", "ORGANISM", 191, 199], ["hematological malignancies", "CANCER", 205, 231], ["children", "SPECIES", 191, 199], ["SARS-CoV", "SPECIES", 167, 175], ["multiple etiological examinations", "TEST", 11, 44], ["DISCUSSIONMultiple multi-site nucleic acid tests", "TEST", 94, 142], ["SARS", "PROBLEM", 167, 171], ["hematological malignancies", "PROBLEM", 205, 231], ["hematological", "ANATOMY", 205, 218], ["malignancies", "OBSERVATION", 219, 231]]], ["In this study, 258 children underwent SARS-CoV-2 nucleic acid detection, and some patients underwent multiple and multi-site nucleic acid detection to reduce the false negative rate.", [["SARS-CoV-2 nucleic acid", "CHEMICAL", 38, 61], ["nucleic acid", "CHEMICAL", 125, 137], ["children", "ORGANISM", 19, 27], ["patients", "ORGANISM", 82, 90], ["children", "SPECIES", 19, 27], ["patients", "SPECIES", 82, 90], ["this study", "TEST", 3, 13], ["SARS", "TEST", 38, 42], ["CoV", "TEST", 43, 46], ["nucleic acid detection", "TEST", 49, 71], ["multi-site nucleic acid detection", "TREATMENT", 114, 147], ["false negative rate", "OBSERVATION", 162, 181]]], ["In the early stage of COVID-19, the positive rate of qualified respiratory samples was higher, and the positive rate of anal swab or stool samples was significantly higher than that of respiratory samples in the recovery stage of the disease [12] .", [["respiratory samples", "ANATOMY", 63, 82], ["anal swab", "ANATOMY", 120, 129], ["stool samples", "ANATOMY", 133, 146], ["respiratory samples", "ANATOMY", 185, 204], ["anal swab", "ORGANISM_SUBSTANCE", 120, 129], ["stool samples", "ORGANISM_SUBSTANCE", 133, 146], ["COVID", "TEST", 22, 27], ["qualified respiratory samples", "TEST", 53, 82], ["anal swab", "TEST", 120, 129], ["stool samples", "TEST", 133, 146], ["respiratory samples", "TEST", 185, 204], ["the disease", "PROBLEM", 230, 241], ["disease", "OBSERVATION", 234, 241]]], ["For children with thrombocytopenia, it is recommended to collect throat swab samples to reduce the damage and bleeding to the nasal mucosa, while collecting anal swab samples to assist in the diagnosis.DISCUSSIONDuring the current pandemic, taking effective protective measures is still the best choice to reduce the risk of SARS-CoV-2 infection.", [["throat swab samples", "ANATOMY", 65, 84], ["nasal mucosa", "ANATOMY", 126, 138], ["anal swab samples", "ANATOMY", 157, 174], ["thrombocytopenia", "DISEASE", 18, 34], ["bleeding", "DISEASE", 110, 118], ["SARS-CoV-2 infection", "DISEASE", 325, 345], ["children", "ORGANISM", 4, 12], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 126, 138], ["anal swab samples", "TISSUE", 157, 174], ["SARS-CoV-2", "ORGANISM", 325, 335], ["children", "SPECIES", 4, 12], ["SARS-CoV-2", "SPECIES", 325, 335], ["thrombocytopenia", "PROBLEM", 18, 34], ["throat swab samples", "TEST", 65, 84], ["the damage", "PROBLEM", 95, 105], ["bleeding to the nasal mucosa", "PROBLEM", 110, 138], ["collecting anal swab samples", "TEST", 146, 174], ["effective protective measures", "TREATMENT", 248, 277], ["SARS", "PROBLEM", 325, 329], ["CoV", "PROBLEM", 330, 333], ["2 infection", "PROBLEM", 334, 345], ["thrombocytopenia", "OBSERVATION", 18, 34], ["damage", "OBSERVATION", 99, 105], ["bleeding", "OBSERVATION", 110, 118], ["nasal mucosa", "ANATOMY", 126, 138], ["anal", "ANATOMY", 157, 161], ["SARS", "OBSERVATION", 325, 329], ["infection", "OBSERVATION", 336, 345]]], ["On one hand, patients and their companions should take effective personal protection, such as hand hygiene, maintaining social distance in public places, and wearing masks correctly.", [["hand", "ANATOMY", 94, 98], ["patients", "ORGANISM", 13, 21], ["hand", "ORGANISM_SUBDIVISION", 94, 98], ["patients", "SPECIES", 13, 21]]], ["On the other hand, hospitals and medical staffs need to do a good job in the following measures: the evaluation of chemotherapy patients, strict screening of COVID-19 for children and attendants before admission and ward management.", [["patients", "ORGANISM", 128, 136], ["children", "ORGANISM", 171, 179], ["patients", "SPECIES", 128, 136], ["children", "SPECIES", 171, 179], ["the evaluation", "TEST", 97, 111], ["chemotherapy", "TREATMENT", 115, 127], ["strict screening", "TEST", 138, 154], ["ward management", "TREATMENT", 216, 231]]]]}